Gene expression profiles associated with sub-clinical kidney transplant rejection

ABSTRACT

By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with subclinical acute rejection (subAR). These genes sets are useful for diagnosis, prognosis, monitoring of subAR.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 15/358,390 (filed Nov. 22, 2016; now pending), which is a continuation of PCT/US2015/032202 (filed May 22, 2015; now expired). PCT/US2015/032202 claims the benefit of priority to each of U.S. application Ser. No. 14/481,167 (filed Sep. 9, 2014; now abandoned), International Application No. PCT/US2014/054735 (filed Sep. 9, 2014; now expired), U.S. Provisional Application No. 62/029,038 (filed Jul. 25, 2014; now expired), U.S. Provisional Application No. 62/001,889 (filed May 22, 2014; now expired), U.S. Provisional Application No. 62/001,902 (filed May 22, 2014; now expired), and U.S. Provisional Application No. 62/001,909 (filed May 22, 2014; now expired). The full disclosures of the priority applications are incorporated herein by reference in their entirety and for all purposes.

STATEMENT CONCERNING GOVERNMENT SUPPORT

This invention was made with government support under grant numbers AI063603, AI084146, and AI052349 awarded by the National Institutes of Health. The government has certain rights in the invention.

COPYRIGHT NOTIFICATION

Pursuant to 37 C.F.R. § 1.71(e), Applicants note that a portion of this disclosure contains material which is subject to copyright protection. The copyright owner has no objection to the facsimile reproduction by anyone of the patent document or patent disclosure, as it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.

BACKGROUND OF THE INVENTION

Kidney transplantation offers a significant improvement in life expectancy and quality of life for patients with end stage renal disease. Unfortunately, graft losses due to allograft dysfunction or other uncertain etiologies have greatly hampered the therapeutic potential of kidney transplantation. Among various types of graft losses, subclinical acute rejection (subAR or SCAR) is histologically defined as acute rejection characterized by tubule-interstitial mononuclear infiltration identified from a biopsy specimen, but without concurrent functional deterioration (variably defined as a serum creatinine not exceeding 10%, 20% or 25% of baseline values).

A critically important challenge for the future of molecular diagnostics in transplantation based on peripheral blood profiling is to predict a state of adequate immunosuppression with immune mediated kidney injury before there is a change in the serum creatinine. This is the challenge of identifying subclinical acute rejection, which at this time is only occasionally and accidentally picked up by protocol biopsies done at arbitrary time points.

The terms subAR and SCAR are used interchangeably herein to refer to subclinical acute rejection. SubAR (or SCAR) is distinct from clinical acute rejection, which is characterized by acute functional renal impairment. The differences between subAR or SCAR and acute rejection (which may appear histologically indistinguishable on a limited sample) can be explained by real quantitative differences of renal cortex affected, qualitative differences (such as increased perforin, granzyme, c-Bet expression or macrophage markers), or by an increased ability of the allograft to withstand immune injury (‘accommodation’). SubAR or SCAR is often diagnosed only on biopsies taken as per protocol at a fixed time after transplantation, rather than driven by clinical indication. Its diagnosis cannot rely on traditional kidney function measurements like serum creatinine and glomerular filtration rates. Predicting graft outcomes strictly based on the kidney biopsy is difficult and this invasive procedure has significant costs and risks for patients. Organ biopsy results can also be inaccurate, particularly if the area biopsied is not representative of the health of the organ as a whole (e.g., as a result of sampling error). There can be significant differences between individual observers when they read the same biopsies independently and these discrepancies are particularly an issue for complex histologies that can be challenging for clinicians. In addition, the early detection of rejection of a transplant organ may require serial monitoring by obtaining multiple biopsies, thereby multiplying the risks to the patients, as well as the associated costs.

Transplant rejection is a marker of ineffective immunosuppression and ultimately if it cannot be resolved, a failure of the chosen therapy. The fact that 50% of kidney transplant patients will lose their grafts by ten years post-transplant reveals the difficulty of maintaining adequate and effective long-term immunosuppression. Currently, there are no other effective and reliable blood-based or any other tests for subAR or SCAR diagnosis. Thus, there is a pressing medical need to identify minimally invasive biomarkers that are able to identify subAR or SCAR at a time that changes in therapy may alter outcomes. The present invention addresses this and other unfulfilled needs in the art.

SUMMARY OF THE INVENTION

In one aspect, the disclosure provides methods of detecting, prognosing, diagnosing or monitoring subclinical acute rejection (subAR or SCAR). These methods typically entail obtaining nucleic acids of interest, and then (a) determining or detecting expression levels in a subject of at least 5 genes (e.g., at least 10 genes, at least 20 genes, at least 50 genes, at least 100 genes, at least 300 genes, at least 500 genes, etc.); and (b) detecting, prognosing, diagnosing or monitoring subAR or SCAR in the subject from the expression levels. In some methods, the nucleic acids of interest comprise mRNA extracted from a sample from the subject or nucleic acids derived from the mRNA extracted from the sample from the subject. The methods are particularly useful for analysis of blood samples.

Some of the methods are directed to subjects who have or are at risk of developing subAR or SCAR or acute rejection (AR), or have well-functioning normal transplant (TX). In some of the methods, the subject has a serum creatinine level of less than 3 mg/dL, less than 2.5 mg/dL, less than 2.0 mg/dL, or less than 1.5 mg/dL. In some methods, the subject has a normal serum creatinine level. In some of the methods, for each of the at least five genes, step (b) involves comparing the expression level of the gene in the subject to one or more reference expression levels of the gene associated with subAR or SCAR, acute rejection (AR) or lack of transplant rejection (TX). In some of these methods, step (b) further includes, for each of the at least five genes, assigning the expression level of the gene in the subject a value or other designation providing an indication whether the subject has or is at risk of developing SCAR, has acute rejection (AR), or has well-functioning normal transplant (TX). In some methods, the expression level of each of the at least five genes is assigned a value on a normalized scale of values associated with a range of expression levels in kidney transplant patients with SCAR, with AR, or with TX. In some methods, the expression level of each of the at least five genes is assigned a value or other designation providing an indication that the subject has or is at risk of SCAR, has or is at risk of AR, has well-functioning normal transplant, or that the expression level is uninformative. In some methods, step (b) further includes combining the values or designations for each of the genes to provide a combined value or designation providing an indication whether the subject has or is at risk of SCAR, has acute rejection (AR), or has well-functioning normal transplant (TX). In some embodiments, the method can be repeated at different times on the subject. Some of these methods are directed to subjects who have been receiving a drug, and a change in the combined value or designation over time provides an indication of the effectiveness of the drug.

In some embodiments, the expression level is determined in a subject of at least five genes selected from the genes in one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. In another aspect, the methods comprise detecting or determining the expression level of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 genes selected from at least one of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, and 18.

In some embodiments, the detection of expression levels comprises applying a two-step classifier to the gene expression levels. In some embodiments, one step in the two-step classifier distinguishes between normal transplant (TX) and AR+subAR. In some embodiments, one step in the two-step classifier distinguishes between AR and subAR.

In various embodiments, the subjects suitable for methods of the invention are patients who have undergone a kidney transplant. Often, the subject has received the kidney transplant within 1 month, 3 months, 1 year, 2 years, 3 years or 5 years of performing step (a). In some methods of the invention, step (a) is performed on a blood sample of the subject. In some methods, the sample is a blood sample and comprises whole blood, peripheral blood, serum, plasma, PBLs, PBMCs, T cells, CD4 T cells CD8 T cells, or macrophages. In some methods, step (a) is performed on a urine sample of the subject. In some methods, step (a) is performed on a biopsy from the subject, preferably a kidney biopsy. In some methods, step (a) is performed on at least 10, 20, 40, 50, 70, 100, 150, 200, 250, 300, 400, or 500 genes from one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. Some methods further include changing the treatment regime of the patient responsive to the detecting, prognosing, diagnosing or monitoring step. In these methods, the subject can be one who has received a drug before performing the methods, and the change comprises administering an additional drug or administering a higher dose of the same drug, or administering a lower dose of the same drug, or stopping administering the same drug.

Some methods of the invention further include performing an additional procedure to detect SCAR or risk thereof if the determining step provides an indication the subject has or is at risk of SCAR. The additional procedure can be, e.g., examination of a kidney biopsy sample. In some methods of the invention, expression levels of the genes are determined at the mRNA level or at the protein level. In some methods, step (b) can be performed by a computer. In some preferred embodiments, the at least five genes are selected from one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18.

In a related aspect, the invention provides methods of detecting, prognosing, diagnosing or monitoring subclinical acute rejection (subAR or SCAR) in a subject having normal serum creatinine level. These methods involve obtaining nucleic acids of interest, and then (a) determining or detecting expression levels in the subject of at least 2 genes; and (b) detecting, prognosing, diagnosing or monitoring subAR or SCAR in the subject from the expression levels. In some of these methods, the methods comprise determining or detecting the expression levels in the subject of at least five genes. In some of these methods, the at least two genes or the at least five genes are selected from the genes in one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. In some of these methods, the nucleic acids of interest comprise mRNA extracted from a sample from a subject or nucleic acids derived from the mRNA extracted from the sample from the subject. In some methods, the sample is a blood sample. In some methods, the nucleic acids of interest are contacted with probes, wherein the probes are specific for the at least two genes or the at least five genes. In some of these methods, for each of the at least two genes or the at least five genes, step (b) entails comparing the expression level of the gene in the subject to one or more reference expression levels of the gene associated with SCAR, or lack of transplant rejection (TX). In some of these methods, step (b) further includes, for each of the at least two genes or the at least five genes, assigning the expression level of the gene in the subject a value or other designation providing an indication whether the subject has or is at risk of developing SCAR. In some methods, the expression level of each of the at least two genes or the at least five genes is assigned a value on a normalized scale of values associated with a range of expression levels in kidney transplant patients with and without SCAR. In some methods, the expression level of each of the at least two genes or at least five genes is assigned a value or other designation providing an indication that the subject has or is at risk of SCAR, lacks and is not at risk of SCAR, or that the expression level is uninformative. In some of these methods, step (b) further includes combining the values or designations for each of the genes to provide a combined value or designation providing an indication whether the subject has or is at risk of subAR or SCAR.

In various embodiments, the method can be repeated at different times on the subject. In some methods, the subject can be one who is receiving a drug, and a change in the combined value or designation over time provides an indication of the effectiveness of the drug. Some methods of the invention are directed to subjects who have undergone a kidney transplant within 1 month, 3 months, 1 year, 2 years, 3 years or 5 years of performing step (a). In some methods, step (a) is performed on a blood sample of the subject. In some methods, the sample is a blood sample and comprises whole blood, peripheral blood, serum, plasma, PBLs, PBMCs, T cells, CD4 T cells CD8 T cells, or macrophages. In some methods, step (a) is performed on a urine sample of the subject. In some methods, step (a) is performed on at least 3, 4, 5, 10, 15, 20, 30 or more genes. In some methods, step (a) is performed on at least 10, 20, 40, or 100 or more genes selected from at least one of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, and 18. Some of the methods further include changing the treatment regime of the patient responsive to the detecting, prognosing, diagnosing or monitoring step. In some of these methods, the subject is one who has received a drug before performing the methods, and the change comprises administering an additional drug or administering a higher dose of the same drug, or administering a lower dose of the same drug, or stopping administering the same drug. Some other methods can further include performing an additional procedure to detect SCAR or risk thereof if the determining step provides an indication the subject has or is at risk of SCAR, e.g., a kidney biopsy. In various embodiments, expression levels of the genes can be determined at the mRNA level or at the protein level. In some methods, step (b) is performed by a computer.

In various embodiments, the methods provided herein compare the gene expression profile in the peripheral blood of patients with acute cellular rejection (AR) on a surveillance protocol biopsy (SCAR-normal creatinine) with that of patients with normal protocol surveillance biopsies (TX—normal creatinine), or with a previously validated peripheral blood profile for patients with clinical acute cellular rejection (CAR-elevated creatinine) found on a “for cause” biopsy.

In another aspect, the invention provides arrays which contain a support or supports bearing a plurality of nucleic acid probes complementary to a plurality of mRNAs fewer than 5000 in number. Typically, the plurality of mRNAs includes mRNAs expressed by at least five genes selected from one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. In some embodiments, the plurality of mRNAs are fewer than 1000 or fewer than 100 in number. In some embodiments, the plurality of nucleic acid probes are attached to a planar support or to beads. In some embodiments, the at least five genes are selected from one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. In a related aspect, the invention provides arrays that contain a support or supports bearing a plurality of ligands that specifically bind to a plurality of proteins fewer than 5000 in number. The plurality of proteins typically includes at least five proteins encoded by genes selected from one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. In some embodiments, the plurality of proteins are fewer than 1000 or fewer than 100 in number. In some embodiments, the plurality of ligands are attached to a planar support or to beads. In some embodiments, the at least five proteins are encoded by genes selected from one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. In some embodiments, the ligands are different antibodies that bind to different proteins of the plurality of proteins.

In still another aspect, the invention provides methods of expression analysis. These methods involve determining expression levels of up to 2,000 genes (including at least 5 genes selected from one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18) in a sample from a subject having a kidney transplant. In some methods, the expression levels of up to 100 or 1000 genes are determined. The gene expression levels can be determined at the mRNA level or at the protein level. For example, the expression levels can be determined by quantitative PCR or hybridization to an array or sequencing.

The invention additionally provides methods of screening a compound for activity in inhibiting or treating SCAR. The methods involve (a) administering the compound to a subject having or at risk of SCAR; (b) determining, before and after administering the compound to the subject, expression levels of at least five genes in the subject selected from one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18 and species variants thereof, and (c) determining whether the compound has activity in inhibiting or treating SCAR from a change in expression levels of the genes after administering the compound. In some methods, step (c) entails, for each of the at least five changes, assigning a value or designation depending on whether the change in the expression level of the gene relative to one or more reference levels indicating presence or absence of SCAR. Some methods further include determining a combined value or designation for the at least five genes from the values or designations determined for each gene. In some preferred embodiments, the subject is human or a nonhuman animal model of SCAR.

In another aspect, the methods disclosed herein have an error rate of less than about 40%. In some embodiments, the method has an error rate of less than about 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 3%, 2%, or 1%. For example, the method has an error rate of less than about 10%. In some embodiments, the methods disclosed herein have an accuracy of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%. For example, the method has an accuracy of at least about 70%. In some embodiments, the methods disclosed herein have a sensitivity of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%. For example, the method has a sensitivity of at least about 80%. In some embodiments, the methods disclosed herein have a positive predictive value of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%. In some embodiments, the methods disclosed herein have a negative predictive value of at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%.

In some embodiments, the gene expression products described herein are RNA (e.g., mRNA). In some embodiments, the gene expression products are polypeptides. In some embodiments, the gene expression products are DNA complements of RNA expression products from the transplant recipient.

In an embodiment, the algorithm described herein is a trained algorithm. In another embodiment, the trained algorithm is trained with gene expression data from biological samples from at least three different cohorts. In another embodiment, the trained algorithm comprises a linear classifier. In another embodiment, the linear classifier comprises one or more linear discriminant analysis, Fisher's linear discriminant, Naïve Bayes classifier, Logistic regression, Perceptron, Support vector machine (SVM) or a combination thereof. In another embodiment, the algorithm comprises a Diagonal Linear Discriminant Analysis (DLDA) algorithm. In another embodiment, the algorithm comprises a Nearest Centroid algorithm. In another embodiment, the algorithm comprises a Random Forest algorithm or statistical bootstrapping. In another embodiment, the algorithm comprises a Prediction Analysis of Microarrays (PAM) algorithm. In another embodiment, the algorithm is not validated by a cohort-based analysis of an entire cohort. In another embodiment, the algorithm is validated by a combined analysis with an unknown phenotype and a subset of a cohort with known phenotypes.

In another aspect, the sample is a blood sample or is derived from a blood sample. In another embodiment, the blood sample is a peripheral blood sample. In another embodiment, the blood sample is a whole blood sample. In another embodiment, the sample does not comprise tissue from a biopsy of a transplanted organ of the transplant recipient. In another embodiment, the sample is not derived from tissue from a biopsy of a transplanted organ of the transplant recipient.

In another aspect, the assay is a microarray, SAGE, blotting, RT-PCR, sequencing and/or quantitative PCR assay. In another embodiment, the assay is a microarray assay. In another embodiment, the microarray assay comprises the use of an Affymetrix Human Genome U133 Plus 2.0 GeneChip. In another embodiment, the mircroarray uses the Hu133 Plus 2.0 cartridge arrays plates. In another embodiment, the microarray uses the HT HG-U133+ PM array plates. In another embodiment, determining the assay is a sequencing assay. In another embodiment, the assay is a RNA sequencing assay.

In some embodiments, the subject or transplant recipient has a serum creatinine level of less than 3.0 mg/dL, less than 2.5 mg/dL, less than 2.0 mg/dL, or less than 1.5 mg/dL. The subject may have a serum creatinine level that is stable over time. In some cases, the subject or transplant recipient has a serum creatinine level of at least 0.4 mg/dL, 0.6 mg/dL, 0.8 mg/dL, 1.0 mg/dL, 1.2 mg/dL, 1.4 mg/dL, 1.6 mg/dL, 1.8 mg/dL, 2.0 mg/dL, 2.2 mg/dL, 2.4 mg/dL, 2.6 mg/dL, 2.8 mg/dL, 3.0 mg/dL, 3.2 mg/dL, 3.4 mg/dL, 3.6 mg/dL, 3.8 mg/dL, or 4.0 mg/dL. For example, the transplant recipient has a serum creatinine level of at least 1.5 mg/dL. In another example, the transplant recipient has a serum creatinine level of at least 3 mg/dL.

In one aspect, the invention provides methods of detecting subclinical acute rejection (subAR) in a subject comprising: (a) obtaining nucleic acids of interest, wherein the nucleic acids of interest comprise mRNA extracted from a sample from the subject or nucleic acids derived from the mRNA extracted from the sample from the subject; (b) detecting expression levels in the subject of at least five genes using the nucleic acids of interest obtained in step (a); and (c) detecting subAR in the subject from the expression levels detected in step (b). In an example, the sample from the subject is a blood sample.

In another aspect, the method detects subAR with an accuracy of greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%. In another aspect, the method detects subAR with a sensitivity of greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%. For example, the method detects subAR with an accuracy of greater than 75% or a sensitivity of greater than 75%.

In another aspect, the method further comprises contacting the nucleic acids of interest with probes, wherein the probes are specific for the at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 genes selected in step (b).

In another aspect, detecting subAR comprises detecting a risk of developing subAR, detecting acute rejection (AR), detecting a risk of having acute rejection (AR), or detecting a well-functioning normal transplant (TX). In another aspect, for each of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, or 2000 genes, step (c) of the method comprises comparing the expression level of the gene in the subject to one or more reference expression levels of genes associated with subAR, acute rejection (AR) or lack of transplant rejection (TX).

A further understanding of the nature and advantages of the present invention may be realized by reference to the remaining portions of the specification and claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a schematic overview of certain methods in the disclosure.

FIG. 2 shows a schematic overview of certain methods of acquiring samples, analyzing results, and transmitting reports over a computer network.

FIG. 3 is an illustration of hierarchical clustering of gene expression signals of 33 probesets used to differentiate SCAR versus TX.

FIG. 4 shows a computer system for implementing the methods of the disclosure.

FIG. 5 shows a correlation of fold-change between microarray and NGS analyses (1066 common genes).

FIG. 6 shows a heat map and clustering of fold changes (Microarrays vs NGS) of 1066 genes.

FIG. 7 shows correlation of fold-change between microarray and NGS analyses (all expressed NGS 7076 genes).

DETAILED DESCRIPTION

Sub-clinical acute rejection (referred to herein as “subAR” or “SCAR,” interchangeably) is normally defined as histologic kidney rejection (e.g., histologic acute cellular rejection) with normal serum creatinine, and is associated with worse long term graft survival. In some cases, creatinine can be a lagging indicator of renal injury. Most times acute rejection (AR) of kidney graft is detected only after the initial injury has started. Early detection of subAR or SCAR can avoid unnecessary complications later in the course of graft life. However, normally subAR or SCAR is detected using a protocol kidney biopsy which is invasive, expensive and involves substantial risk. The present invention is predicated in part on the development by the inventors of a peripheral blood gene expression profiling signature that can distinguish Sub-Clinical Acute Rejection (subAR or SCAR), well-functioning normal transplant (TX) and Acute Rejection (AR). As detailed herein, the present inventors have identified consensus sets of gene expression-based molecular biomarkers associated with SCAR. This was accomplished via a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood. More than 2,000 sequences were found to have differential expressions among the 3 different patient groups (Table 4). Among these sequences, the inventors further identified the top 200 differentially expressed probesets (Table 2), which can provide more focused and better expression profiles for differentiating the three classes of patients. In addition, a set of genes with differential expression levels only between SCAR and non-rejected transplants (TX) were also identified (Table 3). Expression rotocs based on the genes in this set are predictive in differentiating between transplant patients who will develop SCAR and patients who will maintain non-rejected transplants.

Results from the present inventors' studies provide the basis of a molecular test that can diagnose subAR or SCAR, and also enables minimally invasive methods for monitoring kidney transplant recipients. The value of a blood test for subAR or SCAR is that it allows detection of subclinical immune-mediated transplant rejection prior to clinical evidence of kidney injury and dysfunction. This blood-based test is minimally invasive and amenable to serial monitoring. Moreover, peripheral blood gene expression profiling may be used to inform when to perform a biopsy in patients with normal renal function and/or to replace surveillance protocol biopsies. Therefore, the invention is useful for post-transplant management of kidney recipients. Additional advantages of the test is that serial monitoring of all patients with a blood test for SCAR and treatment of all patients with SCAR by increasing the level of effective immunosuppression may significantly improve long term graft function and survival.

An overview of certain methods in the disclosure is provided in FIG. 1. In some instances, a method comprises obtaining a sample from a transplant recipient in a minimally invasive manner (110), such as via a blood draw. The sample may comprise gene expression products (e.g., polypeptides, RNA, mRNA isolated from within cells or a cell-free source) associated with the status of the transplant (e.g., subAR). In some instances, the method may involve reverse-transcribing RNA within the sample to obtain cDNA that can be analyzed using the methods described herein. The method may also comprise assaying the level of the gene expression products (or the corresponding DNA) using methods such as microarray or sequencing technology (120). The method may also comprise applying an algorithm to the assayed gene expression levels (130) in order to detect subAR. After detection of the presence or absence of subAR, a treatment decision may be made. In some cases, the treatment decision may be that the transplant recipient should be treated more aggressively to mitigate the risk of acute rejection. In some cases, the treatment decision may be to reduce an existing treatment regimen, particularly if subAR is not detected. In the event that no subAR is detected, the treatment decision may involve a decision to forego or delay obtaining a kidney biopsy from the patient.

The following sections provide guidance for carrying out the methods of the invention.

I. Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which this invention pertains. The following references provide one of skill with a general definition of many of the terms used in this invention: Academic Press Dictionary of Science and Technology, Morris (Ed.), Academic Press (1^(st) ed., 1992); Illustrated Dictionary of Immunology, Cruse (Ed.), CRC Pr I LIc (2^(nd) ed., 2002); Oxford Dictionary of Biochemistry and Molecular Biology, Smith et al. (Eds.), Oxford University Press (revised ed., 2000); Encyclopaedic Dictionary of Chemistry, Kumar (Ed.), Anmol Publications Pvt. Ltd. (2002); Dictionary of Microbiology and Molecular Biology, Singleton et al. (Eds.), John Wiley & Sons (3^(rd) ed., 2002); Dictionary of Chemistry, Hunt (Ed.), Routledge (1^(st) ed., 1999); Dictionary of Pharmaceutical Medicine, Nahler (Ed.), Springer-Verlag Telos (1994); Dictionary of Organic Chemistry, Kumar and Anandand (Eds.), Anmol Publications Pvt. Ltd. (2002); and A Dictionary of Biology (Oxford Paperback Reference), Martin and Hine (Eds.), Oxford University Press (4^(th) ed., 2000). In addition, the following definitions are provided to assist the reader in the practice of the invention.

Transplantation is the transfer of tissues, cells or an organ from a donor into a recipient. If the donor and recipient as the same person, the graft is referred to as an autograft and as is usually the case between different individuals of the same species an allograft. Transfer of tissue between species is referred to as a xenograft.

A biopsy is a specimen obtained from a living patient for diagnostic or prognostic evaluation. Kidney biopsies can be obtained with a needle.

An average value can refer to any of a mean, median or mode.

A gene expression level is associated with a particular phenotype e.g., presence of subAR (SCAR) or AR if the gene is differentially expressed in a patient having the phenotype relative to a patient lacking the phenotype to a statistically significant extent. Unless otherwise apparent from the context a gene expression level can be measured at the mRNA and/or protein level.

A target nucleic acid may be a nucleic acid (often derived from a biological sample), to which a polynucleotide probe is designed to specifically hybridize. The probe can detect presence, absence and/or amount of the target. The term target nucleic acid can refer to the specific subsequence of a larger nucleic acid to which the probe is directed or to the overall sequence (e.g., cDNA or mRNA) whose expression level is to be detected. The term target nucleic acid can also refer to a nucleic acid that is analyzed by any method, including by sequencing, PCR, microarray, or other method known in the art.

The term subject or patient can include human or non-human animals. Thus, the methods and described herein are applicable to both human and veterinary disease and animal models. Preferred subjects are “patients,” i.e., living humans that are receiving medical care for a disease or condition. This includes persons with no defined illness who are being investigated for signs of pathology. The term subject or patient can include transplant recipients or donors or healthy subjects. The methods can be particularly useful for human subjects who have undergone a kidney transplant although they can also be used for subjects who have gone other types of transplant (e.g., heart, liver, lung, stem cell, etc.). The subjects may be mammals or non-mammals. Preferably, the subject is a human but in some cases, the subject is a non-human mammal, such as a non-human primate (e.g., ape, monkey, chimpanzee), cat, dog, rabbit, goat, horse, cow, pig, rodent, mouse, SCID mouse, rat, guinea pig, or sheep. The subject may be male or female; the subject may be and, in some cases, the subject may be an infant, child, adolescent, teenager or adult. In some cases, the methods provided herein are used on a subject who has not yet received a transplant, such as a subject who is awaiting a tissue or organ transplant. In other cases, the subject is a transplant donor. In some cases, the subject has not received a transplant and is not expected to receive such transplant. In some cases, the subject may be a subject who is suffering from diseases requiring monitoring of certain organs for potential failure or dysfunction. In some cases, the subject may be a healthy subject.

Often, the subject is a patient or other individual undergoing a treatment regimen, or being evaluated for a treatment regimen (e.g., immunosuppressive therapy). However, in some instances, the subject is not undergoing a treatment regimen. A feature of the graft tolerant phenotype detected or identified by the subject methods is that it is a phenotype which occurs without immunosuppressive therapy, e.g., it is present in a subject that is not receiving immunosuppressive therapy.

A transplant recipient may be a recipient of a solid organ or a fragment of a solid organ such as a kidney. Preferably, the transplant recipient is a kidney transplant or allograft recipient. In some instances, the transplant recipient may be a recipient of a tissue or cell. In some particular examples, the transplanted kidney may be a kidney differentiated in vitro from pluripotent stem cell(s) (e.g., induced pluripotent stem cells or embryonic stem cells).

The donor organ, tissue, or cells may be derived from a subject who has certain similarities or compatibilities with the recipient subject. For example, the donor organ, tissue, or cells may be derived from a donor subject who is age-matched, ethnicity-matched, gender-matched, blood-type compatible, or HLA-type compatible with the recipient subject.

In various embodiments, the subjects suitable for methods of the invention are patients who have undergone an organ transplant within 6 hours, 12 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 20 days, 25 days, 1 month, 2 months, 3 months, 4 months, 5 months, 7 months, 9 months, 11 months, 1 year, 2 years, 4 years, 5 years, 10 years, 15 years, 20 years or longer of prior to receiving a classification obtained by the methods disclosed herein, such as detection of subAR.

Diagnosis refers to methods of estimating or determining whether or not a patient is suffering from a given disease or condition or severity of the condition. Diagnosis does not require ability to determine the presence or absence of a particular disease with 100% accuracy, or even that a given course or outcome is more likely to occur than not. Instead, the “diagnosis” refers to an increased probability that a certain disease or condition is present in the subject compared to the probability before the diagnostic test was performed. Similarly, a prognosis signals an increased probability that a given course or outcome will occur in a patient relative to the probability before the prognostic test.

A probe or polynucleotide probe is a nucleic acid capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation, thus forming a duplex structure. The probe binds or hybridizes to a “probe binding site.” A probe can include natural (e.g., A, G, C, U, or T) or modified bases (e.g., 7-deazaguanosine, inosine). A probe can be an oligonucleotide and may be a single-stranded DNA or RNA. Polynucleotide probes can be synthesized or produced from naturally occurring polynucleotides. In addition, the bases in a probe can be joined by a linkage other than a phosphodiester bond, so long as it does not interfere with hybridization. Thus, probes can include, for example, peptide nucleic acids in which the constituent bases are joined by peptide bonds rather than phosphodiester linkages (see, e.g., Nielsen et al., Science 254, 1497-1500 (1991)). Some probes can have leading and/or trailing sequences of noncomplementarity flanking a region of complementarity.

A perfectly matched probe has a sequence perfectly complementary to a particular target sequence. The probe is typically perfectly complementary to a portion (subsequence) of a target sequence. The term “mismatch probe” refer to probes whose sequence is deliberately selected not to be perfectly complementary to a particular target sequence.

The term “isolated,” “purified” or “substantially pure” means an object species (e.g., a nucleic acid sequence described herein or a polypeptide encoded thereby) has been at least partially separated from the components with which it is naturally associated.

Differential expression refers to a statistically significant difference in expression levels of a gene between two populations of samples (e.g., samples with and without SCAR). The expression levels can differ for example by at least a factor of 1.5 or 2 between such populations of samples. Differential expression includes genes that are expressed in one population and are not expressed (at least at detectable levels) in the other populations. Unique expression refers to detectable expression in one population and undetectable expression (i.e., insignificantly different from background) in the other population using the same technique (e.g., as in the present example for detection).

Control populations for comparison with populations undergoing SCAR are usually referred to as being without SCAR. In some embodiments, such a control population also means subjects without acute kidney rejection.

Hybridization reactions are preferably performed under stringent conditions in which probes or primers hybridize to their intended target with which they have perfect complementarity and not to or at least to a reduced extent to other targets. An example of stringent hybridization conditions are hybridization in 6×sodium chloride/sodium citrate (SSC) at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 50° C., 55° C., 60° C., and even more or 65° C.

Statistical significance means p<0.05 or <0.01 or even <0.001 level.

II. Genes in Profiles

Table 4 lists more than 2000 probesets with corresponding genes whose expression changes significantly between kidney transplant patients undergoing SCAR compared with patients not undergoing rejection (TX) and also patients undergoing acute rejection (AR) (3-way prediction). The columns in the table have the following meanings: column 1 is a number assigned to a gene, column 2 is an Affymetrix number indicating a set of probes suitable for measuring expression of the gene, column 3 is a gene name (recognized names of HUGO or similar bodies are used when available), column 4 is a further description of the gene, column 5 is a raw uncorrected measure of the statistical significance of change in gene expression between the above patient populations, column 6 corresponds to a value of the statistical significance after correction for the false discovery rate (FDR), and columns 7-9 respectively show mean expression levels of AR, SCAR, and TX patients. Table 2 similarly provides a subset of 200 preferred genes from Table 4. Table 3 provides similar information for a subset of genes from Table 4 which show differential expression between kidney transplant patients undergoing SCAR with kidney transplant patients not undergoing rejection (TX) (2-way prediction).

The genes referred to in the above tables are human genes. In some methods, species variants or homologs of these genes are used in a non-human animal model. Species variants are the genes in different species having greatest sequence identity and similarity in functional properties to one another. Many species variants of the above human genes are listed in the Swiss-Prot database.

To identify differentially expressed genes, raw gene expression levels are comparable between different genes in the same sample but not necessarily between different samples. As noted above, values given for gene expression levels can be normalized so that values for particular genes are comparable within and between the populations being analyzed. The normalization eliminates or at least reduces to acceptable levels any sample to sample differences arising from factors other than SCAR (e.g. differences in overall transcription levels of patients due to general state of health and differences in sample preparation or nucleic acid amplification between samples). The normalization effectively applies a correction factor to the measured expression levels from a given array such that a profile of many expression levels in the array are the same between different patient samples. Software for normalizing overall expression patterns between different samples is both commercially and publically available (e.g., XRAY from Biotique Systems or BRB ArrayTools from the National Cancer Institute). After applying appropriate normalizing factors to the measured expression value of a particular gene in different samples, an average or mean value of the expression level is determined for the samples in a population. The average or mean values between different populations are then compared to determine whether expression level has changed significantly between the populations. The changes in expression level indicated for a given gene represent the relative expression level of that gene in samples from a population of individuals with a defined condition (e.g., transplant patients with SCAR) relative to samples from a control population (kidney transplant patients not undergoing rejection). In some cases, the population of individuals with a defined condition may be transplant recipients with SCAR identified by acute cellular rejection (AR) on a surveillance protocol biopsy (SCAR-normal creatinine) and the control population is patients (e.g., transplant recipients) with normal protocol surveillance biopsies (TX-normal creatine). In some cases, this SCAR gene expression profile is compared with a previously validated peripheral blood profile/signature for patients with clinical acute cellular rejection (CAR-elevated creatinine), such as a CAR identified with a “for cause” biopsy.

Similar principles apply in normalizing gene expression levels at the mRNA and protein levels. Comparisons between populations are made at the same level (e.g., mRNA levels in one population are compared with mRNA levels in another population or protein levels in one population with protein levels in another population).

III. Subject Populations

The methods are suitable for detecting subAR or SCAR in transplant patients, and are particularly useful for detecting subAR or SCAR without relying on a histologic analysis or obtaining a biopsy. Subclinical rejection (SCR) including subAR generally refers to histologically defined acute rejection—particularly, histologically defined acute cellular rejection—characterized by tubule-interstitial mononuclear infiltration identified from a biopsy specimen, but without concurrent functional deterioration (variably defined as a serum creatinine not exceeding 10%, 20% or 25% of baseline values). Some instances of SCR or subAR may represent the beginning or conclusion of an alloimmune infiltrate diagnosed fortuitously by protocol sampling, and some episodes of clinical rejection may actually represent subAR or SCAR with an alternative cause of functional decline, such as concurrent calcineurin inhibitor (CNI) nephrotoxicity A subAR subject may have normal and stable organ function. For example, a subAR subject typically shows normal and/or stable serum creatinine levels or eGFR. SubAR is usually diagnosed through biopsies that are taken at a fixed time after transplantation (e.g., protocol biopsies or serial monitoring biopsies) which are not driven by clinical indications but rather by standards of care. The biopsies may be analyzed histologically in order to detect the subAR. SubAR may be subclassified by some into acute subAR (subAR) or a milder form called borderline subAR (suspicious for acute rejection) based on the biopsy histology). A failure to recognize, diagnose and treat subclinical AR before significant tissue injury has occurred and the transplant shows clinical signs of dysfunction could be a major cause of irreversible organ damage. Moreover, a failure to recognize a chronic, subclinical immune-mediated organ damage and a failure to make appropriate changes in immunosuppressive therapy to restore a state of effective immunosuppression in that patient could contribute to late organ transplant failure. The methods disclosed herein can reduce or eliminate these and other problems associated with transplant rejection or failure.

In some instances, a normal serum creatinine level and/or a normal estimated glomerular filtration rate (eGFR) may indicate or correlate with healthy transplant (TX) or subclinical rejection (SCAR). For example, typical reference ranges for serum creatinine are 0.5 to 1.0 mg/dL for women and 0.7 to 1.2 mg/dL for men, though typical kidney transplant patients have creatinines in the 0.8 to 1.5 mg/dL range for women and 1.0 to 1.9 mg/dL range for men. This may be due to the fact that most kidney transplant patients have a single kidney. In some instances, the trend of serum creatinine levels over time can be used to evaluate the recipient's organ function. This is why it may be important to consider both “normal” serum creatinine levels and “stable” serum creatinine levels in making clinical judgments, interpreting testing results, deciding to do a biopsy or making therapy change decisions including changing immunosuppressive drugs. For example, the transplant recipient may show signs of a transplant dysfunction or rejection as indicated by an elevated serum creatinine level and/or a decreased eGFR. In some instances, a transplant subject with a particular transplant condition (e.g., AR, ADNR) may have an increase of a serum creatinine level of at least 0.1 mg/dL, 0.2 mg/dL, 0.3 mg/dL, 0.4 mg/dL, 0.5 mg/dL, 0.6 mg/dL, 0.7 mg/dL 0.8 mg/dL, 0.9 mg/dL, 1.0 mg/dL, 1.1 mg/dL, 1.2 mg/dL, 1.3 mg/dL, 1.4 mg/dL, 1.5 mg/dL, 1.6 mg/dL, 1.7 mg/dL, 1.8 mg/dL, 1.9 mg/dL, 2.0 mg/dL, 2.1 mg/dL, 2.2 mg/dL, 2.3 mg/dL, 2.4 mg/dL, 2.5 mg/dL, 2.6 mg/dL, 2.7 mg/dL, 2.8 mg/dL, 2.9 mg/dL, 3.0 mg/dL, 3.1 mg/dL, 3.2 mg/dL, 3.3 mg/dL, 3.4 mg/dL, 3.5 mg/dL, 3.6 mg/dL, 3.7 mg/dL, 3.8 mg/dL, 3.9 mg/dL, or 4.0 mg/dL. In some instances, a transplant subject with a certain transplant condition (e.g., AR, ADNR) may have an increase of a serum creatinine level of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% from baseline. In some instances, a transplant subject with a certain transplant condition (e.g., AR, ADNR, etc.) may have an increase of a serum creatinine level of at least 1-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, or 10-fold from baseline. In some cases, the increase in serum creatinine (e.g., any increase in the concentration of serum creatinine described herein) may occur over about 0.25 days, 0.5 days, 0.75 days, 1 day, 1.25 days, 1.5 days, 1.75 days, 2.0 days, 3.0 days, 4.0 days, 5.0 days, 6.0 days, 7.0 days, 8.0 days, 9.0 days, 10.0 days, 15 days, 30 days, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months, or more. In some instances, a transplant subject with a particular transplant condition (e.g., AR, ADNR, CAN, etc.) may have a decrease of a eGFR of at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% from baseline. In some cases, the decrease in eGFR may occur over 0.25 days, 0.5 days, 0.75 days, 1 day, 1.25 days, 1.5 days, 1.75 days, 2.0 days, 3.0 days, 4.0 days, 5.0 days, 6.0 days, 7.0 days, 8.0 days, 9.0 days, 10.0 days, 15 days, 30 days, 1 month, 2 months, 3 months, 4 months, 5 months, or 6 months, or more. In some instances, diagnosing, predicting, or monitoring the status or outcome of a transplant or condition comprises determining transplant recipient-specific baselines and/or thresholds. The methods are particularly useful on human subjects who have undergone a kidney transplant although can also be used on subjects who have undergone other types of transplant (e.g., heart, liver, lungs, stem cell) or on non-humans who have undergone kidney or other transplant. As detailed herein, the methods can be employed to distinguish transplant patients who (1) have or are at risk of having acute rejection (AR), (2) have or are at risk of having SCAR, and (3) have normal functional transplant (TX). In some other applications, the methods are more practically employed to distinguish patients who either are either transplant excellent (TX) or have existing SCAR (or risk of developing SCAR). This is because patients with acute rejections can usually be easily diagnosed via conventional assays, e.g., those based on serum creatinine level.

As such, the methods of the invention can be used in patients who have normal and stable creatinine levels to diagnose or prognose hidden SCAR without depending on invasive biopsies. In some cases, the serum creatinine levels of the transplant recipient are stable over at least 10 days, 20 days, 30 days, 40 days, 50 days, 60 days, 90 days, 100 days, 200 days, 300 days, 400 days or longer. In some cases, the transplant recipient has a serum creatinine level of less than 0.2 mg/dL, less than 0.3 mg/dL, less than 0.4 mg/dL, less than 0.5 mg/dL, less than 0.6 mg/dL, less than 0.7 mg/dL less than 0.8 mg/dL, less than 0.9 mg/dL, less than 1.0 mg/dL, less than 1.1 mg/dL, less than 1.2 mg/dL, less than 1.3 mg/dL, 1.4 mg/dL, less than 1.5 mg/dL, less than 1.6 mg/dL, less than 1.7 mg/dL, less than 1.8 mg/dL, less than 1.9 mg/dL, less than 2.0 mg/dL, less than 2.1 mg/dL, less than 2.2 mg/dL, less than 2.3 mg/dL, less than 2.4 mg/dL, less than 2.5 mg/dL, less than 2.6 mg/dL, less than 2.7 mg/dL, less than 2.8 mg/dL, less than 2.9 mg/dL, or less than 3.0 mg/dL.

As mentioned, often the methods provided herein can be used to detect subAR as opposed to a condition such as acute rejection (AR), or to predict whether the subject is at risk of having AR. Acute rejection (AR) or clinical acute rejection may occur when transplanted tissue is rejected by the recipient's immune system, which damages or destroys the transplanted tissue unless immunosuppression is achieved. T-cells, B-cells and other immune cells as well as possibly antibodies of the recipient may cause the graft cells to lyse or produce cytokines that recruit other inflammatory cells, eventually causing necrosis of allograft tissue. In some instances, AR may be diagnosed by a biopsy of the transplanted organ. In the case of kidney transplant recipients, AR may be associated with an increase in serum creatinine levels. The treatment of AR may include using immunosuppressive agents, corticosteroids, polyclonal and monoclonal antibodies, engineered and naturally occurring biological molecules, and antiproliferatives. AR more frequently occurs in the first three to 12 months after transplantation but there is a continued risk and incidence of AR for the first five years post transplant and whenever a patient's immunosuppression becomes inadequate for any reason for the life of the transplant.

The methods herein may also be used to distinguish between a kidney transplant patient with subAR and a normally functioning kidney transplant. Typically, when the patient does not exhibit symptoms or test results of organ dysfunction or rejection, the transplant is considered a normal functioning transplant (TX: Transplant eXcellent). An unhealthy transplant recipient may exhibit signs of organ dysfunction and/or rejection (e.g., an increasing serum creatinine

Regardless of the specific subject population, gene expression levels in the patients can be measured, for example, within, one month, three months, six months, one year, two years, five years or ten years after a kidney transplant. In some methods, gene expression levels are determined at regular intervals, e.g., every 3 months, 6 months or every year posttransplant, either indefinitely, or until evidence of SCAR is observed, in which case the frequency of monitoring is sometimes increased. In some methods, baseline values of expression levels are determined in a subject before a kidney transplant in combination with determining expression levels at one or more time points thereafter. Similar methods can be practiced in non-human species, in which cases, the expression levels measured are the species equivalent of the human genes referenced above.

IV. Methods of Measuring Profiles

Samples

The preferred sample type for analysis is a blood sample, which refers to whole blood or fractions thereof, such as plasma, or lymphocytes. Other samples that can be analyzed include urine, feces, saliva, and a kidney biopsy. The samples are typically isolated from a subject, particularly as a peripheral blood sample, and not returned to the subject. The analytes of interests in the samples can be analyzed with or without further processing of the sample, such as purification and amplification. Samples not requiring biopsy to obtain, particularly peripheral blood, are preferred. However, a sample may be any material containing tissues, cells, nucleic acids, genes, gene fragments, expression products, polypeptides, exosomes, gene expression products, or gene expression product fragments of a subject to be tested. In some cases, the sample is from a single patient. In some cases, the method comprises analyzing multiple samples at once, e.g., via massively parallel sequencing.

The sample is preferably blood. In some cases, the sample comprises whole blood, plasma, peripheral blood lymphocytes (PBLs), peripheral blood mononuclear cells (PBMCs), serum, T cells, B Cells, CD3 cells, CD8 cells, CD4 cells, or other immune cells.

The methods, kits, and systems disclosed herein may comprise specifically detecting, profiling, or quantitating molecules (e.g., nucleic acids, DNA, RNA, polypeptides, etc.) that are within the biological samples. In some instances, genomic expression products, including RNA, or polypeptides, may be isolated from the biological samples. In some cases, nucleic acids, DNA, RNA, polypeptides may be isolated from a cell-free source. In some cases, nucleic acids, DNA, RNA, polypeptides may be isolated from cells derived from the transplant recipient.

The sample may be obtained using any method known to the art that can provide a sample suitable for the analytical methods described herein. The sample may be obtained by a non-invasive method such as a throat swab, buccal swab, bronchial lavage, urine collection, scraping of the skin or cervix, swabbing of the cheek, saliva collection, feces collection, menses collection, or semen collection.

The sample may be obtained by a minimally-invasive method such as a blood draw. The sample may be obtained by venipuncture. In other instances, the sample is obtained by an invasive procedure including but not limited to: biopsy, alveolar or pulmonary lavage, or needle aspiration. The method of biopsy may include surgical biopsy, incisional biopsy, excisional biopsy, punch biopsy, shave biopsy, or skin biopsy. The sample may be formalin fixed sections. The method of needle aspiration may further include fine needle aspiration, core needle biopsy, vacuum assisted biopsy, or large core biopsy. In some embodiments, multiple samples may be obtained by the methods herein to ensure a sufficient amount of biological material. In some instances, the sample is not obtained by biopsy. In some instances, the sample is not a kidney biopsy.

Expression Profiles

For prognosis or diagnosis of SCAR in patients as opposed to both patients with acute rejection (AR) and patients without rejection (TX), the profiles can contain genes selected from at least one of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, and 18, for example, from Table 2. In some other methods, when the prognosis or diagnosis is intended to distinguish between patients having or at risk of developing SCAR and patients without rejection (TX), the genes in the profiles can be selected from at least one of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, and 18, for example, from Table 3.

Expression profiles are preferably measured at the nucleic acid level, meaning that levels of mRNA or nucleic acid derived therefrom (e.g., cDNA or cRNA). An expression profile refers to the expression levels of a plurality of genes in a sample. A nucleic acid derived from mRNA means a nucleic acid synthesized using mRNA as a template. Methods of isolation and amplification of mRNA are well known in the art, e.g., as described in WO 97/10365, WO 97/27317, Chapter 3 of Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation, (P. Tijssen, ed.) Elsevier, N.Y. (1993). If mRNA or a nucleic acid therefrom is amplified, the amplification is performed under conditions that approximately preserve the relative proportions of mRNA in the original samples, such that the levels of the amplified nucleic acids can be used to establish phenotypic associations representative of the mRNAs.

A variety of approaches are available for determining mRNA levels including probe arrays and quantitative PCR. A number of distinct array formats are available. Some arrays, such as an Affymetrix HG-U133 PM microarray or other Affymetrix GeneChip® array, have different probes occupying discrete known areas of a contiguous support. Exemplary microarrays include but are not limited to the Affymetrix Human Genome U133 Plus 2.0 GeneChip or the HT HG-U133+ PM Array Plate.

Other arrays, such as arrays from Illumina, have different probes attached to different particles or beads. In such arrays, the identity of which probe is attached to which particle or beads is usually determinable from an encoding system. The probes can be oligonucleotides. In such case, typically several match probes are included with perfect complementarity to a given target mRNA together, optionally together with mismatch probes differing from the match probes are a known number of oligonucleotides (Lockhart, et al., Nature Biotechnology 14:1675-1680 (1996); and Lipschutz, et al., Nature Genetics Supplement 21: 20-24, 1999). Other arrays including full length cDNA sequences with perfect or near perfect complementarity to a particular cDNA (Schena et al. (Science 270:467-470 (1995); and DeRisi et al. (Nature Genetics 14:457-460 (1996)). Such arrays can also include various control probes, such as a probe complementarity with a house keeping gene likely to be expressed in most samples. Regardless of the specifics of array design, an array contains one or more probes either perfectly complementary to a particular target mRNA or sufficiently complementarity to the target mRNA to distinguish it from other mRNAs in the sample, and the presence of such a target mRNA can be determined from the hybridization signal of such probes, optionally by comparison with mismatch or other control probes included in the array. Typically, the target bears a fluorescent label, in which case hybridization intensity can be determined by, for example, a scanning confocal microscope in photon counting mode. Appropriate scanning devices are described by e.g., U.S. Pat. Nos. 5,578,832, and 5,631,734. The intensity of labeling of probes hybridizing to a particular mRNA or its amplification product provides a raw measure of expression level.

In other methods, expression levels are determined by so-called “real time amplification” methods also known as quantitative PCR or Taqman (see, e.g., U.S. Pat. No. 5,210,015 to Gelfand, U.S. Pat. No. 5,538,848 to Livak, et al., and U.S. Pat. No. 5,863,736 to Haaland, as well as Heid, C. A., et al., Genome Research, 6:986-994 (1996); Gibson, U. E. M, et al., Genome Research 6:995-1001 (1996); Holland, P. M., et al., Proc. Natl. Acad. Sci. USA 88:7276-7280, (1991); and Livak, K. J., et al., PCR Methods and Applications 357-362 (1995)). The basis for this method of monitoring the formation of amplification product is to measure continuously PCR product accumulation using a dual-labeled fluorogenic oligonucleotide probe. The probe used in such assays is typically a short (ca. 20-25 bases) polynucleotide that is labeled with two different fluorescent dyes. The 5′ terminus of the probe is typically attached to a reporter dye and the 3′ terminus is attached to a quenching dye The probe is designed to have at least substantial sequence complementarity with a site on the target mRNA or nucleic acid derived from. Upstream and downstream PCR primers that bind to flanking regions of the locus are also added to the reaction mixture. When the probe is intact, energy transfer between the two fluorophors occurs and the quencher quenches emission from the reporter. During the extension phase of PCR, the probe is cleaved by the 5′ nuclease activity of a nucleic acid polymerase such as Taq polymerase, thereby releasing the reporter from the polynucleotide-quencher and resulting in an increase of reporter emission intensity which can be measured by an appropriate detector. The recorded values can then be used to calculate the increase in normalized reporter emission intensity on a continuous basis and ultimately quantify the amount of the mRNA being amplified. mRNA levels can also be measured without amplification by hybridization to a probe, for example, using a branched nucleic acid probe, such as a QuantiGene® Reagent System from Panomics.

In certain preferred embodiments, the expression level of the gene products (e.g., RNA) is determined by sequencing, such as by RNA sequencing or by DNA sequencing (e.g., of cDNA generated from reverse-transcribing RNA (e.g., mRNA) from a sample). Sequencing may be performed by any available method or technique. Sequencing methods may include: Next Generation sequencing, high-throughput sequencing, pyrosequencing, classic Sangar sequencing methods, sequencing-by-ligation, sequencing by synthesis, sequencing-by-hybridization, RNA-Seq (Illumina), Digital Gene Expression (Helicos), next generation sequencing, single molecule sequencing by synthesis (SMSS) (Helicos), Ion Torrent Sequencing Machine (Life Technologies/Thermo-Fisher), massively-parallel sequencing, clonal single molecule Array (Solexa), shotgun sequencing, Maxim-Gilbert sequencing, primer walking, and any other sequencing methods known in the art.

Measuring gene expression levels may comprise reverse transcribing RNA (e.g., mRNA) within a sample in order to produce cDNA. The cDNA may then be measured using any of the methods described herein (e.g., PCR, digital PCR, qPCR, microarray, SAGE, blotting, sequencing, etc.).

Alternatively or additionally, expression levels of genes can be determined at the protein level, meaning that levels of proteins encoded by the genes discussed above are measured. Several methods and devices are well known for determining levels of proteins including immunoassays such as described in e.g., U.S. Pat. Nos. 6,143,576; 6,113,855; 6,019,944; 5,985,579; 5,947,124; 5,939,272; 5,922,615; 5,885,527; 5,851,776; 5,824,799; 5,679,526; 5,525,524; and 5,480,792. These assays include various sandwich, competitive, or non-competitive assay formats, to generate a signal that is related to the presence or amount of an protein analyte of interest. Any suitable immunoassay may be utilized, for example, lateral flow, enzyme-linked immunoassays (ELISA), radioimmunoassays (RIAs), competitive binding assays, and the like. Numerous formats for antibody arrays have been described proposed employing antibodies. Such arrays typically include different antibodies having specificity for different proteins intended to be detected. For example, usually at least one hundred different antibodies are used to detect one hundred different protein targets, each antibody being specific for one target. Other ligands having specificity for a particular protein target can also be used, such as the synthetic antibodies disclosed in WO/2008/048970. Other compounds with a desired binding specificity can be selected from random libraries of peptides or small molecules. U.S. Pat. No. 5,922,615 describes a device that utilizes multiple discrete zones of immobilized antibodies on membranes to detect multiple target antigens in an array. U.S. Pat. Nos. 5,458,852, 6,019,944, 6,143,576. Microtiter plates or automation can be used to facilitate detection of large numbers of different proteins. Protein levels can also be determined by mass spectrometry as described in the examples.

The selection of genes for determination of expression levels depends on the particular application. In general, the genes are selected from one of the tables indicated above as appropriate for the application. In some methods, expression levels of at least 2, 3, 4, 5, 10, 20, 25, 50, 100, 150, 250 (e.g. 100-250) genes shown in any of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18 are determined. In some methods, expression levels of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 200, 300, 400, 500, 1000 or more genes found in Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18 are determined. In some methods, genes are selected such that genes from several different pathways are represented. The genes within a pathway tend to be expressed in a coordinated expression whereas genes from different pathways tend to be expressed more independently. Thus, changes in expression based on the aggregate changes of genes from different pathways can have greater statistical significance than aggregate changes of genes within a pathway. In some cases, expression levels of the top 5, top 10, top 15, top 20, top 25, top 30, top 35, top 40, top 45, top 50, top 55, top 60, top 65, top 70, top 75, top 80, top 85, top 90, top 95, top 100, top 150, top 200, top 250 or top 300 genes listed in Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18 are determined.

Expression levels of the present genes and/or proteins can be combined with or without determination of expression levels of any other genes or proteins of interest (e.g., genes or proteins associated with rejection of kidneys or other organs in WO 2007/104537, WO 2009/060035), Anglicheau et al., PNAS 106, 5330-5335 (2009)) and references, 16, 20, 21, 22, 23, 25, 26, 37 and 39. In some methods, the genes in the expression profiles to be measured do not include at least one or all of the genes encoding urinary granzyme A, granzyme B, glyceraldehyde 3-phospate dehydrogenase (GAPDH), perforin, Fas ligand, CXCL9, CXCL10, and other proteins involved in patients' cytolytic attack against the transplant.

Regardless of the format adopted, the present methods can (but need not) be practiced by detection expression levels of a relatively small number of genes or proteins compared with the whole genome level expression analysis described in the Examples. In some methods, the total number of genes whose expression levels are determined is less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3. In some methods, the total number of genes whose expression level is determined is 100-1500, 100-250, 500-1500 or 750-1250. In some methods, the total number of proteins whose expression levels are determined is less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3. In some methods, the total number of proteins whose expression level is determined is 100-1500, 100-250, 500-1500 or 750-1250. Correspondingly, when an array form is used for detection of expression levels, the array includes probes or probes sets for less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3 genes. Thus, for example, an Affymetrix GeneChip® expression monitoring array contains a set of about 20-50 oligonucleotide probes (half match and half-mismatch) for monitoring each gene of interest. Such an array design would include less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3 such probes sets for detecting less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3 genes. By further example, an alternative array including one cDNA for each gene whose expression level is to be detected would contain less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3 such cDNAs for analyzing less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3 genes. By further example, an array containing a different antibody for each protein to be detected would containing less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3 different antibodies for analyzing less than 5000, 1000, 500, 200, 100, 50, 25, 10, 5 or 3 gene products.

As described herein, in some cases the methods involve obtaining or analyzing a biopsy sample (e.g., kidney biopsy). The biopsy sample may be used for different purposes including to develop an expression profile signature. In some cases, an analysis described herein may be performed on a biopsy obtained from a transplant recipient in order to predict, monitor, or detect SCAR in the transplant recipient. In cases where biopsies are obtained, the biopsies may be processed included by placing the samples in a vessel (e.g., tube, PAX tube, vial, microfuge tube, etc.) and storing them at a specific location such as a biorepository. The samples may also be processed by treatment with a specific agent, such as an agent that prevents nucleic acid degradation or deterioration, particularly an agent that protects RNA (e.g., RNALater) or DNA. In some cases, biopsies subjected to histologic analysis including staining (e.g., hematoxylin and eosin (H&E) stain) probing (e.g., a probe attached to a dye, a probe attached to a fluorescent label). In some cases, the staining (e.g., H&E) may be analyzed by a blinded physician such as a blinded pathologist, or at least two blinded pathologists, using criteria such as BANFF criteria. In some cases, a histologic diagnosis is reconciled with laboratory data and clinical courses by one or more clinicians (e.g., at least two clinicians) prior to biomarker analyses.

V. Analysis of Expression Levels

Analysis of expression levels initially provides a measurement of the expression level of each of several individual genes. The expression level can be absolute in terms of a concentration of an expression product, or relative in terms of a relative concentration of an expression product of interest to another expression product in the sample. For example, relative expression levels of genes can be expressed with respect to the expression level of a house-keeping gene in the sample. Relative expression levels can also be determined by simultaneously analyzing differentially labeled samples hybridized to the same array. Expression levels can also be expressed in arbitrary units, for example, related to signal intensity.

The individual expression levels, whether absolute or relative, can be converted into values or other designations providing an indication of presence or risk of SCAR by comparison with one or more reference points. Preferably, genes in Table 2 and/or one or more of Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18 are used for such analysis. The reference points can include a measure of an average or mean expression level of a gene in subjects having had a kidney transplant without SCAR, an average or mean value of expression levels in subjects having had a kidney transplant with SCAR, and/or an average/mean value of expression levels in subjects having had a kidney transplant with acute rejection. The reference points can also include a scale of values found in kidney transplant patients including patients having and not having SCAR. The reference points can also or alternatively include a reference value in the subject before kidney transplant, or a reference value in a population of patients who have not undergone kidney transplant. Such reference points can be expressed in terms of absolute or relative concentrations of gene products as for measured values in a sample.

For comparison between a measured expression level and reference level(s), the measured level sometimes needs to be normalized for comparison with the reference level(s) or vice versa. The normalization serves to eliminate or at least minimize changes in expression level unrelated to SCAR (e.g., from differences in overall health of the patient or sample preparation). Normalization can be performed by determining what factor is needed to equalize a profile of expression levels measured from different genes in a sample with expression levels of these genes in a set of reference samples from which the reference levels were determined. Commercial software is available for performing such normalizations between different sets of expression levels.

Comparison of the measured expression level of a gene with one or more of the above reference points provides a value (i.e., numerical) or other designation (e.g., symbol or word(s)) of presence or susceptibility to SCAR. In some methods, a binary system is used; that is a measured expression level of a gene is assigned a value or other designation indicating presence or susceptibility to SCAR or lack thereof without regard to degree. For example, the expression level can be assigned a value of 1 to indicate presence or susceptibility to SCAR and −1 to indicate absence or lack of susceptibility to SCAR. Such assignment can be based on whether the measured expression level is closer to an average or mean level in kidney transplant patients having or not having SCAR. In other methods, a ternary system is used in which an expression level is assigned a value or other designation indicating presence or susceptibility to SCAR or lack thereof or that the expression level is uninformative. Such assignment can be based on whether the expression level is closer to the average or mean level in kidney transplant patient undergoing SCAR, closer to an average or mean level in kidney transplant patients lacking SCAR or intermediate between such levels. For example, the expression level can be assigned a value of +1, −1 or 0 depending on whether it is closer to the average or mean level in patients undergoing SCAR, is closer to the average or mean level in patients not undergoing SCAR or is intermediate. In other methods, a particular expression level is assigned a value on a scale, where the upper level is a measure of the highest expression level found in kidney transplant patients and the lowest level of the scale is a measure of the lowest expression level found in kidney transplant patients at a defined time point at which patients may be susceptible to SCAR (e.g., one year post transplant). Preferably, such a scale is normalized scale (e.g., from 0-1) such that the same scale can be used for different genes. Optionally, the value of a measured expression level on such a scale is indicated as being positive or negative depending on whether the upper level of the scale associates with presence or susceptibility to SCAR or lack thereof. It does not matter whether a positive or negative sign is used for SCAR or lack thereof as long as the usage is consistent for different genes.

Values or other designation can also be assigned based on a change in expression level of a gene relative to a previous measurement of the expression level of gene in the same patient. Here as elsewhere expression level of a gene can be measured at the protein or nucleic acid level. Such a change can be characterized as being toward, away from or neutral with respect to average or mean expression levels of the gene in kidney transplant patients undergoing or not undergoing SCAR. For example, a gene whose expression level changes toward an average or mean expression level in kidney transplant patients undergoing SCAR can be assigned a value of 1 and a gene whose express level changes way from an average or mean expression level in kidney transplant patients undergoing SCAR and toward an average or mean expression level in kidney transplant patients not undergoing SCAR can be assigned a value −1. Of course, more sophisticated systems of assigning values are possible based on the magnitude of changes in expression of a gene in a patient.

Having determined values or other designations of expression levels of individual genes providing an indication of presence or susceptibility to subAR (or SCAR) or lack thereof, the values or designations may be combined to provide an aggregate value for all of the genes in the signature being analyzed. If each gene is assigned a score of +1 if its expression level indicates presence or susceptibility to subAR (or SCAR) and −1 if its expression level indicates absence or lack of susceptibility to subAR and optionally zero if uninformative, the different values can be combined by addition. The same approach can be used if each gene is assigned a value on the same normalized scale and assigned as being positive or negative depending whether the upper point of the scale is associate with presence or susceptibility to subAR or lack thereof. In some cases, the signal intensity for each gene is obtained and used to compute a score. The score may be obtained by adding up the values for the upregulated genes to obtain an upregulated gene value and adding up the values of the downregulated genes to obtain a downregulated gene value; the downregulated gene value may be compared with the upregulated value (e.g., by calculating a ratio) to determine the score. Other methods of combining values for individual markers of disease into a composite value that can be used as a single marker are described in US20040126767 and WO/2004/059293. In some cases, the score may be used to evaluate severity of a transplant condition, such as by comparing the score with a score normally associated with subAR. In some cases, the score may be used to monitor a subject transplant recipient over time. In such case, scores at a plurality of timepoints maybe compared in order to assess the relative condition of the subject. For example, if the subject's score rises over time, that may indicate that the subject has subAR and that his or her condition is worsening over time.

Sample Data

The data pertaining to the sample may be compared to data pertaining to one or more control samples, which may be samples from the same patient at different times. In some cases, the one or more control samples may comprise one or more samples from healthy subjects, unhealthy subjects, or a combination thereof. The one or more control samples may comprise one or more samples from healthy subjects, subjects suffering from transplant dysfunction with no rejection, subjects suffering from transplant rejection, or a combination thereof. The healthy subjects may be subjects with normal transplant function. The data pertaining to the sample may be sequentially compared to two or more classes of samples. The data pertaining to the sample may be sequentially compared to three or more classes of samples. The classes of samples may comprise control samples classified as being from subjects with normal transplant function, control samples classified as being from subjects suffering from transplant dysfunction with no rejection, control samples classified as being from subjects suffering from transplant rejection, or a combination thereof

Classifiers

The methods include using a trained classifier or algorithm to analyze sample data, particularly to detect subAR. In some instances, the expression levels from sample are used to develop or train an algorithm or classifier provided herein. In some instances, gene expression levels are measured in a sample from a transplant recipient (or a healthy or transplant excellent control) and a classifier or algorithm (e.g., trained algorithm) is applied to the resulting data in order to detect, predict, monitor, or estimate the risk of a transplant condition (e.g., subAR).

Training of multi-dimensional classifiers (e.g., algorithms) may be performed using numerous samples. For example, training of the multi-dimensional classifier may be performed using at least about 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200 or more samples. In some cases, training of the multi-dimensional classifier may be performed using at least about 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 350, 400, 450, 500 or more samples. In some cases, training of the multi-dimensional classifier may be performed using at least about 525, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 2000 or more samples.

Further disclosed herein are classifier sets and methods of producing one or more classifier sets. The classifier set may comprise one or more genes, particularly genes from Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. In some cases, the classifier set may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 150, 200, 300 or more genes from Tables 2, 3, 4, 7, 8, 11, 12, 14, 15, 17, or 18. Disclosed herein is the use of a classification system comprises one or more classifiers. In some instances, the classifier is a 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10-way classifier. In some instances, the classifier is a 15-, 20-, 25-, 30-, 35-, 40-, 45-, 50-, 55-, 60-, 65-, 70-, 75-, 80-, 85-, 90-, 95-, or 100-way classifier. In some preferred embodiments, the classifier is a three-way classifier. In some embodiments, the classifier is a four-way classifier.

A two-way classifier may classify a sample from a subject into one of two classes. In some instances, a two-way classifier may classify a sample from an organ transplant recipient into one of two classes comprising subAR and normal transplant function (TX). In some instances, a three-way classifier may classify a sample from a subject into one of three classes. A three-way classifier may classify a sample from an organ transplant recipient into one of three classes comprising AR, subAR, and TX In some cases, the classifier may work by applying two or more classifiers sequentially. For example, the first classifier may classify AR+subAR and TX, which results in a set of samples that are classified either as (1) TX or (2) AR or subAR. In some cases, a second classifier capable of distinguishing between AR and subAR is applied to the samples classified as having AR or subAR in order to detect the subAR samples.

Classifiers and/or classifier probe sets may be used to either rule-in or rule-out a sample as healthy. For example, a classifier may be used to classify a sample as being from a healthy subject. Alternatively, a classifier may be used to classify a sample as being from an unhealthy subject. Alternatively, or additionally, classifiers may be used to either rule-in or rule-out a sample as transplant rejection. For example, a classifier may be used to classify a sample as being from a subject suffering from a transplant rejection. In another example, a classifier may be used to classify a sample as being from a subject that is not suffering from a transplant rejection. Classifiers may be used to either rule-in or rule-out a sample as transplant dysfunction with no rejection. For example, a classifier may be used to classify a sample as being from a subject with subAR. In another example, a classifier may be used to classify a sample as not being from a subject suffering from transplant dysfunction with no rejection.

The samples may be classified simultaneously. In some cases, the samples may be classified sequentially. The two or more samples may be classified at two or more time points. The samples may be obtained at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 100 or more time points. The two or more time points may be 1 day, 10 days, 30 days, 60 days, 100 days, 200 days, 1 year, 2 years or more apart.

Methods of simultaneous classifier-based analysis of one or more samples may comprise applying one or more algorithm to data from one or more samples to simultaneously produce one or more lists, wherein the lists comprise one or more samples classified as being from healthy subjects (e.g. subjects with a normal functioning transplant (TX)), unhealthy subjects, subjects suffering from transplant rejection, subjects suffering from transplant dysfunction, subjects with AR, or subjects withsubAR.

The methods, kits, and systems disclosed herein may comprise one or more algorithms or uses thereof. The one or more algorithms may be used to classify one or more samples from one or more subjects. The one or more algorithms may be applied to data from one or more samples. The data may comprise gene expression data. The data may comprise sequencing data. The data may comprise array hybridization data.

The methods disclosed herein may comprise assigning a classification to one or more samples from one or more subjects. Assigning the classification to the sample may comprise applying an algorithm to the expression level. In some cases, the gene expression levels are inputted to a trained algorithm for classifying the sample as one of the conditions comprising subAR, AR, TX, subAR+AR, or other condition.

The algorithm may provide a record of its output including a classification of a sample and/or a confidence level. In some instances, the output of the algorithm can be the possibility of the subject of having a condition, such as subAR. In some instances, the output of the algorithm can be the risk of the subject of having a condition, such as AR. In some instances, the output of the algorithm can be the possibility of the subject of developing into a condition in the future, such as AR.

The algorithm may be a trained algorithm. The algorithm may comprise a linear classifier. The linear classifier may comprise one or more linear discriminant analysis, Fisher's linear discriminant, Naïve Bayes classifier, Logistic regression, Perceptron, Support vector machine, or a combination thereof. The linear classifier may be a Support vector machine (SVM) algorithm.

The algorithm may comprise one or more linear discriminant analysis (LDA), Basic perceptron, Elastic Net, logistic regression, (Kernel) Support Vector Machines (SVM), Diagonal Linear Discriminant Analysis (DLDA), Golub Classifier, Parzen-based, (kernel) Fisher Discriminant Classifier, k-nearest neighbor, Iterative RELIEF, Classification Tree, Maximum Likelihood Classifier, Random Forest, Nearest Centroid, Prediction Analysis of Microarrays (PAM), k-medians clustering, Fuzzy C-Means Clustering, Gaussian mixture models, or a combination thereof. The algorithm may comprise a Diagonal Linear Discriminant Analysis (DLDA) algorithm. The algorithm may comprise a Nearest Centroid algorithm. The algorithm may comprise a Random Forest algorithm. The algorithm may comprise a Prediction Analysis of Microarrays (PAM) algorithm.

The methods disclosed herein may comprise use of one or more classifier equations. Classifying the sample may comprise a classifier equation. The classifier equation may be Equation 1:

${{\delta_{k}\left( x^{*} \right)} = {{\sum\limits_{i = 1}^{p}\frac{\left( {x_{i}^{*} - {\overset{\_}{x}}_{ik}^{\prime}} \right)^{2}}{\left( {s_{i} + s_{0}} \right)^{2}}} - {2\log \; \pi_{k}}}},$

wherein:

k is a number of possible classes;

δ_(k) may be the discriminant score for class k;

x_(i)* represents the expression level of gene i;

x* represents a vector of expression levels for all p genes to be used for classification drawn from the sample to be classified;

x′_(k) may be a shrunken centroid calculated from a training data and a shrinkage factor;

x′_(k) may be a component of x′_(k) corresponding to gene i;

s_(i) is a pooled within-class standard deviation for gene in the training data;

s₀ is a specified positive constant; and

π_(k) represents a prior probability of a sample belonging to class k.

Assigning the classification may comprise calculating a class probability. Calculating the class probability {circumflex over (p)}_(k)(x*) may be calculated by Equation 2:

${{\hat{p}}_{k}\left( x^{*} \right)} = {\frac{e^{{- \frac{1}{2}}{\delta_{k}{(x^{*})}}}}{\sum\limits_{l = 1}^{K}e^{{- \frac{1}{2}}{\delta_{l}{(x^{*})}}}}.}$

Assigning the classification may comprise a classification rule. The classification rule C(x*) may be expressed by Equation 3:

${C\left( x^{*} \right)} = {\underset{k \in {\{{1,K}\}}}{argmax}{{{\hat{p}}_{k}\left( x^{*} \right)}.}}$

VI. Diagnosis, Prognosis and Monitoring

The above described methods can provide a composite or aggregate value or other designation for a patient, which indicates whether the patient either has or is at enhanced risk of SCAR (or AR), or conversely does not have or is at reduced risk of SCAR (or AR). Risk is a relative term in which risk of one patient is compared with risk of other patients either qualitatively or quantitatively. For example, the value of one patient can be compared with a scale of values for a population of patients having undergone kidney transplant to determine whether the patient's risk relative to that of other patients. In general, diagnosis is the determination of the present condition of a patient (e.g., presence or absence of SCAR) and prognosis is developing future course of the patient (e.g., risk of developing SCAR in the future or likelihood of improvement in response to treatment); however, the analyses contemplated by these terms may overlap or even be the same. For example, the present methods alone do not necessarily distinguish between presence and enhanced risk of SCAR. However, these possibilities can be distinguished by additional testing.

The methods provided herein can help determine whether the patient either has or is at enhanced risk of subAR/SCAR (or AR) with a high degree of accuracy, sensitivity, and/or specificity. In some cases, the predictive accuracy (e.g., for predicting subAR/SCAR, for detecting subAR/SCAR, or for distinguishing SCAR versus TX, SCAR versus AR, AR versus TX, and/or any combination thereof) is greater than 75%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, or 99.99%. In some embodiments, the predictive accuracy is 100%. In some cases, the sensitivity (e.g., for detecting or predicting SCAR or for distinguishing SCAR versus TX, SCAR versus AR, AR versus TX, and/or any combination thereof) is greater than 75%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, or 99.99%. In some embodiments the sensitivity is 100%. In some cases, the specificity (e.g., for detecting or predicting SCAR or for distinguishing SCAR versus TX, SCAR versus AR, AR versus TX, and/or any combination thereof) is greater than 75%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, or 99.99%. In some cases, the specificity is 100%. In some cases, the positive predictive value (e.g., for detecting or predicting SCAR or for distinguishing SCAR versus TX, SCAR versus AR, AR versus TX, and/or any combination thereof) of the method is greater than 75%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, or 99.99%. In some cases the positive predictive value is 100%. The AUC after thresholding in any of the methods provided herein may be greater than 0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, 0.99, 0.995, or 0.999. Conversely, the method may predict or determine whether a transplant recipient does not have or is at reduced risk of SCAR (or AR). The negative predictive value (e.g., for predicting or determining that transplant recipient does not have SCAR or is at reduced risk for SCAR or for distinguishing SCAR versus TX, SCAR versus AR, AR versus TX, and/or any combination thereof) may be greater than 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 98.5%, 99.0%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, 99.95%, or 99.99%. In some cases, the negative predictive value is 100%.

In some instances, the methods, compositions, systems and kits described herein provide information to a medical practitioner that can be useful in making a therapeutic decision. Therapeutic decisions may include decisions to: continue with a particular therapy, modify a particular therapy, alter the dosage of a particular therapy, stop or terminate a particular therapy, altering the frequency of a therapy, introduce a new therapy, introduce a new therapy to be used in combination with a current therapy, or any combination of the above. In some instances, the results of diagnosing, predicting, or monitoring a condition of a transplant recipient may be useful for informing a therapeutic decision such as removal of the transplant. In some instances, the removal of the transplant can be an immediate removal. In other instances, the therapeutic decision can be a retransplant. Other examples of therapeutic regimen can include a blood transfusion in instances where the transplant recipient is refractory to immunosuppressive or antibody therapy.

If a patient is indicated as having or being at enhanced risk of subAR or SCAR, the physician can subject the patient to additional testing including performing a kidney biopsy or performing other analyses such as creatinine, BUN or glomerular filtration rate at increased frequency. Additionally or alternatively, the physician can change the treatment regime being administered to the patient. A change in treatment regime can include administering an additional or different drug to a patient, or administering a higher dosage or frequency of a drug already being administered to the patient. Many different drugs are available for treating rejection, such as immunosuppressive drugs used to treat transplant rejection calcineurin inhibitors (e.g., cyclosporine, tacrolimus), mTOR inhibitors (e.g., sirolimus and everolimus), anti-proliferatives (e.g., azathioprine, mycophenolic acid), corticosteroids (e.g., prednisolone and hydrocortisone) and antibodies (e.g., basiliximab, daclizumab, Orthoclone, anti-thymocyte globulin and anti-lymphocyte globulin).

Conversely, if the value or other designation of aggregate expression levels of a patient indicates the patient does not have or is at reduced risk of SCAR, the physician need not order further diagnostic procedures, particularly not invasive ones such as biopsy. Further, the physician can continue an existing treatment regime, or even decrease the dose or frequency of an administered drug.

In some methods, expression levels are determined at intervals in a particular patient (i.e., monitoring). Preferably, the monitoring is conducted by serial minimally-invasive tests such as blood draws; but, in some cases, the monitoring may also involve analyzing a kidney biopsy, either histologically or by analyzing a molecular profile. The monitoring may occur at different intervals, for example the monitoring may be hourly, daily, weekly, monthly, yearly, or some other time period, such as twice a month, three times a month, every two months, every three months, etc.

Such methods can provide a series of values changing over time indicating whether the aggregate expression levels in a particular patient are more like the expression levels in patients undergoing subAR or SCAR or not undergoing subAR or SCAR. Movement in value toward or away from subAR or SCAR can provide an indication whether an existing immunosuppressive regime is working, whether the immunosuppressive regime should be changed or whether a biopsy or increased monitoring by markers such as creatinine or glomerular filtration rate should be performed.

The methods provided herein include administering a blood test (e.g., a test to detect subclinical acute rejection) to a transplant recipient who has already undergone a surveillance or protocol biopsy of the kidney and received a biopsy result in the form of a histological analysis or a molecular profiling analysis. In some particular instances, the analysis of the kidney biopsy (e.g., by histology or molecular profiling) may result in ambiguous, inconclusive or borderline results. In such cases, a blood test provided herein may assist a caregiver with determining whether the transplant recipient has subclinical acute rejection or with interpreting the biopsy. In other cases the biopsy itself may be inconclusive or ambiguous, and in such cases the molecular analysis of the biopsy may be used in adjunct with the histology to confirm a diagnosis. In some instances, the analysis of the kidney biopsy may yield a negative result. In such cases, the subject may receive a blood test provided herein in order to confirm the negative result, or to detect subclinical acute rejection. In some cases, after receiving any type of biopsy result (e.g., negative result, ambiguous, inconclusive, borderline, positive), the patient may receive multiple, serial blood tests to monitor changes in molecular markers correlated with subclinical acute rejection.

The methods provided herein also include administering a biopsy test (e.g., histology or molecular profiling) to a transplant recipient who has received a molecular blood profiling test. For example, the transplant recipient may receive an ambiguous, inconclusive or borderline result on a blood molecular profiling test. In such cases, the patient's healthcare worker may use the results of a kidney biopsy test as a complement to the blood test to determine whether the subject is experiencing subclinical acute rejection. In another example, the transplant recipient may have received a positive result on a blood molecular profiling test, indicating that the transplant recipient has, or likely has, subclinical acute rejection, or even multiple positive results over time. In such cases, the patient's physician or other healthcare worker may decide to biopsy the patient's kidney in order to detect subAR. Such kidney biopsy test may be a molecular profiling analysis of the patient's kidney, as described herein. In some cases, a histological analysis of the kidney biopsy may be performed instead of, or in addition to, the molecular analysis of the biopsy. In some cases, the physician may decide to wait a certain period of time after receiving the positive blood result to perform the biopsy test.

The methods provided herein may often provide early detection of subAR and may help a patient to obtain early treatment such as receiving immunosuppressive therapy or increasing an existing immunosuppressive regimen. Such early treatment may enable the patient to avoid more serious consequences associated with acute rejection later in time, such as allograft loss or procedures such as kidney dialysis. In some cases, such early treatments may be administered after the patient receives both a molecular profiling blood test and a biopsy analyzed either by molecular profiling or histologically.

The diagnosis or detection of condition of a transplant recipient may be particularly useful in limiting the number of invasive diagnostic interventions that are administered to the patient. For example, the methods provided herein may limit or eliminate the need for a transplant recipient (e.g., kidney transplant recipient) to receive a biopsy (e.g., kidney biopsies) or to receive multiple biopsies. In a further embodiment, the methods provided herein can be used alone or in combination with other standard diagnosis methods currently used to detect or diagnose a condition of a transplant recipient, such as but not limited to results of biopsy analysis for kidney allograft rejection, results of histopathology of the biopsy sample, serum creatinine level, creatinine clearance, ultrasound, radiological imaging results for the kidney, urinalysis results, elevated levels of inflammatory molecules such as neopterin, and lymphokines, elevated plasma interleukin (IL)-1 in azathioprine-treated patients, elevated IL-2 in cyclosporine-treated patients, elevated IL-6 in serum and urine, intrarenal expression of cytotoxic molecules (granzyme B and perforin) and immunoregulatory cytokines (IL-2, -4, -10, interferon gamma and transforming growth factor-b 1).

The methods herein may be used in conjunction with kidney function tests, such as complete blood count (CBC), serum electrolytes tests (including sodium, potassium, chloride, bicarbonate, calcium, and phosphorus), blood urea test, blood nitrogen test, serum creatinine test, urine electrolytes tests, urine creatinine test, urine protein test, urine fractional excretion of sodium (FENA) test, glomerular filtration rate (GFR) test. Kidney function may also be assessed by a renal biopsy. Kidney function may also be assessed by one or more gene expression tests.

VII. Drug Screening

The expression profiles associated with SCAR or lack thereof (TX) provided by the invention are useful in screening drugs, either in clinical trials or in animal models of SCAR. A clinical trial can be performed on a drug in similar fashion to the monitoring of an individual patient described above, except that drug is administered in parallel to a population of kidney transplant patients, usually in comparison with a control population administered a placebo.

The changes in expression levels of genes can be analyzed in individual patients and across a treated or control population. Analysis at the level of an individual patient provides an indication of the overall status of the patient at the end of the trial (i.e., whether gene expression profile indicates presence or enhanced susceptibility to SCAR) and/or an indication whether that profile has changed toward or away from such indication in the course of the trial. Results for individual patients can be aggregated for a population allowing comparison between treated and control population.

Similar trials can be performed in non-human animal models of chronic kidney disease, e.g., the mouse model of Mannon et al., Kidney International 55: 1935-1944, 1999. In this case, the expression levels of genes detected are the species variants or homologs of the human genes referenced above in whatever species of non-human animal on which tests are being conducted. Although the average or mean expression levels of human genes determined in human kidney transplant patients undergoing or not undergoing SCAR are not necessarily directly comparable to those of homolog genes in an animal model, the human values can nevertheless be used to provide an indication whether a change in expression level of a non-human homolog is in a direction toward or away from SCAR or susceptibility thereto. The expression profile of individual animals in a trial can provide an indication of the status of the animal at the end of the trial with respect to presence or susceptibility to SCAR and/or change in such status during the trial. Results from individual animals can be aggregated across a population and treated and control populations compared. Average changes in the expression levels of genes can then be compared between the two populations.

VIII. Computer Implemented Methods

Expression levels can be analyzed and associated with status of a subject (e.g., presence or susceptibility to SCAR) in a digital computer. Optionally, such a computer is directly linked to a scanner or the like receiving experimentally determined signals related to expression levels. Alternatively, expression levels can be input by other means. The computer can be programmed to convert raw signals into expression levels (absolute or relative), compare measured expression levels with one or more reference expression levels, or a scale of such values, as described above. The computer can also be programmed to assign values or other designations to expression levels based on the comparison with one or more reference expression levels, and to aggregate such values or designations for multiple genes in an expression profile. The computer can also be programmed to output a value or other designation providing an indication of presence or susceptibility to SCAR as well as any of the raw or intermediate data used in determining such a value or designation.

A typically computer (see U.S. Pat. No. 6,785,613 FIGS. 4 and 5) includes a bus which interconnects major subsystems such as a central processor, a system memory, an input/output controller, an external device such as a printer via a parallel port, a display screen via a display adapter, a serial port, a keyboard, a fixed disk drive and a floppy disk drive operative to receive a floppy disk. Many other devices can be connected such as a scanner via I/O controller, a mouse connected to serial port or a network interface. The computer contains computer readable media holding codes to allow the computer to perform a variety of functions. These functions include controlling automated apparatus, receiving input and delivering output as described above. The automated apparatus can include a robotic arm for delivering reagents for determining expression levels, as well as small vessels, e.g., microtiter wells for performing the expression analysis.

The methods, systems, kits and compositions provided herein may also be capable of generating and transmitting results through a computer network. As shown in FIG. 2, a sample (220) is first collected from a subject (e.g. transplant recipient, 210). The sample is assayed (230) and gene expression products are generated. A computer system (240) is used in analyzing the data and making classification of the sample. The result is capable of being transmitted to different types of end users via a computer network (250). In some instances, the subject (e.g. patient) may be able to access the result by using a standalone software and/or a web-based application on a local computer capable of accessing the internet (260). In some instances, the result can be accessed via a mobile application (270) provided to a mobile digital processing device (e.g. mobile phone, tablet, etc.). In some instances, the result may be accessed by physicians and help them identify and track conditions of their patients (280). In some instances, the result may be used for other purposes (290) such as education and research.

Computer Program

The methods, kits, and systems disclosed herein may include at least one computer program, or use of the same. A computer program may include a sequence of instructions, executable in the digital processing device's CPU, written to perform a specified task. Computer readable instructions may be implemented as program modules, such as functions, objects, Application Programming Interfaces (APIs), data structures, and the like, that perform particular tasks or implement particular abstract data types. In light of the disclosure provided herein, those of skill in the art will recognize that a computer program may be written in various versions of various languages.

The functionality of the computer readable instructions may be combined or distributed as desired in various environments. The computer program will normally provide a sequence of instructions from one location or a plurality of locations. In various embodiments, a computer program includes, in part or in whole, one or more web applications, one or more mobile applications, one or more standalone applications, one or more web browser plug-ins, extensions, add-ins, or add-ons, or combinations thereof.

Further disclosed herein are systems for classifying one or more samples and uses thereof. The system may comprise (a) a digital processing device comprising an operating system configured to perform executable instructions and a memory device; (b) a computer program including instructions executable by the digital processing device to classify a sample from a subject comprising: (i) a first software module configured to receive a gene expression profile of one or more genes from the sample from the subject; (ii) a second software module configured to analyze the gene expression profile from the subject; and (iii) a third software module configured to classify the sample from the subject based on a classification system comprising three or more classes. At least one of the classes may be selected from transplant rejection, transplant dysfunction with no rejection and normal transplant function. At least two of the classes may be selected from transplant rejection, transplant dysfunction with no rejection and normal transplant function. All three of the classes may be selected from transplant rejection, transplant dysfunction with no rejection and normal transplant function. Analyzing the gene expression profile from the subject may comprise applying an algorithm. Analyzing the gene expression profile may comprise normalizing the gene expression profile from the subject. In some instances, normalizing the gene expression profile does not comprise quantile normalization.

FIG. 4 shows a computer system (also “system” herein) 401 programmed or otherwise configured for implementing the methods of the disclosure, such as producing a selector set and/or for data analysis. The system 401 includes a central processing unit (CPU, also “processor” and “computer processor” herein) 405, which can be a single core or multi core processor, or a plurality of processors for parallel processing. The system 401 also includes memory 410 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 415 (e.g., hard disk), communications interface 420 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 425, such as cache, other memory, data storage and/or electronic display adapters. The memory 410, storage unit 415, interface 420 and peripheral devices 425 are in communication with the CPU 405 through a communications bus (solid lines), such as a motherboard. The storage unit 415 can be a data storage unit (or data repository) for storing data. The system 401 is operatively coupled to a computer network (“network”) 430 with the aid of the communications interface 420. The network 430 can be the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet. The network 430 in some instances is a telecommunication and/or data network. The network 430 can include one or more computer servers, which can enable distributed computing, such as cloud computing. The network 430 in some instances, with the aid of the system 401, can implement a peer-to-peer network, which may enable devices coupled to the system 401 to behave as a client or a server.

The system 401 is in communication with a processing system 435. The processing system 435 can be configured to implement the methods disclosed herein. In some examples, the processing system 435 is a nucleic acid sequencing system, such as, for example, a next generation sequencing system (e.g., Illumina sequencer, Ion Torrent sequencer, Pacific Biosciences sequencer). The processing system 435 can be in communication with the system 401 through the network 430, or by direct (e.g., wired, wireless) connection. The processing system 435 can be configured for analysis, such as nucleic acid sequence analysis.

Methods as described herein can be implemented by way of machine (or computer processor) executable code (or software) stored on an electronic storage location of the system 401, such as, for example, on the memory 410 or electronic storage unit 415. During use, the code can be executed by the processor 405. In some examples, the code can be retrieved from the storage unit 415 and stored on the memory 410 for ready access by the processor 405. In some situations, the electronic storage unit 415 can be precluded, and machine-executable instructions are stored on memory 410.

Digital Processing Device

The methods, kits, and systems disclosed herein may include a digital processing device, or use of the same. In further embodiments, the digital processing device includes one or more hardware central processing units (CPU) that carry out the device's functions. In still further embodiments, the digital processing device further comprises an operating system configured to perform executable instructions. In some embodiments, the digital processing device is optionally connected a computer network. In further embodiments, the digital processing device is optionally connected to the Internet such that it accesses the World Wide Web. In still further embodiments, the digital processing device is optionally connected to a cloud computing infrastructure. In other embodiments, the digital processing device is optionally connected to an intranet. In other embodiments, the digital processing device is optionally connected to a data storage device.

In accordance with the description herein, suitable digital processing devices include, by way of non-limiting examples, server computers, desktop computers, laptop computers, notebook computers, sub-notebook computers, netbook computers, netpad computers, set-top computers, handheld computers, Internet appliances, mobile smartphones, tablet computers, personal digital assistants, video game consoles, and vehicles. Those of skill in the art will recognize that many smartphones are suitable for use in the system described herein. Those of skill in the art will also recognize that select televisions, video players, and digital music players with optional computer network connectivity are suitable for use in the system described herein. Suitable tablet computers include those with booklet, slate, and convertible configurations, known to those of skill in the art.

The digital processing device will normally include an operating system configured to perform executable instructions. The operating system is, for example, software, including programs and data, which manages the device's hardware and provides services for execution of applications. Those of skill in the art will recognize that suitable server operating systems include, by way of non-limiting examples, FreeBSD, OpenBSD, NetBSD®, Linux, Apple® Mac OS X Server®, Oracle® Solaris®, Windows Server®, and Novell® NetWare®. Those of skill in the art will recognize that suitable personal computer operating systems include, by way of non-limiting examples, Microsoft® Windows®, Apple® Mac OS X®, UNIX®, and UNIX-like operating systems such as GNU/Linux®. In some embodiments, the operating system is provided by cloud computing. Those of skill in the art will also recognize that suitable mobile smart phone operating systems include, by way of non-limiting examples, Nokia® Symbian® OS, Apple® iOS®, Research In Motion® BlackBerry OS®, Google® Android®, Microsoft® Windows Phone® OS, Microsoft® Windows Mobile® OS, Linux®, and Palm® WebOS®.

The device generally includes a storage and/or memory device. The storage and/or memory device is one or more physical apparatuses used to store data or programs on a temporary or permanent basis. In some embodiments, the device is volatile memory and requires power to maintain stored information. In some embodiments, the device is non-volatile memory and retains stored information when the digital processing device is not powered. In further embodiments, the non-volatile memory comprises flash memory. In some embodiments, the non-volatile memory comprises dynamic random-access memory (DRAM). In some embodiments, the non-volatile memory comprises ferroelectric random access memory (FRAM). In some embodiments, the non-volatile memory comprises phase-change random access memory (PRAM). In other embodiments, the device is a storage device including, by way of non-limiting examples, CD-ROMs, DVDs, flash memory devices, magnetic disk drives, magnetic tapes drives, optical disk drives, and cloud computing based storage. In further embodiments, the storage and/or memory device is a combination of devices such as those disclosed herein.

A display to send visual information to a user will normally be initialized. Examples of displays include a cathode ray tube (CRT, a liquid crystal display (LCD), a thin film transistor liquid crystal display (TFT-LCD, an organic light emitting diode (OLED) display. In various further embodiments, on OLED display is a passive-matrix OLED (PMOLED) or active-matrix OLED (AMOLED) display. In some embodiments, the display may be a plasma display, a video projector or a combination of devices such as those disclosed herein.

The digital processing device would normally include an input device to receive information from a user. The input device may be, for example, a keyboard, a pointing device including, by way of non-limiting examples, a mouse, trackball, track pad, joystick, game controller, or stylus; a touch screen, or a multi-touch screen, a microphone to capture voice or other sound input, a video camera to capture motion or visual input or a combination of devices such as those disclosed herein.

Non-Transitory Computer Readable Storage Medium

The methods, kits, and systems disclosed herein may include one or more non-transitory computer readable storage media encoded with a program including instructions executable by the operating system to perform and analyze the test described herein; preferably connected to a networked digital processing device. The computer readable storage medium is a tangible component of a digital that is optionally removable from the digital processing device. The computer readable storage medium includes, by way of non-limiting examples, CD-ROMs, DVDs, flash memory devices, solid state memory, magnetic disk drives, magnetic tape drives, optical disk drives, cloud computing systems and services, and the like. In some instances, the program and instructions are permanently, substantially permanently, semi-permanently, or non-transitorily encoded on the media.

A non-transitory computer-readable storage media may be encoded with a computer program including instructions executable by a processor to create or use a classification system. The storage media may comprise (a) a database, in a computer memory, of one or more clinical features of two or more control samples, wherein (i) the two or more control samples may be from two or more subjects; and (ii) the two or more control samples may be differentially classified based on a classification system comprising three or more classes; (b) a first software module configured to compare the one or more clinical features of the two or more control samples; and (c) a second software module configured to produce a classifier set based on the comparison of the one or more clinical features.

At least two of the classes may be selected from transplant rejection, transplant dysfunction with no rejection and normal transplant function. All three classes may be selected from transplant rejection, transplant dysfunction with no rejection and normal transplant function. The storage media may further comprise one or more additional software modules configured to classify a sample from a subject. Classifying the sample from the subject may comprise a classification system comprising three or more classes. At least two of the classes may be selected from transplant rejection, transplant dysfunction with no rejection and normal transplant function. All three classes may be selected from transplant rejection, transplant dysfunction with no rejection and normal transplant function.

Web Application

In some embodiments, a computer program includes a web application. In light of the disclosure provided herein, those of skill in the art will recognize that a web application, in various embodiments, utilizes one or more software frameworks and one or more database systems. In some embodiments, a web application is created upon a software framework such as Microsoft® .NET or Ruby on Rails (RoR). In some embodiments, a web application utilizes one or more database systems including, by way of non-limiting examples, relational, non-relational, object oriented, associative, and XML database systems. In further embodiments, suitable relational database systems include, by way of non-limiting examples, Microsoft® SQL Server, mySQL™, and Oracle®. Those of skill in the art will also recognize that a web application, in various embodiments, is written in one or more versions of one or more languages. A web application may be written in one or more markup languages, presentation definition languages, client-side scripting languages, server-side coding languages, database query languages, or combinations thereof. In some embodiments, a web application is written to some extent in a markup language such as Hypertext Markup Language (HTML), Extensible Hypertext Markup Language (XHTML), or eXtensible Markup Language (XML). In some embodiments, a web application is written to some extent in a presentation definition language such as Cascading Style Sheets (CSS). In some embodiments, a web application is written to some extent in a client-side scripting language such as Asynchronous Javascript and XML (AJAX), Flash® Actionscript, Javascript, or Silverlight®. In some embodiments, a web application is written to some extent in a server-side coding language such as Active Server Pages (ASP), ColdFusion®, Perl, Java™, JavaServer Pages (JSP), Hypertext Preprocessor (PHP), Python™, Ruby, Tcl, Smalltalk, WebDNA®, or Groovy. In some embodiments, a web application is written to some extent in a database query language such as Structured Query Language (SQL). In some embodiments, a web application integrates enterprise server products such as IBM® Lotus Domino®. In some embodiments, a web application includes a media player element. In various further embodiments, a media player element utilizes one or more of many suitable multimedia technologies including, by way of non-limiting examples, Adobe® Flash®, HTML 5, Apple® QuickTime®, Microsoft® Silverlight®, Java™, and Unity®.

Mobile Application

In some embodiments, a computer program includes a mobile application provided to a mobile digital processing device. In some embodiments, the mobile application is provided to a mobile digital processing device at the time it is manufactured. In other embodiments, the mobile application is provided to a mobile digital processing device via the computer network described herein.

In view of the disclosure provided herein, a mobile application is created by techniques known to those of skill in the art using hardware, languages, and development environments known to the art. Those of skill in the art will recognize that mobile applications are written in several languages. Suitable programming languages include, by way of non-limiting examples, C, C++, C #, Objective-C, Java™, Javascript, Pascal, Object Pascal, Python™, Ruby, VB.NET, WML, and XHTML/HTML with or without CSS, or combinations thereof.

Suitable mobile application development environments are available from several sources. Commercially available development environments include, by way of non-limiting examples, AirplaySDK, alcheMo, Appcelerator®, Celsius, Bedrock, Flash Lite, .NET Compact Framework, Rhomobile, and WorkLight Mobile Platform. Other development environments are available without cost including, by way of non-limiting examples, Lazarus, MobiFlex, MoSync, and Phonegap. Also, mobile device manufacturers distribute software developer kits including, by way of non-limiting examples, iPhone and iPad (iOS) SDK, Android™ SDK, BlackBerry® SDK, BREW SDK, Palm® OS SDK, Symbian SDK, webOS SDK, and Windows® Mobile SDK.

Those of skill in the art will recognize that several commercial forums are available for distribution of mobile applications including, by way of non-limiting examples, Apple® App Store, Android™ Market, BlackBerry® App World, App Store for Palm devices, App Catalog for webOS, Windows® Marketplace for Mobile, Ovi Store for Nokia® devices, Samsung® Apps, and Nintendo® DSi Shop.

Standalone Application

In some embodiments, a computer program includes a standalone application, which is a program that is run as an independent computer process, not an add-on to an existing process, e.g., not a plug-in. Those of skill in the art will recognize that standalone applications are often compiled. A compiler is a computer program(s) that transforms source code written in a programming language into binary object code such as assembly language or machine code. Suitable compiled programming languages include, by way of non-limiting examples, C, C++, Objective-C, COBOL, Delphi, Eiffel, Java™, Lisp, Python™, Visual Basic, and VB .NET, or combinations thereof. Compilation is often performed, at least in part, to create an executable program. In some embodiments, a computer program includes one or more executable complied applications.

Web Browser Plug-in

In some embodiments, the computer program includes a web browser plug-in. In computing, a plug-in is one or more software components that add specific functionality to a larger software application. Makers of software applications support plug-ins to enable third-party developers to create abilities which extend an application, to support easily adding new features, and to reduce the size of an application. When supported, plug-ins enable customizing the functionality of a software application. For example, plug-ins are commonly used in web browsers to play video, generate interactivity, scan for viruses, and display particular file types. Those of skill in the art will be familiar with several web browser plug-ins including, Adobe® Flash® Player, Microsoft® Silverlight®, and Apple® QuickTime®. In some embodiments, the toolbar comprises one or more web browser extensions, add-ins, or add-ons. In some embodiments, the toolbar comprises one or more explorer bars, tool bands, or desk bands.

In view of the disclosure provided herein, those of skill in the art will recognize that several plug-in frameworks are available that enable development of plug-ins in various programming languages, including, by way of non-limiting examples, C++, Delphi, Java™ PHP, Python™, and VB .NET, or combinations thereof.

Web browsers (also called Internet browsers) are software applications, designed for use with network-connected digital processing devices, for retrieving, presenting, and traversing information resources on the World Wide Web. Suitable web browsers include, by way of non-limiting examples, Microsoft® Internet Explorer®, Mozilla® Firefox®, Google® Chrome, Apple® Safari®, Opera Software® Opera®, and KDE Konqueror. In some embodiments, the web browser is a mobile web browser. Mobile web browsers (also called mircrobrowsers, mini-browsers, and wireless browsers) are designed for use on mobile digital processing devices including, by way of non-limiting examples, handheld computers, tablet computers, netbook computers, subnotebook computers, smartphones, music players, personal digital assistants (PDAs), and handheld video game systems. Suitable mobile web browsers include, by way of non-limiting examples, Google® Android® browser, RIM BlackBerry® Browser, Apple® Safari®, Palm® Blazer, Palm′ WebOS® Browser, Mozilla® Firefox® for mobile, Microsoft® Internet Explorer® Mobile, Amazon® Kindle® Basic Web, Nokia® Browser, Opera Software® Opera® Mobile, and^(Sony)® PSP™ browser.

Software Modules

The methods, kits, and systems disclosed herein may include software, server, and/or database modules, or use of the same. In view of the disclosure provided herein, software modules are created by techniques known to those of skill in the art using machines, software, and languages known to the art. The software modules disclosed herein are implemented in a multitude of ways. In various embodiments, a software module comprises a file, a section of code, a programming object, a programming structure, or combinations thereof. In further various embodiments, a software module comprises a plurality of files, a plurality of sections of code, a plurality of programming objects, a plurality of programming structures, or combinations thereof. In various embodiments, the one or more software modules comprise, by way of non-limiting examples, a web application, a mobile application, and a standalone application. In some embodiments, software modules are in one computer program or application. In other embodiments, software modules are in more than one computer program or application. In some embodiments, software modules are hosted on one machine. In other embodiments, software modules are hosted on more than one machine. In further embodiments, software modules are hosted on cloud computing platforms. In some embodiments, software modules are hosted on one or more machines in one location. In other embodiments, software modules are hosted on one or more machines in more than one location.

Databases

The methods, kits, and systems disclosed herein may comprise one or more databases, or use of the same. In view of the disclosure provided herein, those of skill in the art will recognize that many databases are suitable for storage and retrieval of information pertaining to gene expression profiles, sequencing data, classifiers, classification systems, therapeutic regimens, or a combination thereof. In various embodiments, suitable databases include, by way of non-limiting examples, relational databases, non-relational databases, object oriented databases, object databases, entity-relationship model databases, associative databases, and XML databases. In some embodiments, a database is internet-based. In further embodiments, a database is web-based. In still further embodiments, a database is cloud computing-based. In other embodiments, a database is based on one or more local computer storage devices.

Data Transmission

The methods, kits, and systems disclosed herein may be used to transmit one or more reports. The one or more reports may comprise information pertaining to the classification and/or identification of one or more samples from one or more subjects. The one or more reports may comprise information pertaining to a status or outcome of a transplant in a subject. The one or more reports may comprise information pertaining to therapeutic regimens for use in treating transplant rejection in a subject in need thereof. The one or more reports may comprise information pertaining to therapeutic regimens for use in treating transplant dysfunction in a subject in need thereof. The one or more reports may comprise information pertaining to therapeutic regimens for use in suppressing an immune response in a subject in need thereof.

The one or more reports may be transmitted to a subject or a medical representative of the subject. The medical representative of the subject may be a physician, physician's assistant, nurse, or other medical personnel. The medical representative of the subject may be a family member of the subject. A family member of the subject may be a parent, guardian, child, sibling, aunt, uncle, cousin, or spouse. The medical representative of the subject may be a legal representative of the subject.

EXAMPLES

The following examples are offered to illustrate, but not to limit the present invention.

Example 1 Materials and Methods

This Example describes some of the materials and methods employed in identification of differentially expressed genes in SCAR.

The discovery set of samples consisted of the following biopsy-documented peripheral blood samples. 69 PAXgene whole blood samples were collected from kidney transplant patients. The samples were histology confirmed, and comprised 3 different phenotypes: (1) Acute Rejection (AR; n=21); (2) Sub-Clinical Acute Rejection (SCAR; n=23); and (3) Transplant Excellent (TX; n=25). Specifically, SCAR was defined by a protocol biopsy done on a patient with totally stable kidney function and the light histology revealed unexpected evidence of acute rejection (16 “Borderline”, 7 Banff 1A). The SCAR samples consisted of 3 month and 1 year protocol biopsies, whereas the TXs were predominantly 3 month protocol biopsies. The mean age of the patients is 49.3 years (ranging from 22-71); 35% female; 52% deceased donors. Table 5 presents time to biopsies where time is defined as days post transplantation. All the AR biopsies were “for cause” where clinical indications like a rise in serum creatinine prompted the need for a biopsy. All patients were induced with Thymoglobulin.

Example 2 Gene Expression Profiling and Data Analysis

All samples were processed on the Affymetrix HG-U133 PM only peg microarrays. To eliminate low expressed signals we used a signal filter cut-off that was data dependent, and therefore expression signals <Log₂ 3.74 (median signals on all arrays) in all samples were eliminated leaving us with 48734 probe sets from a total of 54721 probe sets. We performed a 3-way ANOVA analysis of AR vs. ADNR vs. TX. This yielded over 6000 differentially expressed probesets at a p-value <0.001. Even when a False Discovery rate cut-off of (FDR<10%), was used it gave us over 2700 probesets. The corresponding genes for 2156 probes are listed in Table 4. Therefore for the purpose of a diagnostic signature we used the top 200 differentially expressed probe sets (Table 2) to build predictive models that could differentiate the three classes. The top 200 probesets have FDR values of <0.05%. We used three different predictive algorithms, namely Diagonal Linear Discriminant Analysis (DLDA), Nearest Centroid (NC) and Support Vector Machines (SVM) to build the predictive models. We ran the predictive models using two different methodologies and calculated the Area Under the Curve (AUC). SVM, DLDA and NC picked classifier sets of 200, 192 and 188 probesets as the best classifiers. Since there was very little difference in the AUC's we decided to use all 200 probesets as classifiers for all methods. We also demonstrated that these results were not the consequence of statistical over-fitting by using the replacement method of Harrell to perform a version of 1000-test cross-validation. Table 1 shows the performance of these classifier sets using both one-level cross validation as well as the Optimism Corrected Bootstrapping (1000 data sets).

An important point here is that in real clinical practice the challenge is actually not to distinguish SCAR from AR because generally only AR presents with a significant increase in baseline serum creatinine. The real challenge is to take a patient with normal and stable creatinine and diagnose the hidden SCAR without having to depend on invasive and expensive protocol biopsies that cannot be done frequently in any case. Though we have already successfully done this using our 3-way analysis, we also tested a 2-way prediction of SCAR vs. TX. The point was to further validate that a phenotype as potentially subtle clinically as SCAR can be truly distinguished from TX. At a p-value <0.001, there were 33 probesets whose expression signals highly differentiated SCAR and TX, a result in marked contrast with the >2500 probesets differentially expressed between AR vs. TX at that same p-value. (FIG. 3 shows the hierarchical clustering of gene expression profiling of these 33 probesets.) However, when these 33 probesets (Table 3) were used in NC to predict SCAR and TX creating a 2-way classifier, the predictive accuracies with a one-level cross-validation was 96% and with the Harrell 1000 test optimism correction it was 94%. Thus, we are confident that we can distinguish SCAR, TX and AR by peripheral blood gene expression profiling using this proof of principle data set.

Example 3 Microarray and NGS Analyses

This Example describes the identification of differentially expressed genes in SCAR using microarray and next-generation sequencing (NGS) analyses.

Biopsy Samples

To compare the methods using blood and biopsy samples, we performed microarray and NGS analyses on the blood and biopsy samples from the same kidney transplant patients. The discovery set of blood samples consisted of the following biopsy samples. 68 biopsy samples were collected from kidney transplant patients. The samples were histology confirmed, and comprised 3 different phenotypes: (1) Acute Rejection (AR; n=21); (2) Sub-Clinical Acute Rejection (SCAR; n=22); and (3) Transplant Excellent (TX; n=25). The specific sample characterizations and methods were described in Example 1.

Microarray Analyses—Biopsy Samples

All samples were processed on the HG-U133 Plus PM microarrays. All samples were normalized using RMA in Partek Genomics Suite 6.6. To facilitate biomarker discovery by removing probe sets with low signal intensities we used a signal filter cut-off that was data dependent, and therefore expression signals <Log₂ 4.14 (median signals on all arrays) in all samples were eliminated leaving us with 27980 probe sets representing about 13900 genes.

We first performed a 3-way 1-step ANOVA analysis of AR vs. SCAR (subAR) vs. TX. A False Discovery rate cut-off of (FDR) 1% was set, and after Bonferroni correction of Phenotype (AR vs. SCAR vs. TX) p-values, 1195 genes were selected. Nearest Centroid Algorithm in Partek were used to identify best classifier set that can distinguish all three phenotypes. We demonstrated that the method has an overall predictive accuracy of 85%. As shown in Table 6, the method correctly classified most samples. When Nearest Centroid (NC) was used to predict TX vs. AR, the results showed predictive accuracy of 100%, sensitivity of 100%, specificity of 100%, positive predictive value of 100%, negative predictive value of 100%, and AUC of 1.0. In TX vs. SCAR (subAR), the results showed predictive accuracy of 78%, sensitivity of 81%, specificity of 75%, positive predictive value of 84%, negative predictive value of 71%, and AUC of 0.785. Similarly, in AR vs. SCAR (subAR) 2-way classifier, the results showed predictive accuracy of 76%, sensitivity of 76%, specificity of 75%, positive predictive value of 80%, negative predictive value of 71%, and AUC of 0.768. Thus, we are confident that we can distinguish SCAR, TX and AR by biopsy sample gene expression profiling using the 3-way 1-step analysis.

We then performed a 2-way 2-step ANOVA analysis. Because of the disproportionate distribution (only 46 probesets that differentiate SCAR from TX compared to AR vs. TX (10834 probesets) and AR vs. SCAR (2067 probesets)), we decided to test a 2-step approach where we combined SCAR+AR vs. TX to clearly separate a SCAR or AR from TX as the first step. The second step was using the SCAR vs AR genes to separate the SCARs from the ARs.

We used the 4598 (SCAR+AR vs TX) and the 745 (SCAR vs. AR) unique genes (1322 genes were common between the two groups) to build 2-way classifiers. Nearest Centroid (NC) was used as a two-step prediction. The top 300 genes (based on p-value) for the first step (AR+subAR vs. TX) are listed in Table 7. The top 300 genes (based on p-value) for the second step (AR vs. subAR) are listed in Table 8.

The method correctly classified most samples with an overall predictive accuracy of 94%. As shown in Table 9, in TX vs. AR, the results showed predictive accuracy of 97%, sensitivity of 100%, specificity of 94%, positive predictive value of 95%, negative predictive value of 100%, and AUC of 0.965. In TX vs. SCAR (subAR), the results showed predictive accuracy of 95%, sensitivity of 100%, specificity of 90%, positive predictive value of 91%, negative predictive value of 100%, and AUC of 0.947. Similarly, in AR vs. SCAR (subAR) 2-way classifier, the results showed predictive accuracy of 86%, sensitivity of 90%, specificity of 81%, positive predictive value of 81%, negative predictive value of 90%, and AUC of 0.862. Thus, we are confident that we can distinguish SCAR, TX and AR by biopsy sample gene expression profiling using the 2-way 2-step analysis.

NGS Analyses—Biopsy Samples

All samples were processed on the ION PROTON™ System. Only runs with >10 million reads were used for analysis. There was an average of 16 million reads across all samples. Samples were aligned using the STAR aligner (Dobin et al, Bioinformatics 2012). Differential expression of noramlized (DESeq2 Values) was done using ANOVA in Partek. Samples were first filtered for a minimum of 5 cpm per gene. After filtering, 13191 genes (56%) were eligible for analysis. The same 1 and 2 step methodologies described in the microarray section were tested. When comparing microarray with NGS analyses using biopsy samples at FDR<10% in both cases, 8862 probe sets were identified in microarray analysis, while only 2058 probe sets were identified.

Briefly, the 3-way 1-step method has an overall predictive accuracy of 81%. As shown in Table 10, the method correctly classified most samples. In TX v. AR a, the results showed predictive accuracy of 97%, sensitivity of 100%, specificity of 92%, positive predictive value of 95%, negative predictive value of 100%, and AUC of 0.967. In TX vs. SCAR (subAR), the results showed predictive accuracy of 80%, sensitivity of 72%, specificity of 83%, positive predictive value of 72%, negative predictive value of 91%, and AUC of 0.795. Similarly, in AR vs. SCAR (subAR), the results showed predictive accuracy of 69%, sensitivity of 58%, specificity of 79% positive predictive value of 79%, negative predictive value of 59%, and AUC of 0.689. Thus, we are confident that we can distinguish SCAR, TX and AR from biopsy samples using the next-generation sequencing 3-way 1-step analysis.

We then performed a 2-way 2-step analysis. Similar to the microarray 2-way 2-step analysis, there was a disproportionate distribution: there are only 5 genes that differentiate SCAR from TX compared to AR vs. TX (1510 genes) and AR vs. SCAR (132 genes). And thus, we decided to test a 2-step approach where we combined SCAR+AR vs. TX to clearly separate a SCAR or AR from TX as the first step. The top 200 probe sets (ranked on p-value) of the biopsy NGS signatures for the first step (SCAR+AR vs. TX) is listed in Table 11. The second step was using the SCAR vs AR genes to separate the SCARs from the ARs. The top 160 probe sets (ranked on p-value) of the biopsy NGS signatures for the second step (SCAR vs. AR) is listed in Table 12. As shown in Table 13, when Nearest Centroid (NC) was used as a two-step prediction in the AR and TX 2-way classifier, the results showed predictive accuracy of 95%, sensitivity of 100%, specificity of 88%, positive predictive value of 92%, negative predictive value of 100%, and AUC of 0.943. In the SCAR (subAR) and TX 2-way classifier, the results showed predictive accuracy of 100%, sensitivity of 100%, specificity of 100%, positive predictive value of 100%, negative predictive value of 100%, and AUC of 1.000. Similarly, in the AR and SCAR (subAR) 2-way classifier, the results showed predictive accuracy of 79%, sensitivity of 76%, specificity of 83%, positive predictive value of 83%, negative predictive value of 72%, and AUC of 0.792. The method correctly classified most samples with an overall predictive accuracy of 91%. Thus, we are confident that we can distinguish SCAR, TX and AR by biopsy sample gene expression profiling using the 2-way 2-step analysis.

Next, to show the correlation between the probe sets identified in microarray and NGS analyses, we performed correlation analyses on 1) the 1066 genes common to both microarray and NGS (both differentially expressed at FDR<1%); and 2) all the 7076 NGS expressed genes (above threshold).

We first performed correlation analyses on the 1066 genes common to both microarray and NGS. The genes were found to be highly correlated in correlation of fold-change in directionality analysis, 1063 out of the 1066 genes (99.8%) were found in agreement for AR vs. TX; 1063 out of the 1066 genes (99.8%) were found in agreement for AR vs. SCAR; 1042 out of the 1066 genes (97.8%) were found in agreement for AR vs. TX. We also plotted correlation of absolute fold changes of the 1066 genes in FIG. 5 and generated the heat map showing the clustering of this high correlation in FIG. 6.

We then performed correlation analyses on all the 7076 NGS expressed genes. In correlation of fold-change in directionality analysis, 5747 out of the 7076 genes (81.2%) were found in agreement for AR vs. TX; 6080 out of the 7076 genes (85.9%) were found in agreement for AR vs. SCAR; 5652 out of the 7076 genes (79.8%) were found in agreement for AR vs. TX. We also plotted correlation of absolute fold changes of the 7076 NGS expressed genes in FIG. 7.

Blood Samples

To compare the methods using blood and biopsy samples, we also performed the microarray and NGS analyses on the blood samples from the same kidney transplant patients. Specifically, 68 PAXgene whole blood samples were collected from kidney transplant patients. As described earlier, the samples were histology confirmed, and comprised 3 different phenotypes: (1) Acute Rejection (AR; n=21); (2) Sub-Clinical Acute Rejection (SCAR; n=22); and (3) Transplant Excellent (TX; n=25).

Microarray Analyses—Blood Samples

All samples were processed the same way as the biopsy microarray samples. We first performed a 3-way 1-step ANOVA analysis of AR vs. SCAR (subAR) vs. TX. Nearest Centroid Algorithm in Partek were used to identify best classifier set that can distinguish all three phenotypes. The full 818 probe sets ranked by p-value are listed in Table 14 and the best performing 61 probe sets gene signature picked by the Nearest Centroid Algorithm are listed in Table 15.

We demonstrated that the 3-way 1-step analysis has an overall predictive accuracy of 91%. As shown in Table 16, the method correctly classified most samples. In the AR and TX 2-way classifier, the results showed predictive accuracy of 90%, sensitivity of 95%, specificity of 85%, positive predictive value of 86%, negative predictive value of 94%, and AUC of 0.898. In the SCAR (subAR) and TX 2-way classifier, the results showed predictive accuracy of 91%, sensitivity of 95%, specificity of 87%, positive predictive value of 86%, negative predictive value of 95%, and AUC of 0.912. Similarly, in the AR and SCAR (subAR) 2-way classifier, the results showed predictive accuracy of 91%, sensitivity of 88%, specificity of 94%, positive predictive value of 95%, negative predictive value of 85%, and AUC of 0.905. Thus, we are confident that we can distinguish SCAR, TX and AR by peripheral blood gene expression profiling using this data set.

NGS Analyses—Blood Samples

All samples were processed the same way as the biopsy NGS samples. We first performed a 3-way 1-step ANOVA analysis of AR vs. SCAR (subAR) vs. TX. Nearest Centroid Algorithm in Partek were used to identify best classifier set that can distinguish all three phenotypes. The full 123 probe sets (p<0.01) ranked by p-value are listed in Table 17 and the best performing 53 probe sets gene signature picked by the Nearest Centroid Algorithm are listed in Table 18. Among the gene signatures in Table 18, JUP, XCL1, CRADD, XCL1/XCL2, PRNP, HHEX, FAM43A, and PSMD6-AS2 were also differentially expressed (p<0.05) in the microarray comparisons.

We demonstrated that the 3-way 1-step analysis has an overall predictive accuracy of 89%. As shown in Table 19, the method correctly classified most samples. In the AR and TX 2-way classifier, the results showed predictive accuracy of 92%, sensitivity of 95%, specificity of 90%, positive predictive value of 90%, negative predictive value of 95%, and AUC of 0.921. In the SCAR (subAR) and TX 2-way classifier, the results showed predictive accuracy of 83%, sensitivity of 83%, specificity of 82%, positive predictive value of 83%, negative predictive value of 82%, and AUC of 0.829. Similarly, in the AR and SCAR (subAR) 2-way classifier, the results showed predictive accuracy of 93%, sensitivity of 94%, specificity of 95%, positive predictive value of 94%, negative predictive value of 95%, and AUC of 0.943. Thus, we are confident that we can distinguish SCAR, TX and AR by peripheral blood gene expression profiling using this data set.

Next, similar to the biopsy sample analyses, to show the correlation between the probe sets identified in microarray and NGS analyses, we performed correlation analyses on 1) the 101 genes differentially expressed in both microarray and NGS; and 2) all the 7076 NGS expressed genes (above threshold).

We performed correlation analyses on the 101 genes common to both microarray and NGS. The genes were found to be highly correlated in correlation of fold-change in directionality analysis, 94 out of the 101 genes (93.8%) were found in agreement for AR vs. TX; 100 out of the 101 genes (99.0%) were found in agreement for AR vs. SCAR; 79 out of the 101 genes (78.2%) were found in agreement for AR vs. TX.

Conclusions—Microarray vs. NGS

The comparison demonstrated that microarrays and NGS perform similarly with respect to predictions of phenotypes. Both methods have very high correlation with fold-change especially amongst significantly differentially expressed genes.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.

All publications, GenBank sequences, ATCC deposits, patents and patent applications cited herein are hereby expressly incorporated by reference in their entirety and for all purposes as if each is individually so denoted.

TABLE 1 Blood Expression Profiling of Kidney Transplants: 3-Way Classifier AR vs. SCAR vs. TX Positive Negative AUC after Predictive Sensitivity Specificity Predictive Predictive Algorithm Predictors Comparison Thresholding Accuracy (%) (%) (%) Value (%) Value (%) Nearest Centroid 200 SCAR vs. TX 1.000 100 100 100 100 100 Nearest Centroid 200 SCAR vs. AR 0.953 95 92 100 100 90 Nearest Centroid 200 AR vs. TX 0.932 93 96 90 92 95

TABLE 2 200 Probeset classifer for distinguishing AR, SCAR and TX based on a 3-way ANOVA stepup AR - SCAR - TX - Gene p-value p-value Mean Mean Mean # Probeset ID Symbol Gene Title (Phenotype) (Phenotype) Signal Signal Signal 1 238108_PM_at — — 1.70E−10 8.27E−06 73.3 45.4 44.4 2 243524_PM_at — — 3.98E−10 9.70E−06 72.3 41.3 37.7 3 1558831_PM_x_at — — 5.11E−09 8.30E−05 48.1 30.8 31.4 4 229858_PM_at — — 7.49E−09 8.31E−05 576.2 359.3 348.4 5 236685_PM_at — — 8.53E−09 8.31E−05 409.1 213.3 211.0 6 213546_PM_at DKFZP586|1420 hypothetical protein 3.52E−08 2.60E−04 619.2 453.7 446.0 DKFZp586|1420 7 231958_PM_at C3orf31 Chromosome 3 open 4.35E−08 2.60E−04 22.8 20.1 16.4 reading frame 31 8 210275_PM_s_at ZFAND5 zinc finger, AN1-type 4.96E−08 2.60E−04 1045.9 1513.6 1553.8 domain 5 9 244341_PM_at — — 5.75E−08 2.60E−04 398.3 270.7 262.8 10 1558822_PM_at — — 5.84E−08 2.60E−04 108.6 62.9 56.8 11 242175_PM_at — — 5.87E−08 2.60E−04 69.1 37.2 40.0 12 222357_PM_at ZBTB20 zinc finger and BTB 6.97E−08 2.83E−04 237.4 127.4 109.8 domain containing 20 13 206288_PM_at PGGT1B protein 9.42E−08 3.53E−04 20.8 34.7 34.2 geranylgeranyltransferase type I, beta subunit 14 222306_PM_at — — 1.03E−07 3.59E−04 23.3 15.8 16.0 15 1569601_PM_at — — 1.67E−07 4.80E−04 49.5 34.1 29.7 16 235138_PM_at — — 1.69E−07 4.80E−04 1169.9 780.0 829.7 17 240452_PM_at GSPT1 G1 to S phase transition 1.74E−07 4.80E−04 97.7 54.4 48.6 1 18 243003_PM_at — — 1.77E−07 4.80E−04 92.5 52.5 51.3 19 218109_PM_s_at MFSD1 major facilitator 1.90E−07 4.87E−04 1464.0 1881.0 1886.4 superfamily domain containing 1 20 241681_PM_at — — 2.00E−07 4.87E−04 1565.7 845.7 794.6 21 243878_PM_at — — 2.19E−07 5.08E−04 76.1 39.7 39.5 22 233296_PM_x_at — — 2.33E−07 5.17E−04 347.7 251.5 244.7 23 243318_PM_at DCAF8 DDB1 and CUL4 2.52E−07 5.34E−04 326.2 229.5 230.2 associated factor 8 24 236354_PM_at — — 3.23E−07 6.39E−04 47.1 31.2 27.8 25 243768_PM_at — — 3.35E−07 6.39E−04 1142.0 730.6 768.5 26 238558_PM_at — — 3.65E−07 6.39E−04 728.5 409.4 358.4 27 237825_PM_x_at — — 3.66E−07 6.39E−04 34.2 20.9 19.9 28 244414_PM_at — — 3.67E−07 6.39E−04 548.7 275.2 284.0 29 215221_PM_at — — 4.06E−07 6.83E−04 327.2 176.7 171.9 30 235912_PM_at — — 4.46E−07 7.25E−04 114.1 71.4 59.5 31 239348_PM_at — — 4.87E−07 7.54E−04 20.1 14.5 13.4 32 240499_PM_at — — 5.06E−07 7.54E−04 271.4 180.1 150.2 33 208054_PM_at HERC4 hect domain and RLD 4 5.11E−07 7.54E−04 114.9 57.6 60.0 34 240263_PM_at — — 5.46E−07 7.81E−04 120.9 78.7 66.6 35 241303_PM_x_at — — 5.78E−07 7.81E−04 334.5 250.3 261.5 36 233692_PM_at — — 5.92E−07 7.81E−04 22.4 15.5 15.0 37 243561_PM_at — — 5.93E−07 7.81E−04 341.1 215.1 207.3 38 232778_PM_at — — 6.91E−07 8.86E−04 46.5 31.0 28.5 39 237632_PM_at — — 7.09E−07 8.86E−04 108.8 61.0 57.6 40 233690_PM_at — — 7.30E−07 8.89E−04 351.1 222.7 178.1 41 220221_PM_at VPS13D vacuolar protein sorting 7.50E−07 8.89E−04 93.5 60.0 59.9 13 homolog D (S. cerevisiae) 42 242877_PM_at — — 7.72E−07 8.89E−04 173.8 108.1 104.0 43 218155_PM_x_at TSR1 TSR1, 205 rRNA 7.86E−07 8.89E−04 217.2 165.6 164.7 accumulation, homolog (S. cerevisiae) 44 239603_PM_x_at — — 8.24E−07 8.89E−04 120.9 75.5 81.1 45 242859_PM_at — — 8.48E−07 8.89E−04 221.1 135.4 138.3 46 240866_PM_at — — 8.54E−07 8.89E−04 65.7 33.8 35.2 47 239661_PM_at — — 8.72E−07 8.89E−04 100.5 48.3 45.2 48 224493_PM_x_at C18orf45 chromosome 18 open 8.77E−07 8.89E−04 101.8 78.0 89.7 reading frame 45 49 1569202_PM_x_at — — 8.98E−07 8.89E−04 23.3 18.5 16.6 50 1560474_PM_at — — 9.12E−07 8.89E−04 25.2 17.8 18.5 51 232511_PM_at — — 9.48E−07 9.06E−04 77.2 46.1 49.9 52 228119_PM_at LRCH3 leucine-rich repeats 1.01E−06 9.51E−04 117.2 84.2 76.1 and calponin homology (CH) domain containing 3 53 228545_PM_at ZNF148 zinc finger protein 148 1.17E−06 9.99E−04 789.9 571.1 579.7 54 232779_PM_at — — 1.17E−06 9.99E−04 36.7 26.0 20.7 55 239005_PM_at FLJ39739 Hypothetical FLJ39739 1.18E−06 9.99E−04 339.1 203.7 177.7 56 244478_PM_at LRRC37A3 leucine rich repeat 1.20E−06 9.99E−04 15.7 12.6 12.7 containing 37, member A3 57 244535_PM_at — — 1.28E−06 9.99E−04 261.5 139.5 137.8 58 1562673_PM_at — — 1.28E−06 9.99E−04 77.4 46.5 51.8 59 240601_PM_at — — 1.29E−06 9.99E−04 212.6 107.7 97.7 60 239533_PM_at GPR155 G protein-coupled 1.30E−06 9.99E−04 656.3 396.7 500.1 receptor 155 61 222358_PM_x_at — — 1.32E−06 9.99E−04 355.2 263.1 273.7 62 214707_PM_x_at ALMS1 Alstrom syndrome 1 1.32E−06 9.99E−04 340.2 255.9 266.0 63 236435_PM_at — — 1.32E−06 9.99E−04 144.0 92.6 91.1 64 232333_PM_at — — 1.33E−06 9.99E−04 487.7 243.7 244.3 65 222366_PM_at — — 1.33E−06 9.99E−04 289.1 186.1 192.8 66 215611_PM_at TCF12 transcription factor 12 1.38E−06 1.02E−03 45.5 32.4 30.8 67 1558002_PM_at STRAP Serine/threonine kinase 1.40E−06 1.02E−03 199.6 146.7 139.7 receptor associated protein 68 239716_PM_at — — 1.43E−06 1.02E−03 77.6 49.5 45.5 69 239091_PM_at — — 1.45E−06 1.02E−03 76.9 44.0 45.0 70 238883_PM_at — — 1.68E−06 1.15E−03 857.1 475.5 495.1 71 235615_PM_at PGGT1B protein 1.72E−06 1.15E−03 127.0 235.0 245.6 geranylgeranyltransferase type I, beta subunit 72 204055_PM_s_at CTAGE5 CTAGE family, member 1.77E−06 1.15E−03 178.8 115.2 105.9 5 73 239757_PM_at ZFAND6 Zinc finger, AN1-type 1.81E−06 1.15E−03 769.6 483.3 481.9 domain 6 74 1558409_PM_at — — 1.82E−06 1.15E−03 14.8 10.9 11.8 75 242688_PM_at — — 1.85E−06 1.15E−03 610.5 338.4 363.4 76 242377_PM_x_at THUMPD3 THUMP domain 1.87E−06 1.15E−03 95.5 79.0 81.3 containing 3 77 242650_PM_at — — 1.88E−06 1.15E−03 86.0 55.5 47.4 78 243589_PM_at KIAA1267 /// KIAA1267 /// 1.89E−06 1.15E−03 377.8 220.3 210.4 LOC100294337 hypothetical LOC100294337 79 227384_PM_s_at — — 1.90E−06 1.15E−03 3257.0 2255.5 2139.7 80 237864_PM_at — — 1.91E−06 1.15E−03 121.0 69.2 73.4 81 243490_PM_at — — 1.92E−06 1.15E−03 24.6 17.5 16.5 82 244383_PM_at — — 1.96E−06 1.17E−03 141.7 93.0 77.5 83 215908_PM_at — — 2.06E−06 1.19E−03 98.5 67.9 67.5 84 230651_PM_at — — 2.09E−06 1.19E−03 125.9 74.3 71.5 85 1561195_PM_at — — 2.14E−06 1.19E−03 86.6 45.1 43.9 86 239268_PM_at NDUFS1 NADH dehydrogenase 2.14E−06 1.19E−03 14.0 12.0 11.3 (ubiquinone) Fe—S protein 1, 75 kDa (NADH-coenzyme Q reductase) 87 236431_PM_at SR140 U2-associated SR140 2.16E−06 1.19E−03 69.4 47.9 43.9 protein 88 236978_PM_at — — 2.19E−06 1.19E−03 142.4 88.6 88.1 89 1562957_PM_at — — 2.21E−06 1.19E−03 268.3 181.8 165.4 90 238913_PM_at — — 2.21E−06 1.19E−03 30.9 20.2 20.1 91 239646_PM_at — — 2.23E−06 1.19E−03 100.3 63.1 60.8 92 235701_PM_at — — 2.34E−06 1.24E−03 133.2 66.1 60.0 93 235601_PM_at — — 2.37E−06 1.24E−03 121.9 75.5 79.0 94 230918_PM_at — — 2.42E−06 1.25E−03 170.4 114.5 94.4 95 219112_PM_at FNIP1 /// folliculin interacting 2.49E−06 1.28E−03 568.2 400.2 393.4 RAPGEF6 protein 1 /// Rap guanine nucteotide exchange factor (GEF) 6 96 202228_PM_s_at NPTN neuroplastin 2.52E−06 1.28E−03 1017.7 1331.5 1366.4 97 242839_PM_at — — 2.78E−06 1.39E−03 17.9 14.0 13.6 98 244778_PM_x_at — — 2.85E−06 1.42E−03 105.1 66.0 65.9 99 237388_PM_at — — 2.91E−06 1.42E−03 59.3 38.0 33.0 100 202770_PM_s_at CCNG2 cyclin G2 2.92E−06 1.42E−03 142.2 269.0 270.0 101 240008_PM_at — — 2.96E−06 1.42E−03 96.2 65.6 56.2 102 1557718_PM_at PPP2R5C protein pnosphatase 2, 2.97E−06 1.42E−03 615.2 399.8 399.7 regulatory subunit B′, gamma 103 215528_PM_at — — 3.01E−06 1.42E−03 126.8 62.6 69.0 104 204689_PM_at HHEX hematopoietically 3.08E−06 1.44E−03 381.0 499.9 567.9 expressed homeobox 105 213718_PM_at RBM4 RNA binding motif 3.21E−06 1.46E−03 199.3 140.6 132.2 protein 4 106 243233_PM_at — — 3.22E−06 1.46E−03 582.3 343.0 337.1 107 239597_PM_at — — 3.23E−06 1.46E−03 1142.9 706.6 720.8 108 232890_PM_at — — 3.24E−06 1.46E−03 218.0 148.7 139.9 109 232883_PM_at — — 3.42E−06 1.53E−03 127.5 79.0 73.1 110 241391_PM_at — — 3.67E−06 1.62E−03 103.8 51.9 48.3 111 244197_PM_x_at — — 3.71E−06 1.62E−03 558.0 397.3 418.8 112 205434_PM_s_at AAK1 AP2 associated kinase 1 3.75E−06 1.62E−03 495.2 339.9 301.2 113 235725_PM_at SMAD4 SMAD family member 4 3.75E−06 1.62E−03 147.1 102.1 112.0 114 203137_PM_at WTAP Wilms tumor 1 3.89E−06 1.66E−03 424.1 609.4 555.8 associated protein 115 231075_PM_x_at RAPH1 Ras association 3.91E−06 1.66E−03 30.4 19.3 18.2 (RalGDS/AF-6) and pleckstrin homology domains 1 116 236043_PM_at LOC100130175 hypothetical protein 3.98E−06 1.67E−03 220.6 146.2 146.5 LOC100130175 117 238299_PM_at — — 4.09E−06 1.70E−03 217.1 130.4 130.3 118 243667_PM_at — — 4.12E−06 1.70E−03 314.5 225.3 232.8 119 223937_PM_at FOXP1 forkhead box P1 4.20E−06 1.72E−03 147.7 85.5 90.9 120 238666_PM_at — — 4.25E−06 1.72E−03 219.1 148.3 145.5 121 1554771_PM_at — — 4.28E−06 1.72E−03 67.2 41.5 40.8 122 202379_PM_s_at NKTR natural killer-tumor 4.34E−06 1.73E−03 1498.2 1170.6 1042.6 recognition sequence 123 244695_PM_at GHRLOS ghrelin opposite strand 4.56E−06 1.79E−03 78.0 53.0 52.5 (non-protein coding) 124 239393_PM_at — — 4.58E−06 1.79E−03 852.0 554.2 591.7 125 242920_PM_at — — 4.60E−06 1.79E−03 392.8 220.9 251.8 126 242405_PM_at — — 4.66E−06 1.80E−03 415.8 193.8 207.4 127 1556432_PM_at — — 4.69E−06 1.80E−03 61.5 43.1 38.1 128 1570299_PM_at — — 4.77E−06 1.81E−03 27.0 18.0 19.8 129 225198_PM_at VAPA VAMP (vesicle- 4.85E−06 1.83E−03 192.0 258.3 273.9 associated membrane protein)-associated protein A, 33 kDa 130 230702_PM_at — — 4.94E−06 1.85E−03 28.2 18.4 17.5 131 240262_PM_at — — 5.07E−06 1.88E−03 46.9 22.8 28.0 132 232216_PM_at YME1L1 YME1-like 1 5.14E−06 1.89E−03 208.6 146.6 130.1 (S. cerevisiae) 133 225171_PM_at ARHGAP18 Rho GTPase activating 5.16E−06 1.89E−03 65.9 109.1 121.5 protein 18 134 243992_PM_at — — 5.28E−06 1.92E−03 187.1 116.0 125.6 135 227082_PM_at — — 5.45E−06 1.96E−03 203.8 140.4 123.0 136 239948_PM_at NUP153 nucleoporin 153 kDa 5.50E−06 1.96E−03 39.6 26.5 27.8 137 221905_PM_at CYLD cylindromatosis (turban 5.51E−06 1.96E−03 433.0 316.8 315.1 tumor syndrome) 138 242578_PM_x_at SLC22A3 Solute carrier family 22 5.56E−06 1.96E−03 148.4 109.2 120.1 (extraneuronal monoamine transporter), member 3 139 1569238_PM_a_at — — 5.73E−06 1.99E−03 71.0 33.0 36.1 140 201453_PM_x_at RHEB Ras homolog enriched 5.76E−06 1.99E−03 453.3 600.0 599.0 in brain 141 236802_PM_at — — 5.76E−06 1.99E−03 47.9 29.1 29.6 142 232615_PM_at — — 5.82E−06 1.99E−03 4068.5 3073.4 2907.4 143 237179_PM_at PCMTD2 protein-L-isoaspartate 5.84E−06 1.99E−03 48.7 30.2 26.8 (D-aspartate) O- methyltransferase domain containing 2 144 203255_PM_at FBXO11 F-box protein 11 5.98E−06 2.02E−03 748.3 529.4 539.6 145 212989_PM_at SGMS1 sphingomyelin synthase 6.04E−06 2.03E−03 57.2 93.1 107.9 1 146 236754_PM_at PPP1R2 protein phosphatase 1, 6.17E−06 2.05E−03 505.3 380.7 370.1 regulatory (inhibitor) subunit 2 147 1559496_PM_at PPA2 pyrophosphatase 6.24E−06 2.05E−03 68.8 39.7 39.3 (inorganic) 2 148 236494_PM_x_at — — 6.26E−06 2.05E−03 135.0 91.1 82.9 149 237554_PM_at — — 6.30E−06 2.05E−03 53.4 31.5 30.1 150 243469_PM_at — — 6.37E−06 2.05E−03 635.2 308.1 341.5 151 240155_PM_x_at ZNF493 /// zinc finger protein 493 6.45E−06 2.05E−03 483.9 299.9 316.6 ZNF738 /// zinc finger protein 738 152 222442_PM_s_at ARL8B ADP-ribosylation factor- 6.47E−06 2.05E−03 201.5 292.6 268.3 like 8B 153 240307_PM_at — — 6.48E−06 2.05E−03 55.4 36.8 33.1 154 200864_PM_s_at RAB11A RAB11A, member RAS 6.50E−06 2.05E−03 142.1 210.9 233.0 oncogene family 155 235757_PM_at — — 6.53E−06 2.05E−03 261.4 185.2 158.9 156 222351_PM_at PPP2R1B protein phosphatase 2, 6.58E−06 2.06E−03 75.8 51.1 45.4 regulatory subunit A, beta 157 222788_PM_s_at RSBN1 round spermatid basic 6.63E−06 2.06E−03 389.9 302.7 288.2 protein 1 158 239815_PM_at — — 6.70E−06 2.06E−03 216.9 171.4 159.5 159 219392_PM_x_at PRR11 proline rich 11 6.77E−06 2.07E−03 1065.3 827.5 913.2 160 240458_PM_at — — 6.80E−06 2.07E−03 414.3 244.6 242.0 161 235879_PM_at MBNL1 Muscleblind-like 6.88E−06 2.08E−03 1709.2 1165.5 1098.0 (Drosophila) 162 230529_PM_at HECA headcase homolog 7.08E−06 2.13E−03 585.1 364.3 418.4 (Drosophila) 163 1562063_PM_x_at KIAA1245 /// KIAA1245 /// 7.35E−06 2.20E−03 350.4 238.8 260.8 NBPF1 /// neuroblastoma NBPF10 /// breakpoint family, NBPF11 /// member 1 /// NBPF12 /// neuroblastoma NBPF24 /// breakpoint fam NBPF8 /// NBPF9 164 202769_PM_at CCNG2 cyclin G2 7.42E−06 2.20E−03 697.1 1164.0 1264.6 165 1556493_PM_a_at KDM4C lysine (K)-specific 7.64E−06 2.24E−03 81.4 49.0 44.5 demethylase 4C 166 216509_PM_x_at MLLT10 myeloid/lymphoid or 7.64E−06 2.24E−03 22.4 17.9 19.3 mixed-lineage leukemia (trithorax homolog, Drosophila); translocate 167 223697_PM_x_at C9orf64 chromosome 9 open 7.70E−06 2.25E−03 1013.6 771.2 836.8 reading frame 64 168 235999_PM_at — — 7.77E−06 2.25E−03 227.6 174.1 182.1 169 244766_PM_at LOC100271836 /// SMG1 homolog, 8.03E−06 2.31E−03 133.4 99.4 87.5 LOC440354 /// phosphatidylinositol 3- LOC595101 /// kinase-related kinase LOC641298 /// pseudogene /// PI-3- SMG1 kinase-r 170 230332_PM_at ZCCHC7 Zinc finger, CCHC 8.07E−06 2.31E−03 467.4 265.1 263.2 domain containing 7 171 235308_PM_at ZBTB20 zinc finger and BTB 8.17E−06 2.32E−03 256.7 184.2 167.3 domain containing 20 172 242492_PM_at CLNS1A Chloride channel, 8.19E−06 2.32E−03 128.5 82.8 79.2 nucleotide-sensitive, 1A 173 215898_PM_at TTLL5 tubulin tyrosine ligase- 8.24E−06 2.32E−03 20.9 14.0 13.8 like family, member 5 174 244840_PM_x_at DOCK4 dedicator of cytokinesis 4 8.65E−05 2.42E−03 43.1 16.5 21.5 175 220235_PM_s_at C1orf103 chromosome 1 open 8.72E−06 2.43E−03 88.4 130.5 143.3 reading frame 103 176 229467_PM_at PCBP2 Poly(rC) binding protein 8.80E−06 2.44E−03 186.5 125.4 135.8 2 177 232527_PM_at — — 8.99E−06 2.48E−03 667.4 453.9 461.3 178 243286_PM_at — — 9.24E−06 2.53E−03 142.6 98.2 87.2 179 215628_PM_x_at — — 9.28E−06 2.53E−03 49.6 36.3 39.4 180 1556412_PM_at — — 9.45E−06 2.56E−03 34.9 24.7 23.8 181 204786_PM_s_at IFNAR2 Interferon (alpha, beta 9.64E−06 2.59E−03 795.6 573.0 639.2 and omega) receptor 2 182 234258_PM_at — — 9.73E−06 2.60E−03 27.4 17.8 20.3 183 233274_PM_at — — 9.76E−06 2.60E−03 109.9 77.5 79.4 184 239784_PM_at — — 9.82E−06 2.60E−03 137.0 80.1 70.1 185 242498_PM_x_at — — 1.01E−05 2.65E−03 59.2 40.4 38.9 186 231351_PM_at — — 1.02E−05 2.67E−03 124.8 70.8 60.6 187 222368_PM_at — — 1.03E−05 2.67E−03 89.9 54.5 44.3 188 236524_PM_at — — 1.03E−05 2.67E−03 313.2 234.7 214.2 189 243834_PM_at TNRC6A trinucleotide repeat 1.04E−05 2.67E−03 211.8 145.1 146.9 containing 6A 190 239167_PM_at — — 1.04E−05 2.67E−03 287.4 150.2 160.3 191 239238_PM_at — — 1.05E−05 2.67E−03 136.0 81.6 92.0 192 237194_PM_at — — 1.05E−05 2.67E−03 57.2 34.4 27.9 193 242772_PM_x_at — — 1.06E−05 2.67E−03 299.2 185.2 189.4 194 243827_PM_at — — 1.06E−05 2.67E−03 115.9 50.1 56.4 195 1552536_PM_at VTI1A vesicle transport 1.10E−05 2.75E−03 61.7 35.1 34.6 through interaction with t-SNAREs homolog 1A (yeast) 196 243696_PM_at KIAA0562 KIAA0562 1.12E−05 2.77E−03 19.0 14.8 15.0 197 233648_PM_at — — 1.12E−05 2.77E−03 33.9 21.0 24.1 198 225858_PM_s_at XIAP X-linked Inhibitor of 1.16E−05 2.85E−03 1020.7 760.3 772.6 apoptosis 199 238736_PM_at REV3L REV3-like, catalytic 1.19E−05 2.91E−03 214.2 135.8 151.6 subunit of DNA polymerase zeta (yeast) 200 221192_PM_x_at MFSD11 major facilitator 1.20E−05 2.92E−03 100.4 74.5 81.2 superfamily domain containing 11

TABLE 3 33 probesets that differentiate SCAR and TX at p-value < 0.001 in PAXGene blood tubes Fold- Change Gene p-value (SCAR SCAR - TX - Probeset ID Symbol Gene Title (Phenotype) vs. TX) ID Mean Mean 1553094_PM_at TAC4 tachykinin 4 0.000375027 −1.1 1553094_PM_at 8.7 9.6 (hemokinin) 1553352_PM_x_at ERVWE1 endogenous 0.000494742 −1.26 1553352_PM_x_at 15.5 19.6 retroviral family W, env(C7), member 1 1553644_PM_at C14orf49 chromosome 14 0.000868817 −1.16 1553644_PM_at 10.1 11.7 open reading frame 49 1556178_PM_x_at TAF8 TAF8 RNA 0.000431074 1.24 1556178_PM_x_at 39.2 31.7 polymerase II, TATA box binding protein (TBP)-associated factor, 43 kDa 1559687_PM_at TMEM221 transmembrane 8.09E−05 −1.16 1559687_PM_at 13.0 15.1 protein 221 1562492_PM_at LOC340090 hypothetical 0.00081096 −1.1 1562492_PM_at 8.8 9.7 LOC340090 1563204_PM_at ZNF627 Zinc finger protein 0.000784254 −1.15 1563204_PM_at 10.6 12.2 627 1570124_PM_at — — 0.000824814 −1.14 1570124_PM_at 10.6 12.2 204681_PM_s_at RAPGEF5 Rap guanine 0.000717727 −1.18 204681_PM_s_at 9.6 11.3 nucleotide exchange factor (GEF) 5 206154_PM_at RLBP1 retinaldehyde 0.000211941 −1.13 206154_PM_at 11.0 12.4 binding protein 1 209053_PM_s_at WHSC1 Wolf-Hirschhorn 0.000772412 1.23 209053_PM_s_at 15.1 12.3 syndrome candidate 1 209228_PM_x_at TUSC3 tumor suppressor 0.000954529 −1.13 209228_PM_x_at 8.9 10.1 candidate 3 211701_PM_s_at TRO trophinin 0.000684486 −1.13 211701_PM_s_at 10.0 11.3 213369_PM_at CDHR1 cadherin-related 0.000556648 −1.14 213369_PM_at 10.8 12.3 family member 1 215110_PM_at MBL1P mannose-binding 0.000989176 −1.13 215110_PM_at 9.2 10.4 lectin (protein A) 1, pseudogene 215232_PM_at ARHGAP44 Rho GTPase 0.000332776 −1.18 215232_PM_at 11.1 13.1 activating protein 44 217158_PM_at LOC442421 hypothetical 2.98E−05 1.18 217158_PM_at 14.2 12.0 LOC442421 /// prostaglandin E2 receptor EP4 subtype-like 218365_PM_s_at DARS2 aspartyl-tRNA 0.000716035 1.18 218365_PM_s_at 17.2 14.5 synthetase 2, mitochondrial 219695_PM_at SMPD3 sphingomyelin 0.000377151 −1.47 219695_PM_at 12.0 17.6 phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) 220603_PM_s_at MCTP2 multiple C2 domains, 0.000933412 −1.38 220603_PM_s_at 338.5 465.8 transmembrane 2 224963_PM_at SLC26A2 solute carrier family 0.000961242 1.47 224963_PM_at 94.3 64.0 26 (sulfate transporter), member 2 226729_PM_at USP37 ubiquitin specific 0.000891038 1.24 226729_PM_at 32.9 26.6 peptidase 37 228226_PM_s_at ZNF775 zinc finger protein 0.000589512 1.2 228226_PM_s_at 20.5 17.1 775 230608_PM_at C1orf182 chromosome 1 open 0.000153478 −1.18 230608_PM_at 15.9 18.8 reading frame 182 230756_PM_at ZNF683 zinc finger protein 0.00044751 1.52 230756_PM_at 26.7 17.6 683 231757_PM_at TAS2R5 taste receptor, type 0.000869775 −1.12 231757_PM_at 9.3 10.4 2, member 5 231958_PM_at C3orf31 Chromosome 3 open 4.09E−05 1.22 231958_PM_at 20.1 16.4 reading frame 31 237290_PM_at — — 0.000948318 −1.22 237290_PM_at 10.3 12.5 237806_PM_s_at LOC729296 hypothetical 0.00092234 −1.18 237806_PM_s_at 10.2 12.0 LOC729296 238459_PM_x_at SPATA6 spermatogenesis 0.000116525 −1.15 238459_PM_x_at 9.2 10.5 associated 6 241331_PM_at SKAP2 Src kinase associated 0.000821476 −1.39 241331_PM_at 16.4 22.9 phosphoprotein 2 241368_PM_at PLIN5 perilipin 5 0.000406066 −1.61 241368_PM_at 84.5 136.3 241543_PM_at — — 0.000478221 −1.17 241543_PM_at 9.4 11.0

TABLE 4 List of 2156 differentially expressed probesets between AR, SCAR and TX from a 3-way ANOVA stepup AR - SCAR - TX - Gene p-value p-value Mean Mean Mean # Probeset ID Symbol Gene Title (Phenotype) (Phenotype) Signal Signal Signal 1 238108_PM_at — — 1.70E−10 8.27E−06 73.3 45.4 44.4 2 243524_PM_at — — 3.98E−10 9.70E−06 72.3 41.3 37.7 3 1558831_PM_x_at — — 5.11E−09 8.30E−05 48.1 30.8 31.4 4 229858_PM_at — — 7.49E−09 8.31E−05 576.2 359.3 348.4 5 236685_PM_at — — 8.53E−09 8.31E−05 409.1 213.3 211.0 6 213546_PM_at DKFZP586|1420 hypothetical protein 3.52E−08 2.60E−04 619.2 453.7 446.0 DKFZp586|1420 7 231958_PM_at C3orf31 Chromosome 3 open 4.35E−08 2.60E−04 22.8 20.1 16.4 reading frame 31 8 210275_PM_s_at ZFAND5 zinc finger, AN1-type 4.96E−08 2.60E−04 1045.9 1513.6 1553.8 domain 5 9 244341_PM_at — — 5.75E−08 2.60E−04 398.3 270.7 262.8 10 1558822_PM_at — — 5.84E−08 2.60E−04 108.6 62.9 56.8 11 242175_PM_at — — 5.87E−08 2.60E−04 69.1 37.2 40.0 12 222357_PM_at ZBTB20 zinc finger and BTB 6.97E−08 2.83E−04 237.4 127.4 109.8 domain containing 20 13 206288_PM_at PGGT1B protein 9.42E−08 3.53E−04 20.8 34.7 34.2 geranylgeranyltransferase type I, beta subunit 14 222306_PM_at — — 1.03E−07 3.59E−04 23.3 15.8 16.0 15 1569601_PM_at — — 1.67E−07 4.80E−04 49.5 34.1 29.7 16 235138_PM_at — — 1.69E−07 4.80E−04 1169.9 780.0 829.7 17 240452_PM_at GSPT1 G1 to S phase transition 1 1.74E−07 4.80E−04 97.7 54.4 48.6 18 243003_PM_at — — 1.77E−07 4.80E−04 92.8 52.5 51.3 19 218109_PM_s_at MFSD1 major facilitator 1.90E−07 4.87E−04 1464.0 1881.0 1886.4 superfamily domain containing 1 20 241681_PM_at — — 2.00E−07 4.87E−04 1565.7 845.7 794.6 21 243878_PM_at — — 2.19E−07 5.08E−04 76.1 39.7 39.5 22 233296_PM_x_at — — 2.33E−07 5.17E−04 347.7 251.5 244.7 23 243318_PM_at DCAF8 DDB1 and CUL4 associated 2.52E−07 5.34E−04 326.2 229.5 230.2 factor 8 24 236354_PM_at — — 3.23E−07 6.39E−04 47.1 31.2 27.8 25 243768_PM_at — — 3.35E−07 6.39E−04 1142.0 730.6 768.5 26 238558_PM_at — — 3.65E−07 6.39E−04 728.5 409.4 358.4 27 237825_PM_x_at — — 3.66E−07 6.39E−04 34.2 20.9 19.9 28 244414_PM_at — — 3.67E−07 6.39E−04 548.7 275.2 284.0 29 215221_PM_at — — 4.06E−07 6.83E−04 327.2 176.7 171.9 30 235912_PM_at — — 4.46E−07 7.25E−04 114.1 71.4 59.5 31 239348_PM_at — — 4.87E−07 7.54E−04 20.1 14.5 13.4 32 240499_PM_at — — 5.06E−07 7.54E−04 271.4 180.1 150.2 33 208054_PM_at HERC4 hect domain and RLD 4 5.11E−07 7.54E−04 114.9 57.6 60.0 34 240263_PM_at — — 5.46E−07 7.81E−04 120.9 78.7 66.6 35 241303_PM_x_at — — 5.78E−07 7.81E−04 334.5 250.3 261.5 36 233692_PM_at — — 5.92E−07 7.81E−04 22.4 15.5 15.0 37 243561_PM_at — — 5.93E−07 7.81E−04 341.1 215.1 207.3 38 232778_PM_at — — 6.91E−07 8.86E−04 46.5 31.0 28.5 39 237632_PM_at — — 7.09E−07 8.86E−04 108.8 61.0 57.6 40 233690_PM_at — — 7.30E−07 8.89E−04 351.1 222.7 178.1 41 220221_PM_at VPS13D vacuolar protein sorting 7.50E−07 8.89E−04 93.5 60.0 59.9 13 homolog D (S. cerevisiae) 42 242877_PM_at — — 7.72E−07 8.89E−04 173.8 108.1 104.0 43 218155_PM_x_at TSR1 TSR1, 20S rRNA 7.86E−07 8.89E−04 217.2 165.6 164.7 accumulation, homolog (S. cerevisiae) 44 239603_PM_x_at — — 8.24E−07 8.89E−04 120.9 75.5 81.1 45 242859_PM_at — — 8.48E−07 8.89E−04 221.1 135.4 138.3 46 240866_PM_at — — 8.54E−07 8.89E−04 65.7 33.8 35.2 47 239661_PM_at — — 8.72E−07 8.89E−04 100.5 48.3 45.2 48 224493_PM_x_at C18orf45 chromosome 18 open 8.77E−07 8.89E−04 101.8 78.0 89.7 reading frame 45 49 1569202_PM_x_at — — 8.98E−07 8.89E−04 23.3 18.5 16.6 50 1560474_PM_at — — 9.12E−07 8.89E−04 25.2 17.8 18.5 51 232511_PM_at — — 9.48E−07 9.06E−04 77.2 46.1 49.9 52 228119_PM_at LRCH3 leucine-rich repeats and 1.01E−06 9.51E−04 117.2 84.2 76.1 calponin homology (CH) domain containing 3 53 228545_PM_at ZNF148 zinc finger protein 148 1.17E−06 9.99E−04 789.9 571.1 579.7 54 232779_PM_at — — 1.17E−06 9.99E−04 36.7 26.0 20.7 55 239005_PM_at FLJ39739 Hypothetical FLJ39739 1.18E−06 9.99E−04 339.1 203.7 177.7 56 244478_PM_at LRRC37A3 leucine rich repeat 1.20E−06 9.99E−04 15.7 12.6 12.7 containing 37, member A3 57 244535_PM_at — — 1.28E−06 9.99E−04 261.5 139.5 137.8 58 1562673_PM_at — — 1.28E−06 9.99E−04 77.4 46.5 51.8 59 240601_PM_at — — 1.29E−06 9.99E−04 212.6 107.7 97.7 60 239533_PM_at GPR155 G protein-coupled 1.30E−06 9.99E−04 656.3 396.7 500.1 receptor 155 61 222358_PM_x_at — — 1.32E−06 9.99E−04 355.2 263.1 273.7 62 214707_PM_x_at ALMS1 Alstrom syndrome 1 1.32E−06 9.99E−04 340.2 255.9 266.0 63 236435_PM_at — — 1.32E−06 9.99E−04 144.0 92.6 91.1 64 232333_PM_at — — 1.33E−06 9.99E−04 487.7 243.7 244.3 65 222366_PM_at — — 1.33E−06 9.99E−04 289.1 186.1 192.8 66 215611_PM_at TCF12 transcription factor 12 1.38E−06 1.02E−03 45.5 32.4 30.8 67 1558002_PM_at STRAP Serine/threonine kinase 1.40E−06 1.02E−03 199.6 146.7 139.7 receptor associated protein 68 239716_PM_at — — 1.43E−06 1.02E−03 77.6 49.5 45.5 69 239091_PM_at — — 1.45E−06 1.02E−03 76.9 44.0 45.0 70 238883_PM_at — — 1.68E−06 1.15E−03 857.1 475.5 495.1 71 235615_PM_at PGGT1B protein 1.72E−06 1.15E−03 127.0 235.0 245.6 geranylgeranyltransferase type I, beta subunit 72 204055_PM_s_at CTAGE5 CTAGE family, member 5 1.77E−06 1.15E−03 178.8 115.2 105.9 73 239757_PM_at ZFAND6 Zinc finger, AN1-type 1.81E−06 1.15E−03 769.6 483.3 481.9 domain 6 74 1558409_PM_at — — 1.82E−06 1.15E−03 14.8 10.9 11.8 75 242688_PM_at — — 1.85E−06 1.15E−03 610.5 338.4 363.4 76 242377_PM_x_at THUMPD3 THUMP domain 1.87E−06 1.15E−03 95.5 79.0 81.3 containing 3 77 242650_PM_at — — 1.88E−06 1.15E−03 86.0 55.5 47.4 78 243589_PM_at KIAA1267 /// KIAA1267 /// hypothetical 1.89E−06 1.15E−03 377.8 220.3 210.4 LOC100294337 LOC100294337 79 227384_PM_s_at — — 1.90E−06 1.15E−03 3257.0 2255.5 2139.7 80 237854_PM_at — — 1.91E−06 1.15E−03 121.0 69.2 73.4 81 243490_PM_at — — 1.92E−06 1.15E−03 24.6 17.5 16.5 82 244383_PM_at — — 1.96E−06 1.17E−03 141.7 93.0 77.5 83 215908_PM_at — — 2.06E−06 1.19E−03 98.5 67.9 67.5 84 230651_PM_at — — 2.09E−06 1.19E−03 125.9 74.3 71.5 85 1561195_PM_at — — 2.14E−06 1.19E−03 86.6 45.1 43.9 86 239268_PM_at NDUFS1 NADH dehydrogenase 2.14E−06 1.19E−03 14.0 12.0 11.3 (ubiquinone) Fe—S protein 1, 75 kDa (NADH- coenzyme Q reductase) 87 236431_PM_at SR140 U2-associated SR140 2.16E−06 1.19E−03 69.4 47.9 43.9 protein 88 236978_PM_at — — 2.19E−06 1.19E−03 142.4 88.6 88.1 89 1562957_PM_at — — 2.21E−06 1.19E−03 268.3 181.8 165.4 90 238913_PM_at — — 2.21E−06 1.19E−03 30.9 20.2 20.1 91 239646_PM_at — — 2.23E−06 1.19E−03 100.3 63.1 60.8 92 235701_PM_at — — 2.34E−06 1.24E−03 133.2 66.1 60.0 93 235601_PM_at — — 2.37E−06 1.24E−03 121.9 75.5 79.0 94 230918_PM_at — — 2.42E−06 1.25E−03 170.4 114.5 94.4 95 219112_PM_at FNIP1 /// folliculin interacting 2.49E−06 1.28E−03 568.2 400.2 393.4 RAPGEF6 protein 1 /// Rap guanine nucleotide exchange factor (GEF) 6 96 202228_PM_s_at NPTN neuroplastin 2.52E−06 1.28E−03 1017.7 1331.5 1366.4 97 242839_PM_at — — 2.78E−06 1.39E−03 17.9 14.0 13.6 98 244778_PM_x_at — — 2.85E−06 1.42E−03 205.1 68.0 65.9 99 237388_PM_at — — 2.91E−06 1.42E−03 59.3 38.0 33.0 100 202770_PM_s_at CCNG2 cyclin G2 2.92E−06 1.42E−03 142.2 269.0 270.0 101 240008_PM_at — — 2.96E−06 1.42E−03 96.2 65.6 56.2 102 1557718_PM_at PPP2R5C protein phosphatase 2, 2.97E−06 1.42E−03 615.2 399.8 399.7 regulatory subunit B′, gamma 103 215528_PM_at — — 3.01E−06 1.42E−03 126.8 62.6 69.0 104 204689_PM_at HHEX hematopoietically 3.08E−05 1.44E−03 381.0 499.9 567.9 expressed homeobox 105 213718_PM_at RBM4 RNA binding motif protein 3.21E−06 1.46E−03 199.3 140.6 132.2 4 106 243233_PM_at — — 3.22E−06 1.46E−03 582.3 343.0 337.1 107 239597_PM_at — — 3.23E−06 1.46E−03 1142.9 706.6 720.8 108 232890_PM_at — — 3.24E−06 1.46E−03 218.0 148.7 139.9 109 232883_PM_at — — 3.42E−06 1.53E−03 127.5 79.0 73.1 110 241391_PM_at — — 3.67E−06 1.62E−03 103.8 51.9 48.3 111 244197_PM_x_at — — 3.71E−06 1.62E−03 558.0 397.3 418.8 112 205434_PM_s_at AAK1 AP2 associated kinase 1 3.75E−06 1.62E−03 495.2 339.9 301.2 113 235725_PM_at SMAD4 SMAD family member 4 3.75E−06 1.62E−03 147.1 102.1 112.0 114 203137_PM_at WTAP Wilms tumor 1 associated 3.89E−06 1.66E−03 424.1 609.4 555.8 protein 115 231075_PM_x_at RAPH1 Ras association 3.91E−06 1.66E−03 30.4 193 18.2 (RalGDS/AF-6) and pleckstrin homology domains 1 116 236043_PM_at LOC100130175 hypothetical protein 3.98E−06 1.67E−03 220.6 146.2 146.5 LOC100130175 117 238299_PM_at — — 4.09E−06 1.70E−03 217.1 130.4 130.3 118 243667_PM_at — — 4.12E−06 1.70E−03 314.5 225.3 232.8 119 223937_PM_at FOXP1 forkhead box P1 4.20E−06 1.72E−03 147.7 85.5 90.9 120 238666_PM_at — — 4.25E−06 1.72E−03 219.1 1483 145.5 121 1554771_PM_at — — 4.28E−06 1.72E−03 67.2 41.5 40.8 122 202379_PM_s_at NKTR natural killer-tumor 4.34E−06 1.73E−03 1498.2 1170.6 1042.6 recognition sequence 123 244695_PM_at GHRLOS ghrelin opposite strand 4.56E−06 1.79E−03 78.0 53.0 52.5 (non-protein coding) 124 239393_PM_at — — 4.58E−06 1.79E−03 852.0 554.2 591.7 125 242920_PM_at — — 4.60E−06 1.79E−03 392.8 220.9 251.8 126 242405_PM_at — — 4.66E−06 1.80E−03 415.8 193.8 207.4 127 1556432_PM_at — — 4.69E−06 1.80E−03 61.5 43.1 38.1 128 1570299_PM_at — — 4.77E−06 1.81E−03 27.0 18.0 19.8 129 225198_PM_at VAPA VAMP (vesicle-associated 4.85E−06 1.83E−03 192.0 258.3 273.9 membrane protein)- associated protein A, 33 kDa 130 230702_PM_at — — 4.94E−06 1.85E−03 28.2 18.4 17.5 131 240262_PM_at — — 5.07E−06 1.88E−03 46.9 22.8 28.0 132 232216_PM_at YME1L1 YME1-like 1 (S. cerevisiae) 5.14E−06 1.89E−03 208.6 146.6 130.1 133 225171_PM_at ARHGAP18 Rho GTPase activating 5.16E−06 1.89E−03 65.9 109.1 121.5 protein 18 134 243992_PM_at — — 5.28E−06 1.92E−03 187.1 115.0 125.6 135 227082_PM_at — — 5.45E−06 1.96E−03 203.8 140.4 123.0 136 239948_PM_at NUP153 nucleoporin 153 kDa 5.50E−06 1.96E−03 39.6 26.5 27.8 137 221905_PM_at CYLD cylindromatosis (turban 5.51E−06 1.96E−03 433.0 316.8 315.1 tumor syndrome) 138 242578_PM_x_at SLC22A3 Solute carrier family 22 5.56E−06 1.96E−03 148.4 109.2 120.1 (extraneuronal monoamine transporter), member 3 139 1569238_PM_a_at — — 5.73E−06 1.99E−03 71.0 33.0 36.1 140 201453_PM_x_at RHEB Ras homolog enriched in 5.76E−06 1.99E−03 453.3 600.0 599.0 brain 141 236802_PM_at — — 5.76E−06 1.99E−03 47.9 29.1 29.6 142 232615_PM_at — — 5.82E−06 1.99E−03 4068.5 3073.4 2907.4 143 237179_PM_at PCMTD2 protein-L-isoaspartate (D- 5.84E−06 1.99E−03 48.7 30.2 26.8 aspartate) O- methyltransferase domain containing 2 144 203255_PM_at FBXO11 F-box protein 11 5.98E−06 2.02E−03 748.3 529.4 539.6 145 212989_PM_at SGMS1 sphingomyelin synthase 1 6.04E−06 2.03E−03 57.2 93.1 107.9 146 236754_PM_at PPP1R2 protein phosphatase 1, 6.17E−06 2.05E−03 505.3 380.7 370.1 regulatory (inhibitor) subunit 2 147 1559456_PM_at PPA2 pyrophosphatase 6.24E−06 2.05E−03 68.8 39.7 39.3 (inorganic) 2 148 236494_PM_x_at — — 6.26E−06 2.05E−03 135.0 91.1 82.9 149 237554_PM_at — — 6.30E−06 2.05E−03 53.4 31.5 30.1 150 243469_PM_at — — 6.37E−06 2.05E−03 635.2 308.1 341.5 151 240155_PM_x_at ZNF493 /// zinc finger protein 493 /// 6.45E−06 2.05E−03 483.9 299.9 316.6 ZNF738 zinc finger protein 738 152 222442_PM_s_at ARL8B ADP-ribosylation factor- 6.47E−06 2.05E−03 201.5 292.6 268.3 like 8B 153 240307_PM_at — — 6.48E−06 2.05E−03 55.4 36.8 33.1 154 200864_PM_s_at RAB11A RAB11A, member RAS 6.50E−06 2.05E−03 142.1 210.9 233.0 oncogene family 155 235757_PM_at — — 6.53E−06 2.05E−03 261.4 185.2 158.9 156 222351_PM_at PPP2R1B protein phosphatase 2, 6.58E−06 2.06E−03 75.8 51.1 45.4 regulatory subunit A, beta 157 222788_PM_s_at RSBN1 round spermatid basic 6.63E−06 2.06E−03 389.9 302.7 288.2 protein 1 158 239815_PM_at — — 6.70E−06 2.06E−03 216.9 171.4 159.5 159 219392_PM_x_at PRR11 proline rich 11 6.77E−06 2.07E−03 1065.3 827.5 913.2 160 240458_PM_at — — 6.80E−06 2.07E−03 414.3 244.6 242.0 161 235879_PM_at MBNL1 Muscleblind-like 6.88E−06 2.08E−03 1709.2 1165.5 1098.0 (Drosophila) 162 230529_PM_at HECA headcase homolog 7.08E−06 2.13E−03 585.1 364.3 418.4 (Drosophila) 163 1562063_PM_x_at KIAA1245 /// KIAA1245 /// 7.35E−06 2.20E−03 350.4 238.8 260.8 NBPF1 /// neuroblastoma breakpoint NBPF10 /// family, member 1 /// NBPF11 /// neuroblastoma breakpoint NBPF12 /// fam NBPF24 /// NBPF8 /// NBPF9 164 202769_PM_at CCNG2 cyclin G2 7.42E−06 2.20E−03 697.1 1164.0 1264.6 165 1556493_PM_a_at KDM4C lysine (K)-specific 7.64E−06 2.24E−03 81.4 49.0 44.5 demethylase 4C 166 216509_PM_x_at MLLT10 myeloid/lymphoid or 7.64E−06 2.24E−03 22.4 17.9 19.3 mixed-lineage leukemia (trithorax homolog, Drosophila); translocate 167 223697_PM_x_at C9orf64 chromosome 9 open 7.70E−06 2.25E−03 1013.6 771.2 836.8 reading frame 64 168 235999_PM_at — — 7.77E−06 2.25E−03 227.6 174.1 182.1 169 244766_PM_at LOC100271836 /// SMG1 homolog, 8.03E−06 2.31E−03 133.4 99.4 87.5 LOC440354 /// phosphatldylinositol 3- LOC595101 /// kinase-related kinase LOC541298 /// pseudogene /// PI-3- SMG1 kinase-r 170 230332_PM_at ZCCHC7 Zinc finger, CCHC domain 8.07E−06 2.31E−03 467.4 265.1 263.2 containing 7 171 235308_PM_at ZBTB20 zinc finger and BTB 8.17E−06 2.32E−03 256.7 184.2 167.3 domain containing 20 172 242492_PM_at CLNS1A Chloride channel, 8.19E−06 2.32E−03 128.5 82.8 79.2 nucleotide-sensitive, 1A 173 215898_PM_at TTLL5 tubulin tyrosine ligase-like 8.24E−05 2.32E−03 20.9 14.0 13.8 family, member 5 174 244840_PM_x_at DOCK4 dedicator of cytokinesis 4 8.65E−06 2.42E−03 43.1 16.5 21.5 175 220235_PM_s_at C1orf103 chromosome 1 open 8.72E−06 2.43E−03 88.4 130.5 143.3 reading frame 103 176 229467_PM_at PCBP2 Poly(rC) binding protein 2 8.80E−06 2.44E−03 186.5 125.4 135.8 177 232527_PM_at — — 8.99E−06 2.48E−03 667.4 453.9 461.3 178 243286_PM_at — — 9.24E−06 2.53E−03 142.6 98.2 87.2 179 215628_PM_x_at — — 9.28E−06 2.53E−03 49.6 36.3 39.4 180 1556412_PM_at — — 9.45E−06 2.56E−03 34.9 24.7 23.8 181 204786_PM_s_at IFNAR2 Interferon (alpha, beta 9.64E−06 2.59E−03 795.6 573.0 639.2 and omega) receptor 2 182 234258_PM_at — — 9.73E−06 2.60E−03 27.4 17.8 20.3 183 233274_PM_at — — 9.76E−06 2.60E−03 109.9 77.5 79.4 184 239784_PM_at — — 9.82E−05 2.60E−03 137.0 80.1 70.1 185 242498_PM_x_at — — 1.01E−05 2.65E−03 59.2 40.4 38.9 186 231351_PM_at — — 1.02E−05 2.67E−03 124.8 70.8 60.6 187 222368_PM_at — — 1.03E−05 2.67E−03 89.9 54.5 44.3 188 236524_PM_at — — 1.03E−05 2.67E−03 313.2 234.7 214.2 189 243834_PM_at TNRC6A trinucleotide repeat 1.04E−05 2.67E−03 211.8 145.1 146.9 containing 6A 190 239167_PM_at — — 1.04E−05 2.67E−03 287.4 150.2 160.3 191 239238_PM_at — — 1.05E−05 2.67E−03 136.0 81.6 92.0 192 237194_PM_at — — 1.05E−05 2.67E−03 57.2 34.4 27.9 193 242772_PM_x_at — — 1.06E−05 2.67E−03 299.2 185.2 189.4 194 243827_PM_at — — 1.06E−05 2.67E−03 115.9 50.1 56.4 195 1552536_PM_at VTI1A vesicle transport through 1.10E−05 2.75E−03 61.7 35.1 34.6 interaction with t-SNAREs homolog 1A (yeast) 196 243696_PM_at KIAA0562 KIAA0562 1.12E−05 2.77E−03 19.0 14.8 15.0 197 233648_PM_at — — 1.12E−05 2.77E−03 33.9 21.0 24.1 198 225858_PM_s_at XIAP X-linked inhibitor of 1.16E−05 2.85E−03 1020.7 760.3 772.6 apoptosis 199 238736_PM_at REV3L REV3-like, catalytic 1.19E−05 2.91E−03 214.2 135.8 151.6 subunit of DNA polymerase zeta (yeast) 200 221192_PM_x_at MFSD11 major facilitator 1.20E−05 2.92E−03 100.4 74.5 81.2 superfamily domain containing 11 201 238549_PM_at CBFA2T2 core-binding factor, runt 1.22E−05 2.95E−03 277.5 222.0 206.6 domain, alpha subunit 2; translocated to, 2 202 213015_PM_at BBX bobby sox homolog 1.23E−05 2.96E−03 567.2 446.8 419.6 (Drosophila) 203 60528_PM_at JMJD7- JMJD7-PLA2G4B 1.28E−05 3.07E−03 37.3 29.2 28.7 PLA2G4B /// readthrough /// PLA2G4B phospholipase A2, group IVB (cytosolic) 204 242014_PM_at — — 1.30E−05 3.09E−03 121.9 75.6 86.1 205 238277_PM_at — — 1.30E−05 3.09E−03 30.9 20.4 20.9 206 243527_PM_at — — 1.32E−05 3.11E−03 869.5 517.7 530.8 207 237383_PM_at — — 1.33E−05 3.11E−03 167.0 86.8 93.6 208 218854_PM_at DSE dermatan sulfate 1.33E−05 3.11E−03 223.0 318.1 360.7 epimerase 209 239331_PM_at — — 1.35E−05 3.14E−03 556.5 296.9 302.5 210 228105_PM_at — — 1.35E−05 3.14E−03 387.4 274.0 270.3 211 237006_PM_at — — 1.37E−05 3.15E−03 316.4 177.8 185.3 212 244822_PM_at — — 1.40E−05 3.21E−03 45.3 32.6 27.3 213 241965_PM_at — — 1.43E−05 3.27E−03 194.7 121.1 130.9 214 230389_PM_at FNBP1 formin binding protein 1 1.45E−05 3.30E−03 760.9 567.6 527.1 215 239171_PM_at — — 1.45E−05 3.30E−03 112.1 67.6 65.2 216 236450_PM_at — — 1.46E−05 3.30E−03 28.3 20.2 18.5 217 204236_PM_at FLI1 Friend leukemia virus 1.48E−05 3.33E−03 862.0 1066.1 1074.7 integration 1 218 235925_PM_at — — 1.49E−05 3.33E−03 61.2 41.7 35.3 219 243736_PM_at — — 1.50E−05 3.33E−03 131.8 76.7 70.0 220 236293_PM_at PDSS1 Prenyl (decaprenyl) 1.51E−05 3.33E−03 79.7 59.5 60.9 diphosphate synthase, subunit 1 221 1558410_PM_s_at — — 1.51E−05 3.33E−03 40.1 24.8 22.6 222 1570621_PM_at — — 1.52E−05 3.33E−03 24.1 16.1 18.0 223 233228_PM_at — — 1.54E−05 3.35E−03 256.6 149.9 137.1 224 244801_PM_at PSMB7 Proteasome (prosome, 1.54E−05 3.35E−03 71.6 53.7 48.7 macropain) subunit, beta type, 7 225 236779_PM_at MRPS5 Mitochondrial ribosomal 1.55E−05 3.35E−03 25.4 20.5 17.1 protein S5 226 241063_PM_at — — 1.55E−05 3.35E−03 16.8 13.4 12.4 227 239166_PM_at — — 1.56E−05 3.35E−03 151.4 84.6 79.8 228 222371_PM_at — — 1.59E−05 3.38E−03 1038.5 638.6 629.2 229 1553349_PM_at ARID2 AT rich interactive domain 1.59E−05 3.38E−03 98.2 66.1 65.9 2 (ARID, RFX-like) 230 238894_PM_at — — 1.60E−05 3.38E−03 95.0 58.9 56.8 231 236621_PM_at RPS27 ribosomal protein S27 1.61E−05 3.40E−03 74.6 38.2 41.4 232 222310_PM_at SFRS15 splicing factor, 1.62E−05 3.41E−03 154.5 95.5 106.7 arginine/serine-rich 15 233 1569180_PM_at — — 1.65E−05 3.44E−03 232.8 126.6 126.8 234 240544_PM_at — — 1.67E−05 3.48E−03 45.3 24.9 25.8 235 226062_PM_x_at FAM63A family with sequence 1.74E−05 3.61E−03 532.9 375.1 412.3 similarity 63, member A 236 210679_PM_x_at — — 1.75E−05 3.62E−03 167.5 119.6 123.6 237 203482_PM_at FAM178A family with sequence 1.76E−05 3.62E−03 88.2 69.3 66.3 similarity 178, member A 238 203318_PM_s_at ZNF148 zinc finger protein 148 1.86E−05 3.80E−03 812.1 633.8 647.6 239 233027_PM_at — — 1.87E−05 3.80E−03 167.2 107.4 119.2 240 236966_PM_at ARMC8 armadillo repeat 1.87E−05 3.80E−03 373.4 272.2 240.4 containing 8 241 217446_PM_x_at — — 1.89E−05 3.82E−03 204.7 158.6 170.8 242 241508_PM_at — — 1.91E−05 3.85E−03 106.6 62.3 69.3 243 213940_PM_s_at FNBP1 formin binding protein 1 1.94E−05 3.87E−03 911.3 766.0 710.7 244 215373_PM_x_at — — 1.94E−05 3.87E−03 77.9 54.4 65.9 245 242480_PM_at — — 1.95E−05 3.89E−03 605.9 358.6 393.2 246 228271_PM_at — — 1.97E−05 3.90E−03 109.8 81.3 64.9 247 216211_PM_at — — 1.98E−05 3.90E−03 182.9 132.4 111.1 248 1557632_PM_at — — 1.99E−05 3.90E−03 576.5 426.5 400.0 249 244826_PM_at — — 2.00E−05 3.90E−03 363.7 257.1 267.9 250 239264_PM_at — — 2.01E−05 3.90E−03 162.6 98.9 89.0 251 227931_PM_at INO80D INO80 complex subunit D 2.01E−05 3.90E−03 841.6 635.5 661.8 252 242563_PM_at — — 2.03E−05 3.93E−03 246.4 126.9 135.0 253 238172_PM_at — — 2.05E−05 3.95E−03 88.6 56.1 51.4 254 241893_PM_at — — 2.06E−05 3.96E−03 123.1 59.6 59.3 255 233323_PM_at — — 2.08E−05 3.96E−03 223.8 136.7 135.2 256 242865_PM_at — — 2.08E−05 3.96E−03 382.4 247.8 273.3 257 226252_PM_at — — 2.09E−05 3.97E−03 124.6 91.1 84.0 258 225490_PM_at ARID2 AT rich interactive domain 2.11E−05 3.97E−03 240.9 185.3 169.2 2 (ARID, RFX-like) 259 208654_PM_s_at CD164 CD164 molecule, 2.12E−05 3.97E−03 676.3 1044.0 939.9 sialomucin 260 215338_PM_s_at NKTR natural killer-tumor 2.13E−05 3.97E−03 457.1 352.4 328.2 recognition sequence 261 242110_PM_at — — 2.13E−05 3.97E−03 54.2 31.6 29.8 262 218360_PM_at RAB22A RAB22A, member RAS 2.15E−05 4.00E−03 78.8 122.7 118.7 oncogene family 263 1570166_PM_a_at — — 2.16E−05 4.00E−03 38.7 26.0 27.1 264 208724_PM_s_at RAB1A RAB1A, member RAS 2.17E−05 4.00E−03 1357.9 1688.2 1672.7 oncogene family 265 239901_PM_at — — 2.19E−05 4.03E−03 455.7 255.1 273.1 266 238988_PM_at — — 2.21E−05 4.05E−03 315.4 194.7 209.8 267 235023_PM_at VPS13C Vacuolar protein sorting 2.23E−05 4.08E−03 649.4 471.9 435.1 13 homolog C (S. cerevisiae) 268 217619_PM_x_at — — 2.24E−05 4.08E−03 48.0 39.5 43.3 269 215618_PM_at RSU1 Ras suppressor protein 1 2.27E−05 4.10E−03 34.5 24.9 25.4 270 230779_PM_at TNRC68 trinucleotide repeat 2.27E−05 4.10E−03 767.7 495.5 508.6 containing 6B 271 243981_PM_at STK4 serine/threonine kinase 4 2.31E−05 4.16E−03 490.0 312.1 335.1 272 1569181_PM_x_at — — 2.33E−05 4.17E−03 233.9 127.7 121.5 273 203321_PM_s_at ADNP2 ADNP homeobox 2 2.34E−05 4.17E−03 150.5 117.4 113.4 274 204373_PM_s_at CEP350 centrosomal protein 2.36E−05 4.19E−03 439.2 350.3 352.4 350 kDa 275 239071_PM_at RBBP4 Retinoblastoma binding 2.37E−05 4.20E−03 173.1 131.7 122.9 protein 4 276 224437_PM_s_at VTA1 Vps20-associated 1 2.38E−05 4.21E−03 229.2 335.9 330.0 homolog (S. cerevisiae) 277 243522_PM_at — — 2.41E−05 4.24E−03 14.9 12.5 11.7 278 237803_PM_x_at — — 2.42E−05 4.24E−03 89.4 65.8 54.7 279 229036_PM_at TNRC6B trinucleotide repeat 2.45E−05 4.28E−03 575.8 426.5 436.5 containing 6B 280 222282_PM_at — — 2.47E−05 4.29E−03 340.4 214.0 230.4 281 227074_PM_at LOC100131564 hypothetical 2.49E−05 4.32E−03 389.3 291.8 239.7 LOC100131564 282 242343_PM_x_at — — 2.55E−05 4.38E−03 595.3 403.5 403.1 283 213086_PM_s_at CSNK1A1 casein kinase 1, alpha 1 2.55E−05 4.38E−03 565.0 667.9 660.5 284 205383_PM_s_at ZBTB20 zinc finger and BTB 2.56E−05 4.38E−03 151.5 104.9 92.1 domain containing 20 285 233919_PM_s_at HASP4 hyaluronan binding 2.57E−05 4.38E−03 33.3 22.3 20.4 protein 4 286 231552_PM_at — — 2.57E−05 4.38E−03 258.2 173.1 182.0 287 239017_PM_at LOC100507273 collagen alpha-4(VI) chain- 2.58E−05 4.39E−03 75.4 40.3 39.1 like 288 240072_PM_at ASXL2 Additional sex combs like 2.61E−05 4.42E−03 81.5 50.0 56.0 2 (Drosophila) 289 242362_PM_at — — 2.65E−05 4.47E−03 414.8 279.8 307.1 290 238317_PM_x_at — — 2.67E−05 4.49E−03 386.3 284.6 287.8 291 242471_PM_at — — 2.71E−05 4.53E−03 741.8 426.8 386.9 292 209308_PM_s_at BNIP2 BCL2/adenovirus E1B 2.73E−05 4.55E−03 306.3 444.4 450.1 19 kDa interacting protein 2 293 240254_PM_at — — 2.75E−05 4.57E−03 41.2 27.6 21.5 294 233313_PM_at — — 2.80E−05 4.61E−03 46.3 33.3 30.5 295 1559401_PM_a_at — — 2.80E−05 4.61E−03 20.0 14.2 13.3 296 217158_PM_at LOC442421 /// hypothetical LOC442421 /// 2.82E−05 4.61E−03 12.6 14.2 12.0 LOC728297 prostaglandin E2 receptor EP4 subtype-like 297 239758_PM_at — — 2.82E−05 4.61E−03 133.3 79.2 78.9 298 232882_PM_at — — 2.82E−05 4.61E−03 203.8 95.0 85.1 299 226250_PM_at — — 2.83E−05 4.61E−03 151.7 105.8 97.6 300 201619_PM_at PRDX3 peroxiredoxin 3 2.84E−05 4.62E−03 605.8 852.3 804.1 301 213229_PM_at DICER1 dicer 1, ribonuclease type 2.87E−05 4.62E−03 971.6 652.0 668.8 III 302 242068_PM_at — — 2.87E−05 4.62E−03 281.2 157.5 152.9 303 243470_PM_at — — 2.87E−05 4.62E−03 60.0 43.1 44.4 304 218519_PM_at SLC35A5 solute carrier family 35, 2.88E−05 4.62E−03 173.2 228.3 234.9 member A5 305 240399_PM_at — — 2.92E−05 4.64E−03 15.6 11.2 12.6 306 241501_PM_at — — 2.92E−05 4.64E−03 265.7 175.6 164.5 307 228623_PM_at — — 2.93E−05 4.64E−03 369.6 223.4 226.0 308 225007_PM_at G3BP1 GTPase activating protein 2.99E−05 4.72E−03 549.8 423.9 371.4 (SH3 domain) binding protein 1 309 244239_PM_at — — 3.04E−05 4.78E−03 13.6 9.8 9.9 310 243054_PM_at — — 3.04E−05 4.78E−03 73.9 53.0 50.8 311 219724_PM_s_at KIAA0748 KIAA0748 3.07E−05 4.81E−03 16.6 12.4 12.0 312 240594_PM_at — — 3.09E−05 4.82E−03 44.0 27.7 28.2 313 208003_PM_s_at NFAT5 nuclear factor of activated 3.13E−05 4.88E−03 763.2 510.3 539.6 T-cells 5, tonicity- responsive 314 243147_PM_x_at — — 3.16E−05 4.91E−03 420.2 325.4 351.8 315 236742_PM_at — — 3.18E−05 4.92E−03 102.3 61.7 60.2 316 209964_PM_s_at ATXN7 ataxin 7 3.20E−05 4.92E−03 361.1 250.7 229.7 317 202106_PM_at GOLGA3 golgin A3 3.20E−05 4.92E−03 136.8 110.1 96.0 318 237001_PM_at — — 3.22E−05 4.93E−03 64.6 39.1 38.5 319 202539_PM_s_at HMGCR 3-hydroxy-3- 3.25E−05 4.93E−03 128.3 175.3 192.0 methylglutaryl-CoA reductase 320 244474_PM_at — — 3.26E−05 4.93E−03 86.2 62.4 52.5 321 41512_PM_at BRAP BRCA1 associated protein 3.26E−05 4.93E−03 287.1 234.9 234.3 322 215707_PM_s_at PRNP prion protein 3.27E−05 4.93E−03 25.5 42.5 34.2 323 243088_PM_at — — 3.27E−05 4.93E−03 201.5 119.7 132.3 324 244733_PM_at — — 3.29E−05 4.95E−03 38.9 27.1 26.4 325 223215_PM_s_at JKAMP JNK1/MAPK8-associated 3.31E−05 4.96E−03 327.6 455.8 450.7 membrane protein 326 1559410_PM_at — — 3.34E−05 4.96E−03 31.4 20.7 16.7 327 222311_PM_s_at SFRS15 splicing factor, 3.34E−05 4.96E−03 121.9 92.5 89.7 arginine/serine-rich 15 328 242696_PM_at — — 3.34E−05 4.96E−03 138.7 100.5 88.5 329 223021_PM_x_at VTA1 Vps20-associated 1 3.35E−05 4.96E−03 140.1 205.9 194.5 homolog (S. cerevisiae) 330 241472_PM_at — — 3.36E−05 4.97E−03 172.1 122.6 120.7 331 238000_PM_at — — 3.37E−05 4.97E−03 131.5 83.1 82.0 332 236492_PM_at PPP2R2A protein phosphatase 2, 3.41E−05 5.01E−03 307.2 195.9 205.4 regulatory subunit B, alpha 333 220939_PM_s_at DPP8 dipeptidyl-peptidase 8 3.44E−05 5.02E−03 1061.4 845.7 839.7 334 200733_PM_s_at PTP4A1 protein tyrosine 3.44E−05 5.02E−03 198.9 272.5 268.8 phosphatase type IVA, member 1 335 233440_PM_at — — 3.50E−05 5.06E−03 58.5 35.2 36.5 336 205435_PM_s_at AAK1 AP2 associated kinase 1 3.51E−05 5.06E−03 71.1 51.7 42.0 337 233893_PM_s_at KIAA1530 KIAA1530 3.51E−05 5.06E−03 470.7 303.9 368.9 338 232180_PM_at UGP2 UDP-glucose 3.52E−05 5.06E−03 276.2 182.6 185.7 pyrophosphorylase 2 339 244450_PM_at — — 3.52E−05 5.06E−03 88.9 59.8 59.7 340 238619_PM_at — — 3.53E−05 5.06E−03 906.1 477.0 493.4 341 1555372_PM_at BCL2L11 BCL2-like 11 (apoptosis 3.56E−05 5.08E−03 254.9 161.0 194.6 facilitator) 342 210742_PM_at CDC14A CDC14 cell division cycle 3.59E−05 5.09E−03 214.1 160.8 113.2 14 homolog A (S. cerevisiae) 343 225351_PM_at FAM45A family with sequence 3.59E−05 5.09E−03 421.1 568.4 623.5 similarity 45, member A 344 231716_PM_at RC3H2 ring finger and CCCH-type 3.61E−05 5.11E−03 334.5 272.9 279.1 domains 2 345 239673_PM_at — — 3.63E−05 5.13E−03 71.8 29.9 21.2 346 232509_PM_at PDE4DIP phosphodiesterase 4D 3.66E−05 5.15E−03 19.8 15.3 15.2 interacting protein 347 202749_PM_at WRB tryptophan rich basic 3.77E−05 5.30E−03 240.9 333.2 316.9 protein 348 231199_PM_at — — 3.79E−05 5.30E−03 415.2 293.5 303.8 349 215513_PM_at HYMAI hydatidiform mole 3.80E−05 5.30E−03 66.4 35.9 42.9 associated and imprinted (non-protein coding) 350 232323_PM_s_at TTC17 tetratricopeptide repeat 3.81E−05 5.30E−03 354.0 286.9 265.6 domain 17 351 240824_PM_at — — 3.85E−05 5.34E−03 300.3 202.7 216.3 352 243640_PM_x_at — — 3.86E−05 5.34E−03 36.3 26.9 25.6 353 239902_PM_at — — 3.96E−05 5.47E−03 40.7 32.0 25.5 354 244495_PM_x_at C18orf45 chromosome 18 open 4.00E−05 5.48E−03 111.4 89.7 100.0 reading frame 45 355 221176_PM_x_at — — 4.02E−05 5.48E−03 135.2 107.7 114.4 356 236243_PM_at ZCCHC6 Zinc finger, CCHC domain 4.03E−05 5.48E−03 868.0 534.2 530.6 containing 6 357 243964_PM_at — — 4.03E−05 5.48E−03 114.0 75.3 69.3 358 226970_PM_at FBXO33 F-box protein 33 4.03E−05 5.48E−03 460.9 359.9 344.0 359 206169_PM_x_at ZC3H7B zinc finger CCCH-type 4.04E−05 5.48E−03 439.3 319.9 341.9 containing 7B 360 227969_PM_at LOC400960 hypothetical LOC400960 4.05E−05 5.48E−03 65.4 50.7 46.7 361 207186_PM_s_at BPTF bromodomain PHD finger 4.09E−05 5.52E−03 1217.2 958.4 894.3 transcription factor 362 242918_PM_at NASP Nuclear autoantigenic 4.13E−05 5.56E−03 212.8 127.0 158.1 sperm protein (histone- binding) 363 241226_PM_at — — 4.14E−05 5.56E−03 32.6 22.4 21.0 364 1556382_PM_a_at NAA15 N(alpha)-acetyltransferase 4.15E−05 5.56E−03 15.9 12.4 12.3 15, NatA auxiliary subunit 365 237018_PM_at — — 4.19E−05 5.58E−03 460.1 322.7 305.5 366 225367_PM_at PGM2 phosphoglucomutase 2 4.20E−05 5.58E−03 550.7 709.4 778.0 367 236134_PM_at DCAF7 DDB1 and CUL4 associated 4.20E−05 5.58E−03 120.0 78.1 74.3 factor 7 368 242143_PM_at — — 4.24E−05 5.62E−03 295.6 177.4 179.6 369 237881_PM_at — — 4.31E−05 5.69E−03 128.5 56.6 52.1 370 203100_PM_s_at CDYL chromodomain protein, Y- 4.32E−05 5.69E−03 85.5 116.1 121.1 like 371 244236_PM_at — — 4.34E−05 5.70E−03 22.7 18.1 16.0 372 236561_PM_at — — 4.36E−05 5.71E−03 577.8 412.5 389.2 373 236149_PM_at — — 4.38E−05 5.71E−03 52.7 31.8 29.7 374 214715_PM_x_at ZNF160 zinc finger protein 160 4.38E−05 5.71E−03 860.0 646.3 690.2 375 219326_PM_s_at B3GNT2 UDP-GlcNAc:betaGal beta- 4.40E−05 5.72E−03 18.1 26.8 28.6 1,3-N- acetylglucosaminyltransferase 2 376 201959_PM_s_at MYCBP2 MYC binding protein 2 4.44E−05 5.75E−03 1010.4 762.0 722.2 377 236404_PM_at — — 4.47E−05 5.77E−03 310.1 182.7 185.3 378 233037_PM_at — — 4.52E−05 5.83E−03 19.4 14.3 14.8 379 237768_PM_x_at — — 4.55E−05 5.85E−03 531.4 367.3 361.5 380 202549_PM_at VAPB VAMP (vesicle-associated 4.57E−05 5.86E−03 21.9 15.6 18.9 membrane protein)- associated protein B and C 381 237264_PM_at — — 4.61E−05 5.89E−03 192.5 114.0 115.6 382 226465_PM_s_at SON SON DNA binding protein 4.64E−05 5.89E−03 1664.7 1345.0 1359.5 383 226412_PM_at SFRS18 splicing factor, 4.65E−05 5.89E−03 619.8 443.1 467.6 arginine/serine-rich 18 384 244860_PM_at — — 4.66E−05 5.89E−03 37.8 22.5 21.1 385 240139_PM_at — — 4.67E−05 5.89E−03 162.8 110.0 101.9 386 238807_PM_at GAPDHP62 glyceraldehyde 3 4.67E−05 5.89E−03 126.7 88.3 78.4 phosphate dehydrogenase pseudogene 62 387 230866_PM_at CYSLTR1 cysteinyl leukotriene 4.72E−05 5.93E−03 171.2 267.5 284.1 receptor 1 388 236000_PM_s_at — — 4.72E−05 5.93E−03 326.9 240.3 242.0 389 237895_PM_at — — 4.74E−05 5.94E−03 469.8 258.1 223.3 390 243966_PM_at — — 4.79E−05 5.97E−03 227.7 174.9 165.4 391 1556060_PM_a_at ZNF451 zinc finger protein 451 4.80E−05 5.97E−03 550.1 418.5 416.6 392 242598_PM_at — — 4.81E−05 5.97E−03 465.2 250.1 308.0 393 1569237_PM_at — — 4.83E−05 5.97E−03 52.8 35.4 37.1 394 232791_PM_at — — 4.83E−05 5.97E−03 25.2 17.7 16.8 395 1565567_PM_at — — 4.85E−05 5.97E−03 1032.1 665.2 779.1 396 222252_PM_x_at UBQLN4 ubiquilin 4 4.85E−05 5.97E−03 73.1 59.3 61.8 397 229765_PM_at ZNF207 zinc finger protein 207 4.90E−05 6.01E−03 722.8 581.6 540.4 398 201302_PM_at ANXA4 annexin A4 4.92E−05 6.01E−03 303.7 429.1 454.7 399 1556783_PM_a_at — — 4.92E−05 6.01E−03 15.2 11.7 11.7 400 215200_PM_x_at — — 4.94E−05 6.02E−03 97.7 79.4 80.4 401 231005_PM_at — — 4.98E−05 6.04E−03 243.5 155.8 167.8 402 243249_PM_at — — 4.99E−05 6.04E−03 832.1 598.5 633.0 403 233702_PM_x_at — — 5.00E−05 6.04E−03 381.5 289.0 318.0 404 1564077_PM_at — — 5.01E−05 6.04E−03 99.8 65.3 47.8 405 232613_PM_at PBRM1 polybromo 1 5.04E−05 6.06E−03 152.3 108.9 117.0 406 225859_PM_at XIAP X-linked inhibitor of 5.11E−05 6.13E−03 716.1 535.6 524.7 apoptosis 407 240302_PM_at — — 5.20E−05 6.23E−03 70.6 46.5 42.3 408 244791_PM_at — — 5.22E−05 6.24E−03 72.4 41.7 43.0 409 244508_PM_at 7-Sep Septin 7 5.26E−05 6.26E−03 80.0 50.2 46.2 410 1554251_PM_at HP1BP3 heterochromatin protein 5.28E−05 6.26E−03 192.1 150.9 123.2 1, binding protein 3 411 242862_PM_x_at — — 5.28E−05 6.26E−03 114.4 82.9 88.5 412 243381_PM_at — — 5.29E−05 6.26E−03 35.7 24.3 23.6 413 1561763_PM_at — — 5.38E−05 6.35E−03 92.4 56.7 59.8 414 239102_PM_s_at — — 5.41E−05 6.35E−03 1585.7 933.9 1087.2 415 215179_PM_x_at PGF Placental growth factor 5.41E−05 6.35E−03 820.1 625.4 683.9 416 200730_PM_s_at PTP4A1 protein tyrosine 5.42E−05 6.35E−03 76.9 120.8 125.1 phosphatase type IVA, member 1 417 233309_PM_at — — 5.44E−05 6.35E−03 142.7 89.0 102.0 418 210282_PM_at ZMYM2 zinc finger, MYM-type 2 5.48E−05 6.39E−03 246.4 166.5 163.2 419 243025_PM_at — — 5.62E−05 6.53E−03 74.0 52.0 54.7 420 237475_PM_x_at CCDC152 coiled-coil domain 5.72E−05 6.63E−03 830.9 624.3 684.3 containing 152 421 212526_PM_at SPG20 spastic paraplegia 20 5.73E−05 6.63E−03 150.6 197.3 204.9 (Troyer syndrome) 422 210146_PM_x_at LILRB2 leukocyte 5.75E−05 6.64E−03 992.0 1158.5 1393.3 immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 423 236274_PM_at EIF3B eukaryotic translation 5.76E−05 6.64E−03 30.4 24.7 22.7 initiation factor 3, subunit B 424 232383_PM_at TFEC transcription factor EC 5.79E−05 6.66E−03 49.6 132.2 94.3 425 235803_PM_at — — 5.84E−05 6.70E−03 116.0 73.4 66.2 426 208238_PM_x_at — — 5.86E−05 6.70E−03 589.1 460.7 496.6 427 1555057_PM_at NDUFS4 NADH dehydrogenase 5.87E−05 6.70E−03 27.7 20.0 19.1 (ubiquinone) Fe—S protein 4, 18 kDa (NADH- coenzyme Q reductase) 428 209188_PM_x_at DR1 down-regulator of 5.88E−05 6.70E−03 157.9 207.6 214.8 transcription 1, TBP- binding (negative cofactor 2) 429 1559020_PM_a_at — — 5.92E−05 6.73E−03 60.4 39.6 38.3 430 212872_PM_s_at MED20 mediator complex subunit 5.95E−05 6.75E−03 65.5 89.8 88.9 20 431 234032_PM_at — — 5.98E−05 6.76E−03 245.4 134.1 120.3 432 232516_PM_x_at YY1AP1 YY1 associated protein 1 6.02E−05 6.76E−03 277.0 206.7 227.8 433 218611_PM_at IER5 immediate early response 5 6.02E−05 6.76E−03 384.0 516.5 548.6 434 242712_PM_x_at RANBP2 /// RAN binding protein 2 /// 6.02E−05 6.76E−03 92.4 52.4 61.2 RGPD1 /// RANBP2-like and GRIP RGPD2 /// domain containing 1 /// RGPD3 /// RANBP2-like and RGPD4 /// RGPD5 /// RGPD6 /// RGPD8 435 229434_PM_at — — 6.10E−05 6.81E−03 1281.8 990.5 982.0 436 236379_PM_at — — 6.11E−05 6.81E−03 489.0 318.7 299.6 437 231495_PM_at — — 6.12E−05 6.81E−03 261.0 163.0 135.0 438 232012_PM_at CAPN1 calpain 1, (mu/l) large 6.13E−05 6.81E−03 179.6 143.7 133.3 subunit 439 1558740_PM_s_at — — 6.15E−05 6.81E−03 246.8 179.6 171.8 440 235837_PM_at — — 6.17E−05 6.81E−03 97.7 76.6 73.6 441 201737_PM_s_at 6-Mar membrane-associated ring 6.18E−05 6.81E−03 558.7 409.2 370.6 finger (C3HC4) 6 442 239561_PM_at — — 6.20E−05 6.81E−03 143.1 75.4 80.9 443 243473_PM_at — — 6.23E−05 6.81E−03 20.0 15.1 15.1 444 215887_PM_at ZNF277 zinc finger protein 277 6.24E−05 6.81E−03 144.3 101.2 106.6 445 241155_PM_at — — 6.25E−05 6.81E−03 308.3 207.2 204.8 446 1563455_PM_at SIK3 SIK family kinase 3 6.27E−05 6.81E−03 133.1 86.6 90.7 447 243089_PM_at — — 6.27E−05 6.81E−03 49.4 28.7 24.7 448 232726_PM_at — — 6.27E−05 6.81E−03 185.5 77.8 84.3 449 238880_PM_at GTF3A general transcription 6.28E−05 6.81E−03 471.0 322.6 305.2 factor IIIA 450 216652_PM_s_at DR1 down-regulator of 6.30E−05 6.82E−03 110.6 152.5 153.6 transcription 1, TBP- binding (negative cofactor 2) 451 215605_PM_at NCOA2 Nuclear receptor 6.41E−05 6.92E−03 302.5 184.3 220.5 coactivator 2 452 239383_PM_at — — 6.47E−05 6.98E−03 95.2 62.9 54.6 453 230713_PM_at — — 6.50E−05 6.99E−03 179.2 116.7 108.1 454 201300_PM_s_at PRNP prion protein 6.53E−05 7.01E−03 327.7 516.1 538.4 455 232264_PM_at — — 6.59E−05 7.06E−03 124.7 63.8 62.6 456 243759_PM_at SFRS15 Splicing factor, 6.65E−05 7.11E−03 103.6 67.4 71.4 arginine/serine-rich 15 457 235493_PM_at — — 6.72E−05 7.16E−03 97.5 67.3 66.6 458 1561346_PM_at — — 6.73E−05 7.16E−03 126.0 89.3 97.7 459 234989_PM_at — — 6.78E−05 7.19E−03 560.8 300.7 287.5 460 221616_PM_s_at TAF9B TAF9B RNA polymerase II, 6.87E−05 7.27E−03 241.5 162.4 168.8 TATA box binding protein (TBP)-associated factor, 31 kDa 461 1562062_PM_at KIAA1245 /// KIAA1245 /// 6.93E−05 7.31E−03 345.4 232.4 266.6 NBPF1 /// neuroblastoma breakpoint NBPF10 /// family, member 1 /// NBPF11 /// neuroblastoma breakpoint NBPF12 /// fam NBPF24 /// NBPF8 /// NBPF9 462 202829_PM_s_at VAMP7 vesicle-associated 6.93E−05 7.31E−03 563.9 752.2 674.2 membrane protein 7 463 1557830_PM_at — — 7.06E−05 7.42E−03 48.1 33.4 29.9 464 200667_PM_at UBE2D3 ubiquitin-conjugating 7.06E−05 7.42E−03 1057.4 1367.1 1384.4 enzyme E2D 3 (UBC4/5 homolog, yeast) 465 221899_PM_at N4BP2L2 NEDD4 binding protein 2- 7.10E−05 7.44E−03 4054.4 3196.6 3171.5 like 2 466 236934_PM_at — — 7.13E−05 7.45E−03 143.5 63.2 56.1 467 1565762_PM_at — — 7.21E−05 7.50E−03 59.0 40.2 33.8 468 222316_PM_at — — 7.21E−05 7.50E−03 247.1 154.8 164.9 469 239811_PM_at — — 7.26E−05 7.53E−03 1050.3 645.8 708.3 470 212326_PM_at VPS13D vacuolar protein sorting 7.26E−05 7.53E−03 30.4 23.0 23.6 13 homolog D (S. cerevisiae) 471 228070_PM_at PPP2R5E protein phosphatase 2, 7.29E−05 7.54E−03 365.2 286.1 275.0 regulatory subunit B′, epsilon isoform 472 1563080_PM_at — — 7.33E−05 7.56E−03 21.3 16.7 15.5 473 1560082_PM_at — — 7.41E−05 7.63E−03 39.8 29.5 27.4 474 224778_PM_s_at — — 7.44E−05 7.65E−03 1054.6 845.9 906.9 475 240174_PM_at — — 7.48E−05 7.66E−03 249.8 144.1 143.7 476 1566887_PM_x_at — — 7.48E−05 7.66E−03 320.8 247.9 284.8 477 222104_PM_x_at GTF2H3 general transcription 7.54E−05 7.70E−03 468.3 361.7 374.9 factor IIH, polypeptide 3, 34 kDa 478 233427_PM_x_at — — 7.58E−05 7.73E−03 278.5 218.3 236.5 479 241917_PM_at — — 7.60E−05 7.74E−03 115.7 62.5 64.7 480 230392_PM_at — — 7.63E−05 7.74E−03 119.3 80.5 83.5 481 242876_PM_at AKT3 V-akt murine thymoma 7.74E−05 7.83E−03 29.6 19.3 18.5 viral oncogene homolog 3 (protein kinase B, gamma) 482 217482_PM_at — — 7.74E−05 7.83E−03 53.7 33.0 30.6 483 205647_PM_at RAD52 RAD52 homolog 7.76E−05 7.83E−03 17.6 15.1 13.8 (S. cerevisiae) 484 1570007_PM_at LRRC8C leucine rich repeat 7.80E−05 7.85E−03 21.6 15.4 16.5 containing 8 family, member C 485 230505_PM_at LOC145474 hypothetical LOC145474 7.81E−05 7.85E−03 302.3 137.3 148.1 486 232929_PM_at — — 7.87E−05 7.89E−03 51.2 28.8 28.1 487 239868_PM_at — — 7.91E−05 7.92E−03 21.5 14.5 14.5 488 236974_PM_at — — 8.05E−05 8.04E−03 245.7 165.1 165.5 489 204342_PM_at SLC25A24 solute carrier family 25 8.09E−05 8.06E−03 281.9 464.1 438.3 (mitochondrial carrier; phosphate carrier), member 24 490 229574_PM_at TRA2A transformer 2 alpha 8.10E−05 8.06E−03 850.9 620.8 645.7 homolog (Drosophila) 491 228694_PM_at — — 8.13E−05 8.07E−03 167.1 125.4 121.9 492 208082_PM_x_at — — 8.15E−05 8.07E−03 716.5 587.4 601.3 493 235983_PM_at — — 8.28E−05 8.18E−03 121.1 88.8 72.2 494 232169_PM_x_at NDUFS8 NADH dehydrcgenase 8.39E−05 8.28E−03 466.1 349.6 373.1 (ubiquinone) Fe—S protein 8, 23 kDa (NADH- coenzyme Q reductase) 495 237290_PM_at — — 8.52E−05 8.38E−03 10.1 10.3 12.5 496 244599_PM_at — — 8.54E−05 8.39E−03 257.4 185.5 169.4 497 1557433_PM_at — — 8.56E−05 8.39E−03 23.1 17.8 16.7 498 244433_PM_at — — 8.59E−05 8.39E−03 752.7 478.2 540.7 499 242748_PM_at SREBF2 sterol regulatory element 8.59E−05 8.39E−03 87.0 61.1 61.9 binding transcription factor 2 500 1563505_PM_at DUSP16 Dual specificity 8.73E−05 8.51E−03 14.0 11.0 11.7 phosphatase 16 501 237987_PM_x_at — — 8.76E−05 8.51E−03 8.4 8.8 9.8 502 239808_PM_at — — 8.77E−05 8.51E−03 210.2 163.0 137.8 503 232584_PM_at — — 8.82E−05 8.53E−03 21.4 13.1 11.9 504 243993_PM_at — — 8.82E−05 8.53E−03 194.6 118.3 117.0 505 54051_PM_at PKNOX1 PBX/knotted 1 homeobox 8.84E−05 8.53E−03 39.4 30.4 30.7 1 506 225522_PM_at AAK1 AP2 associated kinase 1 8.97E−05 8.64E−03 223.6 176.1 151.7 507 222667_PM_s_at ASH1L ash1 (absent, small, or 9.02E−05 8.67E−03 1637.7 1288.3 1282.8 homeotic)-like (Drosophila) 508 202822_PM_at LPP LIM domain containing 9.05E−05 8.69E−03 371.8 281.4 299.5 preferred translocation partner in lipoma 509 242995_PM_at — — 9.10E−05 8.70E−03 59.4 38.9 36.7 510 243512_PM_x_at — — 9.11E−05 8.70E−03 36.0 22.1 22.0 511 243826_PM_at — — 9.12E−05 8.70E−03 317.0 181.4 215.2 512 201443_PM_s_at ATP6AP2 ATPase, H+ transporting, 9.16E−05 8.72E−03 1784.1 2195.2 2170.5 lysosomal accessory protein 2 513 243578_PM_at — — 9.20E−05 8.73E−03 26.9 18.2 17.5 514 240971_PM_x_at — — 9.21E−05 8.73E−03 215.1 144.4 139.0 515 238853_PM_at RAB3IP RAB3A interacting protein 9.23E−05 8.73E−03 35.1 22.9 23.6 (rabin3) 516 221829_PM_s_at TNPO1 transportin 1 9.28E−05 8.76E−03 1035.0 803.0 842.0 517 242529_PM_x_at — — 9.30E−05 8.77E−03 34.6 23.5 22.3 518 239301_PM_at — — 9.34E−05 8.78E−03 226.9 128.8 139.8 519 1570194_PM_x_at — — 9.38E−05 8.81E−03 196.3 91.9 121.4 520 233867_PM_at — — 9.49E−05 8.89E−03 863.1 555.6 564.0 521 242479_PM_s_at — — 9.52E−05 8.90E−03 9.5 10.4 11.4 522 217679_PM_x_at — — 9.54E−05 8.90E−03 680.8 483.9 513.8 523 1559142_PM_at MYST3 MYST histone 9.60E−05 8.94E−03 25.5 19.8 21.0 acetyltransferase (monocytic leukemia) 3 524 209089_PM_at RAB5A RAB5A, member RAS 9.75E−05 9.06E−03 740.4 904.4 950.5 oncogene family 525 232372_PM_at — — 9.84E−05 9.13E−03 23.3 17.3 17.1 526 218534_PM_s_at AGGF1 angiogenic factor with G 9.91E−05 9.18E−03 82.0 118.9 114.9 patch and FHA domains 1 527 1559723_PM_s_at — — 9.99E−05 9.20E−03 20.1 14.8 14.3 528 232784_PM_at — — 0.000100001 0.00919631 68.2 51.7 46.1 529 242233_PM_at — — 0.000100081 0.00919631 614.1 453.5 466.0 530 223662_PM_x_at DDX59 DEAD (Asp-Glu-Ala-Asp) 0.000100162 0.00919631 129.3 106.9 114.9 box polypeptide 59 531 244865_PM_at — — 0.000100377 0.00919631 24.8 19.1 19.7 532 242121_PM_at NCRNA00182 non-protein coding RNA 0.000100405 0.00919631 1332.1 853.7 927.4 182 533 202946_PM_s_at BTBD3 BTB (POZ) domain 0.000100622 0.00919889 26.6 42.1 44.6 containing 3 534 244611_PM_at MED13 Mediator complex subunit 0.000102003 0.00928958 65.6 43.8 38.7 13 535 205992_PM_s_at IL15 Interleukin 15 0.000102174 0.00928958 177.2 292.0 335.6 536 242889_PM_x_at LOC645431 hypothetical LOC645431 0.000102186 0.00928958 170.7 141.4 145.9 537 243030_PM_at — — 0.000102974 0.00933895 384.8 242.9 256.3 538 242482_PM_at PRKAR1A protein kinase, cAMP- 0.000103274 0.00933895 131.2 79.8 90.5 dependent, regulatory, type I, alpha (tissue specific extinguisher 539 220085_PM_at HELLS helicase, lymphoid-specific 0.000103304 0.00933895 18.5 15.4 12.7 540 219017_PM_at ETNK1 ethanolamine kinase 1 0.000103707 0.00935802 52.2 83.1 91.3 541 240665_PM_at — — 0.000104299 0.0093768 1121.4 732.2 726.7 542 230097_PM_at — — 0.0001043 0.0093768 96.4 68.6 58.9 543 237868_PM_x_at — — 0.000104648 0.00939076 167.5 123.1 138.3 544 201298_PM_s_at MOBKL1B MOB1, Mps One Binder 0.000105824 0.00947713 1271.1 1594.0 1649.3 kinase activator-like 1B (yeast) 545 236931_PM_at — — 0.000106187 0.00947713 145.2 76.8 65.6 546 222230_PM_s_at ACTR10 actin-related protein 10 0.000106194 0.00947713 641.3 778.2 745.3 homolog (S. cerevisiae) 547 217662_PM_x_at — — 0.000106587 0.00947997 49.5 41.1 43.3 548 224787_PM_s_at RAB18 RAB18, member RAS 0.000106745 0.00947997 233.3 359.4 359.2 oncogene family 549 240019_PM_at — — 0.000106882 0.00947997 653.3 366.6 385.3 550 204771_PM_s_at TTF1 transcription termination 0.000107004 0.00947997 468.3 364.4 376.0 factor, RNA polymerase I 551 238875_PM_at — — 0.000109875 0.00971666 159.5 114.3 108.4 552 213574_PM_s_at — — 0.000110256 0.00973269 1540.5 1142.7 1168.0 553 1558237_PM_x_at — — 0.000112606 0.00990882 275.2 205.9 217.7 554 244771_PM_at KBTBD12 kelch repeat and BTB 0.000112658 0.00990882 11.0 9.1 10.2 (POZ) domain containing 12 555 239049_PM_at — — 0.000113136 0.00992062 357.9 233.0 253.1 556 215191_PM_at — — 0.000113298 0.00992062 300.6 196.1 185.8 557 226651_PM_at HOMER1 homer homolog 1 0.000113403 0.00992062 63.4 42.8 43.1 (Drosophila) 558 215383_PM_x_at SPG21 spastic paraplegia 21 0.000114806 0.0100254 666.6 540.4 568.6 (autosomal recessive, Mast syndrome) 559 227435_PM_at KIAA2018 KIAA2018 0.000115657 0.0100816 501.0 352.7 394.7 560 205104_PM_at SNPH syntaphilin 0.000117244 0.0102017 21.9 17.7 17.0 561 1558569_PM_at LOC100131541 Hypothetical 0.00011856 0.0102806 104.4 51.7 55.9 LOC100131541 562 243404_PM_at — — 0.00011868 0.0102806 198.4 140.6 145.0 563 220467_PM_at — — 0.000118879 0.0102806 205.4 130.1 107.4 564 211509_PM_s_at RTN4 reticulon 4 0.000119113 0.0102806 1430.3 1755.3 1868.7 565 204715_PM_at PANX1 pannexin 1 0.000119206 0.0102806 16.5 22.6 21.9 566 235847_PM_at — — 0.000120325 0.0103588 329.6 175.4 160.4 567 239600_PM_at — — 0.000120761 0.010378 281.8 144.6 145.5 568 244457_PM_at — — 0.000121998 0.0104658 241.3 153.0 150.3 569 226140_PM_s_at OTUD1 OTU domain containing 1 0.00012251 0.0104913 407.3 538.5 585.7 570 227576_PM_at — — 0.000123208 0.0105326 377.0 214.1 192.3 571 242739_PM_at — — 0.000123432 0.0105332 41.3 28.0 24.7 572 244625_PM_at — — 0.000123749 0.0105418 39.7 22.7 23.5 573 228415_PM_at AP1S2 adaptor-related protein 0.000125275 0.0106532 141.1 213.5 223.3 complex 1, sigma 2 subunit 574 214902_PM_x_at — — 0.000126202 0.0106943 470.2 356.8 390.5 575 241460_PM_at — — 0.000126341 0.0106943 423.2 274.7 295.1 576 1564733_PM_at — — 0.000126417 0.0106943 137.6 93.8 92.7 577 235959_PM_at — — 0.000126652 0.0106956 309.3 200.7 227.3 578 1556420_PM_s_at YPEL2 yippee-like 2 (Drosophila) 0.000127836 0.0107739 110.9 77.0 79.7 579 243450_PM_at — — 0.000128021 0.0107739 51.7 31.2 30.3 580 234048_PM_s_at KIAA1632 KIAA1632 0.000128316 0.0107801 12.9 10.6 11.7 581 201057_PM_s_at GOLGB1 golgin B1 0.000129333 0.0108468 196.9 149.2 148.0 582 242827_PM_x_at — — 0.000130436 0.0109205 345.7 226.7 192.8 583 230607_PM_at — — 0.000131409 0.0109798 29.9 22.3 18.8 584 218379_PM_at RBM7 RNA binding motif protein 7 0.000131656 0.0109798 249.9 336.2 329.5 585 241930_PM_x_at — — 0.00013191 0.0109798 27.0 20.7 20.0 586 235804_PM_at — — 0.000132077 0.0109798 42.3 33.0 28.3 587 241688_PM_at — — 0.000132271 0.0109798 32.0 21.7 22.8 588 230970_PM_at — — 0.000133316 0.0110392 1228.2 700.6 742.7 589 235613_PM_at — — 0.000133562 0.0110392 113.6 77.4 73.3 590 214990_PM_at PIGO phosphatidylinositol 0.000133666 0.0110392 11.9 9.6 10.3 glycan anchor biosynthesis, class O 591 242349_PM_at HECTD1 HECT domain containing 1 0.000134359 0.0110777 95.2 68.2 67.4 592 225204_PM_at PPTC7 PTC7 protein phosphatase 0.000134942 0.011107 790.6 552.0 605.7 homolog (S. cerevisiae) 593 235660_PM_at — — 0.000136056 0.0111798 130.3 89.4 97.7 594 216682_PM_s_at FAM48A Family with sequence 0.000136461 0.0111942 232.3 149.8 165.4 similarity 48, member A 595 1556373_PM_a_at — — 0.000136827 0.0112053 321.3 172.5 180.8 596 1556352_PM_at — — 0.000137503 0.0112418 256.9 139.8 138.1 597 239655_PM_at — — 0.00013785 0.0112513 110.5 74.2 73.5 598 240600_PM_at — — 0.000138859 0.0113048 324.9 212.7 211.5 599 1556462_PM_a_at — — 0.00013897 0.0113048 99.4 61.8 42.5 600 1556323_PM_at CELF2 CUGBP, Elav-like family 0.000139628 0.0113223 1100.4 748.0 757.0 member 2 601 225207_PM_at PDK4 pyruvate dehydrogenase 0.00013965 0.0113223 85.6 214.9 192.3 kinase, isozyme 4 602 235811_PM_at — — 0.000140131 0.0113425 802.0 498.5 381.6 603 226952_PM_at EAF1 ELL associated factor 1 0.000141842 0.0114619 129.3 158.6 157.6 604 202484_PM_s_at MBD2 methyl-CpG binding 0.000144855 0.011686 799.5 984.4 1005.3 domain protein 2 605 217803_PM_at GOLPH3 golgi phosphoprotein 3 0.000146215 0.0117762 690.0 818.8 813.0 (coat-protein) 606 213624_PM_at SMPDL3A sphingomyelin 0.000147195 0.0118356 113.5 213.6 238.0 phosphodiesterase, acid- like 3A 607 229528_PM_at SBNO1 strawberry notch homolog 0.000148186 0.0118956 177.6 129.9 124.2 1 (Drosophila) 603 230669_PM_at RASA2 RAS p21 protein activator 0.00014871 0.0119178 1010.8 776.3 762.2 2 609 242369_PM_x_at — — 0.000148951 0.0119173 234.7 155.9 163.8 610 239978_PM_at — — 0.000149912 0.011975 185.5 145.0 134.1 611 235841_PM_at — — 0.000150894 0.0119968 182.1 93.8 106.3 612 229457_PM_at ANKHD1 ankyrin repeat and KH 0.000150905 0.0119968 94.5 65.6 61.7 domain containing 1 613 240997_PM_at — — 0.000150923 0.0119968 25.9 20.3 22.3 614 1554595_PM_at SYMPK symplekin 0.000151416 0.0120164 157.9 108.3 107.0 615 201097_PM_s_at ARF4 ADP-ribosylatlon factor 4 0.000151957 0.0120262 1063.5 1248.9 1279.6 616 233319_PM_x_at — — 0.000152034 0.0120262 23.2 18.3 19.5 617 232834_PM_at — — 0.000153247 0.0121025 84.1 52.9 40.6 618 225236_PM_at RDM18 RNA binding motif protein 0.000153692 0.0121151 104.6 142.4 140.8 18 619 239285_PM_at — — 0.000154204 0.0121151 260.6 184.2 159.7 620 239409_PM_at — — 0.000154229 0.0121151 694.8 433.8 443.4 621 213860_PM_x_at CSNK1A1 casein kinase 1, alpha 1 0.000154641 0.0121151 679.8 796.3 765.4 622 215600_PM_x_at FBXW12 F-box and WD repeat 0.000154649 0.0121151 449.4 342.1 375.4 domain containing 12 623 234043_PM_at — — 0.000155523 0.012164 16.1 11.7 11.8 624 238214_PM_at LRRC69 leucine rich repeat 0.000157072 0.0122546 85.9 62.5 59.4 containing 69 625 243170_PM_at — — 0.000157184 0.0122546 869.6 505.9 573.4 626 241906_PM_at — — 0.000158212 0.012315 315.8 182.8 218.3 627 217713_PM_x_at — — 0.000159055 0.0123617 132.7 106.6 120.4 628 213404_PM_s_at RHEB Ras homolog enriched in 0.000159625 0.0123757 216.5 277.0 267.3 brain 629 1563130_PM_a_at — — 0.000159754 0.0123757 129.8 89.9 95.1 630 213936_PM_x_at SFTPB surfactant protein B 0.00016064 0.0124057 69.3 56.9 57.5 631 222380_PM_s_at PDCD6 Programmed cell death 6 0.00016065 0.0124057 244.5 160.8 166.0 632 222313_PM_at — — 0.00016118 0.0124269 284.8 214.1 218.2 633 232420_PM_x_at LOC100289341 Similar to hCG2022304 0.000162106 0.012472 86.6 68.9 77.8 634 225041_PM_at MPHOSPH8 M-phase phosphoprotein 8 0.000162277 0.012472 826.1 647.9 621.4 635 243559_PM_at — — 0.000163991 0.0125745 23.6 16.6 16.1 636 201218_PM_at CTBP2 C-terminal binding protein 2 0.000164126 0.0125745 475.6 589.0 644.6 637 244292_PM_at — — 0.000164428 0.0125778 107.0 69.3 60.4 638 232874_PM_at DOCK9 dedicator of cytokinesis 9 0.00016535 0.0126285 31.3 19.1 15.3 639 1565886_PM_at — — 0.000165997 0.0126581 151.6 99.6 94.8 640 208873_PM_s_at REEP5 receptor accessory protein 0.000166895 0.0127067 449.8 656.5 674.1 5 641 242077_PM_x_at C6orf150 chromosome 6 open 0.000167363 0.0127225 1009.1 819.5 869.4 reading frame 150 642 214722_PM_at NOTCH2NL notch 2 N-terminal like 0.000168102 0.0127587 1850.6 1351.5 1425.5 643 1558014_PM_s_at FAR1 fatty acyl CoA reductase 1 0.000169744 0.0128455 41.8 79.3 73.2 644 1563204_PM_at ZNF627 Zinc finger protein 627 0.000169773 0.0128455 10.5 10.6 12.2 645 204181_PM_s_at ZBTB43 zinc finger and BTB 0.000170738 0.0128985 146.3 112.8 105.2 domain containing 43 646 241491_PM_at — — 0.000171717 0.0129524 25.9 18.5 18.7 647 206965_PM_at KLF12 Kruppel-like factor 12 0.000173042 0.0130322 72.3 46.6 37.1 648 1562364_PM_at GVIN1 GTPase, very large 0.000174604 0.0131295 43.6 29.8 27.8 interferon inducible 1 649 217810_PM_x_at LARS leucyl-tRNA synthetase 0.000175517 0.013168 324.3 259.5 248.2 650 225890_PM_at C20orf72 chromosome 20 open 0.000175656 0.013168 191.3 269.4 253.2 reading frame 72 651 241041_PM_at — — 0.000176027 0.0131755 168.1 70.3 79.7 652 226261_PM_at ZNRF2 zinc and ring finger 2 0.000176915 0.0132217 34.7 48.9 49.9 653 240134_PM_at — — 0.000177936 0.0132776 145.1 82.6 89.0 654 213593_PM_s_at TRA2A transformer 2 alpha 0.000178805 0.0133221 1349.1 958.0 977.3 homolog (Drosophila) 655 244845_PM_at — — 0.000179762 0.0133567 283.3 150.4 159.3 656 236558_PM_at — — 0.000179818 0.0133567 168.5 97.3 92.2 657 239387_PM_at — — 0.000180312 0.013373 89.7 59.2 68.7 658 215378_PM_at — — 0.000181169 0.0134161 79.3 46.5 53.2 659 204516_PM_at ATXN7 ataxin 7 0.000181726 0.013437 948.0 736.1 700.4 660 242337_PM_at — — 0.000183073 0.0135161 153.1 102.2 105.5 661 1557707_PM_at — — 0.00018375 0.0135455 71.2 54.3 543 662 241065_PM_x_at CMAS Cytidine monophosphate 0.000187162 0.0137205 146.0 117.7 124.7 N-acetylneuraminic acid synthetase 663 1557814_PM_a_at — — 0.00018742 0.0137205 153.0 95.7 119.2 664 1559249_PM_at ATXN1 ataxin 1 0.000187463 0.0137205 135.3 79.7 78.1 665 236474_PM_at — — 0.000187832 0.0137205 39.1 26.0 26.2 666 234762_PM_x_at NLN neurolysin 0.000187929 0.0137205 416.0 322.3 333.7 (metallopeptidase M3 family) 667 215529_PM_x_at DIP2A DIP2 disco-interacting 0.00018854 0.0137205 359.6 290.1 291.0 protein 2 homolog A (Drosophila) 668 208648_PM_at VCP valosin-containing protein 0.000188635 0.0137205 264.7 194.0 192.4 669 225612_PM_s_at B3GNT5 UDP-GlcNAc:betaGal beta- 0.00018864 0.0137205 155.2 206.5 290.7 1,3-N- acetylglucosaminyltransferase 5 670 234758_PM_at — — 0.000188803 0.0137205 15.8 12.4 12.3 671 208857_PM_s_at PCMT1 protein-L-isoaspartate (D- 0.000188939 0.0137205 532.7 785.1 766.5 aspartate) O- methyltransferase 672 241438_PM_at — — 0.000189877 0.0137681 43.6 28.5 27.2 673 1558233_PM_s_at ATF1 activating transcription 0.000192141 0.0139007 47.1 78.5 73.9 factor 1 674 240168_PM_at XPO7 exportin 7 0.000192277 0.0139007 27.1 19.5 19.1 675 208662_PM_s_at TTC3 tetratricopeptide repeat 0.000192568 0.0139011 470.2 354.0 311.1 domain 3 676 230629_PM_s_at EP400 E1A binding protein p400 0.000192856 0.0139013 77.5 54.0 43.4 677 244610_PM_x_at — — 0.000194955 0.013997 26.9 18.4 18.8 678 229429_PM_x_at LOC728855 hypothetical LOC728855 0.000195003 0.013997 1167.6 986.3 930.5 679 236829_PM_at — — 0.000195045 0.013997 199.0 138.3 143.6 680 222326_PM_at — — 0.000196028 0.0140277 706.2 438.5 470.9 681 1556442_PM_x_at — — 0.000196049 0.0140277 333.7 272.2 283.4 682 1569477_PM_at — — 0.000197297 0.0140963 120.8 59.0 58.9 683 244046_PM_at URGCP upregulator of cell 0.000198236 0.0141427 108.0 76.3 66.7 proliferation 684 1567044_PM_s_at — — 0.000198703 0.0141553 209.9 146.6 159.4 685 1566491_PM_at — — 0.000199875 0.014191 11.5 9.4 9.6 686 1559097_PM_at C14orf64 chromosome 14 open 0.000199963 0.014191 61.3 42.7 25.5 reading frame 64 687 1565079_PM_at RPS16P5 ribosomal protein S16 0.000200078 0.014191 705.1 416.1 477.2 pseudogene 5 688 202710_PM_at BET1 blocked early in transport 0.000201418 0.0142653 91.6 140.3 137.2 1 homolog (S. cerevisiae) 689 220071_PM_x_at HAUS2 HAUS augmin-like 0.000201879 0.0142772 262.4 219.6 221.5 complex, subunit 2 690 239274_PM_at — — 0.000203017 0.0143368 600.6 310.5 341.3 691 231927_PM_at ATF6 activating transcription 0.000205596 0.0144979 192.0 140.0 146.2 factor 6 692 242361_PM_at IMMT Inner membrane protein, 0.000209917 0.0147813 29.0 23.7 21.6 mitochondrial (mitofilin) 693 236368_PM_at KIAA0368 KIAA0368 0.000210329 0.0147889 93.7 59.9 62.1 694 241737_PM_x_at — — 0.000211224 0.0148304 50.3 35.9 33.5 695 235213_PM_at ITPKB Inositol 1,4,5- 0.000212538 0.0149012 224.7 157.1 139.1 trisphosphate 3-kinase B 696 1562280_PM_at — — 0.000213758 0.0149652 43.1 26.7 27.3 697 236715_PM_x_at UACA uveal autoantigen with 0.000214698 0.0150095 311.8 251.4 282.5 coiled-coil domains and ankyrin repeats 698 242558_PM_at — — 0.000215749 0.0150613 620.4 465.6 453.1 699 225957_PM_at C5orf41 chromosome 5 open 0.000216336 0.0150799 2095.9 1538.8 1569.1 reading frame 41 700 242494_PM_at — — 0.000216773 0.0150799 28.0 18.8 19.4 701 1557238_PM_s_at — — 0.000216944 0.0150799 59.0 41.6 41.6 702 200969_PM_at SERP1 stress-associated 0.000217306 0.0150836 236.0 362.5 361.3 endoplasmic reticulum protein 1 703 234033_PM_at — — 0.000218357 0.015135 201.4 97.1 111.1 704 1556567_PM_at NAP1L4 nucleosome assembly 0.000218709 0.0151378 137.9 111.7 109.3 protein 1-like 4 705 244332_PM_at — — 0.000219503 0.0151712 21.9 15.0 17.2 706 201297_PM_s_at MOBKL1B MOB1, Mps One Binder 0.000220874 0.0152444 361.7 467.5 482.8 kinase activator-like 1B (yeast) 707 202511_PM_s_at ATG5 ATG5 autophagy related 5 0.000221384 0.015258 92.5 138.8 132.5 homolog (S. cerevisiae) 708 240759_PM_at — — 0.000223975 0.0154147 245.6 150.7 144.4 709 200970_PM_s_at SERP1 stress-associated 0.000225987 0.0155094 473.6 677.3 597.2 endoplasmic reticulum protein 1 710 1559687_PM_at TMEM221 transmembrane protein 0.000225987 0.0155094 14.4 13.0 15.1 221 711 210124_PM_x_at SEMA4F sema domain, 0.000227139 0.0155665 18.3 14.7 15.1 immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmi 712 202838_PM_at FUCA1 fucosidase, alpha-L-1, 0.000227972 0.0156017 335.3 478.9 509.8 tissue 713 222697_PM_s_at ABHD10 abhydrolase domain 0.000228563 0.0156202 33.7 51.1 50.2 containing 10 714 215067_PM_x_at PRDX2 peroxiredoxin 2 0.000229843 0.0156857 222.6 180.4 172.9 715 232030_PM_at KIAA1632 KIAA1632 0.000231505 0.0157696 146.0 87.0 88.2 716 1556818_PM_at — — 0.000231721 0.0157696 256.0 175.5 169.8 717 213684_PM_s_at PDLIM5 PDZ and LIM domain 5 0.000233554 0.0158667 45.4 33.0 33.3 718 229268_PM_at FAM105B family with sequence 0.000233799 0.0158667 109.1 80.0 85.0 similarity 105, member B 719 241223_PM_x_at — — 0.000239453 0.0162279 97.7 75.5 83.4 720 1560259_PM_at — — 0.000240266 0.0162603 82.2 53.8 40.2 721 213473_PM_at BRAP BRCA1 associated protein 0.000241741 0.0163375 474.0 404.6 393.7 722 221626_PM_at ZNF506 zinc finger protein 506 0.000242376 0.0163577 65.0 46.8 47.9 723 233834_PM_at — — 0.000243937 0.0164403 126.5 70.0 73.5 724 206792_PM_x_at PDE4C phosphodiesterase 4C, 0.000245343 0.0165122 484.6 390.8 415.9 cAMP-specific 725 241751_PM_at OFD1 oral-facial-digital 0.000246523 0.0165687 213.3 134.2 138.4 syndrome 1 726 219695_PM_at SMPD3 sphingomyelin 0.000249284 0.0167312 13.0 12.0 17.6 phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) 727 232215_PM_x_at PRR11 proline rich 11 0.00025089 0.0167955 560.9 438.6 461.7 728 1569484_PM_S_at MDN1 MDN1, midasin homolog 0.000250931 0.0167955 19.2 12.8 12.9 (yeast) 729 243303_PM_at — — 0.000253404 0.0169377 255.0 170.9 182.6 730 225697_PM_at CDK12 cyclin-dependent kinase 0.000253787 0.0169401 256.4 204.5 211.2 12 731 1568702_PM_a_at PAAF1 proteasomal ATPase- 0.00025533 0.0170198 20.3 15.9 15.6 associated factor 1 732 225435_PM_at SSR1 signal sequence receptor, 0.000255878 0.017033 234.7 159.6 143.3 alpha 733 220969_PM_s_at — — 0.00025792 0.0171455 84.5 55.9 53.7 734 232909_PM_s_at BPTF bromodomain PHD finger 0.000260807 0.0173036 394.0 315.2 313.4 transcription factor 735 230415_PM_at — — 0.000261008 0.0173036 227.1 144.1 134.3 736 241724_PM_x_at — — 0.000264391 0.017504 30.4 25.9 27.5 737 244061_PM_at — — 0.000265286 0.0175395 1448.2 941.9 1025.5 738 239496_PM_at — — 0.000268384 0.0177203 66.1 49.8 47.6 739 240367_PM_at — — 0.000271372 0.0178933 18.6 15.2 14.7 740 240969_PM_at — — 0.000272419 0.0179381 22.1 16.6 16.0 741 244539_PM_at — — 0.000278311 0.0183013 256.0 173.7 154.7 742 1565913_PM_at — — 0.00028053 0.0184224 116.1 60.3 69.1 743 239545_PM_at — — 0.000281028 0.0184302 157.3 109.5 102.4 744 228590_PM_at PTCD3 Pentatricopeptide repeat 0.000281682 0.0184332 167.3 129.6 109.1 domain 3 745 204038_PM_s_at LPAR1 lysophosphatidic acid 0.000282319 0.0184332 11.6 13.0 16.0 receptor 1 746 242146_PM_at SNRPA1 Small nuclear 0.000282356 0.0184332 134.4 91.6 84.9 ribonucleoprotein polypeptide A′ 747 207654_PM_x_at DR1 down-regulator of 0.000282587 0.0184332 153.3 207.5 204.0 transcription 1, TBP- binding (negative cofactor 2) 748 213254_PM_at TNRC6B trinucleotide repeat 0.000285688 0.0185887 278.5 214.6 213.3 containing 6B 749 1568867_PM_x_at — — 0.000286168 0.0185887 11.3 9.4 9.1 750 240315_PM_at — — 0.000286463 0.0185887 67.1 48.5 44.3 751 224740_PM_at C5orf43 chromosome 5 open 0.000286497 0.0185687 114.1 197.5 163.1 reading frame 43 752 235340_PM_at GANC glucosidase, alpha; neutral 0.00028733 0.0185987 9.4 8.1 9.3 C 753 226432_PM_at ETNK1 ethanolamine kinase 1 0.000287446 0.0185987 58.4 111.9 97.8 754 236462_PM_at — — 0.000287796 0.0185987 45.8 32.3 31.5 755 232396_PM_at — — 0.000288551 0.0186228 611.0 404.4 427.0 756 208185_PM_x_at — — 0.000288946 0.0186236 24.9 19.3 20.3 757 241786_PM_at — — 0.000290529 0.0187009 332.1 222.1 256.0 758 208286_PM_x_at POU5F1 /// POU class 5 homeobox 1 /// 0.000294645 0.0188949 34.0 27.1 27.8 POU5F1B /// POU class 5 homeobox POU5F1P3 /// 1B /// POU class 5 POU5F1P4 homeobox 1 pseudogen 759 238350_PM_at UBN2 ubinuclein 2 0.000294683 0.0188949 159.5 129.5 127.9 760 239451_PM_at — — 0.000294888 0.0188949 63.5 46.9 48.3 761 236930_PM_at NUMB Numb homolog 0.000295483 0.0188949 387.5 234.0 261.8 (Drosophila) 762 242268_PM_at CELF2 CUGBP, Elav-like family 0.000295958 0.0188949 1646.3 1171.9 1088.1 member 2 763 1556461_PM_at — — 0.000296154 0.0188949 27.6 17.7 15.6 764 1560492_PM_at — — 0.000296256 0.0188949 27.0 19.7 20.2 765 227277_PM_at MTDH metadherin 0.000296841 0.0189074 167.6 134.6 123.8 766 225674_PM_at BCAP29 B-cell receptor-associated 0.000297445 0.0189212 155.2 231.0 231.6 protein 29 767 242024_PM_at — — 0.000299844 0.0190371 27.4 19.6 19.0 768 222661_PM_at AGGF1 angiogenic factor with G 0.000300049 0.0190371 104.8 158.7 143.0 patch and FHA domains 1 769 214595_PM_at KCNG1 potassium voltage-gated 0.000301269 0.0190896 12.9 9.4 8.6 channel, subfamily G, member 1 770 242431_PM_at — — 0.000302138 0.0191198 291.4 220.9 238.4 771 1555485_PM_s_at FAM153B family with sequence 0.000304641 0.0192296 12.9 11.0 10.5 similarity 153, member B 772 1556658_PM_a_at — — 0.000304832 0.0192296 234.0 134.6 122.0 773 243997_PM_x_at — — 0.000305056 0.0192296 71.2 45.7 42.8 774 216782_PM_at — — 0.000306202 0.0192769 1179.9 554.5 652.8 775 232670_PM_at — — 0.000306719 0.0192845 40.6 24.4 27.2 776 203457_PM_at STX7 syntaxin 7 0.000309226 0.0194171 160.3 198.1 203.8 777 241494_PM_at — — 0.000311987 0.0195652 15.7 11.3 12.3 778 231281_PM_at — — 0.000312819 0.0195832 167.7 103.7 108.9 779 218423_PM_x_at VPS54 vacuolar protein sorting 0.000313078 0.0195832 71.0 118.1 105.6 54 homoog (S. cerevisiae) 780 215587_PM_x_at — — 0.000314098 0.0196219 185.0 134.1 154.6 781 244642_PM_at — — 0.000315442 0.0196806 162.3 88.4 116.2 782 200731_PM_s_at PTP4A1 protein tyrosine 0.000317118 0.0197599 111.8 158.4 154.4 phosphatase type IVA, member 1 783 243006_PM_at — — 0.000317737 0.0197731 231.8 154.1 127.3 784 233241_PM_at PLK1S1 polo-like kinase 1 0.000318798 0.0198139 101.6 66.1 73.3 substrate 1 785 239876_PM_at — — 0.00031958 0.0198189 200.3 127.8 137.7 786 243509_PM_at — — 0.000319692 0.0198189 187.1 130.6 118.2 787 207657_PM_x_at TNPO1 transportin 1 0.00032118 0.0198746 481.0 406.6 389.3 788 208731_PM_at RAB2A RAB2A, member RAS 0.000321406 0.0198746 499.3 642.0 675.0 oncogene family 789 235482_PM_at LOC400960 hypothetical LOC400960 0.000322138 0.0198946 166.6 126.8 113.8 790 1570021_PM_at — — 0.000322901 0.0199165 105.0 61.6 56.1 791 227012_PM_at SLC25A40 solute carrier family 25, 0.000324196 0.0199607 205.9 347.0 346.6 member 40 792 1564236_PM_at — — 0.00032473 0.0199607 13.3 10.5 9.5 793 237594_PM_at — — 0.000325682 0.0199607 69.8 45.4 40.3 794 205370_PM_x_at DBT dihydrolipoamide 0.000326157 0.0199607 643.8 520.2 544.4 branched chain transacylase E2 795 222590_PM_s_at NLK nemo-like kinase 0.000326287 0.0199607 29.2 39.3 37.3 796 227080_PM_at ZNF697 zinc finger protein 697 0.000326712 0.0199607 25.9 33.0 42.6 797 222984_PM_at PAIP2 poly(A) binding protein 0.000326816 0.0199607 1189.8 1490.1 1482.1 interacting protein 2 798 215385_PM_at — — 0.000326896 0.0199607 89.5 67.0 62.9 799 234788_PM_x_at — — 0.000330026 0.0201266 642.7 487.1 540.2 800 213156_PM_at — — 0.000332799 0.020247 207.5 134.8 138.0 801 238771_PM_at — — 0.000333234 0.020247 68.1 48.8 55.2 802 243954_PM_at LOC285286 hypothetical LOC285286 0.000333247 0.020247 86.4 42.3 50.3 803 217371_PM_s_at IL15 interleukin 15 0.000333774 0.0202538 69.5 102.3 107.6 804 207966_PM_s_at GLG1 golgi glycoprotein 1 0.000334197 0.0202543 565.4 431.9 393.5 805 228812_PM_at — — 0.000335281 0.0202947 194.9 296.3 301.7 806 214055_PM_x_at BAT2L2 HLA-B associated 0.000336279 0.0203299 1235.4 935.3 857.5 transcript 2-like 2 807 212461_PM_at AZIN1 antizyme inhibitor 1 0.000337965 0.0204065 311.7 433.9 363.5 808 232939_PM_at — — 0.000338564 0.0204173 57.3 32.0 30.7 809 243874_PM_at LPP LIM domain containing 0.000339708 0.0204554 89.8 51.9 52.2 preferred translocation partner in lipoma 810 244871_PM_s_at USP32 ubiquitin specific 0.000340034 0.0204554 821.3 495.7 564.1 peptidase 32 811 241769_PM_at — — 0.000341157 0.0204976 124.4 93.8 91.4 812 1559425_PM_at — — 0.000341643 0.0205015 368.8 248.7 153.5 813 219117_PM_s_at FKBP11 FK506 binding protein 11, 0.000342451 0.0205247 272.8 206.2 157.7 19 kDa 814 243454_PM_at — — 0.000346485 0.0207013 64.2 41.7 45.5 815 224726_PM_at MIB1 mindbomb homolog 1 0.000346636 0.0207013 814.7 655.9 693.6 (Drosophila) 816 208097_PM_s_at TMX1 thioredoxin-related 0.000346672 0.0207013 63.6 127.7 102.5 transmembrane protein 1 817 215268_PM_at KIAA0754 KIAA0754 0.000353336 0.0210734 71.5 52.3 50.4 818 217703_PM_x_at — — 0.000360795 0.021492 55.9 48.0 49.6 819 238076_PM_at GATAD2B GATA zinc finger domain 0.000362252 0.0215506 296.9 221.6 231.6 containing 2B 820 223168_PM_at RHOU ras homolog gene family, 0.000362992 0.0215506 128.2 217.8 211.7 member U 821 232814_PM_x_at C14orf153 Chromosome 14 open 0.000363106 0.0215506 353.7 278.7 295.3 reading frame 153 822 244185_PM_at — — 0.000366343 0.0217163 120.6 86.2 81.3 823 222489_PM_s_at WRNIP1 Werner helicase 0.000368949 0.0218442 119.2 158.8 143.9 interacting protein 1 824 231825_PM_x_at ATF7IP activating transcription 0.000370872 0.0219314 735.8 556.6 565.4 factor 7 interacting protein 825 1556277_PM_a_at — — 0.000371726 0.0219553 332.1 197.4 223.8 826 211040_PM_x_at GTSE1 G-2 and S-phase 0.00037274 0.021962 279.4 225.3 246.5 expressed 1 827 242225_PM_at — — 0.000373261 0.021962 167.4 110.8 114.7 828 211559_PM_s_at CCNG2 cyclin G2 0.000373375 0.021962 72.3 152.3 134.6 829 217331_PM_at — — 0.000373643 0.021962 16.7 14.5 14.0 830 239234_PM_at — — 0.000378038 0.0221936 233.6 147.9 150.2 831 235926_PM_at — — 0.000378499 0.0221939 165.9 112.1 104.9 832 230868_PM_at — — 0.000382228 0.0223843 117.2 83.3 82.9 833 244878_PM_at — — 0.000382665 0.0223843 46.5 29.9 28.0 834 233940_PM_at — — 0.000383892 0.0224291 39.0 30.5 26.9 835 236002_PM_at — — 0.000387199 0.0225953 155.0 104.4 96.6 836 237330_PM_at — — 0.000388717 0.0226567 404.4 224.4 219.3 837 225793_PM_at LIX1L Lix1 homolog (mouse)-like 0.000392446 0.0228467 485.3 425.6 383.2 838 240216_PM_at — — 0.000395157 0.022961 46.6 32.5 30.2 839 23187_PM_at C16orf53 chromosome 16 open 0.00039576 0.022961 181.8 144.8 146.6 reading frame 53 840 234649_PM_at — — 0.000395823 0.022961 78.5 51.7 49.3 841 242074_PM_at — — 0.000397651 0.0230396 145.7 113.1 99.5 842 231109_PM_at — — 0.000399417 0.0231145 778.5 455.6 469.9 843 239923_PM_at — — 0.000400186 0.0231315 615.5 352.9 368.1 844 201180_PM_s_at GNAI3 guanine nucleotide 0.000404234 0.0233378 830.7 1001.7 978.1 binding protein (G protein), alpha inhibiting activity polypeptide 3 845 202040_PM_s_at KDM5A lysine (K)-specific 0.000405437 0.0233796 824.0 646.3 703.7 demethylase 5A 846 239969_PM_at — — 0.000406037 0.0233865 89.6 62.7 62.6 847 228180_PM_at — — 0.000408895 0.0235042 202.3 158.5 146.2 848 232134_PM_at — — 0.000409046 0.0235042 121.3 96.1 88.1 849 1570192_PM_at — — 0.000410178 0.0235174 222.3 110.7 140.9 850 223547_PM_at JKAMP JNK1/MAPK8-associated 0.00041024 0.0235174 57.3 84.1 82.3 membrane protein 851 228456_PM_s_at CDS2 /// CDP-diacylglycerol 0.000412023 0.0235756 473.4 361.8 388.5 LOC149832 synthase (phosphatidate cytidylyltransferase) 2 /// hypothetical pro 852 1561167_PM_at — — 0.000412223 0.0235756 318.7 174.6 180.3 853 237456_PM_at — — 0.000413833 0.0236399 197.6 102.4 107.6 854 215203_PM_at GOLGA4 golgin A4 0.000415851 0.0237274 33.5 26.6 27.5 855 244473_PM_at — — 0.000417637 0.023785 24.6 19.7 17.8 856 217745_PM_s_at NAA50 N(alpha)-acetyltransferase 0.000417837 0.023785 342.9 454.8 420.4 50, NatE catalytic subunit 857 232096_PM_x_at — — 0.000423244 0.0240647 132.7 93.5 97.3 858 236367_PM_at SMG7 Smg-7 homolog, nonsense 0.000426413 0.0242038 60.3 43.6 39.9 mediated mRNA decay factor (C. elegans) 859 219099_PM_at C12orf5 chromosome 12 open 0.000426684 0.0242038 143.5 195.8 191.5 reading frame 5 860 239614_PM_x_at — — 0.000428523 0.0242599 83.0 63.3 57.2 861 1565598_PM_at — — 0.000429465 0.0242599 219.4 108.9 116.5 862 244548_PM_at — — 0.000429552 0.0242599 989.0 528.6 550.3 863 222133_PM_s_at PHF20L1 PHD finger protein 20-like 0.000429665 0.0242599 344.9 246.8 263.9 1 864 206095_PM_s_at SRSF10 serine/arginine-rich 0.000430876 0.0243001 169.2 260.5 244.5 splicing factor 10 865 243325_PM_at GSTK1 Glutathione S-transferase 0.000432321 0.0243534 48.8 34.7 36.0 kappa 1 866 32099_PM_at SAFB2 scaffold attachment factor 0.000433362 0.0243839 252.4 183.1 203.6 B2 867 1570200_PM_at HELB helicase (DNA) B 0.000434885 0.0244413 78.9 60.2 52.9 868 238651_PM_at — — 0.000436948 0.024529 298.5 217.3 217.3 869 236617_PM_at — — 0.00043989 0.0246657 18.3 12.2 13.4 870 240148_PM_at MSH6 MutS homolog 6 (E. coli) 0.000440564 0.0246751 26.4 21.5 21.6 871 202874_PM_s_at ATP6V1C1 ATPase, H+ transporting, 0.000441569 0.024703 180.5 283.6 242.1 lysosomal 42 kDa, V1 subunit C1 872 225313_PM_at C20orf177 chromosome 20 open 0.00044279 0.0247389 212.6 288.7 286.2 reading frame 177 873 237189_PM_at LOC100506360 hypothetical 0.000443225 0.0247389 30.5 18.9 18.4 LOC100506360 874 243691_PM_at — — 0.000444048 0.0247564 30.8 21.6 24.6 875 209684_PM_at RIN2 Ras and Rab Interactor 2 0.000444718 0.0247648 136.4 227.4 238.7 876 244078_PM_at — — 0.000445215 0.0247648 35.5 26.5 25.4 877 240939_PM_x_at — — 0.000448669 0.0249274 29.4 21.3 21.6 878 239131_PM_at — — 0.000449161 0.0249274 29.5 20.2 17.8 879 1560199_PM_x_at LOC728153 similar to FAM133B 0.00044992 0.0249411 400.0 271.5 281.7 protein 880 240108_PM_at — — 0.000451383 0.0249938 167.6 119.5 119.7 881 239674_PM_at — — 0.00045305 0.0250575 17.3 14.7 14.3 882 214948_PM_s_at TMF1 TATA element modulatory 0.000454991 0.0251364 517.2 389.8 389.4 factor 1 883 234260_PM_at — — 0.000455932 0.0251599 105.2 74.3 73.8 884 1556925_PM_at SMC3 Structural maintenance of 0.000459008 0.025301 14.0 11.7 11.9 chromosomes 3 885 1558922_PM_at — — 0.000460623 0.0253613 116.9 86.3 78.3 886 215504_PM_x_at — — 0.000462655 0.0254445 705.6 581.4 607.1 887 224986_PM_s_at PDPK1 3-phosphoinositide 0.000464555 0.0255201 313.0 372.9 393.7 dependent protein kinase- 1 888 214100_PM_x_at NSUN5P1 NOP2/Sun domain family, 0.000466365 0.0255446 217.7 195.5 155.9 member 5 pseudogene 1 889 243458_PM_at — — 0.000467592 0.0255446 44.9 31.2 31.0 890 1558135_PM_at TAF11 TAF11 RNA polymerase II, 0.000467741 0.0255446 105.9 72.9 80.8 TATA box binding protein (TBP)-associated factor, 28 kDa 891 211947_PM_s_at BAT2L2 HLA-B associated 0.000467783 0.0255446 394.8 277.9 283.8 transcript 2-like 2 892 244622_PM_at BRWD1 Bromodomain and WD 0.000468257 0.0255446 44.1 32.7 32.9 repeat domain containing 1 893 233836_PM_at TNRC6A trinucleotide repeat 0.00046938 0.0255446 19.5 15.2 15.5 containing 6A 894 1555303_PM_at — — 0.000469387 0.0255446 141.3 79.5 85.0 895 227026_PM_at MPHOSPH8 M-phase phosphoprotein 0.000469724 0.0255446 318.7 234.3 248.6 8 896 244607_PM_at — — 0.000469836 0.0255446 43.4 30.9 33.0 897 227905_PM_s_at AZI2 5-azacytidine induced 2 0.000470243 0.0255446 24.6 37.2 30.8 898 243300_PM_at — — 0.000472394 0.0256052 15.4 11.8 12.8 899 241891_PM_at — — 0.000472887 0.0256052 1177.4 796.8 777.5 900 222514_PM_at RRAGC Ras-related GTP binding C 0.000472935 0.0256052 607.8 722.1 691.1 901 219658_PM_at PTCD2 pentatricopeptide repeat 0.00047383 0.0256252 61.8 52.7 44.8 domain 2 902 215092_PM_s_at NFAT5 nuclear factor of activated 0.000474541 0.0256352 205.3 133.5 151.1 T-cells 5, tonicity- responsive 903 207078_PM_at MED6 mediator complex subunit 0.000475119 0.0256558 58.5 41.8 39.4 6 904 230608_PM_at C1orf182 chromosome 1 open 0.000478577 0.025796 17.0 15.9 18.8 reading frame 182 905 1559101_PM_at FYN FYN oncogene related to 0.000480045 0.0258276 306.8 224.5 184.9 SRC, FGR, YES 906 1562059_PM_at — — 0.000480222 0.0258276 125.5 76.2 87.5 907 206233_PM_at B4GALT6 UDP-Gal:betaGlcNAc beta 0.000482556 0.0259245 9.9 11.3 11.9 1,4-galactosyltransferase, polypeptide 6 908 239571_PM_at — — 0.000484875 0.0260053 352.5 248.8 249.2 909 1558469_PM_at LPP LIM domain containing 0.000485128 0.0260053 17.7 14.0 12.8 preferred translocation partner in lipoma 910 233308_PM_at COPB1 Coatomer protein 0.00048641 0.0260266 99.9 68.6 74.7 complex, subunit beta 1 911 207499_PM_x_at UNC45A unc-45 homolog A 0.000486594 0.0260266 23.4 19.1 20.4 (C. elegans) 912 241240_PM_at — — 0.000488335 0.0260911 245.3 151.5 178.6 913 215604_PM_x_at — — 0.000491675 0.0262191 386.7 308.8 333.0 914 1568866_PM_at — — 0.000491806 0.0262191 46.1 36.8 37.0 915 243801_PM_x_at — — 0.000494418 0.0263295 38.4 31.2 31.7 916 224963_PM_at SLC26A2 solute carrier family 26 0.000496442 0.0264084 88.6 94.3 64.0 (sulfate transporter), member 2 917 223289_PM_s_at USP38 ubiquitin specific 0.000497818 0.0264325 88.8 121.2 112.3 peptidase 38 918 226843_PM_s_at PAPD5 PAP associated domain 0.000498428 0.0264325 449.5 361.7 348.9 containing 5 919 228471_PM_at ANKRD44 ankyrin repeat domain 44 0.000498876 0.0264325 2457.5 1972.3 2043.1 920 237588_PM_at — — 0.000499064 0.0264325 198.7 112.0 101.2 921 237185_PM_at — — 0.000501862 0.0265442 106.8 41.3 58.3 922 1556416_PM_s_at — — 0.000502263 0.0265442 49.8 39.0 35.8 923 239926_PM_at — — 0.000505191 0.0266645 82.1 45.7 55.2 924 231794_PM_at CTLA4 cytotoxic T-lymphocyte- 0.000505633 0.0266645 13.8 13.0 11.5 associated protein 4 925 225366_PM_at PGM2 phosphoglucomutase 2 0.000506926 0.0266801 99.2 146.5 151.2 926 1557706_PM_at ZHX2 zinc fingers and 0.000507025 0.0266801 38.1 24.1 25.8 homeoboxes 2 927 1557278_PM_s_at TNPO1 Transportin 1 0.00051016 0.0267982 50.6 37.7 35.2 928 212907_PM_at SLC30A1 solute carrier family 30 0.000510575 0.0267982 279.7 452.7 413.3 (zinc transporter), member 1 929 228866_PM_at — — 0.00051121 0.0267982 123.7 79.6 76.7 930 200047_PM_s_at YY1 YY1 transcription factor 0.000511468 0.0267982 947.2 1166.0 1192.6 931 214405_PM_at — — 0.000512036 0.0267991 378.5 258.8 245.1 932 204344_PM_s_at SEC23A Sec23 homolog A 0.000513855 0.0268655 18.8 25.8 22.9 (S. cerevisiae) 933 215592_PM_at — — 0.000518172 0.0270383 99.2 65.0 61.2 934 219947_PM_at CLEC4A C-type lectin domain 0.000518808 0.0270383 908.1 1191.3 1202.9 family 4, member A 935 209095_PM_at DLD dihydrolipoamide 0.000518826 0.0270383 318.4 443.1 400.3 dehydrogenase 936 215888_PM_at PDS5B PDS5, regulator of 0.000522684 0.0272103 137.4 96.3 92.6 cohesion maintenance, homolog B (S. cerevisiae) 937 206235_PM_at LIG4 ligase IV, DNA, ATP- 0.000525807 0.0273436 15.7 21.8 19.5 dependent 938 222235_PM_s_at CSGALNACT2 chondroitin sulfate N- 0.000527308 0.0273925 309.6 499.7 460.3 acetytgalatosaminyltransferase 2 939 226587_PM_at SNRPN small nuclear 0.000528757 0.0274201 74.2 41.9 36.9 ribonucleoprotein polypeptide N 940 1556033_PM_at FLJ39739 hypothetical FLI39739 0.000528966 0.0274201 229.2 205.4 172.5 941 218669_PM_at RAP2C RAP2C, member of RAS 0.000532546 0.0275764 317.5 474.9 457.3 oncogene family 942 232190_PM_x_at LOC100133445 /// hypothetical 0.000534373 0.0276416 33.7 28.3 30.4 LOC115110 LOC100133445 /// hypothetical LOC115110 943 212921_PM_at SMYD2 SET and MYND domain 0.000538535 0.0278274 54.8 41.5 34.4 containing 2 944 232266_PM_x_at CDK13 Cyclin-dependent kinase 0.000539275 0.0278361 960.9 730.0 803.7 13 945 219027_PM_s_at MYO9A myosin IXA 0.000544917 0.0280839 57.5 46.0 47.1 946 1560332_PM_at — — 0.000545515 0.0280839 21.5 14.2 17.6 947 240165_PM_at — — 0.000546311 0.0280839 231.0 148.7 172.7 948 231205_PM_at — — 0.000546629 0.0280839 440.9 251.8 278.3 949 241060_PM_x_at — — 0.000546958 0.0280839 29.1 20.6 17.6 950 226975_PM_at RNPC3 RNA-binding region (RNP1, 0.000548452 0.028131 660.2 526.7 538.6 RRM) containing 3 951 226419_PM_s_at FLI44342 hypothetical LOC645460 0.000552685 0.02829 291.7 195.4 218.9 952 203261_PM_at DCTN6 dynactin 6 0.000552713 0.02829 106.4 155.4 155.1 953 224990_PM_at C4orf34 chromosome 4 open 0.000553439 0.0282974 129.9 172.5 178.9 reading frame 34 954 227393_PM_at ANO9 anoctamin 9 0.000554704 0.0283323 17.4 14.9 13.3 955 233099_PM_at — — 0.000556499 0.0283496 13.0 10.3 10.7 956 1559663_PM_at — — 0.000556916 0.0283496 36.6 21.5 23.0 957 203077_PM_s_at SMAD2 SMAD family member 2 0.000557342 0.0283496 109.8 133.3 139.1 958 232347_PM_x_at — — 0.000557372 0.0283496 149.6 112.3 117.7 959 1559136_PM_s_at LOC100272228 hypothetical 0.000557951 0.0283496 10.9 10.5 9.5 LOC100272228 960 239333_PM_x_at GSTK1 glutathione S-transferase 0.000560501 0.0284495 225.0 175.7 187.6 kappa 1 961 244777_PM_at DCP2 DCP2 decapping enzyme 0.000561209 0.0284558 818.1 604.5 698.2 homolog (S. cerevisiae) 962 237953_PM_at — — 0.000564728 0.0286045 24.5 16.1 13.3 963 211084_PM_x_at PRKD3 protein kinase D3 0.000565658 0.0286218 44.2 35.8 34.1 964 218012_PM_at TSPYL2 TSPY-like 2 0.000570721 0.0288481 19.3 16.4 14.8 965 243646_PM_at — — 0.000572724 0.0289193 31.7 24.4 22.1 966 214594_PM_x_at ATP8B1 ATPase, 0.000577893 0.0291079 133.5 93.2 101.8 aminophospholipid transporter, class I, type 8B, member 1 967 243216_PM_x_at — — 0.000578007 0.0291079 125.1 103.4 101.7 968 221523_PM_s_at RRAGD Ras-related GTP binding D 0.000578251 0.0291079 128.2 205.9 191.1 969 1558877_PM_at — — 0.000579125 0.0291218 177.8 89.7 95.9 970 200071_PM_at SMNDC1 survival motor neuron 0.000582434 0.0292484 563.2 694.7 713.0 domain containing 1 971 204681_PM_s_at RAPGEF5 Rap guanine nucleotide 0.000582843 0.0292484 9.3 9.6 11.3 exchange factor (GEF) 5 972 239721_PM_at — — 0.000584451 0.0292839 143.4 96.3 95.6 973 217102_PM_at LOC100287076 Similar to malignancy- 0.000585345 0.0292839 10.7 9.3 9.9 associated protein 974 215232_PM_at ARHGAP44 Rho GTPase activating 0.000585353 0.0292839 12.7 11.1 13.1 protein 44 975 232340_PM_at LOC388889 hypothetical LOC388889 0.000589789 0.0294389 69.9 55.0 48.8 976 244358_PM_at — — 0.000589852 0.0294389 304.7 149.5 155.6 977 226833_PM_at CYB5D1 cytochrome b5 domain 0.000590265 0.0294389 21.1 16.7 16.5 containing 1 978 234731_PM_at — — 0.000591523 0.0294715 801.1 622.0 673.2 979 239163_PM_at UBE2B ubiquitin-conjugating 0.000593286 0.0295292 442.8 263.6 337.4 enzyme E2B (RAD6 homolog) 980 242735_PM_x_at ELF2 E74-like factor 2 (ets 0.000596326 0.0296502 207.9 156.9 168.0 domain transcription factor) 981 234621_PM_at — — 0.000599272 0.0297358 18.9 12.7 13.6 982 242031_PM_at — — 0.000599401 0.0297358 55.6 42.0 32.3 983 235647_PM_at AP4S1 Adaptor-related protein 0.000599879 0.0297358 66.0 49.9 48.6 complex 4, sigma 1 subunit 984 222870_PM_s_at B3GNT2 UDP-GlcNAc:betaGal beta- 0.000601513 0.0297865 115.6 176.2 194.0 1,3-N- acetylglucosaminyltransferase 2 985 220546_PM_at MLL myeloid/lymphoid or 0.000602412 0.0298007 88.2 69.7 61.7 mixed-lineage leukemia (trithorax homolog, Drosophila) 986 214052_PM_x_at BAT2L2 HLA-B associated 0.000603516 0.0298251 78.2 55.7 57.5 transcript 2-like 2 987 230590_PM_at — — 0.000604485 0.0298303 474.5 243.9 242.2 988 218404_PM_at SNX10 sorting nexin 10 0.000605146 0.0298303 975.9 1292.9 1317.3 989 236755_PM_at — — 0.000605459 0.0298303 81.1 57.7 62.3 990 1560171_PM_at — — 0.000607629 0.0299 78.4 64.9 50.2 991 242374_PM_at — — 0.0006081 0.0299 105.3 74.4 69.9 992 201435_PM_s_at EIF4E eukaryotic translation 0.000609565 0.029922 131.1 192.8 172.8 initiation factor 4E 993 218627_PM_at DRAM1 DNA-damage regulated 0.000609775 0.029922 117.1 152.4 184.4 autophagy modulator 1 994 1560552_PM_a_at — — 0.000612413 0.0300212 23.0 16.5 15.4 995 216187_PM_x_at — — 0.000613591 0.0300487 1334.9 1072.4 1127.7 996 234753_PM_x_at — — 0.000617785 0.0302237 17.6 13.7 15.4 997 232556_PM_at — — 0.000623426 0.0304281 32.8 24.8 23.5 998 214705_PM_at INADL InaD-like (Drosophila) 0.000624089 0.0304281 27.6 18.1 16.2 999 207112_PM_s_at GAB1 GRB2-associated binding 0.000624139 0.0304281 11.9 13.5 14.0 protein 1 1000 223886_PM_s_at RNF146 ring finger protein 146 0.000524461 0.0304281 469.8 581.7 633.1 1001 225117_PM_at KIAA1267 KIAA1267 0.000629473 0.0305965 708.1 567.5 592.4 1002 227268_PM_at RNFT1 ring finger protein, 0.000530131 0.0305965 100.0 162.8 165.7 transmembrane 1 1003 235328_PM_at PLXNC1 Plexin C1 0.000630354 0.0305965 27.6 20.9 19.8 1004 222103_PM_at ATF1 activating transcription 0.000630428 0.0305965 121.6 203.3 197.1 factor 1 1005 235084_PM_x_at — — 0.000531188 0.0306029 680.3 521.1 548.9 1006 200056_PM_s_at C1D C1D nuclear receptor 0.00063303 0.0306617 383.0 501.9 499.8 corepressor 1007 218178_PM_s_at CHMP1B chromatin modifying 0.00063573 0.0307619 413.1 622.1 593.8 protein 1B 1008 201876_PM_at PON2 paraoxonase 2 0.000642018 0.0310353 64.4 83.3 103.8 1009 227412_PM_at PPP1R3E protein phosphatese 1, 0.000643748 0.0310881 42.0 31.4 27.0 regulatory (inhibitor) subunit 3E 1010 1560680_PM_at — — 0.000647985 0.0312507 27.6 24.2 21.1 1011 226712_PM_at SSR1 signal sequence receptor, 0.000648398 0.0312507 146.7 108.2 101.4 alpha 1012 220843_PM_s_at DCAF13 DDB1 and CUL4 associated 0.000649108 0.031254 14.9 12.4 11.0 factor 13 1013 243808_PM_at — — 0.000652146 0.0313693 42.7 31.9 26.9 1014 218738_PM_s_at RNF138 ring finger protein 138 0.000655843 0.031516 346.9 514.4 498.2 1015 204185_PM_x_at PPID peptidylprolyl isomerase D 0.000658305 0.0316032 235.6 290.5 285.7 1016 241081_PM_at — — 0.000660309 0.0316682 19.2 14.2 13.5 1017 242851_PM_at KIAA1919 KIAA1919 0.000661733 0.0316927 43.6 31.9 32.3 1018 209066_PM_x_at UQCRB ubiquinol-cytochrome c 0.000662121 0.0316927 170.0 360.1 345.4 reductase binding protein 1019 238970_PM_at — — 0.000664525 0.0317609 155.2 114.4 96.2 1020 216197_PM_at ATF7IP activating transcription 0.000664849 0.0317609 143.4 109.2 98.8 factor 7 interacting protein 1021 221834_PM_at LONP2 Lon peptidase 2, 0.000666186 0.0317936 451.8 354.8 312.9 peroxisomal 1022 219876_PM_s_at GOLGA2B golgin A2 family, member 0.000669547 0.0319227 12.9 10.7 11.9 B 1023 1556568_PM_a_at — — 0.000671247 0.0319431 107.8 74.0 74.0 1024 215269_PM_at TRAPPC10 trafficking protein particle 0.000671285 0.0319431 259.6 180.1 180.4 complex 10 1025 240568_PM_at — — 0.000674356 0.0320579 23.8 17.8 13.6 1026 236437_PM_at — — 0.000678439 0.0322206 154.6 89.5 113.1 1027 240690_PM_at — — 0.00067947 0.0322269 102.0 59.2 58.4 1028 242505_PM_at — — 0.000680031 0.0322269 30.2 22.9 22.5 1029 210711_PM_at NCRNA00260 non-protein coding RNA 0.000680577 0.0322269 89.5 63.5 51.5 260 1030 229491_PM_at NHEDC2 Na+/H+ exchanger domain 0.000681217 0.0322269 21.2 18.7 15.6 containing 2 1031 241997_PM_at — — 0.000687566 0.0324957 140.2 105.5 97.8 1032 1563509_PM_at — — 0.000693415 0.0326067 1276.9 893.8 849.1 1033 203693_PM_s_at E2F3 E2F transcription factor 3 0.000694069 0.0326067 129.9 171.1 179.0 1034 203594_PM_at RTCD1 RNA terminal phosphate 0.000694477 0.0326067 149.6 205.7 170.5 cyclase domain 1 1035 229398_PM_at RAB18 RAB18, member RAS 0.000694934 0.0326067 414.7 289.6 309.1 oncogene family 1036 218465_PM_at TMEM33 transmembrane protein 0.000695471 0.0326067 77.1 113.0 130.5 33 1037 236155_PM_at ZCCHC6 Zinc finger, CCHC domain 0.000695476 0.0326067 1242.2 877.5 826.6 containing 6 1038 209510_PM_at RNF139 ring finger protein 139 0.000695929 0.0326067 387.4 514.6 481.4 1039 1564443_PM_at DLEU2 Deleted in lymphocytic 0.000696802 0.0326067 20.6 14.3 14.7 leukemia 2 (non-protein coding) 1040 208137_PM_x_at ZNF611 zinc finger protein 611 0.000697333 0.0326067 75.5 58.4 59.9 1041 234148_PM_at — — 0.000697378 0.0326067 24.2 18.6 17.1 1042 243064_PM_at — — 0.000697497 0.0326067 44.8 31.5 33.5 1043 201730_PM_s_at TPR translocated promoter 0.000697945 0.0326067 759.5 569.8 580.7 region (to activated MET oncogene) 1044 239629_PM_at CFLAR CASP8 and FADD-like 0.000699042 0.0326256 1603.5 1034.2 1151.0 apoptosis regulator 1045 242320_PM_at — — 0.000701964 0.0327287 327.6 186.6 191.3 1046 230229_PM_at DLG1 Discs, large homolog 1 0.000702654 0.0327287 162.6 134.8 110.5 (Drosophila) 1047 225997_PM_at MOBKL1A MOB1, Mps One Binder 0.000703244 0.0327287 86.8 151.6 150.0 kinase activator-like 1A (yeast) 1048 239724_PM_at — — 0.000703974 0.0327314 42.3 28.3 30.1 1049 236160_PM_at TRIP11 thyroid hormone receptor 0.000706422 0.0327917 67.5 49.3 45.3 interactor 11 1050 236386_PM_at LOC100506501 hypothetical 0.000706617 0.0327917 81.6 57.5 59.8 LOC100506501 1051 231896_PM_s_at DENR density-regulated protein 0.00070898 0.0328701 279.2 383.3 376.1 1052 203159_PM_at GLS glutaminase 0.000712753 0.0329977 271.6 224.4 196.8 1053 225400_PM_at TSEN15 tRNA splicing 0.000713875 0.0329977 25.4 36.7 28.3 endonuclease 15 homolog (S. cerevisiae) 1054 212234_PM_at ASXL1 additional sex combs like 1 0.00071392 0.0329977 55.3 47.0 41.6 (Drosophila) 1055 237337_PM_at — — 0.000714441 0.0329977 59.0 43.2 42.0 1056 217534_PM_at FAM49B family with sequence 0.000717444 0.0331009 138.0 82.9 86.4 similarity 49, member B 1057 238544_PM_at — — 0.00071842 0.0331009 72.4 39.7 35.5 1058 233430_PM_at TBC1D22B TBC1 domain family, 0.000718714 0.0331009 28.4 22.4 19.9 member 22B 1059 221155_PM_x_at — — 0.000722005 0.0332211 62.0 46.7 52.0 1060 244233_PM_at C18orf10 chromosome 18 open 0.000723209 0.0332264 17.8 14.4 14.9 reading frame 10 1061 1558711_PM_at FAM13AOS FAM13A opposite strand 0.000723485 0.0332264 558.5 363.4 368.1 (non-protein coding) 1062 202714_PM_s_at KIAA0391 KIAA0391 0.000730644 0.0335236 13.5 12.3 11.1 1063 1565703_PM_at SMAD4 SMAD family member 4 0.000733037 0.0335891 43.4 30.8 28.9 1064 216000_PM_at — — 0.000733449 0.0335891 33.8 28.8 24.2 1065 225651_PM_at UBE2E2 ubiquitin-conjugating 0.000735351 0.0336446 178.7 226.0 265.1 enzyme E2E 2 (UBC4/5 homolog, yeast) 1066 209566_PM_at INSIG2 insulin induced gene 2 0.000737382 0.0336959 51.0 88.7 79.6 1067 234135_PM_x_at — — 0.000737857 0.0336959 51.0 51.9 54.6 1068 212908_PM_at DNAJC16 DnaJ (Hsp40) homolog, 0.000740783 0.0337979 225.1 188.2 173.3 subfamily C, member 16 1069 212158_PM_at SDC2 syndecan 2 0.000741594 0.0338032 20.7 20.5 34.6 1070 242652_PM_at — — 0.00074305 0.0338277 13.5 11.6 11.6 1071 240478_PM_at — — 0.00074352 0.0338277 176.2 129.2 132.6 1072 44790_PM_s_at C13orf18 chromosome 13 open 0.000744289 0.0338311 452.2 473.1 696.4 reading frame 18 1073 233270_PM_x_at — — 0.000746251 0.0338887 83.1 61.5 62.7 1074 239740_PM_at ETV6 ets variant 6 0.000753532 0.0341875 97.5 60.9 66.4 1075 215588_PM_x_at RIOK3 RIO kinase 3 (yeast) 0.000754615 0.0342048 473.9 368.9 409.2 1076 202536_PM_at CHMP2B chromatin modifying 0.000755843 0.0342286 111.7 163.4 167.2 protein 2B 1077 243963_PM_at SDCCAG8 Serologically defined colon 0.000758246 0.034298 234.5 183.6 179.2 cancer antigen 8 1078 222378_PM_at — — 0.000758784 0.034298 39.0 22.5 24.9 1079 215553_PM_x_at — — 0.000760604 0.0343484 21.9 17.8 18.8 1080 239651_PM_at ANAPC5 anaphase promoting 0.000762903 0.0344203 27.5 20.7 21.2 complex subunit 5 1081 1562528_PM_at — — 0.000764376 0.0344549 97.0 67.3 41.5 1082 239748_PM_x_at OCIAD1 OCIA domain containing 1 0.000766272 0.0345084 930.4 716.6 775.3 1083 238595_PM_at — — 0.000771117 0.0346946 269.3 167.7 171.4 1084 240465_PM_at C4orf32 chromosome 4 open 0.0007729 0.0347427 20.0 15.6 15.2 reading frame 32 1085 236327_PM_at — — 0.000773651 0.0347444 157.1 119.1 121.3 1086 243410_PM_at — — 0.000774723 0.0347605 70.9 55.2 50.7 1087 232588_PM_at STAG1 stromal antigen 1 0.000776932 0.0348276 55.5 40.0 36.5 1088 242457_PM_at — — 0.000779275 0.0349005 137.5 64.9 58.7 1089 207953_PM_at — — 0.000780244 0.0349118 18.6 14.9 14.7 1090 215287_PM_at LOC100288939 Similar to hCG1987955 0.000782993 0.0350027 238.6 180.7 179.6 1091 1560794_PM_at — — 0.000787684 0.0351801 13.2 10.4 11.3 1092 232565_PM_at — — 0.000790598 0.0352779 36.6 28.1 25.2 1093 222169_PM_x_at SH2D3A SH2 domain containing 3A 0.000793064 0.0353556 14.2 12.6 11.8 1094 244868_PM_at — — 0.000794252 0.0353762 33.5 22.8 22.1 1095 201311_PM_s_at SH3BGRL SH3 domain binding 0.000797082 0.0354698 830.9 1084.3 1071.6 glutamic acid-rich protein like 1096 1568815_PM_a_at DDX50 DEAD (Asp-Glu-Ala-Asp) 0.00079804 0.03548 122.3 86.7 91.9 box polypeptide 50 1097 227163_PM_at GSTO2 glutathione S-transferase 0.000814076 0.03616 14.7 12.5 13.5 omega 2 1098 212460_PM_at C14orf147 chromosome 14 open 0.000820682 0.0364202 90.2 137.8 134.3 reading frame 147 1099 1569053_PM_at AP3M2 adaptor-related protein 0.00082218 0.0364535 20.4 17.2 16.8 complex 3, mu 2 subunit 1100 242407_PM_at — — 0.00082641 0.0365795 537.1 400.3 365.6 1101 239946_PM_at — — 0.000826524 0.0365795 317.5 187.7 188.9 1102 215070_PM_x_at RABGAP1 RAB GTPase activating 0.000827856 0.0366052 11.5 9.7 10.3 protein 1 1103 233884_PM_at HIVEP3 human immunodeficiency 0.000832504 0.0367699 31.8 25.8 18.1 virus type I enhancer binding protein 3 1104 217843_PM_s_at MED4 mediator complex subunit 0.000833089 0.0367699 196.9 248.0 257.6 4 1105 238944_PM_at ZNF404 Zinc finger protein 404 0.000835718 0.0368525 34.7 24.3 23.2 1106 1557688_PM_at — — 0.000837575 0.036901 546.6 314.2 328.6 1107 230885_PM_at SPG7 spastic paraplegia 7 (pure 0.000838625 0.0369139 372.5 277.2 282.1 and complicated autosomal recessive) 1108 221268_PM_s_at SGPP1 sphingosine-1-phosphate 0.000839543 0.0369253 25.1 41.9 39.5 phosphatase 1 1109 244581_PM_at — — 0.00084432 0.0370975 29.7 22.6 21.0 1110 215626_PM_at — — 0.000846447 0.0371575 13.3 11.3 10.4 1111 218446_PM_s_at FAM18B1 family with sequence 0.000848307 0.0371994 68.2 108.6 120.4 similarity 18, member B1 1112 203414_PM_at MMD monocyte to macrophage 0.000849571 0.0371994 452.7 712.2 689.2 differentiation-associated 1113 237218_PM_at — — 0.000849691 0.0371994 82.8 53.8 54.7 1114 222553_PM_x_at OXR1 oxidation resistance 1 0.00085174 0.0372556 100.8 160.4 169.3 1115 242824_PM_at — — 0.000854784 0.0373427 34.5 24.5 23.7 1116 206551_PM_x_at KLHL24 kelch-like 24 (Drosophila) 0.000855873 0.0373427 211.6 156.3 174.8 1117 210260_PM_s_at TNFAIP8 tumor necrosis factor, 0.000856031 0.0373427 528.5 780.3 666.8 alpha-induced protein 8 1118 242156_PM_at — — 0.00086286 0.0375636 15.8 11.6 11.5 1119 244571_PM_s_at TTC12 Tetratricopeptide repeat 0.000863136 0.0375636 14.5 11.4 11.2 domain 12 1120 233302_PM_at — — 0.000863406 0.0375636 217.7 146.6 75.8 1121 1558236_PM_at — — 0.000866834 0.0376791 287.5 220.0 226.6 1122 212887_PM_at SEC23A Sec23 homolog A 0.00087007 0.0377662 162.7 225.6 212.1 (S. cerevisiae) 1123 208694_PM_at PRKDC protein kinase, DNA- 0.00087039 0.0377662 310.8 194.2 200.2 activated, catalytic polypeptlde 1124 239917_PM_at VPS8 Vacuolar protein sorting 8 0.00087152 0.0377705 261.2 174.0 187.7 homolog (S. cerevisiae) 1125 228645_PM_at SNHG9 small nucleolar RNA host 0.000872038 0.0377705 23.9 21.1 17.5 gene 9 (non-protein coding) 1126 236007_PM_at AKAP10 A kinase (PRKA) anchor 0.000873781 0.0378124 759.7 582.0 627.1 protein 10 1127 234604_PM_at — — 0.000876504 0.0378965 76.3 38.0 39.8 1128 244290_PM_at — — 0.000882117 0.0380845 21.3 15.0 15.4 1129 203983_PM_at TSNAX translin-associated factor 0.000882415 0.0380845 239.3 365.9 374.5 X 1130 225519_PM_at PPP4R2 protein phosphatase 4, 0.000885487 0.0380901 258.8 370.4 427.5 regulatory subunit 2 1131 227766_PM_at LIG4 ligase IV, DNA, ATP- 0.00088588 0.0380901 22.7 37.2 39.7 dependent 1132 242646_PM_at — — 0.000885928 0.0380901 249.4 193.5 181.7 1133 215750_PM_at KIAA1659 KIAA1659 protein 0.000886213 0.0380901 21.6 16.9 15.5 1134 225222_PM_at HIAT1 hippocampus abundant 0.000886801 0.0380901 479.9 584.0 600.6 transcript 1 1135 240238_PM_at — — 0.000887234 0.0380901 116.7 78.0 73.5 1136 243876_PM_at — — 0.000889423 0.0381505 23.3 18.7 17.0 1137 216263_PM_s_at NGDN neuroguidin, EIF4E binding 0.000890647 0.0381694 25.4 20.3 18.6 protein 1138 215330_PM_at — — 0.000895074 0.038306 43.2 27.1 23.7 1139 1561720_PM_at RECQL5 RecQ protein-like 5 0.000895407 0.038306 15.4 12.6 12.4 1140 232583_PM_at — — 0.000897151 0.0383382 247.3 164.7 142.8 1141 1558996_PM_at FOXP1 forkhead box P1 0.000897734 0.0383382 243.0 177.1 166.9 1142 215615_PM_x_at — — 0.000900021 0.0384022 14.7 12.6 13.6 1143 238800_PM_s_at ZCCHC6 Zinc finger, CCHC domain 0.000901045 0.0384123 561.9 379.1 373.7 containing 6 1144 217856_PM_at RBM8A RNA binding motif protein 0.000902061 0.038422 240.2 196.3 196.1 8A 1145 208370_PM_s_at RCAN1 regulator of calcineurin 1 0.000904627 0.0384976 56.1 81.4 72.8 1146 222262_PM_s_at ETNK1 ethanolamine kinase 1 0.000905546 0.0385031 34.9 47.7 50.2 1147 224870_PM_at KIAA0114 KIAA0114 0.000910077 0.038662 132.2 114.3 77.9 1148 244490_PM_at — — 0.000914068 0.0387977 17.0 15.1 12.5 1149 233223_PM_at — — 0.000916204 0.0388545 229.8 126.8 132.5 1150 241294_PM_at — — 0.000917347 0.0388566 78.9 57.4 53.2 1151 237119_PM_at — — 0.000917848 0.0388566 275.7 172.7 157.4 1152 54632_PM_at THADA thyroid adenoma 0.000918721 0.0388598 65.8 54.9 46.8 associated 1153 215151_PM_at DOCK10 dedicator of cytokinesis 10 0.000919627 0.0388644 68.3 52.4 43.4 1154 222719_PM_s_at PDGFC platelet derived growth 0.000923078 0.0389764 10.0 11.9 12.8 factor C 1155 231890_PM_at — — 0.000929908 0.0392308 91.0 61.5 63.0 1156 1560706_PM_at — — 0.000934795 0.0394027 813.7 489.7 487.1 1157 1562236_PM_at MYST4 MYST histone 0.000935599 0.0394027 16.7 14.7 13.4 acetyltransferase (monocytic leukemia) 4 1158 37079_PM_at NUS1P3 nuclear undecaprenyl 0.000936954 0.0394257 9.2 10.9 10.2 pyrophosphate synthase 1 homolog (S. cerevisiae) pseudogene 3 1159 241331_PM_at SKAP2 Src kinase associated 0.000937938 0.039433 24.9 16.4 22.9 phosphoprotein 2 1160 209187_PM_at DR1 down-regulator of 0.030939306 0.0394565 334.6 522.1 505.2 transcription 1, TBP- binding (negative cofactor 2) 1161 228181_PM_at SLC30A1 solute carrier family 30 0.000940396 0.0394683 27.7 39.3 38.1 (zinc transporter), member 1 1162 226901_PM_at C17orf58 chromosome 17 open 0.000942438 0.0395199 19.8 26.8 25.8 reading frame 58 1163 39313_PM_at WNK1 WNK lysine deficient 0.000944928 0.0395903 113.9 80.5 75.3 protein kinase 1 1164 242279_PM_at — — 0.000947662 0.0396562 124.3 86.5 82.8 1165 223134_PM_at BBX bobby sox homolog 0.000948129 0.0396562 594.6 470.1 457.6 (Drosophila) 1166 204738_PM_s_at KRIT1 KRIT1, ankyrin repeat 0.000950724 0.0397306 41.2 41.2 34.0 containing 1167 233914_PM_s_at SBF2 SET binding factor 2 0.00095246 0.0397369 221.5 144.0 159.3 1168 239449_PM_at — — 0.000952504 0.0397369 37.2 22.9 23.0 1169 1561166_PM_a_at — — 0.000956757 0.0398802 30.6 21.5 21.2 1170 235786_PM_at — — 0.000963166 0.040113 228.1 176.8 165.5 1171 1568986_PM_x_at PIGT phosphatidylinositol 0.000967031 0.0402396 22.7 18.0 19.7 glycan anchor biosynthesis, class T 1172 233800_PM_at — — 0.000969773 0.0403192 207.8 148.8 142.8 1173 208663_PM_s_at TTC3 tetratricopeptide repeat 0.000977441 0.0405812 454.5 378.8 313.8 domain 3 1174 1556646_PM_at — — 0.00097774 0.0405812 104.7 78.1 73.0 1175 213852_PM_at RBM8A RNA binding motif protein 0.000978667 0.0405851 408.4 313.7 313.5 8A 1176 210145_PM_at PLA2G4A phospholipase A2, group 0.000984729 0.0408018 50.8 84.4 84.4 IVA (cytosolic, calcium- dependent) 1177 225770_pM_at RSPRY1 ring finger and SPRY 0.000988575 0.0408945 233.6 203.8 193.3 domain containing 1 1178 234981_PM_x_at CMBL carboxymethylenebutenolidase 0.000988861 0.0408945 1572.4 1302.0 1387.2 homolog (Pseudomonas) 1179 235444_PM_at FOXP1 forkhead box P1 0.000990226 0.0408945 426.6 299.7 316.1 1180 218595_PM_s_at HEATR1 HEAT repeat containing 1 0.000990634 0.0408945 131.9 97.8 101.0 1181 242874_PM_at — — 0.000991162 0.0408945 32.6 23.7 18.1 1182 228315_PM_at ZMAT3 zinc finger, matrin-type 3 0.000992797 0.0409273 651.6 538.8 516.1 1183 215757_PM_at PRKDC Protein kinase, DNA- 0.000998001 0.041107 29.5 15.8 17.5 activated, catalytic polypeptide 1184 215597_PM_x_at — — 0.00100129 0.0412077 13.8 11.9 12.2 1185 1555842_PM_at CYTH2 cytohesin 2 0.00100876 0.04148 15.2 12.0 12.1 1186 1556305_PM_at — — 0.0010118 0.04157 400.4 248.7 281.5 1187 1569597_PM_at — — 0.00101421 0.0416339 53.3 47.0 34.4 1188 232614_PM_at — — 0.00101542 0.0416485 134.2 69.5 48.3 1189 206821_PM_x_at AGFG2 ArfGAP with FG repeats 2 0.00101641 0.041654 11.0 11.1 12.4 1190 229078_PM_s_at KIAA1704 /// KIAA1704 /// hypothetical 0.00102065 0.0417784 128.1 106.6 89.3 LOC100507773 LOC100507773 1191 1559822_PM_s_at MTDH metadherin 0.00102116 0.0417784 135.0 117.7 99.5 1192 206567_PM_s_at PHF20 PHD finger protein 20 0.00102394 0.041857 379.0 287.3 287.7 1193 218496_PM_at RNASEH1 ribonuclease H1 0.00102602 0.0419069 100.7 86.0 68.6 1194 214917_PM_at PRKAA1 protein kinase, AMP- 0.0010283 0.0419648 148.0 103.7 105.4 activated, alpha 1 catalytic subunit 1195 215063_PM_x_at LRRC40 leucine rich repeat 0.00103399 0.0421379 415.2 351.3 361.9 containing 40 1196 217982_PM_s_at MORF4L1 mortality factor 4 like 1 0.00103427 0.0421379 2083.6 2398.1 2340.4 1197 201769_PM_at CLINT1 clathrin interactor 1 0.00103627 0.0421841 427.8 569.7 594.9 1198 244687_PM_at DBT dihydrolipoamide 0.00103809 0.0422064 49.0 41.3 34.0 branched chain transacylase E2 1199 221264_PM_s_at TARDBP TAR DNA binding protein 0.00103855 0.0422064 406.9 328.6 302.5 1200 241242_PM_at — — 0.00104186 0.0423056 198.4 130.9 143.4 1201 215310_PM_at APC adenomatous polyposis 0.00104337 0.0423316 227.1 157.6 168.5 coil 1202 238231_PM_at NFYC Nuclear transcription 0.00104517 0.0423427 98.2 66.4 62.2 factor Y, gamma 1203 238863_PM_x_at — — 0.00104538 0.0423427 20.3 16.7 17.3 1204 1561310_PM_at — — 0.0010478 0.0424054 10.7 9.4 10.1 1205 238560_PM_at CALCOCO2 calcium binding and 0.0010503 0.0424713 146.3 94.4 98.3 coiled-coil domain 2 1206 243546_PM_at — — 0.00105358 0.0425687 95.8 69.2 64.2 1207 244674_PM_at — — 0.00105727 0.0426823 33.6 22.0 23.0 1208 236321_PM_at FAM200B family with sequence 0.00105871 0.0427051 75.1 108.0 114.6 similarity 200, member B 1209 203628_PM_at IGF1R insulin-like growth factor 1 0.00106019 0.0427294 442.5 240.2 246.7 receptor 1210 244312_PM_at — — 0.00106163 0.0427602 414.4 295.2 313.4 1211 215589_PM_at — — 0.0010636 0.0427784 15.4 12.4 11.4 1212 203283_PM_s_at HS2ST1 heparan sulfate 2-O- 0.00106404 0.0427784 46.3 55.0 61.5 sulfotransferase 1 1213 217873_PM_at CAB39 calcium binding protein 39 0.00106547 0.042788 901.3 1106.4 1107.1 1214 243423_PM_at — — 0.00106721 0.042788 115.9 86.4 73.8 1215 218195_PM_at C6orf211 chromosome 6 open 0.00106818 0.042788 193.8 286.2 278.4 reading frame 211 1216 216751_PM_at — — 0.00106819 0.042788 19.1 15.7 15.7 1217 226119_PM_at PCMTD1 protein-L-isoaspartate (D- 0.00106929 0.042788 363.2 622.9 612.1 aspartate) O- methyltransferase domain containing 1 1218 240621_PM_at — — 0.0010696 0.042788 21.6 18.0 18.0 1219 236610_PM_at — — 0.00107052 0.042788 43.8 30.3 26.5 1220 1555446_PM_s_at TRAPPC10 trafficking protein particle 0.00107184 0.042788 270.7 178.4 175.9 complex 10 1221 238468_PM_at TNRC6B trinucleotide repeat 0.00107218 0.042788 494.2 355.2 363.6 containing 6B 1222 222699_PM_s_at PLEKHF2 pleckstrin homology 0.00107435 0.0428128 69.9 110.8 101.8 domain containing, family F (with FYVE domain) member 2 1223 233193_PM_x_at INTS4 integrator complex 0.00107456 0.0428128 13.9 11.9 12.5 subunit 4 1224 227270_PM_at FAM200B family with sequence 0.00108465 0.0431514 64.3 91.5 106.1 similarity 200, member B 1225 217653_PM_x_at — — 0.00108483 0.0431514 47.2 37.5 39.9 1226 212126_PM_at CBX5 chromobox homolog 5 0.00108729 0.043214 156.4 112.9 124.7 1227 240326_PM_at — — 0.00108962 0.0432385 182.3 103.5 119.0 1228 232307_PM_at — — 0.00108968 0.0432385 113.5 64.6 59.1 1229 239232_PM_at MSI2 Musashi homolog 2 0.00109848 0.0435522 39.6 28.7 28.2 (Drosophila) 1230 1552343_PM_s_at PDE7A phosphodiesterase 7A 0.00109961 0.0435615 51.0 35.9 35.9 1231 1557553_PM_at PPP1R12B protein phosphatase 1, 0.00110324 0.0436698 182.7 94.7 102.2 regulatory (inhibitor) subunit 12B 1232 236814_PM_at MDM4 Mdm4 p53 binding protein 0.00110559 0.0437273 1429.5 1127.2 1112.4 homolog (mouse) 1233 234428_PM_at — — 0.00110678 0.0437389 13.1 10.0 10.5 1234 222640_PM_at DNMT3A DNA (cytosine-5-)- 0.00110857 0.0437741 93.3 73.9 71.7 methyltransferase 3 alpha 1235 212027_PM_at RBM25 RNA binding motif protein 0.0011165 0.0440516 702.5 556.5 540.7 25 1236 210561_PM_s_at WSB1 WD repeat and SOCS box- 0.00111899 0.0441141 991.0 1310.4 1331.4 containing 1 1237 1570089_PM_at — — 0.0011224 0.0441774 24.2 20.6 18.8 1238 241913_PM_at — — 0.00112241 0.0441774 56.1 35.6 34.1 1239 202194_PM_at TMED5 transmembrane emp24 0.00112677 0.0442901 705.1 1045.9 972.3 protein transport domain containing 5 1240 207630_PM_s_at CREM cAMP responsive element 0.00112709 0.0442901 28.1 37.5 39.2 modulator 1241 237839_PM_at — — 0.00113444 0.044543 26.4 15.7 13.6 1242 226276_PM_at TMEM167A transmembrane protein 0.00113546 0.0445471 426.3 579.1 594.3 167A 1243 234609_PM_at — — 0.00114012 0.044682 23.3 16.4 16.3 1244 1570210_PM_x_at PPP6R2 protein phosphatase 6, 0.00114073 0.044682 37.7 28.3 27.6 regulatory subunit 2 1245 232628_PM_at — — 0.00114327 0.0447326 334.1 202.5 202.2 1246 203921_PM_at CHST2 carbohydrate (N- 0.00114386 0.0447326 235.8 301.3 363.2 acetylglucosamine-6-O) sulfotransferase 2 1247 225700_PM_at GLCCI1 glucocorticoid induced 0.00114929 0.0449089 39.4 29.6 27.0 transcript 1 1248 222589_PM_at NLK nemo-like kinase 0.00115377 0.0449844 118.3 159.0 160.3 1249 235894_PM_at — — 0.00115378 0.0449844 117.3 86.7 98.0 1250 241993_PM_x_at — — 0.00115399 0.0449844 389.1 290.4 301.5 1251 233473_PM_x_at — — 0.00115584 0.0450205 974.0 689.3 713.7 1252 224984_PM_at NFAT5 nuclear factor of activated 0.00116222 0.0452328 857.3 694.2 743.5 T-cells 5, tonicity- responsive 1253 1570531_PM_at — — 0.00116466 0.0452916 12.4 10.5 12.0 1254 234326_PM_at — — 0.0011656 0.045292 337.1 194.8 209.7 1255 222444_PM_at ARMCX3 armadillo repeat 0.00116672 0.0452994 24.2 32.1 37.0 containing, X-linked 3 1256 243792_PM_x_at PTPN13 Protein tyrosine 0.0011703 0.0454022 19.1 15.6 16.6 phosphatase, non- receptor type 13 (APO- 1/CD95 (Fas)-associated phospha 1257 205202_PM_at PCMT1 protein-L-isoaspartate (D- 0.00117229 0.0454433 509.3 727.1 742.4 aspartate) O- methyltransferase 1258 243739_PM_at — — 0.00117713 0.0455946 62.6 40.9 40.3 1259 215000_PM_s_at FEZ2 fasciculation and 0.00118371 0.0458131 286.2 368.4 385.7 elongation protein zeta 2 (zygin II) 1250 1569815_PM_x_at STRN striatin, calmodulin 0.00118601 0.0458656 28.4 19.4 20.0 binding protein 1261 207365_PM_x_at USP34 ubiquitin specific 0.0011908 0.0460096 258.2 201.7 206.2 peptidase 34 1262 205849_PM_s_at UQCRB ubiquinol-cytochrome c 0.00119162 0.0460096 151.4 304.8 294.7 reductase binding protein 1263 210743_PM_s_at CDC14A CDC14 cell division cycle 0.00119405 0.0460669 21.4 17.3 14.7 14 homolog A (S. cerevisiae) 1264 237180_PM_at PSME4 Proteasome (prosome, 0.00119818 0.0461896 133.8 95.9 109.5 macropain) activator subunit 4 1265 206056_PM_x_at SPN sialophorin 0.00120053 0.0462437 422.4 352.8 366.3 1256 234159_PM_at — — 0.00120174 0.0462537 82.6 57.7 55.6 1267 224104_PM_at — — 0.00120531 0.0463545 9.8 9.7 11.1 1268 219694_PM_at FAM105A family with sequence 0.00120711 0.0463871 123.2 175.8 167.3 similarity 105, member A 1269 237184_PM_at — — 0.001209 0.0464218 26.6 20.2 19.7 1270 204011_PM_at SPRY2 sprouty homolog 2 0.00121023 0.0464218 11.0 14.5 13.6 (Drosophila) 1271 218303_PM_x_at KRCC1 lysine-rich coiled-coil 1 0.00121087 0.0464218 165.2 258.0 253.6 1272 1559391_PM_s_at — — 0.00121924 0.0467059 740.8 414.6 457.1 1273 225837_PM_at C12orf32 chromosome 12 open 0.00122486 0.0468451 36.3 53.4 40.6 reading frame 32 1274 232469_PM_x_at C1orf191 chromosome 1 open 0.0012259 0.0468451 92.0 77.4 71.0 reading frame 191 1275 237216_PM_at — — 0.00122711 0.0468451 23.5 17.6 17.0 1276 1559282_PM_at — — 0.00122737 0.0468451 28.0 21.0 21.3 1277 1554148_PM_a_at SLC33A1 solute carrier family 33 0.00122768 0.0468451 14.7 20.1 16.8 (acetyl-CoA transporter), member 1 1278 228793_PM_at JMJD1C jumonji domain containing 1C 0.00122969 0.0468593 994.7 644.1 725.0 1279 242611_PM_at — — 0.00123041 0.0468593 16.4 13.4 13.5 1280 230086_PM_at FNBP1 formin binding protein 1 0.00123107 0.0468593 18.6 15.0 14.5 1281 215212_PM_at — — 0.0012319 0.0468593 122.8 79.5 79.0 1282 230099_PM_at — — 0.00123347 0.0468824 370.8 275.0 251.1 1283 232555_PM_at CREB5 CAMP responsive element 0.00124092 0.0471288 1517.2 924.2 1042.4 binding protein 5 1284 241036_PM_at — — 0.00124392 0.047206 224.0 169.5 158.1 1285 230270_PM_at PRPF38B PRP38 pre-mRNA 0.00124844 0.0473407 806.4 593.9 635.5 processing factor 38 (yeast) domain containing B 1286 235730_PM_at — — 0.00125167 0.0474262 239.8 174.3 192.8 1287 234423_PM_x_at — — 0.00125281 0.0474325 280.4 230.9 229.0 1288 224751_PM_at PL-5283 PL-5283 protein 0.00125969 0.047656 617.3 876.2 848.8 1289 241368_PM_at PLIN5 perilipin 5 0.00126593 0.0478549 123.5 84.5 136.3 1290 232284_PM_at PSMD6 Proteasome (prosome, 0.0012684 0.0479111 198.2 124.3 123.6 macropain) 26S subunit, non-ATPase, 6 1291 233909_PM_at — — 0.00127099 0.0479718 12.7 10.8 10.8 1292 213164_PM_at SLC5A3 solute carrier family 5 0.00127396 0.0480466 613.0 462.3 491.5 (sodium/myo-inositol cotransporter), member 3 1293 1553644_PM_at C14orf49 chromosome 14 open 0.00127584 0.0480603 10.5 10.1 11.7 reading frame 49 1294 241750_PM_x_at — — 0.00127776 0.0481155 109.8 72.7 81.1 1295 1560926_PM_at — — 0.00127908 0.048128 249.4 159.7 191.7 1296 1559589_PM_a_at — — 0.00128515 0.0483151 28.9 21.7 22.7 1297 237626_PM_at — — 0.00129452 0.0486338 295.5 211.0 216.1 1298 226353_PM_at SPPL2A signal peptide peptidase- 0.00130512 0.0489943 789.5 991.8 943.1 like 2A 1299 211277_PM_x_at APP amyloid beta (A4) 0.00130823 0.0490732 24.3 21.9 21.7 precursor protein 1300 1569450_PM_at CAPZA2 capping protein (actin 0.00131042 0.0491176 30.2 21.4 23.8 filament) muscle Z-line, alpha 2 1301 225600_PM_at C8orf83 chromosome 8 open 0.00131519 0.0492585 59.8 94.1 96.0 reading frame 83 1302 206154_PM_at RLBP1 retinaldehyde binding 0.00131658 0.0492727 12.5 11.0 12.4 protein 1 1303 1561633_PM_at HMGA2 high mobility group AT- 0.00132318 0.0494817 12.7 11.4 10.8 hook 2 1304 207436_PM_x_at KIAA0894 KIAA0894 protein 0.00132539 0.0495263 354.6 306.9 318.7 1305 1557350_PM_at G3BP1 GTPase activating protein 0.00132688 0.049544 44.8 32.4 29.4 (SH3 domain) binding protein 1 1306 202169_PM_s_at AASDHPPT aminoadipate- 0.00132799 0.0495474 178.6 260.1 242.2 semialdehyde dehydrogenase- phosphopantetheinyl transferase 1307 232210_PM_at — — 0.00132904 0.0495487 391.2 221.5 144.3 1308 1558691_PM_a_at DOCK4 dedicator of cytokinesis 4 0.00133158 0.0496054 13.8 12.1 11.3 1309 209833_PM_at CRADD CASP2 and RIPK1 domain 0.00133577 0.04967 35.8 45.8 42.0 containing adaptor with death domain 1310 1554963_PM_at — — 0.00133636 0.04967 13.8 11.1 11.8 1311 234131_PM_at — — 0.00133696 0.04967 106.2 76.1 76.5 1312 1559054_PM_a_at — — 0.00133739 0.04967 68.0 47.8 50.7 1313 242467_PM_at — — 0.00134002 0.0496908 280.3 218.5 215.2 1314 238733_PM_at — — 0.00134142 0.0496908 143.7 88.7 105.1 1315 221808_PM_at RAB9A RAB9A, member RAS 0.00134149 0.0496908 307.4 375.4 369.8 oncogene family 1316 201830_PM_s_at NET1 neuroepithelial cell 0.00134203 0.0496908 18.7 24.9 18.2 transforming 1 1317 217016_PM_x_at TMEM212 transmembrane protein 0.00134421 0.0497337 18.0 14.8 17.0 212 1318 212721_PM_at SREK1 splicing regulatory 0.00134616 0.0497681 105.3 175.8 182.7 glutamine/lysine-rich protein 1 1319 224105_PM_x_at — — 0.00134808 0.0498013 56.2 47.9 51.4 1320 232978_PM_at — — 0.00135736 0.0501061 27.9 24.4 19.4 1321 236370_PM_at — — 0.00136023 0.0501741 40.7 30.8 28.3 1322 208246_PM_x_at — — 0.00136454 0.050295 1858.8 1458.0 1576.1 1323 239701_PM_at — — 0.00136972 0.0504477 202.0 111.2 112.8 1324 224644_PM_at — — 0.0013769 0.0506184 521.7 670.3 638.6 1325 212408_PM_at TOR1AIP1 torsin A interacting 0.00137762 0.0506184 1217.4 1446.6 1448.5 protein 1 1326 205998_PM_x_at CYP3A4 cytochrome P450, family 0.00137763 0.0506184 21.6 18.8 20.6 3, subfamily A, polypeptide 4 1327 224416_PM_s_at MED28 mediator complex subunit 0.00137851 0.0506184 66.6 85.5 90.3 28 1328 220694_PM_at ASAP1-IT ASAP1 intronic transcript 0.00137967 0.0506229 314.9 161.1 189.3 (non-protein coding) 1329 1556728_PM_at — — 0.00138078 0.0506255 75.9 54.2 47.9 1330 236417_PM_at — — 0.00138772 0.0508134 188.3 124.2 115.5 1331 205401_PM_at AGPS alkylglycerone phosphate 0.00138799 0.0508134 26.7 36.6 28.6 synthase 1332 1561130_PM_at C12orf51 chromosome 12 open 0.00139089 0.0508306 29.8 22.8 23.3 reading frame 51 1333 220410_PM_s_at CAMSAP1 calmodulin regulated 0.00139091 0.0508306 21.8 16.6 16.2 spectrin-associated protein 1 1334 219095_PM_at JMJD7-PLA264B /// JMJD7-PLA2G4B 0.00139159 0.0508305 25.6 20.9 20.2 PLA2G4B readthrough /// phospholipase A2, group IVB (cytosolic) 1335 209096_PM_at UBE2V2 ubiquitin-conjugating 0.00139729 0.0510006 89.4 132.0 126.3 enzyme E2 variant 2 1336 218559_PM_s_at MAFB v-maf 0.00140241 0.0511491 592.3 883.7 939.1 musculoaponeurotic fibrosarcoma oncogene homolog B (avian) 1337 242793_PM_at — — 0.00140523 0.0512136 50.0 32.8 31.7 1338 242008_PM_at — — 0.00140833 0.0512516 1505.6 1047.9 1116.4 1339 228913_PM_at LOC100190939 hypothetical 0.00140855 0.0512516 42.8 29.7 29.3 LOC100190939 1340 223336_PM_s_at RAB18 RAB18, member RAS 0.00140948 0.0512516 229.6 362.7 345.9 oncogene family 1341 225147_PM_at CYTH3 cytohesin 3 0.00141048 0.0512516 32.7 36.9 45.9 1342 208278_PM_s_at — — 0.00141367 0.0513293 53.2 31.8 33.6 1343 233678_PM_at — — 0.00141576 0.0513669 14.5 12.9 12.1 1344 244357_PM_at — — 0.00141804 0.0514113 621.3 320.1 324.5 1345 240205_PM_x_at — — 0.00141966 0.0514318 115.2 85.3 88.1 1346 226493_PM_at KCTD18 potassium channel 0.00142551 0.0516054 121.5 161.6 157.9 tetramerisation domain containing 18 1347 216745_PM_x_at — — 0.00142692 0.0516181 39.0 32.0 34.4 1348 233007_PM_at — — 0.00142903 0.05162 60.1 43.8 43.0 1349 1568594_PM_s_at TRIM52 tripartite motif-containing 0.00143095 0.05162 92.5 86.8 71.2 52 1350 1554564_PM_a_at SPPL3 signal peptide peptidase 3 0.00143162 0.05162 29.5 23.7 24.3 1351 225210_PM_s_at FAM103A1 family with sequence 0.00143168 0.05162 444.6 500.7 522.9 similarity 103, member A1 1352 243587_PM_x_at — — 0.00143227 0.05162 85.5 61.0 59.5 1353 1563075_PM_s_at — — 0.00143366 0.0516319 678.1 437.5 494.0 1354 236703_PM_at NT5C2 5′-nucteotidase, cytosolic 0.00143781 0.0517431 425.1 268.3 297.8 II 1355 239227_PM_at — — 0.00144381 0.0519158 65.8 36.7 38.9 1356 244165_PM_at C10orf18 chromosome 10 open 0.00144474 0.0519158 161.6 97.3 90.3 reading frame 18 1357 231087_PM_at — — 0.00144663 0.0519454 35.7 30.6 25.4 1358 1560928_PM_at LOC151657 hypothetical protein 0.00144829 0.0519667 42.0 32.2 31.3 LOC151657 1359 232031_PM_s_at KIAA1632 KIAA1632 0.00145151 0.0520286 33.8 24.3 24.0 1360 1570108_PM_at — — 0.00145234 0.0520286 33.3 24.4 24.3 1361 203883_PM_s_at RAB11FIP2 RAB11 family interacting 0.00145364 0.0520286 433.2 330.8 343.2 protein 2 (class I) 1362 230489_PM_at CD5 CD5 molecule 0.00145462 0.0520286 41.7 37.5 23.5 1363 242136_PM_x_at MGC70870 C-terminal binding protein 0.00145553 0.0520286 35.7 42.5 47.0 2 pseudogene 1364 235288_PM_at — — 0.00145642 0.0520286 209.1 145.5 158.8 1365 243016_PM_at — — 0.00145891 0.052078 26.2 19.4 17.0 1366 222720_PM_x_at C1orf27 chromosome 1 open 0.00145994 0.052078 12.3 15.7 15.0 reading frame 27 1367 236607_PM_at — — 0.00146319 0.052145 86.5 64.5 64.7 1368 213056_PM_at FRMD4B FERM domain containing 0.00146422 0.052145 75.3 96.5 128.6 4B 1369 1557895_PM_at FLI35934 FLI35934 0.00146503 0.052145 25.2 18.1 18.2 1370 218059_PM_at ZNF706 zinc finger protein 706 0.00147057 0.052304 824.7 1059.4 921.0 1371 238303_PM_at STT3B STT3, subunit of the 0.00147382 0.0523813 57.8 43.7 37.9 oligosaccharyltransferase complex, homolog B (S. cerevisiae) 1372 205140_PM_at FPGT fucose-1-phosphate 0.00147672 0.0524307 29.9 47.3 47.5 guanylyltransferase 1373 227916_PM_x_at EXOSC3 exosome component 3 0.00147736 0.0524307 219.2 275.0 268.7 1374 201973_PM_s_at C7orf28B /// chromosome 7 open 0.00148545 0.0526794 809.5 979.5 901.4 CCZ1 reading frame 28B /// CCZ1 vacuolar protein trafficking and biogenesi 1375 209455_PM_at FBXW11 F-box and WD repeat 0.00149798 0.0530851 129.5 150.0 146.2 domain containing 11 1376 201865_PM_x_at NR3C1 nuclear receptor subfamily 0.00150008 0.0531209 2013.9 1715.9 1694.7 3, group C, member 1 (glucocorticoid receptor) 1377 209228_PM_x_at TUSC3 tumor suppressor 0.00150159 0.0531358 9.4 8.9 10.1 candidate 3 1378 240498_PM_at — — 0.0015055 0.0532708 54.8 29.9 31.3 1379 230987_PM_at — — 0.00150865 0.0533082 264.9 153.4 172.8 1380 240626_PM_at — — 0.00150978 0.0533095 15.1 12.7 12.6 1381 231069_PM_at — — 0.0015111 0.0533135 36.6 28.9 29.9 1382 214553_PM_s_at ARPP19 cAMP-regulated 0.0015131 0.0533135 24.5 36.0 33.9 phosphoprotein, 19 kDa 1383 1561060_PM_at — — 0.00151345 0.0533135 11.6 9.9 10.9 1384 242256_PM_X_at — — 0.00151427 0.0533135 34.1 26.5 31.1 1385 233017_PM_x_at — — 0.00151651 0.0533487 141.5 120.1 130.7 1386 208073_PM_x_at TTC3 tetratricopeptide repeat 0.00151746 0.0533487 378.1 300.5 254.2 domain 3 1387 223809_PM_at RGS18 regulator of G-protein 0.00152081 0.0534279 1124.9 1686.1 1664.1 signaling 18 1388 236546_PM_at — — 0.00152367 0.0534898 15.1 12.3 13.2 1389 1557300_PM_s_at — — 0.00152525 0.0534991 45.8 33.1 31.9 1390 232744_PM_x_at — — 0.00152613 0.0534991 147.6 89.9 84.2 1391 238783_PM_at TMEM161B transmembrane protein 0.0015277 0.0535156 158.6 125.3 119.1 161B 1392 218107_PM_at WDR26 WD repeat domain 26 0.00153315 0.0536511 826.4 974.5 1036.8 1393 1558732_PM_at MAP4K4 mitogen-activated protein 0.00153377 0.0536511 244.7 154.4 174.4 kinase kinase kinase kinase 4 1394 229360_PM_at ZNF280B zinc finger protein 280B 0.00153761 0.0537469 15.3 12.5 12.1 1395 225324_PM_at CRLS1 cardiolipin synthase 1 0.00154301 0.053897 61.9 108.9 91.7 1396 209893_PM_s_at FUT4 fucosyltransferase 4 0.00154586 0.0539405 54.5 81.2 64.4 (alpha (1,3) fucosyltransferase, myeloid-specific) 1397 1567045_PM_at — — 0.00154647 0.0539405 33.2 24.5 25.5 1398 227986_PM_at ZNF343 zinc finger protein 343 0.0015482 0.0539622 17.5 14.0 14.8 1399 239788_PM_at — — 0.00154997 0.05397 34.9 25.6 25.0 1400 241851_PM_x_at LOC100130429 hypothetical 0.00155064 0.05397 29.1 20.7 22.3 LOC100130429 1401 232375_PM_at — — 0.0015584 0.0541008 468.2 294.9 276.6 1402 217346_PM_at LOC100293160 /// peptlidyl-prolyl cis-trans 0.00155947 0.0541008 55.0 46.5 47.8 PPIA isomerase A-like /// peptidylprolyl isomerase A (cyclophilin 1403 226941_PM_at ATF6 activating transcription 0.00155955 0.0541008 622.1 497.8 535.6 factor 6 1404 212749_PM_s_at RCHY1 ring finger and CHY zinc 0.00155965 0.0541008 197.3 276.9 253.5 finger domain containing 1 1405 201944_PM_at HEXB hexosaminidase B (beta 0.00155995 0.0541008 847.7 1061.3 1043.5 polypeptide) 1406 1570227_PM_at — — 0.00156173 0.0541241 27.0 22.6 22.1 1407 217152_PM_at — — 0.00156614 0.0542135 158.2 111.0 105.3 1408 211374_PM_x_at — — 0.00156833 0.0542135 26.8 21.7 22.9 1409 210438_PM_x_at TROVE2 TROVE domain family, 0.00156842 0.0542135 693.6 597.4 559.3 member 2 1410 222942_PM_s_at TIAM2 T-cell lymphoma invasion 0.00156876 0.0542135 90.6 50.1 51.0 and metastasis 2 1411 236883_PM_at — — 0.00157206 0.0542719 205.7 153.4 149.9 1412 216006_PM_at — — 0.00157268 0.0542719 108.6 68.0 73.3 1413 1556359_PM_at C6orf89 Chromosome 6 open 0.00157408 0.0542724 54.2 40.5 41.7 reading frame 89 1414 242171_PM_at — — 0.00157492 0.0542724 15.5 12.6 13.4 1415 236941_PM_at C22orf30 chromosome 22 open 0.00157693 0.0543003 110.5 74.9 75.2 reading frame 30 1416 232769_PM_at — — 0.00157796 0.0543003 44.4 27.0 34.9 1417 212132_PM_at LSM14A LSM14A, SCD6 homolog A 0.00158011 0.0543067 314.5 358.5 375.3 (S. cerevisiae) 1418 224642_PM_at FYTTD1 forty-two-three domain 0.00158105 0.0543067 44.2 63.9 56.4 containing 1 1419 201312_PM_s_at SH3BGRL SH3 domain binding 0.00158149 0.0543057 2316.5 2827.1 2855.1 glutamic acid-rich protein like 1420 228654_PM_at SPIN4 spindlin family, member 4 0.00159134 0.0545691 24.3 41.3 45.5 1421 232580_PM_x_at — — 0.0015921 0.0545691 129.6 96.6 94.3 1422 205175_PM_x_at ZNF222 zinc finger protein 222 0.00159338 0.0545691 19.6 24.1 25.3 1423 208866_PM_at CSNK1A1 casein kinase 1, alpha 1 0.00159405 0.0545691 401.6 342.0 314.0 1424 218365_PM_s_at DARS2 aspartyl-tRNA synthetase 0.00159473 0.0545691 16.4 17.2 14.5 2, mitochondrial 1425 236254_PM_at VPS13B vacuolar protein sorting 0.00160153 0.0547633 1169.4 933.1 958.7 13 homolog B (yeast) 1426 244691_PM_at SETD5 SET domain containing 5 0.00160515 0.0548486 22.0 17.4 15.7 1427 1557529_PM_at C12orf51 chromosome 12 open 0.0016064 0.0548529 58.8 46.9 44.1 reading frame 51 1428 228454_PM_at LCOR ligand dependent nuclear 0.00161199 0.0550052 703.4 514.4 559.2 receptor compressor 1429 243554_PM_at — — 0.00161638 0.0551164 77.7 53.9 54.3 1430 221509_PM_at DENR density-regulated protein 0.00162004 0.0551499 219.1 296.9 302.8 1431 237703_PM_at — — 0.0016203 0.0551499 40.8 29.4 30.2 1432 205994_PM_at ELK4 ELK4, ETS-domain protein 0.00162089 0.0551499 10.3 11.5 10.7 (SRF accessory protein 1) 1433 227046_PM_at SLC39A11 solute carrier family 39 0.00162189 0.0551499 62.4 87.0 77.7 (metal ion transporter), member 11 1434 240527_PM_at — — 0.00162319 0.0551556 71.1 52.2 54.9 1435 240154_PM_at — — 0.00163371 0.0554633 1222.2 811.2 806.3 1436 1564773_PM_x_at — — 0.00163452 0.0554633 20.0 17.0 16.3 1437 232341_PM_x_at HABP4 hyaluronan binding 0.00163784 0.0555373 28.7 20.8 19.4 protein 4 1438 215595_PM_x_at — — 0.00163972 0.0555623 29.2 23.4 25.2 1439 224452_PM_s_at C7orf70 chromosome 7 open 0.00164229 0.0555725 244.0 320.1 298.0 reading frame 70 1440 243709_PM_at SLC38A9 solute carrier family 38, 0.0016423 0.0555725 76.1 54.1 57.5 member 9 1441 236592_PM_at — — 0.00164591 0.0556184 119.9 56.1 57.6 1442 236453_PM_at — — 0.00164594 0.0556184 10.7 11.7 14.4 1443 242111_PM_at METTL3 methyltransferase like 3 0.00166042 0.0560644 33.3 25.6 23.6 1444 1560445_PM_x_at ARHGEF1 Rho guanine nucleotide 0.0016618 0.0560644 93.5 71.0 75.4 exchange factor (GEF) 1 1445 239175_PM_at — — 0.00166259 0.0560644 533.1 407.2 435.4 1446 243414_PM_at PPIL2 Peptidylprolyl isomerase 0.0016666 0.0561576 36.8 31.1 27.5 (cyclophilin)-like 2 1447 232659_PM_at — — 0.00166766 0.0561576 41.8 27.6 27.2 1448 201816_PM_s_at GBAS glioblastoma amplified 0.00167064 0.0562191 322.9 439.5 389.3 sequence 1449 225332_PM_at LOC729082 Hypothetical protein 0.0016728 0.056253 684.2 569.3 532.4 LOC729032 1450 242106_PM_at — — 0.00167411 0.0562582 52.7 30.1 31.5 1451 239173_PM_at INADL InaD-like (Drosophila) 0.00167659 0.0563027 22.4 16.8 14.6 1452 1562194_PM_at — — 0.00168148 0.0564239 389.6 240.5 242.9 1453 205931_PM_s_at CREB5 cAMP responsive element 0.0016834 0.0564239 1458.6 949.7 1263.1 binding protein 5 1454 203347_PM_s_at MTF2 metal response element 0.00168467 0.0564239 34.7 52.0 50.7 binding transcription factor 2 1455 244181_PM_at — — 0.0016858 0.0564239 82.8 61.8 58.4 1456 217586_PM_x_at — — 0.00168599 0.0564239 23.3 18.5 19.1 1457 233369_PM_at — — 0.00168731 0.0564293 589.3 362.9 442.4 1458 223169_PM_s_at RHOU ras homolog gene family, 0.00169034 0.0565086 11.3 14.8 15.3 member U 1459 232796_PM_at — — 0.00169555 0.0566272 15.9 12.8 12.3 1460 212250_PM_at MTDH metadherin 0.00169897 0.0566921 268.8 395.3 343.4 1461 227017_PM_at ERICH1 glutamate-rich 1 0.00169982 0.0566921 183.7 214.7 242.6 1462 1569730_PM_at HEATR7B2 HEAT repeat family 0.00170215 0.056731 11.5 10.0 10.8 member 7B2 1463 240446_PM_at — — 0.00170444 0.0567551 33.7 25.2 26.0 1464 239892_PM_at — — 0.0017053 0.0567551 48.7 38.8 35.8 1465 240052_PM_at ITPR1 Inositol 1,4,5-triphosphate 0.00170637 0.0567551 105.7 71.7 73.7 receptor, type 1 1466 244100_PM_at — — 0.00171135 0.056882 29.4 22.5 23.2 1467 242608_PM_x_at FAM161B Family with sequence 0.00171743 0.0569937 603.0 486.0 517.6 similarity 161, member B 1468 216022_PM_at — — 0.00171835 0.0569937 16.0 13.4 12.6 1469 238436_PM_s_at ZNF805 zinc finger protein 805 0.00171856 0.0569937 143.2 124.8 102.8 1470 200753_PM_x_at SRSF2 serine/arginine-rich 0.00171939 0.0569937 162.5 218.7 197.1 splicing factor 2 1471 213922_PM_at TTBK2 tau tubulin kinase 2 0.00172865 0.0572617 164.7 119.5 127.7 1472 226729_PM_at USP37 ubiquitin specific 0.00173056 0.0572706 35.0 32.9 26.6 peptidase 37 1473 204483_PM_at ENO3 enolase 3 (beta, muscle) 0.00173146 0.0572706 15.3 13.5 12.9 1474 240260_PM_at — — 0.00173258 0.0572706 45.6 34.2 31.8 1475 220720_PM_x_at MZT2B mitotic spindle organizing 0.00173362 0.0572706 150.8 118.6 118.7 protein 2B 1476 1562529_PM_s_at — — 0.00173646 0.0573255 508.3 342.7 224.4 1477 1564736_PM_a_at CASP12 caspase 12 0.00173894 0.0573685 10.3 10.3 12.0 (gene/pseudogene) 1478 228516_PM_at CDAN1 congenital 0.00174063 0.0573854 51.1 44.5 38.4 dyserythropoietic anemia, type I 1479 241995_PM_at DGUOK deoxyguanosine kinase 0.00174243 0.0574059 37.8 28.6 28.5 1480 244594_PM_x_at — — 0.00175136 0.0576159 78.1 59.4 61.6 1481 212190_PM_at SERPINE2 serpin peptidase inhibitor, 0.00175198 0.0576159 25.8 26.4 36.5 clade E (nexin, plasminogen activator inhibitor type 1), me 1482 243474_PM_at — — 0.00175235 0.0576159 147.6 84.9 88.8 1483 216278_PM_at — — 0.00175491 0.0576612 38.8 34.0 28.3 1484 234118_PM_at — — 0.00175682 0.0576836 12.4 9.6 10.0 1485 242983_PM_at — — 0.00175796 0.0576836 37.0 31.1 27.2 1486 213956_PM_at CEP350 centrosomal protein 0.00176171 0.0577677 154.0 117.9 111.9 350 kDa 1487 232626_PM_at — — 0.00176762 0.0578856 24.1 17.2 20.6 1488 236005_PM_at — — 0.00176768 0.0578856 23.9 18.0 16.5 1489 222336_PM_at C4orf34 chromosome 4 open 0.00177041 0.0579315 22.6 15.2 17.7 reading frame 34 1490 213317_PM_at CLIC5 chloride intracellular 0.00177146 0.0579315 14.6 12.5 11.7 channel 5 1491 231377_PM_at CXorf65 chromosome X open 0.00177794 0.0580906 87.7 64.8 56.2 reading frame 65 1492 215852_PM_x_at C20orf117 chromosome 20 open 0.00177871 0.0580906 13.9 12.2 12.5 reading frame 117 1493 239778_PM_x_at — — 0.0017819 0.0581223 67.7 45.2 46.6 1494 242732_PM_at — — 0.00178484 0.0581223 38.6 24.2 25.0 1495 227523_PM_s_at PHF20L1 PHD finger protein 20-like 0.00178487 0.0581223 1104.7 904.2 905.0 1 1496 232344_PM_at — — 0.00178515 0.0581223 112.5 76.2 76.8 1497 205438_PM_at PTPN21 protein tyrosine 0.00178672 0.0581223 9.7 9.7 11.6 phosphatase, non- receptor type 21 1498 244208_PM_at — — 0.00178756 0.0581223 26.7 18.7 19.4 1499 243860_PM_at — — 0.00178803 0.0581223 157.5 104.9 113.1 1500 1561139_PM_at — — 0.00179722 0.0583549 31.0 24.3 24.3 1501 231304_PM_at PPP3R2 protein phosphatase 3, 0.00179758 0.0583549 9.5 9.1 10.6 regulatory subunit B, beta 1502 230777_PM_s_at PRDM15 PR domain containing 15 0.0017995 0.0583783 43.9 35.9 33.0 1503 242664_PM_at — — 0.00180506 0.0584844 11.6 9.9 9.6 1504 233399_PM_x_at ZNF252 Zinc finger protein 252 0.00180517 0.0584844 73.9 59.8 63.5 1505 1566166_PM_at — — 0.00181697 0.0588276 27.6 21.2 20.1 1506 238548_PM_at — — 0.00181899 0.0588287 20.6 15.4 16.4 1507 225016_PM_at APCDD1 adenomatosis polyposis 0.00182182 0.0588287 15.8 18.2 22.0 coil down-regulated 1 1508 244032_PM_at — — 0.00182239 0.0588287 17.7 14.9 14.6 1509 202026_PM_at SDHD succinate dehydrogenase 0.00182256 0.0588287 403.6 505.0 510.6 complex, subunit D, integral membrane protein 1510 232466_PM_at CUL4A Cullin 4A 0.00182304 0.0588287 16.7 16.3 13.3 1511 221566_PM_s_at NOL3 nucleolar protein 3 0.00182839 0.0589481 10.0 10.4 11.8 (apoptosis represser with CARD domain) 1512 1560342_PM_at — — 0.00182916 0.0589481 51.7 32.7 34.1 1513 240593_PM_x_at — — 0.00183593 0.0591167 21.4 14.8 15.7 1514 242968_PM_at — — 0.00183682 0.0591167 354.7 260.4 265.7 1515 219892_PM_at TM6SF1 transmembrane 6 0.00184024 0.0591877 295.4 402.3 432.6 superfamily member 1 1516 230747_PM_s_at TTC39C tetratricopeptide repeat 0.0018479 0.0593924 72.8 57.6 45.9 domain 39C 1517 239223_PM_S_at FBXL20 F-box and leucine-rich 0.00184921 0.0593924 124.3 87.3 81.9 repeat protein 20 1518 243819_PM_at — — 0.00185026 0.0593924 593.4 471.6 404.2 1519 227133_PM_at FAM199X family with sequence 0.0018569 0.0594225 120.2 146.3 158.7 similarity 199, X-linked 1520 1557239_PM_at BBX bobby sox homolog 0.00185785 0.0594225 55.9 38.2 37.6 (Drosophila) 1521 230350_PM_at — — 0.00185917 0.0594225 255.5 195.1 184.9 1522 221547_PM_at PRPF18 PRP18 pre-mRNA 0.00185948 0.0594225 65.0 88.7 82.7 processing factor 18 homolog (S. cerevisiae) 1523 214101_PM_s_at NPEPPS Aminopeptidase 0.0018602 0.0594225 120.2 81.0 81.3 puromycin sensitive 1524 221613_PM_s_at ZFAND6 zinc finger, AN1-type 0.00186232 0.0594225 479.2 578.4 589.9 domain 6 1525 223288_PM_at USP38 ubiquitin specific 0.00186358 0.0594225 179.4 221.9 237.0 peptidase 38 1526 239258_PM_at — — 0.00186474 0.0594225 176.4 111.1 121.8 1527 239096_PM_at — — 0.00186551 0.0594225 215.0 167.5 187.3 1528 81811_PM_at — — 0.00186608 0.0594225 55.3 41.5 40.7 1529 231149_PM_s_at ULK4 unc-51-like kinase 4 0.0018674 0.0594225 17.7 13.3 13.1 (C. elegans) 1530 236664_PM_at AKT2 v-akt murine thymoma 0.00186813 0.0594225 28.9 24.1 22.8 viral oncogene homolog 2 1531 226322_PM_at TMTC1 transmembrane and 0.00186893 0.0594225 46.2 92.9 143.5 tetratricopeptide repeat containing 1 1532 207923_PM_x_at PAX8 paired box 8 0.00186921 0.0594225 10.9 9.3 10.3 1533 244682_PM_at CAMSAP1 calmodulin regulated 0.00186949 0.0594225 13.5 10.9 11.9 spectrin-associated protein 1 1534 243612_PM_at NSD1 nuclear receptor binding 0.00187215 0.0594609 148.1 110.2 117.1 SET domain protein 1 1535 232205_PM_at — — 0.00187314 0.0594609 53.3 39.8 39.2 1536 239186_PM_at MGC39372 serpin peptidase inhibitor, 0.0018809 0.0596684 32.5 21.0 20.9 clade B (ovalbumin), member 9 pseudogene 1537 240351_PM_at — — 0.00188672 0.0598141 18.5 14.8 15.3 1538 209363_PM_s_at MED21 mediator complex subunit 21 0.00189018 0.059861 22.3 31.2 25.3 1539 236216_PM_at — — 0.00189247 0.059861 76.6 42.3 45.1 1540 207730_PM_x_at — — 0.0018927 0.059861 528.9 425.8 475.0 1541 210942_PM_s_at ST3GAL6 ST3 beta-galactoside 0.00189461 0.059861 77.6 113.7 124.9 alpha-2,3-sialyltransferase 6 1542 203102_PM_s_at MGAT2 mannosyl (alpha-1,6-)- 0.00189569 0.059861 302.8 410.8 387.0 glycoprotein beta-1,2-N- acetylglucosaminyltransferase 1543 215057_PM_at LOC100272228 hypothetical 0.00189599 0.059861 49.5 34.6 35.9 LOC100272228 1544 1569871_PM_at LMF1 lipase maturation factor 1 0.0018968 0.059861 29.9 23.1 24.2 1545 235990_PM_at LOC100130987 similar to hCG1815675 0.00190152 0.0599711 24.4 19.1 19.4 1546 222752_PM_s_at TMEM206 transmembrane protein 0.00190406 0.0600124 69.6 103.3 105.9 206 1547 242311_PM_x_at — — 0.00190812 0.0600907 46.6 38.8 40.4 1548 232150_PM_at — — 0.00190901 0.0600907 688.6 493.5 539.7 1549 231247_PM_s_at LOC727820 Hypothetical protein 0.00191175 0.0601381 87.0 61.5 68.7 LOC727820 1550 227626_PM_at PAQR8 progestin and adipoQ 0.00191435 0.0601495 171.2 132.9 117.8 receptor family member VIII 1551 212449_PM_s_at LYPLA1 lysophospholipase I 0.00191734 0.0601495 730.3 1021.2 965.0 1552 235616_PM_at TSHZ2 teashirt zinc finger 0.00191751 0.0601495 16.9 12.5 12.9 homeobox 2 1553 225445_PM_at UBN2 ubinuclein 2 0.00191834 0.0601495 220.9 171.9 186.6 1554 234151_PM_at — — 0.00191915 0.0601495 1955.4 1313.1 1262.3 1555 208661_PM_s_at TTC3 tetratricopeptide repeat 0.00191952 0.0601495 329.1 269.7 222.6 domain 3 1556 242195_PM_x_at NUMBL numb homolog 0.00192097 0.0601562 610.5 523.6 550.5 (Drosophila)-like 1557 229483_PM_at — — 0.00192503 0.060238 251.4 176.0 178.2 1558 241268_PM_x_at — — 0.00192669 0.060238 54.4 45.1 46.7 1559 243153_PM_at CDK5RAP2 CDK5 regulatory subunit 0.00192729 0.060238 19.2 16.9 15.0 associated protein 2 1560 208610_PM_s_at SRRM2 serine/arginine repetitive 0.00193003 0.060285 1239.8 918.2 933.7 matrix 2 1561 238159_PM_at — — 0.00193206 0.0602852 48.9 31.9 34.6 1562 204028_PM_s_at RABGAP1 RAB GTPase activating 0.00193251 0.0602852 268.4 228.4 239.8 protein 1 1563 219463_PM_at C20orf103 chromosome 20 open 0.0019351 0.0603273 18.6 20.4 26.0 reading frame 103 1564 230998_PM_at — — 0.00193805 0.0603503 176.2 124.6 145.8 1565 219471_PM_at C13orf18 chromosome 13 open 0.00193993 0.0603503 336.4 358.0 496.3 reading frame 18 1566 244434_PM_at GPR82 6 protein-coupled 0.00194032 0.0603503 15.5 18.4 28.1 receptor 82 1567 1564424_PM_at — — 0.00194079 0.0603503 18.0 14.4 14.5 1568 201100_PM_s_at USP9X ubiquitin specific 0.00194416 0.0603603 1396.1 1129.4 1179.0 peptidase 9, X-linked 1569 1569409_PM_x_at — — 0.00194437 0.0603603 111.5 87.2 89.8 1570 244726_PM_at — — 0.00194483 0.0603603 253.6 152.8 152.8 1571 1552370_PM_at C4orf33 chromosome 4 open 0.0019501 0.0604854 27.3 40.9 41.9 reading frame 33 1572 220113_PM_x_at POLR1B polymerase (RNA) I 0.00195433 0.0605705 74.9 59.3 62.8 polypeptide 8, 128 kDa 1573 226035_PM_at USP31 ubiquitin specific 0.00195533 0.0605705 38.0 29.3 27.7 peptidase 31 1574 244019_PM_at — — 0.00196076 0.0606229 50.9 34.0 34.4 1575 241686_PM_x_at — — 0.0019612 0.0606229 33.2 27.5 29.5 1576 220768_PM_s_at CSNK1G3 casein kinase 1, gamma 3 0.00196126 0.0606229 51.2 73.4 78.2 1577 214241_PM_at NDUFB8 NADH dehydrogenase 0.001962 0.0606229 102.2 85.3 72.9 (ubiquinone) 1 beta subcomplex, 8, 19 kDa 1578 216524_PM_x_at — — 0.00196509 0.0606799 222.8 180.3 198.3 1579 215110_PM_at MBL1P mannose-binding lectin 0.00196859 0.0607495 9.7 9.2 10.4 (protein A) 1, pseudogene 1580 222983_PM_s_at PAIP2 poly(A) binding protein 0.00197803 0.0610022 946.3 1132.8 1164.7 interacting protein 2 1581 224584_PM_at C20orf30 chromosome 20 open 0.00198083 0.0610514 1214.2 1518.9 1382.1 reading frame 30 1582 1555392_PM_at LOC100128868 Testin-related protein TRG 0.00198345 0.061092 196.5 140.7 141.3 1583 1562736_PM_at LHX9 LIM homeobox 9 0.00199467 0.0613988 8.3 8.3 93 1584 217743_PM_s_at TMEM30A transmembrane protein 0.00199593 0.0613988 434.6 564.3 616.8 30A 1585 217985_PM_s_at BAZ1A bromodomain adjacent to 0.00199906 0.0614563 1612.3 1280.7 1389.1 zinc finger domain, 1A 1586 210539_PM_at TTLL5 tubulin tyrosine ligase-like 0.00200268 0.0615287 16.5 12.6 13.6 family, member 5 1587 229364_PM_at — — 0.00200899 0.0616837 68.1 48.3 42.9 1588 225507_PM_at SFRS1B splicing factor, 0.00201916 0.0619569 1153.7 931.0 862.7 arginine/serine-rich 18 1589 211893_PM_x_at CD6 CD6 molecule 0.00202531 0.0620482 17.9 17.1 12.7 1590 1566959_PM_at — — 0.00202547 0.0620482 193.6 105.4 107.9 1591 241920_PM_x_at SPG11 spastic paraplegia 11 0.00202662 0.0620482 28.0 22.0 22.2 (autosomal recessive) 1592 221071_PM_at — — 0.00202821 0.0620482 38.7 29.4 29.0 1593 233411_PM_at — — 0.0020285 0.0620482 193.0 137.8 99.2 1594 1557684_PM_at ZNF286A zinc finger protein 286A 0.00203037 0.0620664 28.6 25.6 20.5 1595 240775_PM_at — — 0.00203278 0.0620778 21.6 15.4 15.8 1596 231288_PM_at CCDC88C coiled-coil domain 0.00203329 0.0620778 97.8 81.1 68.8 containing 88C 1597 224933_PM_s_at JMJD1C jumonji domain containing 1C 0.00203726 0.06216 2710.7 1952.4 2061.8 1598 235927_PM_at XPO1 exportin 1 (CRM1 0.00204212 0.0622693 169.3 129.5 108.4 homolog, yeast) 1599 200829_PM_x_at ZNF207 zinc finger protein 207 0.00204523 0.0623252 492.3 600.0 596.9 1600 225239_PM_at — — 0.00204808 0.0623651 1535.8 882.2 876.0 1601 224838_PM_at FOXP1 forkhead box P1 0.0020491 0.0623651 1161.4 888.0 915.3 1602 202540_PM_s_at HMGCR 3-hydroxy-3- 0.00205127 0.0623922 117.9 144.8 163.6 methylglutaryl-CoA reductase 1603 210905_PM_x_at POU5F1P4 POU class 5 homeobox 1 0.00205558 0.0624842 12.7 10.5 11.1 pseudogene 4 1604 226566_PM_at FAM102B family with sequence 0.00205805 0.0625203 155.4 219.4 221.5 similarity 102, member B 1605 221756_PM_at PIK3IP1 phosphoinositide-3-kinase 0.00206058 0.0625582 315.4 242.7 187.0 interacting protein 1 1606 241988_PM_x_at — — 0.0020683 0.0627535 30.5 22.7 21.8 1607 200777_PM_s_at BZW1 basic leucine zipper and 0.00207506 0.0628699 590.6 782.6 676.4 W2 domains 1 1608 214402_PM_s_at SFI1 Sfi1 homolog, spindle 0.00207518 0.0628699 30.9 25.5 22.7 assembly associated (yeast) 1609 1556203_PM_a_at SRGAP2 SLIT-ROBO Rho GTPase 0.00207655 0.0628699 246.0 183.7 157.1 activating protein 2 1610 232184_PM_at ALS2 amyotrophic lateral 0.0020773 0.0628699 9.5 10.3 11.4 sclerosis 2 (juvenile) 1611 218659_PM_at ASXL2 additional sex combs like 2 0.00207993 0.0629105 485.2 373.5 403.3 (Drosophila) 1612 233289_PM_at — — 0.00208249 0.0629488 66.7 49.3 45.9 1613 204137_PM_at GPR137B G protein-coupled 0.00208751 0.0630614 106.7 150.6 169.9 receptor 137B 1614 226050_PM_at TMCO3 transmembrane and 0.00209242 0.0631705 253.6 311.0 353.6 coiled-coil domains 3 1615 224377_PM_s_at RAB18 RAB18, member RAS 0.0020964 0.0632399 367.1 499.6 515.7 oncogene family 1616 216695_PM_s_at TNKS tankyrase, TRF1- 0.00209731 0.0632399 13.0 11.1 11.9 interacting ankyrin-related ADP-ribose polymerase 1617 205586_PM_x_at VGF VGF nerve growth factor 0.00210124 0.0632482 11.1 9.6 9.6 inducible 1618 1556657_PM_at — — 0.00210147 0.0632482 221.5 133.9 124.3 1619 202147_PM_s_at IFRD1 interferon-related 0.00210148 0.0632482 283.9 372.9 436.2 developmental regulator 1 1620 200098_PM_s_at ANAPC5 anaphase promoting 0.00211129 0.0635042 688.6 614.3 556.9 complex subunit 5 1621 204403_PM_x_at FAM115A family with sequence 0.00212582 0.0538777 28.1 24.0 25.7 similarity 115, member A 1622 1561263_PM_at C1QTNF3 C1q and tumor necrosis 0.00212633 0.0638777 14.6 12.3 11.9 factor related protein 3 1623 209442_PM_x_at ANK3 ankyrin 3, node of Ranvier 0.00212886 0.0639143 29.8 18.7 16.4 (ankyrin G) 1624 232646_PM_at TTC17 Tetratricopeptide repeat 0.00213201 0.0639695 37.5 27.3 26.4 domain 17 1625 213615_PM_at LPCAT3 Lysophosphatidylcholine 0.00213472 0.0640114 21.7 19.8 16.8 acyltransferase 3 1626 212642_PM_s_at HIVEP2 human immunodeficiency 0.00213796 0.064059 75.5 55.7 55.2 virus type I enhancer binding protein 2 1627 235740_PM_at MCTP1 multiple C2 domains, 0.00213967 0.064059 109.0 168.0 163.5 transmembrane 1 1628 221145_PM_at — — 0.00214126 0.064059 10.9 10.3 12.1 1629 236924_PM_at — — 0.00214209 0.064059 45.1 30.4 28.4 1630 1560443_PM_at — — 0.00214288 0.064059 246.7 150.8 169.6 1631 244301_PM_at — — 0.0021528 0.0643161 8.9 10.0 10.1 1632 225992_PM_at MLLT10 myeloid/lymphoid or 0.00215843 0.0643965 51.9 74.9 64.5 mixed-lineage leukemia (trithorax homolog, Drosophila); translocate 1633 221786_PM_at C6orf120 chromosome 6 open 0.00215863 0.0643965 162.4 223.2 214.2 reading frame 120 1634 1552711_PM_a_at CYB5D1 cytochrome b5 domain 0.00216069 0.0643965 36.4 28.8 28.9 containing 1 1635 242844_PM_at — — 0.00216078 0.0643965 14.6 17.7 20.8 1636 207892_PM_at CD40LG CD40 ligand 0.00216866 0.0645919 20.0 16.4 14.5 1637 237442_PM_at — — 0.00217083 0.064617 671.6 502.7 522.2 1638 242428_PM_at DCUN1D1 DCN1, defective in cullin 0.00217479 0.0646954 184.1 113.6 122.7 neddylation 1, domain containing 1 (S. cerevisiae) 1639 1561927_PM_at C3orf16 chromosome 3 open 0.00218042 0.0648233 14.2 12.1 12.0 reading frame 16 1640 215435_PM_at — — 0.00218988 0.0650184 213.7 131.6 158.6 1641 235798_PM_at TMEM170B transmembrane protein 0.00219052 0.0650184 362.9 561.8 538.5 170B 1642 222654_PM_at IMPAD1 inositol monophosphatase 0.00219198 0.0650184 25.7 37.4 38.8 domain containing 1 1643 235984_PM_at — — 0.00219232 0.0650184 296.8 235.1 242.2 1644 240156_PM_at — — 0.00220135 0.0652465 131.5 63.9 72.5 1645 232991_PM_at — — 0.00220964 0.0654524 85.9 59.2 56.7 1646 1569759_PM_at — — 0.00221902 0.0656903 14.9 12.1 12.9 1647 221617_PM_at TAF9B TAF9B RNA polymerase II, 0.00222895 0.0659442 204.2 144.2 146.6 TATA box binding protein (TBP)-associated factor, 31 kDa 1648 229872_PM_s_at LOC100132999 hypothetical 0.00223246 0.0659972 943.4 778.9 743.2 LOC100132999 1649 218718_PM_at PDGFC platelet derived growth 0.00223345 0.0659972 71.4 106.8 129.1 factor C 1650 1570439_PM_at — — 0.00223614 0.066031 13.2 11.6 11.5 1651 203139_PM_at DAPK1 death-associated protein 0.00223852 0.066031 276.5 370.6 396.6 kinase 1 1652 204177_PM_s_at KLHL20 kelch-like 20 (Drosophila) 0.00223866 0.066031 66.4 66.5 54.7 1653 216245_PM_at IL1RN interleukin 1 receptor 0.00224247 0.0661033 10.3 10.2 11.7 antagonist 1654 202381_PM_at ADAM9 ADAM metallopeptidase 0.00224445 0.0661217 95.2 129.1 153.8 domain 9 1655 226976_PM_at KPNA6 karyopherin alpha 6 0.00224819 0.0661919 295.4 248.6 243.4 (importin alpha 7) 1656 205540_PM_s_at RRAGB Ras-related GTP binding B 0.00224968 0.0661957 14.5 18.0 16.1 1657 215349_PM_at BTBD18 BTB (POZ) domain 0.00225601 0.0663004 25.3 19.4 20.4 containing 18 1658 210281_PM_s_at ZMYM2 zinc finger, MYM-type 2 0.00225691 0.0663004 268.8 199.4 179.7 1659 242645_PM_at — — 0.00225732 0.0663004 57.4 45.6 41.4 1660 234044_PM_at — — 0.00226424 0.0664636 163.7 91.1 94.7 1661 226829_PM_at AFAP1L2 actin filament associated 0.00226642 0.0664876 10.5 12.2 11.2 protein 1-like 2 1662 203165_PM_s_at SLC33A1 solute carrier family 33 0.0022697 0.0665403 13.4 19.3 17.2 (acetyl-CoA transporter), member 1 1663 233816_PM_at — — 0.00227095 0.0665403 282.3 144.3 154.1 1664 226556_PM_at MAP3K13 mitogen-activated protein 0.00227425 0.0665672 34.7 51.5 48.3 kinase kinase kinase 13 1665 242390_PM_at — — 0.0022746 0.0665672 113.8 82.3 74.1 1666 214295_PM_at KIAA0485 hypothetical LOC57235 0.00227737 0.0665968 20.7 15.3 16.3 1667 1557436_PM_at XKR6 XK, Kell blood group 0.00227948 0.0665968 12.9 11.0 11.1 complex subunit-related family, member 6 1668 226858_PM_at CSNK1E casein kinase 1, epsilon 0.00228161 0.0665968 24.3 23.7 19.4 1669 239404_PM_at — — 0.00228336 0.0665968 371.8 250.2 266.3 1670 202713_PM_s_at KIAA0391 KIAA0391 0.00228465 0.0665968 177.0 149.8 131.3 1671 244772_PM_at — — 0.00228494 0.0665968 49.5 39.5 37.8 1672 203123_PM_s_at SLC11A2 solute carrier family 11 0.00228665 0.0665968 72.9 56.7 49.0 (proton-coupled divalent metal ion transporters), member 2 1673 203007_PM_x_at LYPLA1 lysophospholipase I 0.00228733 0.0665958 556.2 723.5 626.0 1674 217671_PM_at — — 0.00228791 0.0665958 88.4 62.1 55.2 1675 236119_PM_s_at SPRR2G small proline-rich protein 0.00229039 0.066609 12.0 10.8 10.4 2G 1676 225876_PM_at NIPAL3 NIPA-like domain 0.00229168 0.066609 168.8 142.1 113.1 containing 3 1677 222432_PM_s_at CCDC47 coiled-coil domain 0.00229243 0.066609 149.3 169.9 192.9 containing 47 1678 228738_PM_at D2HGDH D-2-hydroxyglutarate 0.00229436 0.0666253 28.1 25.3 20.3 dehydrogenase 1679 230712_PM_at NBPF1 neuroblastoma breakpoint 0.0022965 0.0666477 157.3 107.3 103.5 family, member 1 1680 242780_PM_at VAPA VAMP (vesicle-associated 0.00229898 0.0666526 60.8 41.4 47.4 membrane protein)- associated protein A, 33 kDa 1681 1553107_PM_s_at C5orf24 chromosome 5 open 0.00230072 0.0666525 130.7 108.4 108.2 reading frame 24 1682 203885_PM_at RAB21 RAB21, member RAS 0.00230077 0.0566526 184.2 236.8 240.0 oncogene family 1683 243005_PM_at — — 0.0023065 0.0667789 43.4 32.7 30.0 1684 222307_PM_at LOC282997 hypothetical LOC282997 0.00231381 0.0659231 100.3 68.8 65.1 1685 243182_PM_at — — 0.00231423 0.0669231 135.3 83.7 81.2 1686 228249_PM_at C11orf74 chromosome 11 open 0.00231604 0.0669358 13.3 15.3 17.3 reading frame 74 1687 225228_PM_at DRAM2 DNA-damage regulated 0.0023257 0.0671751 111.9 158.2 147.6 autophagy modulator 2 1688 204594_PM_s_at SMCR7L Smith-Magenis syndrome 0.0023287 0.0672219 90.8 78.2 67.1 chromosome region, candidate 7-like 1689 238393_PM_at — — 0.00233582 0.0673875 10.2 8.6 9.2 1690 217945_PM_at BTBD1 BTB (POZ) domain 0.00233926 0.0674236 226.9 290.8 294.2 containing 1 1691 226939_PM_at CPEB2 cytoplasmlc 0.00233984 0.0674236 263.3 395.7 474.0 polyadenylation element binding protein 2 1692 227116_PM_at MON1B MON1 homolog B (yeast) 0.00234772 0.0675747 296.8 367.9 364.0 1693 242759_PM_at — — 0.00234837 0.0675747 31.3 25.3 24.0 1694 1553352_PM_x_at ERVWE1 endogenous retroviral 0.00234941 0.0675747 18.5 15.5 19.6 family W, env(C7), member 1 1695 1566889_PM_at THADA Thyroid adenoma 0.00235063 0.0675747 21.6 17.7 16.3 associated 1696 226426_PM_at ADNP activity-dependent 0.00235345 0.0676159 173.2 140.4 137.5 neuroprotector homeobox 1697 243296_PM_at NAMPT Nicotinamide 0.00235557 0.0676369 6234.7 4363.4 5001.5 phosphoribosyltransferase 1698 232330_PM_at — — 0.00235802 0.0676674 353.4 276.0 237.6 1699 230147_PM_at F2RL2 coagulation factor II 0.00236341 0.0677822 8.9 9.8 10.3 (thrombin) receptor-like 2 1700 227752_PM_at SPTLC3 serine 0.00236684 0.0678239 9.6 9.4 10.7 palmitoyltransferase, long chain base subunit 3 1701 242297_PM_at RREB1 ras responsive element 0.00236765 0.0678239 263.6 209.9 203.7 binding protein 1 1702 223391_PM_at SGPP1 sphingosine-1-phosphate 0.0023695 0.067837 98.1 146.7 144.4 phosphatase 1 1703 215612_PM_at — — 0.00238305 0.068164 39.4 30.1 28.8 1704 1570078_PM_a_at DOCK5 dedicator of cytokinesis 5 0.00238372 0.068164 238.5 134.7 130.1 1705 226085_PM_at CBX5 chromobox homolog 5 0.00238525 0.0681678 45.1 32.5 29.3 1706 237943_PM_at — — 0.00238947 0.0682484 206.3 121.3 134.9 1707 241159_PM_x_at — — 0.00239578 0.0683885 34.0 28.0 27.2 1708 1555561_PM_a_at UGGT2 UDP-glucose glycoprotein 0.00240013 0.0684726 8.8 10.5 9.9 glucosyltransferase 2 1709 225040_PM_5_at RPE ribulose-5-phosphate-3- 0.0024137 0.0687956 66.9 108.6 104.9 epimerase 1710 1570335_PM_at — — 0.00241512 0.0687956 15.0 12.2 12.1 1711 201534_PM_s_at UBL3 ubiquitin-like 3 0.00241611 0.0687956 333.0 456.3 410.9 1712 1557283_PM_a_at ZNF519 zinc finger protein 519 0.0024171 0.0687956 15.0 12.1 11.7 1713 237544_PM_at — — 0.00242071 0.0688581 256.5 186.1 171.6 1714 238888_PM_at — — 0.00242768 0.0690161 126.5 88.2 90.5 1715 232763_PM_at TLN1 Talin 1 0.00243337 0.069137 68.8 42.3 52.9 1716 236645_PM_at LOC100506312 hypothetical 0.00243477 0.069137 176.0 119.5 113.9 LOC100506312 1717 218482_PM_at ENY2 enhancer of yellow 2 0.00244156 0.0692326 279.5 381.1 398.2 homolog (Drosophila) 1718 237176_PM_at — — 0.00244236 0.0692326 755.4 544.8 580.0 1719 226176_PM_s_at USP42 ubiquitin specific 0.0024424 0.0692326 250.5 200.0 196.3 peptidase 42 1720 211139_PM_s_at NAB1 NGFI-A binding protein 1 0.00244949 0.0693932 122.4 87.3 88.4 (EGR1 binding protein 1) 1721 202647_PM_s_at NRAS neuroblastoma RAS viral 0.00245174 0.0694166 50.4 71.1 64.3 (v-ras) oncogene homolog 1722 201653_PM_at CNIH cornichon homolog 0.00245348 0.0694255 395.5 542.0 471.3 (Drosophila) 1723 201800_PM_s_at OSBP oxysterol binding protein 0.00245706 0.0694865 145.1 130.5 123.8 1724 234565_PM_x_at — — 0.00246042 0.0695411 23.7 20.0 20.8 1725 242235_PM_x_at — — 0.0024639 0.069563 514.7 396.2 447.4 1726 239063_PM_at — — 0.00246405 0.069563 23.6 21.9 15.8 1727 228660_PM_x_at SEMA4F sema domain, 0.00246807 0.0696004 17.0 14.8 14.1 immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmi 1728 1569041_PM_at — — 0.00246823 0.0696004 15.9 12.4 13.4 1729 229773_PM_at SNAP23 Synaptosomal-associated 0.0024732 0.0697002 176.6 119.6 128.5 protein, 23 kDa 1730 221735_PM_at WDR48 WD repeat domain 48 0.00247658 0.0697551 383.4 349.4 325.4 1731 228902_PM_at NUP214 nucleoporin 214 kDa 0.00248086 0.0698353 74.2 97.1 99.1 1732 200833_PM_s_at RAP1B RAP1B, member of RAS 0.00248892 0.0700217 2219.0 3042.4 2647.5 oncogene family 1733 228512_PM_at PTCD3 Pentatricopeptide repeat 0.00249085 0.0700356 85.7 69.5 61.6 domain 3 1734 232653_PM_at — — 0.00249628 0.0701385 200.2 122.6 134.9 1735 1556151_PM_at ITFG1 Integrin alpha FG-GAP 0.00249739 0.0701385 311.4 371.2 395.4 repeat containing 1 1736 224098_PM_at — — 0.00250148 0.0702129 78.9 55.1 46.8 1737 202079_PM_s_at TRAK1 trafficking protein, kinesin 0.00251159 0.0704561 52.9 72.4 70.4 binding 1 1738 241642_PM_x_at TLK1 tousled-like kinase 1 0.00251368 0.0704742 113.5 94.7 97.3 1739 219292_PM_at THAP1 THAP domain containing, 0.00251533 0.0704799 44.0 65.0 61.5 apoptosis associated protein 1 1740 206862_PM_at ZNF254 zinc finger protein 254 0.00251742 0.0704979 11.5 12.9 14.8 1741 223511_PM_at C1orf124 chromosome 1 open 0.0025221 0.0705884 17.1 23.8 23.8 reading frame 124 1742 242728_PM_at — — 0.00252386 0.0705971 44.3 36.2 34.5 1743 232560_PM_at UROS uroporphyrinogen III 0.00252897 0.0706265 9.4 10.4 10.5 synthase 1744 241435_PM_at — — 0.00252939 0.0706265 1042.7 727.8 585.8 1745 243280_PM_at — — 0.00253007 0.0706265 106.8 75.9 76.7 1746 219157_PM_at KLHL2 kelch-like 2, Mayven 0.00253071 0.0706265 479.7 694.1 769.2 (Drosophila) 1747 1569512_PM_at — — 0.00253461 0.0706949 253.0 138.5 149.2 1748 244425_PM_at — — 0.00253824 0.0707556 202.7 139.5 142.0 1749 226217_PM_at SLC30A7 solute carrier family 30 0.00254144 0.0708043 549.2 467.6 440.6 (zinc transporter), member 7 1750 224985_PM_at NRAS neuroblastoma RAS viral 0.00254497 0.0708515 260.7 368.1 329.9 (v-ras) oncogene homolog 1751 215270_PM_at LFNG LFNG O-fucosylpeptide 3- 0.00254604 0.0708515 23.6 33.9 32.4 beta-N- acetylglucosaminyltransferase 1752 237750_PM_at XPNPEP3 X-prolyl aminopeptidase 0.00255399 0.0709593 29.5 22.7 21.5 (aminopeptidase P) 3, putative 1753 227744_PM_s_at HNRNPD Heterogeneous nuclear 0.00255406 0.0709593 10.4 10.5 11.9 ribonucleoprotein D (AU- rich element RNA binding protein 1, 37 kDa 1754 218196_PM_at OSTM1 osteopetrosis associated 0.00255465 0.0709593 257.5 381.6 339.6 transmembrane protein 1 1755 204634_PM_at NEK4 NIMA (never in mitosis 0.00255574 0.0709593 48.5 71.9 73.7 gene a)-related kinase 4 1756 1568834_PM_s_at CCDC90B coiled-coil domain 0.00255881 0.0710041 119.1 88.9 86.5 containing 90B 1757 212660_PM_at PHF15 PHD finger protein 15 0.00256264 0.0710677 172.7 144.7 116.6 1758 233976_PM_at — — 0.00256539 0.0710677 198.4 152.6 158.3 1759 237239_PM_at — — 0.00256548 0.0710677 369.0 258.8 281.9 1760 234883_PM_x_at TRBV7-3 T cell receptor beta 0.00257058 0.0711686 23.7 21.9 15.7 variable 7-3 1761 237412_PM_at — — 0.00257386 0.0711823 21.6 18.3 17.0 1762 223065_PM_s_at STARD3NL STARD3 N-terminal like 0.002574 0.0711823 370.9 489.3 516.4 1763 233300_PM_at — — 0.00258302 0.0713305 145.5 99.1 99.1 1764 241219_PM_at — — 0.00258359 0.0713305 43.4 32.8 31.5 1765 238473_PM_at LOC100216545 hypothetical 0.00258375 0.0713305 17.1 13.9 14.2 LOC100216545 1766 218754_PM_at NOL9 nucleolar protein 9 0.00258597 0.0713514 136.3 122.6 96.6 1767 212833_PM_at SLC25A46 solute carrier family 25, 0.00259083 0.0714078 259.1 361.0 335.9 member 46 1768 216994_PM_s_at RUNX2 runt-related transcription 0.00259224 0.0714078 10.7 9.4 9.4 factor 2 1769 1556672_PM_a_at RBM6 RNA binding motif protein 0.00259241 0.0714078 24.7 17.4 17.9 6 1770 231212_PM_x_at — — 0.00259651 0.0714803 17.2 14.5 16.7 1771 231035_PM_s_at — — 0.00260088 0.0715432 42.1 59.5 67.4 1772 230756_PM_at ZNF683 zinc finger protein 683 0.00260173 0.0715432 21.2 26.7 17.6 1773 241448_PM_at — — 0.00260385 0.0715611 29.1 23.2 22.8 1774 233693_PM_at C1orf201 chromosome 1 open 0.00260717 0.0716119 17.0 14.0 15.6 reading frame 201 1775 1557505_PM_a_at — — 0.0026167 0.0718332 85.3 58.4 61.0 1776 234657_PM_at — — 0.0026244 0.072004 22.8 17.7 19.2 1777 225383_PM_at ZNF275 zinc finger protein 275 0.00263161 0.0721612 158.4 133.1 96.6 1778 213292_PM_s_at SNX13 sorting nexin 13 0.00263732 0.0722771 101.7 141.5 138.5 1779 218265_PM_at SECISBP2 SECIS binding protein 2 0.00264018 0.0723148 167.1 135.1 136.3 1780 238459_PM_x_at SPATA6 spermatogenesis 0.0026484 0.0724992 9.8 9.2 10.5 associated 6 1781 212852_PM_5_at TROVE2 TROVE domain family, 0.00265056 0.0725176 1001.7 839.5 867.1 member 2 1782 236963_PM_at — — 0.00265207 0.0725182 22.9 15.9 15.2 1783 1560771_PM_at — — 0.00265437 0.0725404 10.6 9.6 11.4 1784 232500_PM_at RALGAPA2 Ral GTPase activating 0.00265586 0.0725404 844.3 552.7 563.1 protein, alpha subunit 2 (catalytic) 1785 214188_PM_at HEXIM1 Hexamethylene bis- 0.00267308 0.0729698 92.1 62.0 69.8 acetamide inducible 1 1786 225225_PM_at LOC729082 Hypothetical protein 0.00268123 0.0731513 816.1 728.6 684.3 LOC729082 1787 214925_PM_s_at SPTAN1 spectrin, alpha, non- 0.00268359 0.0731748 18.5 14.9 13.7 erythrocytic 1 (alpha- fodrin) 1788 210619_PM_s_at HYAL1 hyaluronoglucosaminidase 1 0.00268625 0.0732063 123 12.5 14.6 1789 225785_PM_at REEP3 receptor accessory protein 0.00269026 0.0732746 155.5 216.8 220.9 3 1790 203248_PM_at ZNF24 zinc finger protein 24 0.00269663 0.0734071 25.1 32.1 31.7 1791 236946_PM_at — — 0.00270089 0.0734562 35.5 25.9 29.2 1792 224667_PM_X_at ANAPC16 anaphase promoting 0.00270145 0.0734562 965.2 789.1 852.8 complex subunit 16 1793 202538_PM_s_at CHMP2B chromatin modifying 0.00271151 0.0736886 261.4 335.9 311.5 protein 2B 1794 225774_PM_at RSPRY1 ring finger and SPRY 0.00271833 0.0738328 79.8 108.0 94.2 domain containing 1 1795 219482_PM_at SETD4 SET domain containing 4 0.00272531 0.0739812 48.4 43.1 36.7 1796 216107_PM_at LOC100129503 hypothetical 0.00272787 0.0740094 11.0 10.6 12.2 LOC100129503 1797 243931_PM_at — — 0.00273033 0.0740349 1040.1 794.8 804.1 1798 220603_PM_s_at MCTP2 multiple C2 domains, 0.00273533 0.0741293 330.0 339.5 465.8 transmembrane 2 1799 243361_PM_at SREK1 splicing regulatory 0.00274347 0.0742805 44.4 35.3 35.6 glutamine/lysine-rich protein 1 1800 225484_PM_at TSGA14 testis specific, 14 0.00274396 0.0742805 39.7 33.5 29.7 1801 244249_PM_at — — 0.00274878 0.0743697 31.1 22.7 25.8 1802 218474_PM_s_at KCTD5 potassium channel 0.00275283 0.0744379 141.9 210.2 182.5 tetramerisation domain containing 5 1803 205277_PM_at PRDM2 PR domain containing 2, 0.00275856 0.0744924 102.5 78.6 66.3 with ZNF domain 1804 221013_PM_s_at APOL2 apolipoprotein L, 2 0.00276054 0.0744924 25.7 21.7 20.9 1805 220863_PM_at MIP major intrinsic protein of 0.00276109 0.0744924 10.7 11.0 12.3 lens fiber 1806 216555_PM_at C22orf30 chromosome 22 open 0.00276119 0.0744924 334.7 263.2 302.6 reading frame 30 1807 203132_PM_at RB1 retinoblastoma 1 0.00276249 0.0744924 123.5 169.0 178.7 1808 228613_PM_at RAB11FIP3 RAB11 family interacting 0.00277251 0.0747213 88.9 60.0 52.1 protein 3 (class II) 1809 241588_PM_at — — 0.00277507 0.0747489 18.3 15.8 14.4 1810 242216_PM_at — — 0.00279169 0.0751551 41.1 31.4 28.1 1811 243442_PM_x_at — — 0.00279361 0.0751652 35.2 29.8 31.8 1812 238860_PM_at C6orf130 chromosome 6 open 0.00280565 0.0754475 145.8 120.8 112.2 reading frame 130 1813 217164_PM_at — — 0.00281545 0.0756693 309.4 245.1 197.5 1814 225501_PM_at XPNPEP3 X-prolyl aminopeptidase 0.00281717 0.0756738 133.0 96.7 98.4 (aminopeptidase P) 3, putative 1815 230324_PM_at — — 0.00282409 0.0757882 123.6 91.1 88.4 1816 210266_PM_s_at TRIM33 tripartite motif-containing 0.00282454 0.0757882 891.0 758.8 761.0 33 1817 231302_PM_at — — 0.00282886 0.0758491 137.7 86.0 97.4 1818 1557733_PM_a_at — — 0.00283039 0.0758491 55.2 30.3 27.6 1819 204325_PM_s_at NF1 neurofibromin 1 0.00283195 0.0758491 11.3 9.6 9.6 1820 204226_PM_at STAU2 staufen, RNA binding 0.00283353 0.0758491 41.7 62.6 57.3 protein, homolog 2 (Drosophila) 1821 1556053_PM_at DNAJC7 DnaJ (Hsp40) homolog, 0.00283528 0.0758491 263.2 211.4 219.2 subfamily C, member 7 1822 204165_PM_at WASF1 WAS protein family, 0.00283615 0.0758491 20.1 23.2 32.0 member 1 1823 232304_PM_at PELI1 Pellino homolog 1 0.00283972 0.0759029 1637.9 1045.8 1096.8 (Drosophila) 1824 221841_PM_s_at KLF4 Kruppel-like factor 4 (gut) 0.00284676 0.0760384 365.1 487.7 528.4 1825 242440_PM_at — — 0.00284916 0.0760384 30.0 19.9 20.9 1826 239726_PM_at — — 0.00284947 0.0760384 40.2 26.5 21.4 1827 1563320_PM_at — — 0.00285747 0.0761441 26.6 21.5 21.1 1828 242854_PM_x_at DLEU2 deleted in lymphocytic 0.00285768 0.0761441 161.6 125.0 112.2 leukemia 2 (non-protein coding) 1829 224645_PM_at EIF4EBP2 eukaryotic translation 0.00285812 0.0761441 210.2 174.5 159.1 initiation factor 4E binding protein 2 1830 203496_PM_s_at MED1 mediator complex subunit 0.0028614 0.0761498 171.9 145.5 134.9 1 1831 1553282_PM_at C21orf128 chromosome 21 open 0.00286146 0.0761498 9.6 9.2 8.6 reading frame 128 1832 242070_PM_at LOC728485 hypothetical LOC728485 0.00286444 0.0761872 10.9 11.4 12.7 1833 227208_PM_at CCDC84 coiled-coil domain 0.00286599 0.0761872 216.6 174.9 168.8 containing 84 1834 1557797_PM_a_at — — 0.00286808 0.0762012 309.0 220.5 223.1 1835 210820_PM_x_at COQ7 coenzyme Q7 homolog, 0.00287385 0.0762795 13.0 16.6 17.4 ubiquinone (yeast) 1836 231775_PM_at TNFRSF10A tumor necrosis factor 0.00287422 0.0762795 180.6 145.4 125.6 receptor superfamlly, member 10a 1837 219520_PM_s_at WWC3 WWC family member 3 0.00287674 0.0762795 756.0 570.8 589.3 1838 228983_PM_at — — 0.00287729 0.0762795 33.4 25.1 27.5 1839 207761_PM_s_at METTL7A methyltransferase like 7A 0.00287972 0.0763024 1051.5 1303.3 1344.0 1840 218873_PM_at GON4L gon-4-like (C. elegans) 0.0028832 0.0763331 142.0 122.9 109.0 1841 242357_PM_x_at — — 0.00288474 0.0763331 19.9 16.4 16.2 1842 236493_PM_at NKAPP1 NFKB activating protein 0.00288558 0.0763331 17.0 14.8 13.7 pseudogene 1 1843 233775_PM_x_at LOC100289333 Hypothetical protein 0.00289763 0.0766103 769.1 631.0 679.7 LOC100289333 1844 222930_PM_s_at AGMAT agmatine ureohydrolase 0.00290397 0.0767363 14.1 13.0 11.6 (agmatinase) 1845 217885_PM_at IPO9 importin 9 0.00290642 0.0767594 227.8 183.0 171.3 1846 244354_PM_at LOC100288939 Similar to hCG1987955 0.00291439 0.0768645 262.1 211.6 206.8 1847 240410_PM_at — — 0.00291445 0.0768645 252.9 193.0 189.1 1848 230018_PM_at DPP9 dipeptidyl-peptidase 9 0.00291513 0.0768645 49.0 42.2 46.2 1849 217579_PM_x_at — — 0.00291775 0.0768919 217.6 178.8 186.1 1850 218337_PM_at FAM160B2 family with sequence 0.00292068 0.0769276 53.1 50.8 43.0 similarity 160, member B2 1851 225232_PM_at MTMR12 myotubularin related 0.00292317 0.0769515 305.0 361.8 389.4 protein 12 1852 243677_PM_at GORASP1 Golgi reassembly stacking 0.00293066 0.0771071 9.7 10.1 10.9 protein 1, 65 kDa 1853 225446_PM_at BRWD1 bromodomain and WD 0.00293424 0.0771219 47.9 62.2 47.6 repeat domain containing 1 1854 241727_PM_x_at DHFRL1 dihydrofolate reductase- 0.00293439 0.0771219 82.0 68.9 70.9 like 1 1855 210285_PM_x_at WTAP Wilms tumor 1 associated 0.00294086 0.0772503 94.4 149.5 115.1 protein 1856 232432_PM_s_at SLC30A5 solute carrier family 30 0.00294546 0.0773294 79.1 113.1 86.3 (zinc transporter), member 5 1857 238694_PM_at DGKE diacylglycerol kinase, 0.00294979 0.0774014 27.3 22.0 18.3 epsilon 64 kDa 1858 1558142_PM_at TNRC6B trinucleotide repeat 0.00295374 0.0774477 435.3 330.1 377.1 containing 6B 1859 1569296_PM_a_at LOC493754 RAB guanine nucleotide 0.00295656 0.0774477 28.2 22.8 22.7 exchange factor (GEF) 1 pseudogene 1860 217970_PM_s_at CNOT6 CCR4-NOT transcription 0.00295761 0.0774477 69.0 101.6 83.5 complex, subunit 6 1861 1558289_PM_at RFT1 RFT1 homolog 0.00295791 0.0774477 22.6 19.9 18.4 (S. cerevisiae) 1862 1570496_PM_at — — 0.00295955 0.077449 14.2 12.3 12.4 1863 1552652_PM_at HPS4 Hermansky-Pudlak 0.00296203 0.0774723 16.6 14.0 14.6 syndrome 4 1864 1553466_PM_at CXorf59 chromosome X open 0.00297091 0.0776165 10.4 9.4 9.3 reading frame 59 1865 1557486_PM_at — — 0.00297149 0.0776165 13.7 10.8 11.7 1866 201417_PM_at SOX4 SRY (sex determining 0.00297303 0.0776165 122.3 169.0 185.8 region Y)-box 4 1867 208772_PM_at ANKHD1 /// ankyrin repeat and KH 0.00297453 0.0776165 546.6 459.2 414.6 ANKHD1-EIF4EBP3 domain containing 1 /// ANKHD1-EIF4EBP3 readthrough 1868 207133_PM_x_at ALPK1 alpha-kinase 1 0.00297551 0.0776165 217.3 173.6 181.1 1869 1560512_PM_at — — 0.0029797 0.0776842 18.8 13.9 12.4 1870 238064_PM_at — — 0.00298875 0.0778785 669.2 441.3 512.2 1871 1559949_PM_at — — 0.002993 0.0779476 38.0 26.2 30.0 1872 236116_PM_at — — 0.00300046 0.0781001 26.7 21.8 20.0 1873 223871_PM_x_at ING5 Inhibitor of growth family, 0.00300704 0.0782296 22.2 18.5 20.9 member 5 1874 1561606_PM_at — — 0.00302995 0.0787613 11.8 11.5 13.3 1875 222345_PM_at — — 0.00303071 0.0787613 11.6 10.7 9.9 1876 212079_PM_s_at MLL myeloid/lymphoid or 0.00303461 0.0787729 155.0 119.7 104.9 mixed-lineage leukemia (trithorax homolog, Drosophila) 1877 244579_PM_at — — 0.00303534 0.0787729 397.7 260.5 288.6 1878 244168_PM_s_at ULK4 unc-51-like kinase 4 0.003037 0.0787729 20.5 16.5 16.7 (C. elegans) 1879 204842_PM_x_at PRKAR2A protein kinase, cAMP- 0.00303806 0.0787729 535.4 456.5 466.2 dependent, regulatory, type II, alpha 1880 209704_PM_at MTF2 metal response element 0.00303924 0.0787729 37.4 53.0 48.2 binding transcription factor 2 1881 1555908_PM_at FAM120A family with sequence 0.00304219 0.0788074 14.4 15.8 17.8 similarity 120A 1882 243178_PM_at — — 0.00304966 0.0789333 1388.5 913.1 948.5 1883 206308_PM_at TRDMT1 tRNA aspartic acid 0.00305143 0.0789333 16.4 21.0 20.6 methyltransferase 1 1884 217971_PM_at MAPKSP1 MAPK scaffold protein 1 0.00305191 0.0789333 366.5 504.9 497.5 1885 226808_PM_at ZNF862 zinc finger protein 862 0.00305746 0.0790349 392.1 308.8 321.6 1886 243988_PM_at — — 0.00306374 0.0791106 13.0 10.8 11.0 1887 232232_PM_s_at SLC22A16 solute carrier family 22 0.00306384 0.0791106 30.7 45.8 53.9 (organic cation/carnitine transporter), member 16 1888 232532_PM_at QRICH2 glutamine rich 2 0.00306539 0.0791106 11.5 11.3 10.3 1889 215854_PM_at — — 0.00306688 0.0791106 18.7 14.7 15.3 1890 236919_PM_at — — 0.00306986 0.0791455 24.1 18.3 18.2 1891 202069_PM_s_at IDH3A isocitrate dehydrogenase 0.00307338 0.0791944 63.0 85.5 79.3 3 (NAD+) alpha 1892 212818_PM_s_at ASB1 ankyrin repeat and SOCS 0.00308003 0.0793069 52.1 47.2 41.4 box-containing 1 1893 203440_PM_at CDH2 cadherin 2, type 1, N- 0.003081 0.0793069 11.9 11.5 16.0 cadherin (neuronal) 1894 233326_PM_at CCDC39 coiled-coil domain 0.00309364 0.0795902 9.0 8.8 10.4 containing 39 1895 225956_PM_at C5orf41 chromosome 5 open 0.00309558 0.0795981 1312.0 1010.4 1112.8 reading frame 41 1896 242875_PM_at — — 0.00310427 0.0797794 207.1 137.4 142.5 1897 215208_PM_x_at RPL35A Ribosomal protein L35a 0.00311137 0.0799079 77.7 61.4 64.7 1898 244035_PM_at — — 0.00311297 0.0799079 66.4 42.0 31.3 1899 226379_PM_s_at C19orf25 chromosome 19 open 0.00311564 0.0799079 16.9 14.6 14.8 reading frame 25 1900 219345_PM_at BOLA1 bolA homolog 1 (E. coli) 0.00311784 0.0799079 35.6 37.0 29.7 1901 202195_PM_s_at TMED5 transmembrane emp24 0.00311821 0.0799079 81.8 107.9 107.9 protein transport domain containing 5 1902 1560861_PM_at — — 0.00311953 0.0799079 12.6 11.0 10.5 1903 240528_PM_s_at EXOC4 exocyst complex 0.00312075 0.0799079 47.4 42.9 33.2 component 4 1904 243295_PM_at RBM27 RNA binding motif protein 0.00312686 0.0800223 342.8 282.8 288.6 27 1905 1557235_PM_at LOC100128002 Hypothetical 0.00312941 0.080026 9.2 9.5 10.5 LOC100128002 1906 1557246_PM_at KIDINS220 kinase D-interacting 0.00313029 0.080026 347.0 245.0 265.2 substrate, 220 kDa 1907 220349_PM_s_at ENGASE endo-beta-N- 0.00314235 0.0802887 63.2 48.8 42.8 acetylglucosaminidase 1908 200732_PM_s_at PTP4A1 protein tyrosine 0.00314386 0.0802887 310.1 384.3 363.2 phosphatase type IVA, member 1 1909 240016_PM_at — — 0.00314629 0.0803087 117.2 79.4 76.8 1910 222393_PM_s_at NAA50 N(alpha)-acetyltransferase 0.00315072 0.0803577 118.2 157.8 139.5 50, NatE catalytic subunit 1911 232586_PM_x_at OR7E126P olfactory receptor, family 0.00315151 0.0803577 25.8 24.5 20.0 7, subfamily E, member 126 pseudogene 1912 212500_PM_at ADO 2-aminoethanethiol 0.00315656 0.0804444 63.4 94.0 88.7 (cysteamine) dioxygenase 1913 240613_PM_at JAK1 Janus kinase 1 0.00316752 0.0806815 18.1 13.9 15.0 1914 215577_PM_at — — 0.00317601 0.0808555 22.3 17.0 16.7 1915 231235_PM_at NKTR natural killer-tumor 0.00317914 0.0808929 120.6 88.6 75.7 recognition sequence 1916 213566_PM_at 6-Sep septin 6 0.00318269 0.0809166 261.2 200.3 180.0 1917 237317_PM_at — — 0.00318339 0.0809166 26.6 24.2 19.8 1918 220925_PM_at NAA35 N(alpha)-acetyltransferase 0.00319274 0.0811119 111.8 106.3 90.3 35, NatC auxiliary subunit 1919 214016_PM_s_at LOC100506168 /// hypothetical 0.00319481 0.0811222 873.4 726.2 724.4 SFPQ LOC100506168 /// splicing factor proline/glutamine- rich 1920 232371_PM_at 7-Mar Membrane-associated ring 0.00319954 0.0812 148.4 101.0 98.8 finger (C3HC4) 7 1921 1557504_PM_at — — 0.00320409 0.0812322 26.5 19.4 20.2 1922 223328_PM_at ARMC10 armadillo repeat 0.00320626 0.0312322 131.8 172.1 139.9 containing 10 1923 218516_PM_s_at IMPAD1 inositol monophosphatase 0.0032072 0.0312322 18.5 25.3 24.2 domain containing 1 1924 233674_PM_at — — 0.00320811 0.0812322 170.7 95.5 91.3 1925 219485_PM_s_at P5MD10 proteasome (prosome, 0.00321022 0.0812322 213.8 289.3 263.0 macropain) 26S subunit, non-ATPase, 10 1926 231316_PM_at — — 0.00321081 0.0812322 78.9 65.9 58.9 1927 233333_PM_x_at AVIL advillin 0.00321804 0.0812981 32.2 24.6 26.4 1928 1563502_PM_at ZDHHC2 Zinc finger, DHHC-type 0.00321858 0.0812981 29.9 23.3 20.9 containing 2 1929 212098_PM_at LOC151162 /// hypothetical LOC151162 /// 0.00321918 0.0812981 284.9 209.3 215.4 MGAT5 mannosyl (alpha-1,6-)- glycoprotein beta-1,6-N- acetyl-glucosa 1930 1551652_PM_at BECN1 Beclin 1, autophagy 0.00322009 0.0812981 15.0 12.6 13.4 related 1931 201339_PM_s_at SCP2 sterol carrier protein 2 0.00322271 0.0813062 379.6 504.0 439.2 1932 236066_PM_at — — 0.00322375 0.0813062 30.3 27.6 24.5 1933 220127_PM_s_at FBXL12 F-box and leucine-rich 0.00322582 0.0813164 97.4 121.1 111.0 repeat protein 12 1934 206748_PM_s_at SPAG9 sperm associated antigen 0.00323155 0.0814013 23.2 17.0 18.7 9 1935 211795_PM_s_at FYB FYN binding protein 0.00323253 0.0814013 4480.5 3726.3 3726.9 1936 218313_PM_s_at GALNT7 UDP-N-acetyl-alpha-D- 0.00324116 0.0815764 213.4 276.0 290.7 galactosamine: polypeptide N-acetylgalactosaminyltransferase 7 (Gal 1937 1564753_PM_at — — 0.00324528 0.081591 12.9 10.7 11.8 1938 226544_PM_x_at MUTED muted homolog (mouse) 0.00324648 0.081591 343.5 298.8 310.5 1939 228097_PM_at MYLIP myosin regulatory light 0.00324676 0.081591 129.4 87.6 80.9 chain interacting protein 1940 224047_PM_at — — 0.00325581 0.081766 8.6 8.4 9.5 1941 242352_PM_at NIPBL Nipped-B homolog 0.00325708 0.081766 1020.9 808.3 835.7 (Drosophila) 1942 227121_PM_at — — 0.00326653 0.081961 67.1 48.7 47.0 1943 232174_PM_at — — 0.00327857 0.0821646 369.3 203.0 212.0 1944 230526_PM_at LOC100131096 hypothetical 0.0032788 0.0821646 85.3 79.7 62.4 LOC100131096 1945 244347_PM_at — — 0.00328111 0.0821646 37.1 25.3 24.0 1946 1562591_PM_a_at OFCC1 orofacial cleft 1 candidate 0.00328139 0.0821646 10.8 9.9 11.4 1 1947 243608_PM_at COG2 component of oligomeric 0.00328364 0.0821787 33.9 27.7 25.7 golgi complex 2 1948 207027_PM_at HGFAC HGF activator 0.00330422 0.0826513 10.0 9.8 10.9 1949 235513_PM_at — — 0.00330961 0.0827436 296.4 212.1 239.3 1950 230821_PM_at ZNF148 zinc finger protein 148 0.00331765 0.0829024 90.4 79.7 67.9 1951 237591_PM_at NCRNA00173 non-protein coding RNA 0.0033227 0.0829809 623.6 365.2 524.8 173 1952 215207_PM_x_at NUS1 /// nuclear undecaprenyl 0.00332421 0.0829809 26.0 34.8 32.8 NUS1P3 pyrophosphate synthase 1 homolog (S. cerevisiae) /// nuclear undec 1953 1560395_PM_at — — 0.00333835 0.0832578 11.3 9.8 9.4 1954 232587_PM_at EML4 echinoderm microtubule 0.00333872 0.0832578 42.6 32.3 28.3 associated protein like 4 1955 234059_PM_at — — 0.00334076 0.0832661 10.7 9.3 10.4 1956 220618_PM_s_at ZCWPW1 zinc finger, CW type with 0.00334668 0.083371 15.6 12.7 14.0 PWWP domain 1 1957 238735_PM_at — — 0.00336694 0.0838328 34.3 26.7 23.4 1958 1562028_PM_at CCND3 Cyclin D3 0.00337137 0.0839003 15.6 11.7 11.9 1959 1565689_PM_at — — 0.00337532 0.0839557 46.8 35.6 37.0 1960 217344_PM_at FDPS farnesyl diphosphate 0.00338219 0.0840837 9.4 9.9 10.7 synthase 1961 214719_PM_at SLC46A3 solute carrier family 46, 0.00338423 0.0840915 419.8 342.3 348.5 member 3 1962 233439_PM_at LETM1 leucine zipper-EF-hand 0.00338723 0.0840983 13.4 12.3 11.6 containing transmembrane protein 1 1963 203803_PM_at PCYOX1 prenylcysteine oxidase 1 0.0033906 0.0840983 20.7 18.8 15.6 1964 239296_PM_at — — 0.00339104 0.0840983 104.3 66.0 80.3 1965 213351_PM_s_at TMCC1 transmembrane and 0.00339141 0.0840983 446.1 281.1 311.4 coiled-coil domain family 1 1966 237181_PM_at — — 0.00339341 0.0841051 27.0 19.7 17.2 1967 231016_PM_s_at ARNT Aryl hydrocarbon receptor 0.00339928 0.0842078 21.4 21.6 26.7 nuclear translator 1968 233713_PM_at — — 0.00340118 0.084212 65.9 51.2 43.3 1969 220735_PM_s_at SENP7 SUMO1/sentrin specific 0.00341419 0.0844912 12.4 17.4 16.1 peptidase 7 1970 221904_PM_at FAM131A family with sequence 0.00341688 0.0845149 125.6 152.3 169.4 similarity 131, member A 1971 218292_PM_s_at PRKAG2 protein kinase, AMP- 0.00342353 0.0846231 78.7 107.9 100.2 activated, gamma 2 non- catalytic subunit 1972 210810_PM_s_at SLC6A5 solute carrier family 6 0.00342473 0.0846231 10.4 9.2 9.9 (neurotransmitter transporter, glycine), member 5 1973 240865_PM_at — — 0.00343655 0.0848722 29.3 22.0 17.9 1974 233656_PM_s_at VPS54 vacuolar protein sorting 0.00344076 0.0849061 72.2 119.2 100.9 54 homolog (S. cerevisiae) 1975 244813_PM_at — — 0.00344188 0.0349061 19.5 15.2 15.1 1976 211565_PM_at SH3GL3 SH3-domain GRB2-like 3 0.00344315 0.0849061 10.8 11.8 12.9 1977 214321_PM_at NOV nephroblastoma 0.00345461 0.0851456 77.2 88.5 163.6 overexpressed gene 1978 222266_PM_at C19orf2 Chromosome 19 open 0.00345958 0.0851917 321.2 256.1 206.0 reading frame 2 1979 239307_PM_at LOC100509703 hypothetical 0.00345998 0.0851917 255.5 155.4 188.5 LOC100509703 1980 200624_PM_s_at MATR3 matrin 3 0.00347416 0.0854977 255.1 378.0 322.4 1981 222048_PM_at CRYBB2P1 crystallin, beta B2 0.0034836 0.0856867 30.4 25.6 23.7 pseudogene 1 1982 226756_PM_at — — 0.00348639 0.0857087 53.5 77.9 91.0 1983 239391_PM_at FAM120AOS Family with sequence 0.00348801 0.0857087 53.8 43.6 50.8 similarity 120A opposite strand 1984 211764_PM_s_at UBE2D1 ubiquitin-conjugating 0.00349414 0.0857522 1682.5 2015.0 2192.3 enzyme E2D 1 (UBC4/5 homolog, yeast) 1985 222835_PM_at THSD4 thrombospondin, type I, 0.00349443 0.0857522 10.6 9.8 11.2 domain containing 4 1986 232313_PM_at TMEM132C transmembrane protein 0.00349506 0.0857522 11.7 11.0 12.5 132C 1987 230735_PM_at — — 0.00350442 0.0859385 921.5 683.6 628.9 1988 1555536_PM_at ANTXR2 anthrax toxin receptor 2 0.00350943 0.0860181 65.7 55.0 53.3 1989 241905_PM_at PIK3C2A Phosphoinositide-3- 0.00351172 0.085031 127.2 95.1 96.4 kinase, class 2, alpha polypeptide 1990 201784_PM_s_at C11orf58 chromosome 11 open 0.00351433 0.0860516 484.3 641.2 610.2 reading frame 58 1991 203224_PM_at RFK riboflavin kinase 0.0035255 0.0862084 127.7 179.7 175.5 1992 1566897_PM_at — — 0.00352577 0.0862084 40.5 30.3 28.5 1993 233598_PM_at C20orf187 chromosome 20 open 0.00352604 0.0862084 9.3 9.4 10.3 reading frame 187 1994 212519_PM_at UBE2E1 ubiquitin-conjugating 0.00353349 0.0863142 694.7 905.4 845.0 enzyme E2E 1 (UBC4/5 homolog, yeast) 1995 210119_PM_at KCNJ15 potassium inwardly- 0.00353391 0.0863142 2213.3 1462.5 1794.1 rectifying channel, subfamily J, member 15 1996 241932_PM_at — — 0.00353801 0.0863346 27.5 20.4 20.2 1997 230261_PM_at ST8SIA4 ST8 alpha-N-acetyl- 0.00353829 0.0863346 223.7 281.2 329.5 neuraminide alpha-2,8- sialyltransferase 4 1998 204725_PM_s_at NCK1 NCK adaptor protein 1 0.00354863 0.0865436 62.3 93.1 83.9 1999 235965_PM_at — — 0.00355144 0.0865688 8.7 9.1 10.5 2000 210368_PM_at PCDHGA8 protocadherin gamma 0.0035662 0.0868851 12.4 10.6 11.6 subfamily A, 8 2001 231107_PM_at — — 0.00357367 0.0870236 47.2 37.3 35.4 2002 234439_PM_at — — 0.0035897 0.0873703 11.5 10.0 10.0 2003 243869_PM_at — — 0.0035929 0.0874045 214.0 183.6 147.6 2004 235766_PM_x_at RAB27A RAB27A, member RAS 0.00359922 0.0875146 1165.1 1438.5 1374.3 oncogene family 2005 242853_PM_at — — 0.00360722 0.0876653 52.3 38.3 41.2 2006 40446_PM_at PHF1 PHD finger protein 1 0.0036114 0.0876843 263.3 227.3 227.3 2007 244646_PM_at — — 0.0036116 0.0876843 113.5 85.0 87.2 2008 232097_PM_at TOX4 TOX high mobility group 0.00361452 0.0877115 159.7 112.9 128.3 box family member 4 2009 217877_PM_s_at GPBP1L1 GC-rich promoter binding 0.00351929 0.0877835 327.8 387.8 381.1 protein 1-like 1 2010 1557452_PM_at — — 0.00362626 0.0879088 46.4 33.4 36.8 2011 222214_PM_at — — 0.00364195 0.0882453 40.0 27.0 26.2 2012 220918_PM_at C21orf96 chromosome 21 open 0.00364716 0.0883276 364.2 294.9 224.1 reading frame 96 2013 1552563_PM_a_at — — 0.00365851 0.0885585 14.2 12.3 11.9 2014 1568857_PM_a_at NBR1 Neighbor of BRCA1 gene 1 0.00366507 0.0886732 134.8 97.1 98.6 2015 1557501_PM_a_at — — 0.00366836 0.0887088 38.9 31.1 30.6 2016 222182_PM_s_at CNOT2 CCR4-NOT transcription 0.00367216 0.0887566 466.6 388.5 402.9 complex, subunit 2 2017 1560144_PM_at — — 0.00367869 0.0888704 9.5 9.1 10.2 2018 202704_PM_at TOB1 transducer of ERBB2, 1 0.00368242 0.0889164 337.2 449.9 455.5 2019 223490_PM_s_at EXOSC3 exosome component 3 0.00368908 0.0890331 60.7 88.7 71.7 2020 228027_PM_at GPRASP2 G protein-coupled 0.00369478 0.0891265 11.1 10.3 9.4 receptor associated sorting protein 2 2021 225805_PM_at HNRNPU heterogeneous nuclear 0.00369714 0.0891393 22.1 31.7 25.1 ribonucleoprotein U (scaffold attachment factor A) 2022 228628_PM_at SRGAP2P1 SLIT-ROBO Rho GTPase 0.00371487 0.0894886 461.9 362.6 338.6 activating protein 2 pseudogene 1 2023 225023_(——)PM_at GOPC golgi-associated PDZ and 0.0037153 0.0894886 33.6 42.6 42.5 coiled-coil motif containing 2024 215169_PM_at SLC35E2 solute carrier family 35, 0.00372164 0.089597 157.6 108.2 117.3 member E2 2025 230856_PM_at — — 0.00372727 0.0896882 113.2 84.2 84.6 2026 208669_PM_s_at EID1 EP300 interacting inhibitor 0.00373918 0.0899183 553.2 801.6 679.5 of differentiation 1 2027 203226_PM_s_at TSPAN31 tetraspanin 31 0.00374052 0.0899183 64.9 90.1 76.5 2028 243765_PM_at — — 0.00375004 0.0901027 19.5 17.2 16.2 2029 1562468_PM_at — — 0.00376362 0.0903403 24.4 17.4 17.0 2030 209076_PM_s_at WDR45L WDR45-like 0.00376364 0.0903403 142.3 162.8 167.8 2031 241543_PM_at — — 0.00376716 0.0903803 10.4 9.4 11.0 2032 1559201_PM_a_at — — 0.00378405 0.0906794 613.6 450.2 499.4 2033 224796_PM_at ASAP1 ArfGAP with SH3 domain, 0.00378442 0.0906794 1795.7 1328.9 1478.4 ankyrin repeat and PH domain 1 2034 233041_PM_x_at — — 0.00378521 0.0906794 855.4 706.6 739.4 2035 232597_PM_x_at SRSF2IP serine/arginine-rich 0.00378854 0.090698 766.8 615.4 621.3 splicing factor 2, interacting protein 2036 217550_PM_at ATF6 activating transcription 0.00378971 0.090698 220.4 149.4 200.6 factor 6 2037 233476_PM_at — — 0.00379655 0.0908171 420.4 284.9 293.1 2038 1554559_PM_at GPR62 G protein-coupled 0.00382185 0.0913775 13.4 11.6 12.1 receptor 62 2039 217654_PM_at CFLAR CASP8 and FADD-like 0.00382481 0.0914006 42.1 26.0 26.3 apoptosis regulator 2040 224674_PM_at TTYH3 tweety homolog 3 0.00382657 0.0914006 31.7 40.5 41.7 (Drosophila) 2041 232773_PM_at — — 0.00383209 0.091467 107.9 81.8 78.2 2042 242232_PM_at — — 0.00383319 0.091467 27.9 19.9 20.0 2043 239224_PM_at FBXL20 F-box and leucine-rich 0.00383498 0.091467 38.6 31.3 31.1 repeat protein 20 2044 1552714_PM_at CREG2 cellular repressor of E1A- 0.00385834 0.0919468 10.2 9.7 11.5 stimulated genes 2 2045 225677_PM_at BCAP29 B-cell receptor-associated 0.00386012 0.0919468 49.1 69.2 74.5 protein 29 2046 238886_PM_at TMED10 transmembrane emp24- 0.00386076 0.0919468 45.5 32.9 33.1 like trafficking protein 10 (yeast) 2047 237426_PM_at SP100 SP100 nuclear antigen 0.00386538 0.0919651 344.2 223.2 258.5 2048 239431_PM_at TICAM2 /// toll-like receptor adaptor 0.00386718 0.0919651 42.0 59.7 60.8 TMED7-TICAM2 molecule 2 /// TMED7- TICAM2 readthrough 2049 243013_PM_at — — 0.00386719 0.0919651 68.1 53.2 48.5 2050 236612_PM_at — — 0.00387911 0.092128 14.2 12.0 13.1 2051 222582_PM_at PRKAG2 protein kinase, AMP- 0.00387911 0.092128 158.1 194.8 206.7 activated, gamma 2 non- catalytic subunit 2052 227205_PM_at TAF1 TAF1 RNA polymerase II, 0.00387971 0.092128 45.6 60.0 51.5 TATA box binding protein (TBP)-associated factor, 250 kDa 2053 236836_PM_at — — 0.00388617 0.0922081 85.6 72.4 60.0 2054 201375_PM_s_at PPP2CB protein phosphatase 2, 0.00388709 0.0922081 410.6 507.3 496.6 catalytic subunit, beta isozyme 2055 209130_PM_at SNAP23 synaptosomal-associated 0.00389024 0.0922081 1604.7 1776.5 1930.4 protein, 23 kDa 2056 224177_PM_s_at CXorf26 chromosome X open 0.00389364 0.0922081 51.1 76.8 57.5 reading frame 26 2057 202505_PM_at SNRPB2 small nuclear 0.00389463 0.0922081 392.0 508.0 467.4 ribonucleoprotein polypeptide B 2058 1570124_PM_at — — 0.00389516 0.0922081 11.6 10.6 12.2 2059 231968_PM_at UGGT1 UDP-glucose glycoprotein 0.00389633 0.0922081 302.7 247.7 259.2 glucosyltransferase 1 2060 222631_PM_at PI4K2B phosphatidylinositol 4- 0.00390047 0.0922427 42.2 64.7 62.0 kinase type 2 beta 2061 235805_PM_at — — 0.00390158 0.0922427 48.0 30.8 32.9 2062 230582_PM_at HECA Headcase homolog 0.00390887 0.0923703 15.5 13.2 13.6 (Drosophila) 2063 223011_PM_s_at OCIAD1 OCIA domain containing 1 0.00391975 0.0925825 608.3 727.8 657.3 2064 232135_PM_at SAP30L SAP30-like 0.00392804 0.0927333 309.6 233.1 252.6 2065 206366_PM_X_at XCL1 chemokine (C motif) 0.00393296 0.0928045 205.2 302.0 368.0 ligand 1 2066 226368_PM_at CHST11 carbohydrate (chondroitin 0.00395067 0.0931773 1079.8 818.7 836.0 4) sulfotransferase 11 2067 205068_PM_s_at ARHGAP26 Rho GTPase activating 0.00396416 0.0933895 1314.3 888.0 1031.9 protein 26 2068 204037_PM_at LPAR1 lysophosphatidic acid 0.00396514 0.0933895 20.3 23.4 27.6 receptor 1 2069 206499_PM_s_at RCC1 regulator of chromosome 0.00395759 0.0933895 24.4 32.1 25.4 condensation 1 2070 239955_PM_at — — 0.00396859 0.0933895 166.5 121.4 113.9 2071 222728_PM_s_at TAF1D TATA box binding protein 0.00397247 0.0933895 591.6 472.2 470.7 (TBP)-associated factor, RNA polymerase I, D, 41 kDa 2072 228787_PM_s_at BCAS4 breast carcinoma 0.00397319 0.0933895 24.3 22.9 19.6 amplified sequence 4 2073 212802_PM_s_at GAPVD1 GTPase activating protein 0.00397442 0.0933895 482.4 412.6 428.7 and VP59 domains 1 2074 223501_PM_at TNFSF13B tumor necrosis factor 0.00397788 0.0933895 2123.6 2619.4 2925.4 (ligand) superfamily, member 13b 2075 241425_PM_at NUPL1 nucleoporin like 1 0.00397867 0.0933895 506.9 376.8 406.3 2076 208853_PM_s_at CANX calnexin 0.00398028 0.0933895 142.7 193.8 170.5 2077 1557813_PM_at — — 0.00398075 0.0933895 161.6 103.7 117.7 2078 225626_PM_at PAG1 phosphoprotein 0.00398708 0.0934504 1834.4 1353.6 1349.3 associated with glycosphingolipid microdomains 1 2079 AFFX-r2-P1-cre-5_at — — 0.00398718 0.0934504 10155.6 9861.1 10591.3 2080 225091_PM_at ZCCHC3 zinc finger, CCHC domain 0.00400655 0.0938592 106.6 132.3 117.4 containing 3 2081 233669_PM_s_at TRIM54 tripartite motif-containing 0.00401166 0.0939338 12.0 10.7 11.8 54 2082 218325_PM_s_at DIDO1 death inducer-obliterator 0.00401405 0.0939446 122.7 106.7 98.9 1 2083 1558486_PM_at ZNF493 zinc finger protein 493 0.00402068 0.0940546 404.2 284.3 271.1 2084 219715_PM_s_at TDP1 tyrosyl-DNA 0.00402559 0.0941242 51.5 46.8 39.4 phosphodiesterase 1 2085 1554806_PM_a_at FBXO8 F-box protein 8 0.00402917 0.0941438 64.3 91.0 72.2 2086 215545_PM_at — — 0.00403029 0.0941438 69.3 56.4 55.5 2087 232835_PM_at — — 0.004036 0.0941915 361.6 219.4 215.7 2088 229556_PM_at LOC100288893 hypothetical 0.0040362 0.0941915 12.6 14.9 16.1 LOC100288893 2089 221883_PM_at PKNOX1 PBX/knotted 1 homeobox 0.00404237 0.0942721 67.9 51.4 46.6 1 2090 241018_PM_at TMEM59 transmembrane protein 0.00404702 0.0942721 52.1 39.9 37.4 59 2091 224673_PM_at LENG8 leukocyte receptor cluster 0.00404728 0.0942721 30.1 22.9 22.0 (LRC) member 8 2092 211406_PM_at IER3IP1 immediate early response 0.00404739 0.0942721 15.9 18.5 19.5 3 interacting protein 1 2093 201056_PM_at GOLGB1 golgin B1 0.00405091 0.094309 89.6 70.1 71.1 2094 217911_PM_s_at BAG3 BCL2-associated 0.00405374 0.0943298 43.6 31.9 25.2 athanogene 3 2095 237107_PM_at PRKRA protein kinase, interferon- 0.00407199 0.0946579 56.7 37.6 39.8 inducible double stranded RNA dependent activator 2096 202442_PM_at AP3S1 adaptor-related protein 0.00407287 0.0946579 783.8 948.8 953.9 complex 3, sigma 1 subunit 2097 203410_PM_at AP3M2 adaptor-related protein 0.00407367 0.0946579 58.6 45.9 40.2 complex 3, mu 2 subunit 2098 235985_PM_at — — 0.00407823 0.0947187 110.9 84.1 75.6 2099 242371_PM_x_at — — 0.00408809 0.094856 16.5 13.9 14.0 2100 228190_PM_at ATG4C /// ATG4 autophagy related 4 0.00408993 0.094856 51.6 70.4 78.4 CTR9 homolog C (S. cerevisiae) /// Ctr9, Paf1/RNA polymerase II com 2101 203024_PM_s_at C5orf15 chromosome 5 open 0.00409089 0.094856 418.3 545.0 531.4 reading frame 15 2102 202872_PM_at ATP6V1C1 ATPase, H+ transporting, 0.00409559 0.094855 81.6 115.8 118.9 lysosomal 42 kDa, V1 subunit C1 2103 233496_PM_s_at CFL2 cofilin 2 (muscle) 0.0040962 0.094856 9.5 9.6 10.8 2104 202080_PM_s_at TRAK1 trafficking protein, kinesin 0.00409747 0.094856 135.4 162.1 171.8 binding 1 2105 243262_PM_at — — 0.00409802 0.094856 19.5 15.0 15.8 2106 228087_PM_at CCDC126 coiled-coil domain 0.00410037 0.094856 80.0 119.2 136.9 containing 126 2107 230630_PM_at AK4 adenylate kinase 4 0.00410166 0.094856 14.0 12.2 13.2 2108 218494_PM_s_at SLC2A4RG SLC2A4 regulator 0.00410524 0.0948938 69.3 73.8 48.0 2109 211387_PM_x_at RNGTT RNA guanylyltransferase 0.00411271 0.0950213 24.5 19.9 22.1 and 5′-phosphatase 2110 230980_PM_x_at — — 0.00412014 0.0951479 27.7 22.3 22.1 2111 236562_PM_at ZNF439 zinc finger protein 439 0.00413239 0.0953856 25.7 36.6 43.4 2112 239848_PM_at — — 0.00413966 0.0955082 24.9 18.6 18.5 2113 226459_PM_at PIK3AP1 phosphoinositide-3-kinase 0.00415318 0.0957598 2062.2 2494.4 2596.3 adaptor protein 1 2114 224837_PM_at FOXP1 forkhead box P1 0.00415683 0.0957598 688.1 567.3 535.8 2115 213500_PM_at — — 0.00415703 0.0957598 75.5 61.9 62.1 2116 1556178_PM_x_at TAF8 TAF8 RNA polymerase II, 0.00416035 0.0957598 33.1 39.2 31.7 TATA box binding protein (TBP)-associated factor, 43 kDa 2117 204837_PM_at MTMR9 myotubularin related 0.00416123 0.0957598 315.8 269.5 270.1 protein 9 2118 238812_PM_at — — 0.00416236 0.0957598 153.0 105.4 101.1 2119 215127_PM_s_at RBMS1 RNA binding motif, single 0.00416626 0.0957867 2167.2 1825.2 2003.6 stranded interacting protein 1 2120 222202_PM_at — — 0.00416849 0.0957867 11.0 9.9 11.2 2121 226438_PM_at SNTB1 syntrophin, beta 1 0.0041701 0.0957867 83.2 129.3 116.4 (dystrophin-associated protein A1, 59 kDa, basic component 1) 2122 222032_PM_s_at USP7 ubiquitin specific 0.00417139 0.0957867 22.9 18.3 20.0 peptidase 7 (herpes virus- associated) 2123 238631_PM_at ZNF140 Zinc finger protein 140 0.0041831 0.0960103 15.9 13.6 12.3 2124 218514_PM_at C17orf71 chromosome 17 open 0.00419327 0.0961984 94.3 118.2 111.3 reading frame 71 2125 213369_PM_at CDHR1 cadherin-related family 0.00419612 0.0962185 11.9 10.8 12.3 member 1 2126 240737_PM_at — — 0.00420555 0.0963894 143.2 116.6 115.7 2127 216626_PM_at — — 0.00423185 0.0969466 11.9 10.1 10.2 2128 241351_PM_at — — 0.00423575 0.0969903 48.6 39.4 37.1 2129 1554964_PM_x_at — — 0.00423798 0.0969958 13.8 11.0 11.9 2130 231601_PM_at LOC100507224 hypothetical 0.0042559 0.0973602 10.4 10.1 11.3 LOC100507224 2131 200776_PM_s_at BZW1 basic leucine zipper and 0.00426985 0.0975934 196.4 240.6 239.9 W2 domains 1 2132 239861_PM_at — — 0.0042701 0.0975934 360.5 261.9 284.1 2133 1561006_PM_at — — 0.00427945 0.0977613 13.5 12.8 11.9 2134 242443_PM_at EML5 Echinoderm microtubule 0.00428213 0.0977766 25.4 18.7 18.7 associated protein like 5 2135 212078_PM_s_at MLL myeloid/lymphoid or 0.0042932 0.0979835 186.7 143.2 117.3 mixed-lineage leukemia (trithorax homolog, Drosophila) 2136 215470_PM_at GTF2H2B general transcription 0.00429999 0.0980854 246.2 184.6 138.8 factor IIH, polypeptide 2B 2137 224641_PM_at FYTTD1 forty-two-three domain 0.00430169 0.0980854 330.1 444.5 371.2 containing 1 2138 209027_PM_s_at ABI2 abl-interactor 1 0.00430504 0.0981158 537.3 673.6 648.2 2139 224698_PM_at ESYT2 extended synaptotagmin- 0.00431319 0.0982556 437.9 373.9 323.4 like protein 2 2140 225783_PM_at UBE2F ubiquitin-conjugating 0.00431806 0.0983206 262.9 338.1 367.5 enzyme E2F (putative) 2141 230742_PM_at — — 0.00432039 0.098321 161.8 115.4 106.3 2142 232148_PM_at NSMAF Neutral sphingomyelinase 0.00432334 0.098321 144.0 94.9 94.9 (N-SMase) activation associated factor 2143 244636_PM_at — — 0.00432413 0.098321 31.1 22.7 20.7 2144 244686_PM_at TCOF1 Treacher Collins- 0.00433005 0.0984099 14.2 12.6 14.4 Franceschetti syndrome 1 2145 1569806_PM_at — — 0.00435008 0.0987818 13.3 11.7 13.1 2146 235623_PM_at ELP2 Elongation protein 2 0.00435048 0.0987818 148.9 119.0 117.2 homolog (S. cerevisiae) 2147 222207_PM_x_at — — 0.00435892 0.0989274 752.8 633.6 673.2 2148 202544_PM_at GMFB glia maturation factor, 0.00436196 0.0989503 350.5 476.6 471.2 beta 2149 1553176_PM_at SH2D1B SH2 domain containing 1B 0.00436721 0.0990233 11.4 12.7 13.5 2150 243492_PM_at THEM4 thioesterase superfamily 0.00437206 0.0990871 28.2 20.9 17.9 member 4 2151 244154_PM_at DDHD1 DDHD domain containing 0.00437947 0.0992089 110.5 83.5 83.9 1 2152 242946_PM_at — — 0.00438297 0.0992421 2226.9 1788.3 1732.9 2153 232665_PM_x_at — — 0.00438865 0.0993245 17.4 14.9 16.1 2154 222035_PM_s_at PAPOLA poly(A) polymerase alpha 0.00440072 0.0994865 299.9 376.9 346.1 2155 1566958_PM_at — — 0.00440104 0.0994865 15.9 12.8 13.8 2156 215978_PM_x_at ZNF721 zinc finger protein 721 0.00440193 0.0994865 1251.4 972.1 1042.4

TABLE 5 Time to biopsy (days post transplant). SCAR CAR TX Mean 287.6 921.2 267.8 Range 8-748 15-2876 84-2228

TABLE 6 3-Way 1-Step Microarray Analysis (AR v. subAR v. TX) using biopsy samples- Results Real\Predicted AR Bx TX Bx SCAR Bx AR Bx 16 0 4 TX Bx 0 21 4 SCAR Bx 5 5 12 % Positive Negative Predictive Sensitivity Specificity Predictive Predicitve Method Classifies Accuracy (%) (%) Value (%) Value (%) AUC Nearest Centroid TX vs. AR 100% 100% 100% 100% 100% 1.000 (1 Step Prediction) TX vs. SCAR  78%  81%  75%  84%  71% 0.785 AR vs. SCAR  76%  76%  75%  80%  71% 0.768

TABLE 7 Biopsy Microarray Signatures for subAR using a 2-way 2-Step approach - first step (AR + subAR vs .TX) p-value (subAR + cAR Probeset ID Gene Symbol Gene Title Bx vs. TX Bx) 211796_PM_s_at TRBC1 /// T cell receptor beta constant 1 /// T cell receptor 4.15E−12 TRBC2 beta constant 2 213193_PM_x_at TRBC1 T cell receptor beta constant 1 3.16E−11 207238_PM_s_at PTPRC protein tyrosine phosphatase, receptor type, C 3.47E−11 204118_PM_at CD48 CD48 molecule 4.03E−11 212587_PM_s_at PTPRC protein tyrosine phosphatase, receptor type, C 4.49E−11 204655_PM_at CCL5 chemokine (C-C motif) ligand 5 4.82E−11 34210_PM_at CD52 CD52 molecule 5.80E−11 210915_PM_x_at TRBC2 T cell receptor beta constant 2 6.47E−11 1405_PM_i_at CCL5 chemokine (C-C motif) ligand 5 8.99E−11 1555759_PM_a_at CCL5 chemokine (C-C motif) ligand 5 9.93E−11 204661_PM_at CD52 CD52 molecule 1.03E−10 213539_PM_at CD3D CD3d molecule, delta (CD3-TCR complex) 1.14E−10 204774_PM_at EVI2A ecotropic viral integration site 2A 1.38E−10 226789_PM_at EMB embigin 1.45E−10 212588_PM_at PTPRC protein tyrosine phosphatase, receptor type, C 2.06E−10 205831_PM_at CD2 CD2 molecule 2.10E−10 224356_PM_x_at MS4A6A membrane-spanning 4-domains, subfamily A, 2.11E−10 member 6A 206011_PM_at CASP1 caspase 1, apoptosis-related cysteine peptidase 2.51E−10 (interleukin 1, beta, convertase) 223280_PM_x_at MS4A6A membrane-spanning 4-domains, subfamily A, 3.37E−10 member 6A 229041_PM_s_at EST — 4.24E−10 229041_PM_s_at 213566_PM_at RNASE6 ribonuclease, RNase A family, k6 4.26E−10 213603_PM_s_at RAC2 ras-related C3 botulinum toxin substrate 2 (rho 4.52E−10 family, small GTP binding protein Rac2) 210972_PM_x_at TRAC /// T cell receptor alpha constant /// T cell receptor 4.73E−10 TRAJ17 /// alpha joining 17 /// T cell receptor TRAV20 211742_PM_s_at EVI2B ecotropic viral integration site 2B 4.95E−10 205488_PM_at GZMA granzyme A (granzyme 1, cytotoxic T-lymphocyte- 5.04E−10 associated serine esterase 3) 202957_PM_at HCLS1 hematopoietic cell-specific Lyn substrate 1 6.04E−10 223922_PM_x_at MS4A6A membrane-spanning 4-domains, subfamily A, 6.82E−10 member 6A 206978_PM_at CCR2 chemokine (C-C motif) receptor 2 7.07E−10 219666_PM_at MS4A6A membrane-spanning 4-domains, subfamily A, 7.80E−10 member 6A 209671_PM_x_at TRAC T cell receptor alpha constant 8.57E−10 226818_PM_at MPEG1 Macrophage expressed 1 8.65E−10 212671_PM_s_at HLA-DQA1 /// major histocompatibility complex, class II, DQ alpha 1 /// 9.14E−10 HLA-DQA2 major histocompatibility com 228532_PM_at C1orf162 chromosome 1 open reading frame 162 9.60E−10 204912_PM_at IL10RA interleukin 10 receptor, alpha 1.01E−09 205821_PM_at KLRK1 killer cell lectin-like receptor subfamily K, member 1 1.19E−09 204205_PM_at APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic 1.19E−09 polypeptide-like 3G 214181_PM_x_at LST1 leukocyte specific transcript 1 1.20E−09 214470_PM_at KLRB1 killer cell lectin-like receptor subfamily B, member 1 1.35E−09 201137_PM_s_at HLA-DPB1 major histocompatibility complex, class II, DP beta 1 1.35E−09 211902_PM_x_at TRD@ T cell receptor delta locus 1.50E−09 210982_PM_s_at HLA-DRA major histocompatibility complex, class II, DR alpha 1.74E−09 209835_PM_x_at CD44 CD44 molecule (Indian blood group) 2.10E−09 206666_PM_at GZMK granzyme K (granzyme 3; tryptase II) 2.13E−09 203760_PM_s_at SLA Src-like-adaptor 2.13E−09 202644_PM_s_at TNFAIP3 tumor necrosis factor, alpha-induced protein 3 2.24E−09 204446_PM_s_at ALOX5 arachidonate 5-lipoxygenase 2.34E−09 213416_PM_at ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of 2.40E−09 VLA-4 receptor) 209083_PM_at CORO1A coronin, actin binding protein, 1A 2.41E−09 225701_PM_at AKNA AT-hook transcription factor 2.49E−09 224927_PM_at KIAA1949 KIAA1949 2.95E−09 211991_PM_s_at HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 3.00E−09 235964_PM_x_at SAMHD1 SAM domain and HD domain 1 3.04E−09 202207_PM_at ARL4C ADP-ribosylation factor-like 4C 3.09E−09 210895_PM_s_at CD86 CD86 molecule 3.43E−09 1555691_PM_a_at KLRK1 killer cell lectin-like receptor subfamily K, member 1 3.43E−09 226841_PM_at MPEG1 macrophage expressed 1 3.66E−09 205269_PM_at LCP2 lymphocyte cytosolic protein 2 (SH2 domain 3.68E−09 containing leukocyte protein of 76 kDa) 203416_PM_at CD53 CD53 molecule 3.82E−09 204959_PM_at MNDA myeloid cell nuclear differentiation antigen 3.96E−09 223322_PM_at RASSF5 Ras association (RalGDS/AF-6) domain family 4.29E−09 member 5 209970_PM_x_at CASP1 caspase 1, apoptosis-related cysteine peptidase 4.61E−09 (interleukin 1, beta, convertase) 1552703_PM_s_at CARD16 /// caspase recruitment domain family, member 16 /// 4.62E−09 CASP1 caspase 1, apoptosis-related cysteine 221698_PM_s_at CLEC7A C-type lectin domain family 7, member A 4.92E−09 1559584_PM_a_at C16orf54 chromosome 16 open reading frame 54 5.09E−09 205270_PM_s_at LCP2 lymphocyte cytosolic protein 2 (SH2 domain 5.11E−09 containing leukocyte protein of 76 kDa) 209670_PM_at TRAC T cell receptor alpha constant 5.15E−09 209606_PM_at CYTIP cytohesin 1 interacting protein 5.42E−09 204891_PM_s_at LCK lymphocyte-specific protein tyrosine kinase 5.54E−09 1553906_PM_s_at FGD2 FYVE, RhoGEF and PH domain containing 2 5.99E−09 223344_PM_s_at MS4A7 membrane-spanning 4-domains, subfamily A, 6.00E−09 member 7 236295_PM_a_at NLRC3 NLR family, CARD domain containing 3 6.07E−09 217733_PM_s_at TMSB10 thymosin beta 10 6.08E−09 205081_PM_at CRIP1 cysteine-rich protein 1 (intestinal) 6.14E−09 208885_PM_at LCP1 lymphocyte cytosolic protein 1 (L-plastin) 6.27E−09 219161_PM_s_at CKLF chemokine-like factor 6.34E−09 227346_PM_at IKZF1 IKAROS family zinc finger 1 (Ikaros) 6.48E−09 223620_PM_at GPR34 G protein-coupled receptor 34 6.60E−09 213888_PM_s_at TRAF3IP3 TRAF3 interacting protein 3 6.77E−09 232024_PM_at GIMAP2 GTPase, IMAP family member 2 6.89E−09 206682_PM_at CLEC10A C-type lectin domain family 10, member A 7.07E−09 208894_PM_at HLA-DRA major histocompatibility complex, class II, DR alpha 7.95E−09 204971_PM_at CSTA cystatin A (stefin A) 8.19E−09 202208_PM_s_at ARL4C ADP-ribosylation factor-like 4C 8.47E−09 226218_PM_at IL7R interleukin 7 receptor 8.48E−09 211368_PM_s_at CASP1 caspase 1, apoptosis-related cysteine peptidase 8.75E−09 (interleukin 1, beta, convertase) 211366_PM_x_at CASP1 caspase 1, apoptosis-related cysteine peptidase 8.89E−09 (interleukin 1, beta, convertase) 205789_PM_at CD1D CD1d molecule 9.29E−09 1554240_PM_a_at ITGAL integrin, alpha L (antigen CD11A (p180), lymphocyte 9.60E−09 function-associated antigen 1; alph 211367_PM_s_at CASP1 caspase 1, apoptosis-related cysteine peptidase 1.01E−08 (interleukin 1, beta, convertase) 226525_PM_at STK17B serine/threonine kinase 17b 1.04E−08 218223_PM_s_at PLEKHO1 pleckstrin homology domain containing, family O 1.06E−08 member 1 214574_PM_x_at LST1 leukocyte specific transcript 1 1.10E−08 209732_PM_at CLEC2B C-type lectin domain family 2, member B 1.10E−08 210538_PM_s_at BIRC3 baculoviral IAP repeat-containing 3 1.17E−08 202157_PM_s_at CELF2 CUGBP, Elav-like family member 2 1.17E−08 217456_PM_x_at HLA-E major histocompatibility complex, class I, E 1.23E−08 211582_PM_x_at LST1 leukocyte specific transcript 1 1.27E−08 223451_PM_s_at CKLF chemokine-like factor 1.30E−08 226474_PM_at NLRC5 NLR family, CARD domain containing 5 1.31E−08 229390_PM_at FAM26F family with sequence similarity 26, member F 1.47E−08 201721_PM_s_at LAPTM5 lysosomal protein transmembrane 5 1.56E−08 202206_PM_at ARL4C ADP-ribosylation factor-like 4C 1.64E−08 201666_PM_at TIMP1 TIMP metallopeptidase inhibitor 1 1.69E−08 205898_PM_at CX3CR1 chemokine (C-X3-C motif) receptor 1 1.74E−08 204336_PM_s_at RGS19 regulator of G-protein signaling 19 1.82E−08 208306_PM_x_at HLA-DRB1 Major histocompatibility complex, class II, DR beta 1 1.84E−08 227353_PM_at TMC8 transmembrane channel-like 8 1.85E−08 201288_PM_at ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 1.90E−08 224964_PM_s_at GNG2 guanine nucleotide binding protein (G protein), 1.93E−08 gamma 2 202643_PM_s_at TNFAIP3 tumor necrosis factor, alpha-induced protein 3 1.96E−08 209846_PM_s_at BTN3A2 butyrophilin, subfamily 3, member A2 2.07E−08 222858_PM_s_at DAPP1 dual adaptor of phosphotyrosine and 3- 2.08E−08 phosphoinositides 201858_PM_s_at SRGN serglycin 2.30E−08 204924_PM_at TLR2 toll-like receptor 2 2.35E−08 203741_PM_s_at ADCY7 adenylate cyclase 7 2.37E−08 213160_PM_at DOCK2 dedicator of cytokinesis 2 2.38E−08 213975_PM_s_at LYZ lysozyme 2.39E−08 1552316_PM_a_at GIMAP1 GTPase, IMAP family member 1 2.40E−08 200905_PM_x_at HLA-E major histocompatibility complex, class I, E 2.50E−08 226219_PM_at ARHGAP30 Rho GTPase activating protein 30 2.52E−08 209312_PM_x_at HLA-DRB1 /// major histocompatibility complex, class II, DR beta 1 /// 2.53E−08 HLA-DRB4 major histocompatibility comp 202803_PM_s_at ITGB2 integrin, beta 2 (complement component 3 receptor 2.55E−08 3 and 4 subunit) 33304_PM_at ISG20 interferon stimulated exonuclease gene 20 kDa 2.56E−08 228071_PM_at GIMAP7 GTPase, IMAP family member 7 2.57E−08 201720_PM_s_at LAPTM5 lysosomal protein transmembrane 5 2.59E−08 219033_PM_at PARP8 poly (ADP-ribose) polymerase family, member 8 2.70E−08 200833_PM_s_at RAP1B RAP1B, member of RAS oncogene family 2.72E−08 227184_PM_at PTAFR platelet-activating factor receptor 2.73E−08 222217_PM_s_at SLC27A3 solute carrier family 27 (fatty acid transporter), 2.74E−08 member 3 224451_PM_x_at ARHGAP9 Rho GTPase activating protein 9 2.76E−08 206118_PM_at STAT4 signal transducer and activator of transcription 4 2.78E−08 229391_PM_s_at FAM26F family with sequence similarity 26, member F 2.81E−08 218870_PM_at ARHGAP15 Rho GTPase activating protein 15 2.83E−08 224916_PM_at TMEM173 transmembrane protein 173 2.83E−08 209795_PM_at CD69 CD69 molecule 2.89E−08 208965_PM_s_at IFI16 interferon, gamma-inducible protein 16 2.91E−08 209723_PM_at SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), 2.91E−08 member 9 1555852_PM_at LOC100507463 hypothetical LOC100507463 2.93E−08 1552701_PM_a_at CARD16 caspase recruitment domain family, member 16 3.05E−08 201859_PM_at SRGN serglycin 3.07E−08 219574_PM_at MAR1 membrane-associated ring finger (C3HC4) 1 3.20E−08 230391_PM_at CD84 CD84 molecule 3.30E−08 235529_PM_x_at SAMHD1 SAM domain and HD domain 1 3.35E−08 228055_PM_at NAPSB napsin B aspartic peptidase pseudogene 3.36E−08 212014_PM_x_at CD44 CD44 molecule (Indian blood group) 3.46E−08 211656_PM_x_at HLA-DQB1 /// major histocompatibility complex, class II, DQ beta 1 /// 3.52E−08 LOC100133583 HLA class II histocompatibili 203761_PM_at SLA Src-like-adaptor 3.53E−08 209933_PM_s_at CD300A CD300a molecule 3.53E−08 203233_PM_at IL4R interleukin 4 receptor 3.54E−08 204563_PM_at SELL selectin L 3.58E−08 215633_PM_x_at LST1 leukocyte specific transcript 1 3.61E−08 234987_PM_at SAMHD1 SAM domain and HD domain 1 3.61E−08 242946_PM_at EST — 3.63E−08 242946_PM_at 235385_PM_at MAR2 membrane-associated ring finger (C3HC4) 1 3.67E−08 210113_PM_s_at NLRP1 NLR family, pyrin domain containing 1 3.67E−08 228376_PM_at GGTA1 glycoprotein, alpha-galactosyltransferase 1 3.68E−08 pseudogene 205039_PM_s_at IKZF1 IKAROS family zinc finger 1 (ikaros) 3.69E−08 217362_PM_x_at HLA-DRB6 major histocompatibility complex, class II, DR beta 6 3.71E−08 (pseudogene) 209879_PM_at SELPLG selectin P ligand 3.77E−08 204698_PM_at ISG20 interferon stimulated exonuclease gene 20 kDa 3.87E−08 215493_PM_x_at BTN2A1 butyrophilin, subfamily 2, member A1 3.95E−08 211395_PM_x_at FCGR2C Fc fragment of IgG, low affinity IIc, receptor for 4.15E−08 (CD32) (gene/pseudogene) 223773_PM_s_at SNHG12 small nucleolar RNA host gene 12 (non-protein 4.22E−08 coding) 219279_PM_at DOCK10 dedicator of cytokinesis 10 4.25E−08 225353_PM_s_at C1QC complement component 1, q subcomponent C chain 4.33E−08 216920_PM_s_at TARP /// TRGC2 TCR gamma alternate reading frame protein /// T cell 4.35E−08 receptor gamma constant 2 207651_PM_at GPR171 G protein-coupled receptor 171 4.42E−08 227178_PM_at CELF2 CUGBP, Elav-like family member 2 4.42E−08 202510_PM_s_at TNFAIP2 tumor necrosis factor, alpha-induced protein 2 4.50E−08 209823_PM_x_at HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 4.63E−08 1555756_PM_a_at CLEC7A C-type lectin domain family 7, member A 4.72E−08 223809_PM_at RGS18 regulator of G-protein signaling 18 4.72E−08 243366_PM_s_at EST — 4.75E−08 243366_PM_s_at 204222_PM_s_at GLIPR1 GLI pathogenesis-related 1 4.82E−08 204220_PM_at GMFG glia maturation factor, gamma 4.92E−08 1557905_PM_s_at CD44 CD44 molecule (Indian blood group) 5.25E−08 229625_PM_at GBP5 guanylate binding protein 5 5.25E−08 213414_PM_s_at RPS19 ribosomal protein S19 5.30E−08 230499_PM_at EST — 5.38E−08 230499_PM_at 215193_PM_x_at HLA-DRB1 /// major histocompatibility complex, class II, DR beta 1 /// 5.40E−08 HLA-DRB3 /// major histocompatibility comp HLA-DRB4 /// HLA-DRB5 /// LOC100133661 /// LOC100294036 /// LOC100509582 /// LOC100510495 /// LOC100510519 232724_PM_at MS4A6A membrane-spanning 4-domains, subfamily A, 5.40E−08 member 6A 210140_PM_at CST7 cystatin F (leukocystatin) 5.42E−08 224252_PM_s_at FXYD5 FXYD domain containing ion transport regulator 5 5.47E−08 219191_PM_s_at BIN2 bridging integrator 2 5.50E−08 206991_PM_s_at CCR5 chemokine (C-C motif) receptor 5 5.54E−08 208966_PM_x_at IFI16 interferon, gamma-inducible protein 16 5.60E−08 210785_PM_s_at C1orf38 chromosome 1 open reading frame 38 5.62E−08 242814_PM_at SERPINB9 serpin peptidase inhibitor, clade B (ovalbumin), 5.71E−08 member 9 232543_PM_x_at ARHGAP9 Rho GTPase activating protein 9 5.73E−08 213418_PM_at HSPA6 heat shock 70 kDa protein 6 (HSP70B′) 5.80E−08 212829_PM_at PIP4K2A phosphatidylinositol-5-phosphate 4-kinase, type II, 5.85E−08 alpha 223501_PM_at TNFSF13B tumor necrosis factor (ligand) superfamily, member 5.88E−08 13b 211581_PM_x_at LST1 leukocyte specific transcript 1 5.92E−08 202748_PM_at GBP2 guanylate binding protein 2, interferon-inducible 6.11E−08 230925_PM_at APBB1IP amyloid beta (A4) precursor protein-binding, family 6.25E−08 B, member 1 interacting protein 209827_PM_s_at IL16 interleukin 16 (lymphocyte chemoattractant factor) 6.49E−08 204882_PM_at ARHGAP25 Rho GTPase activating protein 25 7.19E−08 204319_PM_s_at RGS10 regulator of G-protein signaling 10 7.27E−08 217985_PM_s_at BAZ1A bromodomain adjacent to zinc finger domain, 1A 7.33E−08 212998_PM_x_at HLA-DQB1 /// major histocompatibility complex, class II, DQ beta 1 /// 7.42E−08 LOC100133583 HLA class II histocompatibili 205159_PM_at CSF2RB colony stimulating factor 2 receptor, beta, low- 7.44E−08 affinity (granulocyte-macrophage) 204670_PM_x_at HLA-DRB1 /// major histocompatibility complex, class II, DR beta 1 /// 7.56E−08 HLA-DRB4 major histocompatibility comp 221903_PM_s_at CYLD cylindromatosis (turban tumor syndrome) 7.60E−08 223343_PM_at MS4A7 membrane-spanning 4-domains, subfamily A, 7.76E−08 member 7 205285_PM_s_at FYB FYN binding protein 7.83E−08 220005_PM_at P2RY13 purinergic receptor P2Y, G-protein coupled, 13 8.02E−08 218157_PM_x_at CDC42SE1 CDC42 small effector 1 8.09E−08 204438_PM_at MRC1 /// mannose receptor, C type 1 /// mannose receptor, C 8.23E−08 MRC1L1 type 1-like 1 211654_PM_x_at HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 8.44E−08 224882_PM_at ACSS1 acyl-CoA synthetase short-chain family member 1 8.52E−08 214567_PM_s_at XCL1 /// XCL2 chemokine (C motif) ligand 1 /// chemokine (C motif) 8.56E−08 ligand 2 223502_PM_s_at TNFSF13B tumor necrosis factor (ligand) superfamily, member 8.61E−08 13b 228581_PM_at KCNJ10 potassium inwardly-rectifying channel, subfamily J, 8.69E−08 member 10 229383_PM_at MAR3 membrane-associated ring finger (C3HC4) 1 8.72E−08 202649_PM_x_at RPS19 ribosomal protein S19 8.78E−08 210889_PM_s_at FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32) 8.93E−08 204174_PM_at ALOX5AP arachidonate 5-lipoxygenase-activating protein 9.16E−08 204502_PM_at SAMHD1 SAM domain and HD domain 1 9.17E−08 223640_PM_at HCST hematopoietic cell signal transducer 9.31E−08 211597_PM_s_at HOPX HOP homeobox 9.39E−08 216834_PM_at RGS1 regulator of G-protein signaling 1 9.57E−08 212063_PM_at CD44 CD44 molecule (Indian blood group) 9.76E−08 208805_PM_at PSMA6 proteasome (prosome, macropain) subunit, alpha 9.90E−08 type, 6 210279_PM_at GPR18 G protein-coupled receptor 18 1.00E−07 204057_PM_at IRF8 interferon regulatory factor 8 1.00E−07 226055_PM_at ARRDC2 arrestin domain containing 2 1.00E−07 205758_PM_at CD8A CD8a molecule 1.01E−07 229723_PM_at TAGAP T-cell activation RhoGTPase activating protein 1.01E−07 218084_PM_x_at FXYD5 FXYD domain containing ion transport regulator 5 1.01E−07 218802_PM_at CCDC109B coiled-coil domain containing 109B 1.02E−07 205987_PM_at CD1C CD1c molecule 1.04E−07 205859_PM_at LY86 lymphocyte antigen 86 1.05E−07 207794_PM_at CCR2 chemokine (C-C motif) receptor 2 1.09E−07 204122_PM_at TYROBP TYRO protein tyrosine kinase binding protein 1.10E−07 229560_PM_at TLR8 toll-like receptor 8 1.12E−07 203923_PM_s_at CYBB cytochrome b-245, beta polypeptide 1.12E−07 225479_PM_at LRRC58 leucine rich repeat containing 58 1.17E−07 222592_PM_s_at ACSL5 acyl-CoA synthetase long-chain family member 5 1.23E−07 230550_PM_at MS4A6A membrane-spanning 4-domains, subfamily A, 1.23E−07 member 6A 222859_PM_s_at DAPP1 dual adaptor of phosphotyrosine and 3- 1.24E−07 phosphoinositides 226810_PM_at OGFRL1 opioid growth factor receptor-like 1 1.28E−07 221666_PM_s_at PYCARD PYD and CARD domain containing 1.29E−07 203729_PM_at EMP3 epithelial membrane protein 3 1.29E−07 211990_PM_at HLA-DPA1 major histocompatibility complex, class II, DP alpha 1 1.29E−07 226136_PM_at GLIPR1 GLI pathogenesis-related 1 1.32E−07 201426_PM_s_at VIM vimentin 1.32E−07 205298_PM_s_at BTN2A2 butyrophilin, subfamily 2, member A2 1.33E−07 206332_PM_s_at IFI16 interferon, gamma-inducible protein 16 1.36E−07 211339_PM_s_at ITK IL2-inducible T-cell kinase 1.37E−07 204490_PM_s_at CD44 CD44 molecule (Indian blood group) 1.38E−07 230669_PM_at RASA2 RAS p21 protein activator 2 1.39E−07 200003_PM_s_at RPL28 ribosomal protein L28 1.39E−07 217478_PM_s_at HLA-DMA major histocompatibility complex, class II, DM alpha 1.40E−07 236280_PM_at EST — 1.41E−07 236280_PM_at 222976_PM_s_at TPM3 tropomyosin 3 1.42E−07 232311_PM_at B2M Beta-2-microglobulin 1.42E−07 220577_PM_at GVINP1 GTPase, very large interferon inducible pseudogene 1 1.43E−07 238668_PM_at EST — 1.44E−07 238668_PM_at 232617_PM_at CTSS cathepsin S 1.45E−07 224833_PM_at ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 1.46E−07 (avian) 219014_PM_at PLAC8 placenta-specific 8 1.49E−07 219243_PM_at GIMAP4 GTPase, IMAP family member 4 1.49E−07 209829_PM_at FAM65B family with sequence similarity 65, member B 1.50E−07 203471_PM_s_at PLEK pleckstrin 1.53E−07 211144_PM_x_at TARP /// TRGC2 TCR gamma alternate reading frame protein /// T cell 1.54E−07 receptor gamma constant 2 211528_PM_x_at HLA-G major histocompatibility complex, class I, G 1.55E−07 206584_PM_at LY96 lymphocyte antigen 96 1.57E−07 231747_PM_at CYSLTR1 cysteinyl leukotriene receptor 1 1.59E−07 230735_PM_at EST — 1.61E−07 230735_PM_at 225604_PM_s_at GLIPR2 GLI pathogenesis-related 2 1.62E−07 210072_PM_at CCL19 chemokine (C-C motif) ligand 19 1.63E−07 221058_PM_s_at CKLF chemokine-like factor 1.63E−07 204923_PM_at SASH3 SAM and SH3 domain containing 3 1.68E−07 227677_PM_at JAK3 Janus kinase 3 1.69E−07 201012_PM_at ANXA1 annexin A1 1.70E−07 229155_PM_at EST — 1.72E−07 229155_PM_at 205101_PM_at CIITA class II, major histocompatibility complex, 1.74E−07 transactivator 216438_PM_s_at TMSB4X /// thymosin beta 4, X-linked /// thymosin-like 3 1.75E−07 TMSL3 1552318_PM_at GIMAP1 GTPase, IMAP family member 1 1.77E−07 213095_PM_x_at AIF1 allograft inflammatory factor 1 1.80E−07 204316_PM_at RGS10 regulator of G-protein signaling 10 1.82E−07 203927_PM_at NFKBIE nuclear factor of kappa light polypeptide gene 1.83E−07 enhancer in B-cells inhibitor, epsilon 217523_PM_at CD44 CD44 molecule (Indian blood group) 1.84E−07 209901_PM_x_at AIF1 allograft inflammatory factor 1 1.84E−07 203508_PM_at TNFRSF1B tumor necrosis factor receptor superfamily, member 1.85E−07 1B 208944_PM_at TGFBR2 transforming growth factor, beta receptor II 1.86E−07 (70/80 kDa) 210031_PM_at CD247 CD247 molecule 1.87E−07 202953_PM_at C1QB complement component 1, q subcomponent, B chain 1.87E−07 213733_PM_at MYO1F myosin IF 1.88E−07 201738_PM_at EIF1B eukaryotic translation initiation factor 1B 1.88E−07 205884_PM_at ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of 1.93E−07 VLA-4 receptor) 204820_PM_s_at BTN3A2 /// butyrophilin, subfamily 3, member A2 /// 1.99E−07 BTN3A3 butyrophilin, subfamily 3, member A3 218805_PM_at GIMAP5 GTPase, IMAP family member 5 1.99E−07 212873_PM_at HMHA1 histocompatibility (minor) HA-1 1.99E−07 217979_PM_at TSPAN13 tetraspanin 13 2.02E−07 228471_PM_at ANKRD44 ankyrin repeat domain 44 2.03E−07 218322_PM_s_at ACSL5 acyl-CoA synthetase long-chain family member 5 2.03E−07 215051_PM_x_at AIF1 allograft inflammatory factor 1 2.04E−07 213398_PM_s_at SDR39U1 short chain dehydrogenase/reductase family 39U, 2.04E−07 member 1 206637_PM_at P2RY14 purinergic receptor P2Y, G-protein coupled, 14 2.05E−07

TABLE 8 Biopsy Microarray Signatures for subAR using a 2-way 2-Step approach - second step (AR vs. subAR) p-value(cAR Bx vs. subAR Probeset ID Gene Symbol Gene Title Bx) 227801_PM_at TRIM59 tripartite motif-containing 59 1.69E−08 212951_PM_at GPR116 G protein-coupled receptor 116 6.33E−08 226668_PM_at WDSUB1 WD repeat, sterile alpha motif and U-box domain 7.62E−08 containing 1 202357_PM_s_at CFB complement factor B 1.28E−07 211075_PM_s_at CD47 CD47 molecule 1.32E−07 204213_PM_at PIGR polymeric immunoglobulin receptor 1.54E−07 226459_PM_at PIK3AP1 phosphoinositide-3-kinase adaptor protein 1 1.54E−07 231779_PM_at IRAK2 interleukin-1 receptor-associated kinase 2 1.70E−07 235085_PM_at SGK223 homolog of rat pragma of Rnd2 1.84E−07 226714_PM_at SAMD4B sterile alpha motif domain containing 4B 1.98E−07 202242_PM_at TSPAN7 tetraspanin 7 2.17E−07 213857_PM_s_at CD47 CD47 molecule 2.57E−07 205105_PM_at MAN2A1 mannosidase, alpha, class 2A, member 1 2.62E−07 204924_PM_at TLR2 toll-like receptor 2 2.69E−07 204470_PM_at CXCL1 chemokine (C-X-C motif) ligand 1 (melanoma growth 3.07E−07 stimulating activity, alpha) 204108_PM_at NFYA nuclear transcription factor Y, alpha 3.20E−07 236155_PM_at ZCCHC6 Zinc finger, CCHC domain containing 6 4.22E−07 212950_PM_at GPR116 G protein-coupled receptor 116 4.37E−07 209774_PM_x_at CXCL2 chemokine (C-X-C motif) ligand 2 5.78E−07 207966_PM_s_at GLG1 golgi glycoprotein 1 6.24E−07 211758_PM_x_at TXNDC9 thioredoxin domain containing 9 6.38E−07 238178_PM_at EST — 7.69E−07 238178_PM_at 202334_PM_s_at UBE2B ubiquitin-conjugating enzyme E2B (RAD6 homolog) 7.75E−07 231334_PM_at EST — 8.26E−07 231334_PM_at 223809_PM_at RGS18 regulator of G-protein signaling 18 8.34E−07 210405_PM_x_at TNFRSF10B tumor necrosis factor receptor superfamily, member 9.02E−07 10b 230777_PM_s_at PRDM15 PR domain containing 15 9.91E−07 202907_PM_s_at NBN nibrin 1.02E−06 202621_PM_at IRF3 interferon regulatory factor 3 1.04E−06 219938_PM_s_at PSTPIP2 proline-serine-threonine phosphatase interacting 1.07E−06 protein 2 223047_PM_at CMTM6 CKLF-like MARVEL transmembrane domain containing 1.08E−06 6 202018_PM_s_at LTF lactotransferrin 1.10E−06 233878_PM_s_at XRN2 5′-3′ exoribonuclease 2 1.19E−06 244353_PM_s_at SLC2A12 solute carrier family 2 (facilitated glucose transporter), 1.20E−06 member 12 204785_PM_x_at IFNAR2 interferon (alpha, beta and omega) receptor 2 1.21E−06 226000_PM_at CTTNBP2NL CTTNBP2 N-terminal like 1.24E−06 241891_PM_at EST — 1.30E−06 241891_PM_at 208791_PM_at CLU clusterin 1.38E−06 233047_PM_at FRMD7 FERM domain containing 7 1.39E−06 226538_PM_at MAN2A1 mannosidase, alpha, class 2A, member 1 1.44E−06 208792_PM_s_at CLU clusterin 1.48E−06 218313_PM_s_at GALNT7 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- 1.60E−06 acetylgalactosaminyltransferase 7 (Gal 203568_PM_s_at TRIM38 tripartite motif-containing 38 1.62E−06 223218_PM_s_at NFKBIZ nuclear factor of kappa light polypeptide gene 1.69E−06 enhancer in B-cells inhibitor, zeta 224358_PM_s_at MS4A7 membrane-spanning 4-domains, subfamily A, member 1.76E−06 7 227125_PM_at IFNAR2 interferon (alpha, beta and omega) receptor 2 1.78E−06 1552615_PM_at ACACB acetyl-CoA carboxylase beta 1.84E−06 218865_PM_at MOSC1 MOCO sulphurase C-terminal domain containing 1 1.87E−06 210031_PM_at CD247 CD247 molecule 1.91E−06 212226_PM_s_at PPAP2B phosphatidic acid phosphatase type 2B 1.95E−06 230912_PM_at ASPDH aspartate dehydrogenase domain containing 2.08E−06 201042_PM_at TGM2 transglutaminase 2 (C polypeptide, protein-glutamine- 2.14E−06 gamma-glutamyltransferase) 203513_PM_at SPG11 spastic paraplegia 11 (autosomal recessive) 2.39E−06 243088_PM_at EST — 2.58E−06 243088_PM_at 204324_PM_s_at GOLIM4 golgi integral membrane protein 4 2.58E−06 235905_PM_at ZNF704 zinc finger protein 704 2.65E−06 1564679_PM_at ASB15 ankyrin repeat and SOCS box-containing 15 2.71E−06 203868_PM_s_at VCAM1 vascular cell adhesion molecule 1 2.72E−06 212695_PM_at CRY2 cryptochrome 2 (photolyase-like) 2.77E−06 223217_PM_s_at NFKBIZ nuclear factor of kappa light polypeptide gene 2.78E−06 enhancer in B-cells inhibitor, zeta 227213_PM_at ADAT2 adenosine deaminase, tRNA-specific 2, TAD2 homolog 2.91E−06 (S. cerevisiae) 206513_PM_at AIM2 absent in melanoma 2 2.96E−06 1552749_PM_a_at KLC3 kinesin light chain 3 2.96E−06 240413_PM_at PYHIN1 pyrin and HIN domain family, member 1 3.05E−06 238960_PM_s_at LARP4 La ribonucleoprotein domain family, member 4 3.06E−06 1562966_PM_at KIAA1217 KIAA1217 3.10E−06 202898_PM_at SDC3 syndecan 3 3.16E−06 229872_PM_s_at LOC100132999 hypothetical LOC100132999 3.22E−06 218404_PM_at SNX10 sorting nexin 10 3.44E−06 219998_PM_at HSPC159 galectin-related protein 3.50E−06 211003_PM_x_at TGM2 transglutaminase 2 (C polypeptide, protein-glutamine- 3.52E−06 gamma-glutamyltransferase) 203008_PM_x_at TXNDC9 thioredoxin domain containing 9 3.59E−06 213513_PM_x_at ARPC2 actin related protein 2/3 complex, subunit 2, 34 kDa 3.77E−06 203765_PM_at GCA grancalcin, EF-hand calcium binding protein 3.83E−06 221510_PM_s_at GLS glutaminase 3.91E−06 214791_PM_at SP140L SP140 nuclear body protein-like 4.01E−06 217947_PM_at CMTM6 CKLF-like MARVEL transmembrane domain containing 4.12E−06 6 206503_PM_x_at PML promyelocytic leukemia 4.26E−06 222033_PM_s_at FLT1 fms-related tyrosine kinase 1 (vascular endothelial 4.32E−06 growth factor/vascular permeability 202651_PM_at LPGAT1 lysophosphatidylglycerol acyltransferase 1 4.48E−06 237587_PM_at EST — 4.55E−06 237587_PM_at 209970_PM_x_at CASP1 caspase 1, apoptosis-related cysteine peptidase 4.57E−06 (interleukin 1, beta, convertase) 222976_PM_s_at TPM3 tropomyosin 3 4.61E−06 227678_PM_at XRCC6BP1 XRCC6 binding protein 1 4.64E−06 209035_PM_at MDK midkine (neurite growth-promoting factor 2) 4.78E−06 205624_PM_at CPA3 carboxypeptidase A3 (mast cell) 4.78E−06 203332_PM_s_at INPP5D inositol polyphosphate-5-phosphatase, 145 kDa 4.82E−06 211917_PM_s_at PRLR prolactin receptor 4.86E−06 219283_PM_at C1GALT1C1 C1GALT1-specific chaperone 1 4.94E−06 239005_PM_at FLJ39739 Hypothetical FLJ39739 4.99E−06 228114_PM_x_at C16orf13 chromosome 16 open reading frame 13 5.00E−06 205295_PM_at CKMT2 creatine kinase, mitochondrial 2 (sarcomeric) 5.19E−06 242131_PM_at ATP6 ATP synthase F0 subunit 6 5.23E−06 202688_PM_at TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 5.33E−06 235536_PM_at SNORD89 small nucleolar RNA, C/D box 89 5.35E−06 214212_PM_x_at FERMT2 fermitin family member 2 5.35E−06 212148_PM_at PBX1 pre-B-cell leukemia homeobox 1 5.38E−06 212504_PM_at DIP2C DIP2 disco-interacting protein 2 homolog C 5.51E−06 (Drosophila) 201697_PM_s_at DNMT1 DNA (cytosine-5-)-methyltransferase 1 5.53E−06 212501_PM_at CEBPB CCAAT/enhancer binding protein (C/EBP), beta 5.54E−06 204446_PM_s_at ALOX5 arachidonate 5-lipoxygenase 5.57E−06 206011_PM_at CASP1 caspase 1, apoptosis-related cysteine peptidase 5.63E−06 (interleukin 1, beta, convertase) 224663_PM_s_at CFL2 cofilin 2 (muscle) 5.75E−06 201949_PM_x_at CAPZB capping protein (actin filament) muscle Z-line, beta 5.91E−06 219436_PM_s_at EMCN endomucin 5.96E−06 220146_PM_at TLR7 toll-like receptor 7 6.03E−06 209310_PM_s_at CASP4 caspase 4, apoptosis-related cysteine peptidase 6.11E−06 207702_PM_s_at MAGI2 membrane associated guanylate kinase, WW and PDZ 6.12E−06 domain containing 2 204794_PM_at DUSP2 dual specificity phosphatase 2 6.14E−06 219202_PM_at RHBDF2 rhomboid 5 homolog 2 (Drosophila) 6.28E−06 233496_PM_s_at CFL2 cofilin 2 (muscle) 6.38E−06 224578_PM_at RCC2 regulator of chromosome condensation 2 6.46E−06 223104_PM_at JAGN1 jagunal homolog 1 (Drosophila) 6.54E−06 219161_PM_s_at CKLF chemokine-like factor 6.57E−06 226612_PM_at UBE2QL1 ubiquitin-conjugating enzyme E2Q family-like 1 6.62E−06 204974_PM_at RAB3A RAB3A, member RAS oncogene family 6.66E−06 223002_PM_s_at XRN2 5′-3′ exoribonuclease 2 6.67E−06 242601_PM_at HEPACAM2 HEPACAM family member 2 6.71E−06 205102_PM_at TMPRSS2 transmembrane protease, serine 2 6.93E−06 1569926_PM_s_at SLC34A3 solute carrier family 34 (sodium phosphate), member 7.01E−06 3 213596_PM_at CASP4 caspase 4, apoptosis-related cysteine peptidase 7.18E−06 200713_PM_s_at MAPRE1 microtubule-associated protein, RP/EB family, 7.54E−06 member 1 203132_PM_at RB1 retinoblastoma 1 7.60E−06 209752_PM_at REG1A regenerating islet-derived 1 alpha 7.65E−06 211573_PM_x_at TGM2 transglutaminase 2 (C polypeptide, protein-glutamine- 7.82E−06 gamma-glutamyltransferase) 207213_PM_s_at USP2 ubiquitin specific peptidase 2 7.87E−06 217984_PM_at RNASET2 ribonuclease T2 7.97E−06 1553304_PM_at LSM14B LSM14B, SCD6 homolog B (S. cerevisiae) 7.97E−06 229937_PM_x_at LILRB1 Leukocyte immunoglobulin-like receptor, subfamily B 7.98E−06 (with TM and ITIM domains), member 200609_PM_s_at WDR1 WD repeat domain 1 8.01E−06 205467_PM_at CASP10 caspase 10, apoptosis-related cysteine peptidase 8.03E−06 225331_PM_at CCDC50 coiled-coil domain containing 50 8.05E−06 1560017_PM_at TMTC3 transmembrane and tetratricopeptide repeat 8.07E−06 containing 3 200797_PM_s_at MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 8.10E−06 231337_PM_at LOC100505498 hypothetical LOC100505498 8.35E−06 221666_PM_s_at PYCARD PYD and CARD domain containing 8.67E−06 217733_PM_s_at TMSB10 thymosin beta 10 8.89E−06 220933_PM_s_at ZCCHC6 zinc finger, CCHC domain containing 6 8.92E−06 235050_PM_at SLC2A12 solute carrier family 2 (facilitated glucose transporter), 8.98E−06 member 12 200634_PM_at PFN1 profilin 1 9.10E−06 227727_PM_at MRGPRF MAS-related GPR, member F 9.13E−06 216638_PM_s_at PRLR prolactin receptor 9.14E−06 207168_PM_s_at H2AFY H2A histone family, member Y 9.63E−06 226184_PM_at FMNL2 formin-like 2 9.70E−06 204846_PM_at CP ceruloplasmin (ferroxidase) 9.71E−06 210527_PM_x_at TUBA3C tubulin, alpha 3c 9.81E−06 211368_PM_s_at CASP1 caspase 1, apoptosis-related cysteine peptidase 9.84E−06 (interleukin 1, beta, convertase) 1556656_PM_at EST — 9.89E−06 1556656_PM_at 223323_PM_x_at TRPM7 transient receptor potential cation channel, subfamily 9.92E−06 M, member 7 210513_PM_s_at VEGFA vascular endothelial growth factor A 9.95E−06 1553155_PM_x_at ATP6V0D2 ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit 1.01E−05 d2 212010_PM_s_at CDV3 CDV3 homolog (mouse) 1.02E−05 209311_PM_at BCL2L2 BCL2-like 2 1.02E−05 201917_PM_s_at SLC25A36 solute carrier family 25, member 36 1.02E−05 227396_PM_at PTPRJ protein tyrosine phosphatase, receptor type, J 1.04E−05 209278_PM_s_at TFPI2 tissue factor pathway inhibitor 2 1.04E−05 209903_PM_s_at ATR ataxia telangiectasia and Rad3 related 1.06E−05 202763_PM_at CASP3 caspase 3, apoptosis-related cysteine peptidase 1.08E−05 218238_PM_at GTPBP4 GTP binding protein 4 1.09E−05 206226_PM_at HRG histidine-rich glycoprotein 1.10E−05 224462_PM_s_at CHCHD6 coiled-coil-helix-coiled-coil-helix domain containing 6 1.11E−05 220603_PM_s_at MCTP2 multiple C2 domains, transmembrane 2 1.11E−05 235161_PM_at LOC100506451 /// hypothetical LOC100506451 /// hypothetical 1.11E−05 LOC100509094 LOC100509094 211366_PM_x_at CASP1 caspase 1, apoptosis-related cysteine peptidase 1.12E−05 (interleukin 1, beta, convertase) 239636_PM_at MCF2L MCF.2 cell line derived transforming sequence-like 1.12E−05 228740_PM_at EST — 1.12E−05 228740_PM_at 216323_PM_x_at TUBA3C /// tubulin, alpha 3c /// tubulin, alpha 3d /// tubulin, 1.13E−05 TUBA3D /// alpha 3e TUBA3E 205068_PM_s_at ARHGAP26 Rho GTPase activating protein 26 1.13E−05 217983_PM_s_at RNASET2 ribonuclease T2 1.14E−05 206059_PM_at ZNF91 zinc finger protein 91 1.15E−05 206944_PM_at HTR6 5-hydroxytryptamine (serotonin) receptor 6 1.17E−05 215264_PM_at EMX1 empty spiracles homeobox 1 1.18E−05 213551_PM_x_at PCGF2 polycomb group ring finger 2 1.18E−05 218194_PM_at REXO2 REX2, RNA exonuclease 2 homolog (S. cerevisiae) 1.18E−05 227438_PM_at ALPK1 alpha-kinase 1 1.19E−05 1053_PM_at RFC2 replication factor C (activator 1) 2, 40 kDa 1.20E−05 227874_PM_at EMCN endomucin 1.20E−05 201918_PM_at SLC25A36 solute carrier family 25, member 36 1.20E−05 213355_PM_at ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 1.21E−05 213923_PM_at RAP2B RAP2B, member of RAS oncogene family 1.23E−05 220990_PM_s_at MIR21 /// microRNA 21 /// transmembrane protein 49 1.24E−05 TMEM49 213535_PM_s_at UBE2I ubiquitin-conjugating enzyme E2I (UBC9 homolog, 1.25E−05 yeast) 205910_PM_s_at CEL /// carboxyl ester lipase (bile salt-stimulated lipase) /// 1.25E−05 LOC100508206 bile salt-activated lipase-like 204702_PM_s_at NFE2L3 nuclear factor (erythroid-derived 2)-like 3 1.27E−05 230550_PM_at MS4A6A membrane-spanning 4-domains, subfamily A, member 1.29E−05 6A 205027_PM_s_at MAP3K8 mitogen-activated protein kinase kinase kinase 8 1.30E−05 209476_PM_at TMX1 thioredoxin-related transmembrane protein 1 1.30E−05 209422_PM_at PHF20 PHD finger protein 20 1.32E−05 207754_PM_at RASSF8 Ras association (RalGDS/AF-6) domain family (N- 1.33E−05 terminal) member 8 35150_PM_at CD40 CD40 molecule, TNF receptor superfamily member 5 1.34E−05 41220_PM_at SEPT9 septin 9 1.35E−05 227730_PM_at EST — 1.40E−05 227730_PM_at 206613_PM_s_at TAF1A TATA box binding protein (TBP)-associated factor, RNA 1.40E−05 polymerase 1, A, 48 kDa 201179_PM_s_at GNAI3 guanine nucleotide binding protein (G protein), alpha 1.41E−05 inhibiting activity polypeptide 3 208850_PM_s_at THY1 Thy-1 cell surface antigen 1.43E−05 217985_PM_s_at BAZ1A bromodomain adjacent to zinc finger domain, 1A 1.44E−05 200798_PM_x_at MCL1 myeloid cell leukemia sequence 1 (BCL2-related) 1.45E−05 1555486_PM_a_at PRR5L proline rich 5 like 1.45E−05 221932_PM_s_at GLRX5 glutaredoxin 5 1.45E−05 205079_PM_s_at MPDZ multiple PDZ domain protein 1.46E−05 241154_PM_x_at EST — 1.47E−05 241154_PM_x_at 219089_PM_s_at ZNF576 zinc finger protein 576 1.50E−05 206219_PM_s_at VAV1 vav 1 guanine nucleotide exchange factor 1.52E−05 1553153_PM_at ATP6V0D2 ATPase, H+ transporting, lysosomal 38 kDa, V0 subunit 1.54E−05 d2 208540_PM_x_at S100A11 S100 calcium binding protein A11 1.56E−05 223318_PM_s_at ALKBH7 alkB, alkylation repair homolog 7 (E. coli) 1.56E−05 226618_PM_at UBE2QL1 ubiquitin-conjugating enzyme E2Q family-like 1 1.57E−05 218092_PM_s_at AGFG1 ArfGAP with FG repeats 1 1.65E−05 229041_PM_s_at EST — 1.66E−05 229041_PM_s_at 214366_PM_s_at ALOX5 arachidonate 5-lipoxygenase 1.66E−05 226820_PM_at ZNF362 zinc finger protein 362 1.68E−05 210426_PM_x_at RORA RAR-related orphan receptor A 1.68E−05 209545_PM_s_at RIPK2 receptor-interacting serine-threonine kinase 2 1.68E−05 214329_PM_x_at TNFSF10 tumor necrosis factor (ligand) superfamily, member 10 1.69E−05 210176_PM_at TLR1 toll-like receptor 1 1.72E−05 242167_PM_at EST — 1.73E−05 242167_PM_at 224352_PM_s_at CFL2 cofilin 2 (muscle) 1.73E−05 223451_PM_s_at CKLF chemokine-like factor 1.76E−05 202625_PM_at LYN v-yes-1 Yamaguchi sarcoma viral related oncogene 1.79E−05 homolog 202748_PM_at GBP2 guanylate binding protein 2, interferon-inducible 1.81E−05 209906_PM_at C3AR1 complement component 3a receptor 1 1.81E−05 213869_PM_x_at THY1 Thy-1 cell surface antigen 1.84E−05 225994_PM_at CPSF2 cleavage and polyadenylation specific factor 2, 100 kDa 1.84E−05 226048_PM_at MAPK8 mitogen-activated protein kinase 8 1.85E−05 203828_PM_s_at IL32 interleukin 32 1.88E−05 203947_PM_at CSTF3 cleavage stimulation factor, 3′ pre-RNA, subunit 3, 1.88E−05 77 kDa 244811_PM_at PHIP pleckstrin homology domain interacting protein 1.88E−05 236293_PM_at RHOH ras homolog gene family, member H 1.90E−05 214467_PM_at GPR65 G protein-coupled receptor 65 1.91E−05 235309_PM_at RPS15A ribosomal protein S15a 1.91E−05 212024_PM_x_at FLII flightless I homolog (Drosophila) 1.93E−05 205841_PM_at JAK2 Janus kinase 2 1.94E−05 205887_PM_x_at MSH3 mutS homolog 3 (E. coli) 1.95E−05 208743_PM_s_at YWHAB tyrosine 3-monooxygenase/tryptophan 5- 1.98E−05 monooxygenase activation protein, beta polypeptid 238668_PM_at EST — 1.98E−05 238668_PM_at 205809_PM_s_at WASL Wiskott-Aldrich syndrome-like 1.99E−05 218008_PM_at C7orf42 chromosome 7 open reading frame 42 1.99E−05 204198_PM_s_at RUNX3 runt-related transcription factor 3 2.00E−05 201040_PM_at GNAI2 guanine nucleotide binding protein (G protein), alpha 2.01E−05 inhibiting activity polypeptide 2 223010_PM_s_at OCIAD1 OCIA domain containing 1 2.03E−05 225511_PM_at GPRC5B G protein-coupled receptor, family C, group 5, 2.04E−05 member B 226748_PM_at LYSMD2 LysM, putative peptidoglycan-binding, domain 2.05E−05 containing 2 206150_PM_at CD27 CD27 molecule 2.06E−05 213136_PM_at PTPN2 protein tyrosine phosphatase, non-receptor type 2 2.07E−05 202238_PM_s_at NNMT nicotinamide N-methyltransferase 2.07E−05 203079_PM_s_at CUL2 cullin 2 2.07E−05 201724_PM_s_at GALNT1 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N- 2.08E−05 acetylgalactosaminyltransferase 1 (Gal 226147_PM_s_at PIGR polymeric immunoglobulin receptor 2.08E−05 203091_PM_at FUBP1 far upstream element (FUSE) binding protein 1 2.11E−05 219033_PM_at PARP8 poly (ADP-ribose) polymerase family, member 8 2.12E−05 225924_PM_at FNIP2 folliculin interacting protein 2 2.14E−05 230565_PM_at ATP6V1G3 ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit 2.14E−05 G3 1553906_PM_s_at FGD2 FYVE, RhoGEF and PH domain containing 2 2.16E−05 208296_PM_x_at TNFAIP8 tumor necrosis factor, alpha-induced protein 8 2.18E−05 209787_PM_s_at HMGN4 high mobility group nucleosomal binding domain 4 2.18E−05 202957_PM_at HCLS1 hematopoietic cell-specific Lyn substrate 1 2.19E−05 210785_PM_s_at C1orf38 chromosome 1 open reading frame 38 2.20E−05 228770_PM_at GPR146 G protein-coupled receptor 146 2.23E−05 200829_PM_x_at ZNF207 zinc finger protein 207 2.26E−05 223344_PM_s_at MS4A7 membrane-spanning 4-domains, subfamily A, member 2.28E−05 7 222885_PM_at EMCN endomucin 2.30E−05 202211_PM_at ARFGAP3 ADP-ribosylation factor GTPase activating protein 3 2.32E−05 238581_PM_at GBP5 guanylate binding protein 5 2.36E−05 208821_PM_at SNRPB small nuclear ribonucleoprotein polypeptides B and B1 2.38E−05 203137_PM_at WTAP Wilms tumor 1 associated protein 2.38E−05 213102_PM_at ACTR3 ARP3 actin-related protein 3 homolog (yeast) 2.40E−05 227384_PM_s_at EST — 2.41E−05 227384_PM_s_at 233632_PM_s_at XRN1 5′-3′ exoribonuclease 1 2.42E−05 220742_PM_s_at NGLY1 N-glycanase 1 2.44E−05 208642_PM_s_at XRCC5 X-ray repair complementing defective repair in 2.46E−05 Chinese hamster cells 5 (double-strand-b 225814_PM_at XRN1 5′-3′ exoribonuclease 1 2.46E−05 209295_PM_at TNFRSF10B tumor necrosis factor receptor superfamily, member 2.47E−05 10b 218665_PM_at FZD4 frizzled homolog 4 (Drosophila) 2.48E−05 219023_PM_at AP1AR adaptor-related protein complex 1 associated 2.50E−05 regulatory protein 202510_PM_s_at TNFAIP2 tumor necrosis factor, alpha-induced protein 2 2.53E−05 221477_PM_s_at SOD2 superoxide dismutase 2, mitochondrial 2.57E−05 203182_PM_s_at SRPK2 SRSF protein kinase 2 2.59E−05 209189_PM_at FOS FBJ murine osteosarcoma viral oncogene homolog 2.61E−05 219574_PM_at MARCH1 membrane-associated ring finger (C3HC4) 1 2.62E−05 217549_PM_at EST — 2.62E−05 217549_PM_at 210106_PM_at RDH5 retinol dehydrogenase 5 (11-cis/9-cis) 2.64E−05 33760_PM_at PEX14 peroxisomal biogenesis factor 14 2.65E−05 238423_PM_at SYTL3 synaptotagmin-like 3 2.65E−05 230176_PM_at EST — 2.66E−05 230176_PM_at 218546_PM_at C1orf115 chromosome 1 open reading frame 115 2.70E−05 1558702_PM_at TEX10 testis expressed 10 2.75E−05 212733_PM_at KIAA0226 KIAA0226 2.75E−05 229659_PM_s_at EST — 2.76E−05 229659_PM_s_at 207809_PM_s_at ATP6AP1 ATPase, H+ transporting, lysosomal accessory protein 2.77E−05 1 202431_PM_s_at MYC v-myc myelocytomatosis viral oncogene homolog 2.79E−05 (avian) 212433_PM_x_at RPS2 ribosomal protein S2 2.80E−05 223086_PM_x_at MRPL51 mitochondrial ribosomal protein L51 2.81E−05 228162_PM_at ESD esterase D 2.84E−05 214770_PM_at MSR1 macrophage scavenger receptor 1 2.84E−05 201830_PM_s_at NET1 neuroepithelial cell transforming 1 2.85E−05 212314_PM_at SEL1L3 sel-1 suppressor of lin-12-like 3 (C. elegans) 2.86E−05 209360_PM_s_at RUNX1 runt-related transcription factor 1 2.89E−05 221698_PM_s_at CLEC7A C-type lectin domain family 7, member A 2.90E−05 201359_PM_at COPB1 coatomer protein complex, subunit beta 1 2.91E−05 217157_PM_x_at IGK@ /// IGKC immunoglobulin kappa locus /// immunoglobulin 2.92E−05 kappa constant

TABLE 9 2-Way 2-Step Microarray Analysis (AR v. subAR; AR v. TX; and subAR v. TX) using biopsy samples-Results Real\Predicted TX SCAR AR TX 22 2 1 SCAR 0 18 4 AR 0 2 18 Positive Negative % Predictive Sensitivity Specificity Predictive Predicitve Method Classifies Accuracy (%) (%) Value (%) Value (%) AUC Nearest Centroid TX vs. AR 97% 100% 94% 95% 100% 0.965 (2 Step Prediction) TX vs. SCAR 95% 100% 90% 91% 100% 0.947 AR vs. SCAR 86%  90% 81% 81%  90% 0.862

TABLE 10 3-Way 1-Step NGS Analysis (AR v. subAR v. TX) using biopsy samples-Results Real\Predicted TX SUBAR AR TX 22 2 1 SUBAR 8 11 3 AR 0 8 1 Positive Negative % Predictive Sensitivity Specificity Predictive Predicitve Method Classifies Accuracy (%) (%) Value (%) Value (%) AUC Nearest Centroid TX vs. AR 97% 100% 92% 95% 100% 0.967 (1 Step Prediction) TX vs. SCAR 80%  72% 83% 72%  91% 0.795 AR vs. SCAR 69%  58% 79% 79%  59% 0.689

TABLE 11 Biopsy NGS Signatures for subAR using a 2-Step approach (AR + subAR vs. TX and subAR vs TX) - first step: AR + subAR vs. TX Column p-value(AR + ID To Gene Name SCAR vs. TX) 1 CCR2 chemokine (C-C motif) receptor 2 4.89E−13 2 Tbc1d10c TBC1 domain family, member 10C 5.04E−11 3 Ly9 lymphocyte antigen 9 1.88E−10 4 Cd48 CD48 molecule 3.78E−10 5 Bin2 bridging integrator 2 5.43E−10 6 Cd2 CD2 molecule 5.64E−10 7 ALOX5 arachidonate 5-lipoxygenase 7.26E−10 8 IKZF3 IKAROS family zinc finger 3 (Aiolos) 7.80E−10 9 Cd247 CD247 molecule 8.24E−10 10 CD1D CD1d molecule 1.05E−09 11 Cd96 CD96 molecule 1.27E−09 12 Ptprc protein tyrosine phosphatase, receptor 1.61E−09 13 ikzf1 IKAROS family zinc finger 1 (Ikaros) 2.45E−09 14 PTPN22 protein tyrosine phosphatase, non-recep 2.51E−09 15 EMB embigin homolog (mouse) 2.94E−09 16 runx3 runt-related transcription factor 3 3.00E−09 17 MNDA myeloid cell nuclear differentiation an 3.08E−09 18 Arl4c ADP-ribosylation factor-like 4C 3.41E−09 19 IL16 interleukin 16 (lymphocyte chemoattract 4.57E−09 20 DOCK2 dedicator of cytokinesis 2 5.47E−09 21 ITGAL integrin, alpha L (antigen CD11A (p180) 6.07E−09 22 Fgd2 FYVE, RhoGEF and PH domain containing 2 6.43E−09 23 PARVG parvin, gamma 6.49E−09 24 CD3D CD3d molecule, delta (CD3-TCR complex) 6.50E−09 25 Mpeg1 macrophage expressed 1 6.53E−09 26 LCP1 lymphocyte cytosolic protein 1 (L-plast 6.58E−09 27 ARHGAP15 Rho GTPase activating protein 15 7.55E−09 28 NLRC5 NLR family, CARD domain containing 5 7.70E−09 29 GZMK granzyme K (granzyme 3; tryptase II) 7.96E−09 30 BIRC3 baculoviral IAP repeat-containing 3 8.08E−09 31 TMC8 transmembrane channel-like 8 8.56E−09 32 RGS18 regulator of G-protein signaling 18 1.00E−08 33 Cd3g CD3g molecule, gamma (CD3-TCR complex) 1.00E−08 34 Amica1 adhesion molecule, interacts with CXADR 1.04E−08 35 il2rg interleukin 2 receptor, gamma (severe c 1.19E−08 36 Inpp5d inositol polyphosphate-5-phosphatase, 1 1.25E−08 37 cstA cystatin A (stefin A) 1.26E−08 38 LIMD2 LIM domain containing 2 1.44E−08 39 dapp1 dual adaptor of phosphotyrosine and 3-p 1.65E−08 40 NCKAP1L NCK-associated protein 1-like 1.68E−08 41 Ms4a7 membrane-spanning 4-domains, subfamily 1.80E−08 42 TNFAIP3 tumor necrosis factor, alpha-induced pr 1.87E−08 43 IL7R interleukin 7 receptor 1.88E−08 44 EVI2B ecotropic viral integration site 2B 1.88E−08 45 C1orf162 chromosome 1 open reading frame 162 1.98E−08 46 SLAMF7 SLAM family member 7 2.09E−08 47 RNASE6 ribonuclease, RNase A family, k6 2.20E−08 48 CXorf21 chromosome X open reading frame 21 2.38E−08 49 SCML4 sex comb on midleg-like 4 (Drosophila) 2.42E−08 50 CCL5 chemokine (C-C motif) ligand 5 2.44E−08 51 EST EST2 2.52E−08 52 Pyhin1 pyrin and HIN domain family, member 1 2.64E−08 53 Cd8a CD8a molecule 2.79E−08 54 Cd52 CD52 molecule 2.99E−08 55 SAMD3 sterile alpha motif domain containing 3 3.16E−08 56 btk Bruton agammaglobulinemia tyrosine kina 3.18E−08 57 IRF4 interferon regulatory factor 4 3.24E−08 58 GAB3 GRB2-associated binding protein 3 3.25E−08 59 CSF2RA colony stimulating factor 2 receptor, a 3.36E−08 60 P2RY13 purinergic receptor P2Y, G-protein coup 3.46E−08 61 FYB FYN binding protein (FYB-120/130) 3.58E−08 62 TRAF3IP3 TRAF3 interacting protein 3 3.86E−08 63 PTAFR platelet-activating factor receptor 3.94E−08 64 Arhgap25 Rho GTPase activating protein 25 3.99E−08 65 myo1f myosin IF 4.09E−08 66 CELF2 CUG triplet repeat, RNA binding protein 4.18E−08 67 MS4A6A membrane-spanning 4-domains, subfamily 4.18E−08 68 kcna3 potassium voltage-gated channel, shaker 4.30E−08 69 CLIC2 chloride intracellular channel 2 4.33E−08 70 IL10RA interleukin 10 receptor, alpha 4.73E−08 71 NHEDC2 Na+/H+ exchanger domain containing 2 4.76E−08 72 THEMIS thymocyte selection pathway associated 4.88E−08 73 ARHGAP30 Rho GTPase activating protein 30 4.97E−08 74 PRKCB protein kinase C, beta 5.03E−08 75 HCLS1 hematopoietic cell-specific Lyn substra 5.08E−08 76 Rgs10 regulator of G-protein signaling 10 5.66E−08 77 Evi2a ecotropic viral integration site 2A 5.83E−08 78 Spn sialophorin 5.84E−08 79 IL1B interleukin 1, beta 5.88E−08 80 LOC100133678 similar to hCG2042724; similar to HLA c 6.41E−08 81 ITGA4 integrin, alpha 4 (antigen CD49D, alpha 6.94E−08 82 CCDC109B coiled-coil domain containing 109B 7.03E−08 83 Gapt GRB2-binding adaptor protein, transmemb 7.43E−08 84 APBB1IP amyloid beta (A4) precursor protein-bin 7.51E−08 85 arhgdib Rho GDP dissociation inhibitor (GDI) be 7.69E−08 86 CD180 CD180 molecule 7.79E−08 87 PIK3CG phosphoinositide-3-kinase, catalytic, g 7.94E−08 88 CCR5 chemokine (C-C motif) receptor 5 8.05E−08 89 dgkA diacylglycerol kinase, alpha 80 kDa 8.25E−08 90 RASSF2 Ras association (RalGDS/AF-6) domain fa 8.52E−08 91 TAGAP T-cell activation RhoGTPase activating 8.59E−08 92 CASP1 caspase 1, apoptosis-related cysteine p 8.74E−08 93 LOC606724 coronin, actin binding protein, 1A pseu 9.01E−08 94 REEP4 receptor accessory protein 4 9.04E−08 95 GIMAP7 GTPase, IMAP family member 7 9.16E−08 96 KLRB1 killer cell lectin-like receptor subfam 9.85E−08 97 Icp2 lymphocyte cytosolic protein 2 (SH2 dom 9.99E−08 98 Lair1 leukocyte-associated immunoglobulin-lik 1.01E−07 99 CD44 CD44 molecule (Indian blood group) 1.02E−07 100 GZMA granzyme A (granzyme 1, cytotoxic T-lym 1.03E−07 101 rac2 ras-related C3 botulinum toxin substrat 1.13E−07 102 STAMBPL1 STAM binding protein-like 1 1.17E−07 103 FAM78A family with sequence similarity 78, mem 1.33E−07 104 FAIM3 Fas apoptotic inhibitory molecule 3 1.35E−07 105 Cd6 CD6 molecule 1.39E−07 106 EST EST9 1.42E−07 107 MAP4K1 mitogen-activated protein kinase kinase 1.47E−07 108 CLEC10A C-type lectin domain family 10, member 1.52E−07 109 SP140 SP140 nuclear body protein 1.52E−07 110 SELL selectin L 1.59E−07 111 CRTAM cytotoxic and regulatory T cell molecul 1.60E−07 112 FCER1G Fc fragment of IgE, high affinity 1, re 1.64E−07 113 CP ceruloplasmin (ferroxidase) 1.73E−07 114 GPR171 G protein-coupled receptor 171 1.82E−07 115 Cx3cr1 chemokine (C-X3-C motif) receptor 1 1.87E−07 116 TBXAS1 thromboxane A synthase I (platelet) 1.87E−07 117 SLAMF1 signaling lymphocytic activation molecu 1.88E−07 118 P2RX7 purinergic receptor P2X, ligand-gated i 1.93E−07 119 SAMHD1 SAM domain and HD domain 1 1.94E−07 120 EST EST16 2.00E−07 121 Miat myocardial infarction associated transc 2.01E−07 122 gmfg glia maturation factor, gamma 2.07E−07 123 LCK lymphocyte-specific protein tyrosine ki 2.11E−07 124 SLA Src-like-adaptor 2.14E−07 125 CARD16 caspase recruitment domain family, memb 2.15E−07 126 ETS1 v-ets erythroblastosis virus E26 oncoge 2.17E−07 127 BAZ1A bromodomain adjacent to zinc finger dom 2.20E−07 128 Selplg selectin P ligand 2.28E−07 129 IFI16 interferon, gamma-inducible protein 16 2.29E−07 130 rassf5 Ras association (RalGDS/AF-6) domain fa 2.51E−07 131 ADCY7 adenylate cyclase 7 2.58E−07 132 PLCB2 phospholipase C, beta 2 2.59E−07 133 kcnj10 potassium inwardly-rectifying channel, 2.60E−07 134 STAT4 signal transducer and activator of tran 2.62E−07 135 GPR65 G protein-coupled receptor 65 2.66E−07 136 AIM2 absent in melanoma 2 2.69E−07 137 SERPINB9 serpin peptidase inhibitor, clade B (ov 2.69E−07 138 Ccdc88b coiled-coil domain containing 88B 2.71E−07 139 FECH ferrochelatase (protoporphyria) 2.91E−07 140 Akna AT-hook transcription factor 2.99E−07 141 APOBEC3D apolipoprotein B mRNA editing enzyme, c 3.00E−07 142 BTN3A2 butyrophilin, subfamily 3, member A2 3.01E−07 143 ARHGAP9 Rho GTPase activating protein 9 3.20E−07 144 pAG1 phosphoprotein associated with glycosph 3.23E−07 145 SIGLEC10 sialic acid binding Ig-like lectin 10 3.26E−07 146 FGL2 fibrinogen-like 2 3.30E−07 147 Pou2f2 POU class 2 homeobox 2 3.43E−07 148 CYTIP cytohesin 1 interacting protein 3.44E−07 149 Gad1 glutamate decarboxylase 1 (brain, 67 kDa 3.56E−07 150 TLR10 toll-like receptor 10 3.56E−07 151 WAS Wiskott-Aldrich syndrome (eczema-thromb 3.59E−07 152 prex1 phosphatidylinositol-3,4,5-trisphosphat 3.64E−07 153 CD69 CD69 molecule 3.68E−07 154 SLAMF6 SLAM family member 6 3.74E−07 155 CD37 CD37 molecule 3.80E−07 156 ST8SIA4 ST8 alpha-N-acetyl-neuraminide alpha-2, 3.83E−07 157 ANKRD44 ankyrin repeat domain 44 3.90E−07 158 RASAL3 RAS protein activator like 3 3.92E−07 159 KLRD1 killer cell lectin-like receptor subfam 3.93E−07 160 SMAP2 small ArfGAP2 4.13E−07 161 pstpip2 proline-serine-threonine phosphatase in 4.24E−07 162 FAM65B family with sequence similarity 65, mem 4.25E−07 163 GIMAP4 GTPase, IMAP family member 4 4.36E−07 164 LY86 lymphocyte antigen 86 4.42E−07 165 FMNL1 formin-like 1 4.63E−07 166 fermt3 fermitin family homolog 3 (Drosophila) 4.70E−07 167 C1s complement component 1, s subcomponent 4.78E−07 168 BTN2A2 butyrophilin, subfamily 2, member A2 4.78E−07 169 EST EST17 4.92E−07 170 TLR6 toll-like receptor 6 4.94E−07 171 IRF8 interferon regulatory factor 8 4.98E−07 172 CD163 CD163 molecule 5.02E−07 173 LILRB1 leukocyte immunoglobulin-like receptor, 5.03E−07 174 APOBEC3F apolipoprotein B mRNA editing enzyme, c 5.14E−07 175 Itgax integrin, alpha X (complement component 5.19E−07 176 CTSS cathepsin S 5.54E−07 177 HCST hematopoietic cell signal transducer 5.65E−07 178 ccdc69 coiled-coil domain containing 69 5.66E−07 179 C1r complement component 1, r subcomponent 5.67E−07 180 Nkg7 natural killer cell group 7 sequence 5.70E−07 181 csf1 colony stimulating factor 1 (macrophage 5.82E−07 182 pycard PYD and CARD domain containing 5.87E−07 183 SP140L SP140 nuclear body protein-like 5.93E−07 184 Cd53 CD53 molecule 6.01E−07 185 srgn serglycin 6.09E−07 186 SERPINB8 serpin peptidase inhibitor, clade B (ov 6.15E−07 187 IL4R interleukin 4 receptor 6.30E−07 188 GBP2 guanylate binding protein 2, interferon 6.39E−07 189 Fcgr2b Fc fragment of IgG, low affinity IIb, r 6.49E−07 190 TIMP1 TIMP metallopeptidase inhibitor 1 6.55E−07 191 C17orf87 chromosome 17 open reading frame 87 6.64E−07 192 GLIPR2 GLI pathogenesis-related 2 6.65E−07 193 LYZ lysozyme (renal amyloidosis) 7.18E−07 194 KIAA0748 KIAA0748 7.30E−07 195 mybl1 v-myb myeloblastosis viral oncogene hom 7.48E−07 196 CLEC7A C-type lectin domain family 7, member A 7.62E−07 197 KLHL6 kelch-like 6 (Drosophila) 7.67E−07 198 IL4I1 interleukin 4 induced 1 7.87E−07 199 APOBEC3G apolipoprotein B mRNA editing enzyme, c 8.00E−07 200 TRANK1 lupus brain antigen 1 8.20E−07

TABLE 12 Biopsy NGS Signatures for subAR using a 2-Step approach (AR + subAR vs. TX and AR v. subAR) - second step: AR vs. subAR Column p-value (cAR ID To Gene Name vs. subAR) 4057 LTF lactotransferrin 3.02E−07 400746 C1orf130 chromosome 1 open reading frame 130 1.17E−06 4192 Mdk midkine (neurite growth-promoting facto 1.60E−06 51705 EMCN endomucin 3.01E−06 4316 mmp7 matrix metallopeptidase 7 (matrilysin, 4.37E−06 1056 Cel carboxyl ester lipase (bile salt-stimul 5.01E−06 140803 TRPM6 transient receptor potential cation cha 5.75E−06 245973 ATP6V1C2 ATPase, H+ transporting, lysosomal 42 kD 5.97E−06 55917 CTTNBP2NL CTTNBP2 N-terminal like 7.89E−06 221395 Gpr116 G protein-coupled receptor 116 9.47E−06 5284 PIGR polymeric immunoglobulin receptor 1.05E−05 6289 SAA2 serum amyloid A2 1.32E−05 157285 SGK223 homolog of rat pragma of Rnd2 1.38E−05 9021 socs3 suppressor of cytokine signaling 3 1.39E−05 56938 ARNTL2 aryl hydrocarbon receptor nuclear trans 1.45E−05 64332 NFKBIZ nuclear factor of kappa light polypepti 1.47E−05 51279 C1RL complement component 1, r subcomponent- 1.65E−05 834 CASP1 caspase 1, apoptosis-related cysteine p 1.69E−05 1191 clu clusterin 1.91E−05 10560 SLC19A2 solute carrier family 19 (thiamine tran 1.94E−05 2321 FLT1 fms-related tyrosine kinase 1 (vascular 2.00E−05 5452 Pou2f2 POU class 2 homeobox 2 2.09E−05 11228 rassf8 Ras association (RalGDS/AF-6) domain fa 2.21E−05 2919 CXCL1 chemokine (C-X-C motif) ligand 1 (melan 2.34E−05 7102 TSPAN7 tetraspanin 7 2.34E−05 64092 SAMSN1 SAM domain, SH3 domain and nuclear loca 2.50E−05 9447 AIM2 absent in melanoma 2 2.54E−05 133418 EMB embigin homolog (mouse) 2.58E−05 3455 IFNAR2 interferon (alpha, beta and omega) rece 2.63E−05 58475 Ms4a7 membrane-spanning 4-domains, subfamily 2.83E−05 54997 TESC tescalcin 2.84E−05 6372 Cxcl6 chemokine (C-X-C motif) ligand 6 (granu 2.87E−05 201633 TIGIT T cell immunoreceptor with Ig and ITIM 2.99E−05 253012 HEPACAM2 HEPACAM family member 2 3.26E−05 118788 Pik3ap1 phosphoinositide-3-kinase adaptor prote 3.32E−05 245972 Atp6v0d2 ATPase, H+ transporting, lysosomal 38 kD 3.34E−05 7852 CXCR4 chemokine (C-X-C motif) receptor 4 3.36E−05 79668 PARP8 poly (ADP-ribose) polymerase family, me 3.42E−05 942 CD86 CD86 molecule 3.51E−05 112597 LOC541471 hypothetical LOC541471; non-protein cod 3.57E−05 58191 CXCL16 chemokine (C-X-C motif) ligand 16 3.58E−05 22982 dip2c DIP2 disco-interacting protein 2 homolo 3.66E−05 11177 BAZ1A bromodomain adjacent to zinc finger dom 3.79E−05 8635 RNASET2 ribonuclease T2 3.82E−05 3273 HRG histidine-rich glycoprotein 3.85E−05 10346 TRIM22 tripartite motif-containing 22 4.00E−05 83988 NCALD neurocalcin delta 4.07E−05 639 PRDM1 PR domain containing 1, with ZNF domain 4.10E−05 83660 TLN2 talin 2 4.11E−05 284996 Rnf149 ring finger protein 149 4.12E−05 4773 NFATC2 nuclear factor of activated T-cells, cy 4.20E−05 5967 REG1A regenerating islet-derived 1 alpha; reg 4.25E−05 9235 IL32 interleukin 32 4.45E−05 27071 dapp1 dual adaptor of phosphotyrosine and 3-p 4.52E−05 7127 TNFAIP2 tumor necrosis factor, alpha-induced pr 4.64E−05 4064 CD180 CD180 molecule 4.81E−05 10859 LILRB1 leukocyte immunoglobulin-like receptor, 4.87E−05 132160 PPM1M protein phosphatase 1M (PP2C domain con 4.95E−05 10381 MC1R tubulin, beta 3; melanocortin 1 recepto 4.96E−05 7049 Tgfbr3 transforming growth factor, beta recept 5.48E−05 8322 FZD4 frizzled homolog 4 (Drosophila) 5.59E−05 25816 TNFAIP8 tumor necrosis factor, alpha-induced pr 5.72E−05 3574 Il7 interleukin 7 5.74E−05 7097 TLR2 toll-like receptor 2 5.81E−05 55016 1-Mar membrane-associated ring finger (C3HC4) 5.85E−05 93349 SP140L SP140 nuclear body protein-like 5.86E−05 3587 IL10RA interleukin 10 receptor, alpha 5.87E−05 9672 sdc3 syndecan 3 5.87E−05 6648 Sod2 superoxide dismutase 2, mitochondrial 5.88E−05 30817 EMR2 egf-like module containing, mucin-like, 5.92E−05 5724 PTAFR platelet-activating factor receptor 5.94E−05 2650 GCNT1 glucosaminyl (N-acetyl) transferase 1, 6.00E−05 441168 fam26f family with sequence similarity 26, mem 6.06E−05 56253 CRTAM cytotoxic and regulatory T cell molecul 6.08E−05 149773 LOC149773 hypothetical protein LOC149773 6.22E−05 115761 ARL11 ADP-ribosylation factor-like 11 6.25E−05 6775 STAT4 signal transducer and activator of tran 6.39E−05 7008 tef thyrotrophic embryonic factor 6.44E−05 222236 NAPEPLD N-acyl phosphatidylethanolamine phospho 6.47E−05 3158 HMGCS2 3-hydroxy-3-methylglutaryl-Coenzyme A s 6.52E−05 1356 CP ceruloplasmin (ferroxidase) 6.55E−05 57224 nhsl1 NHS-like 1 6.56E−05 9535 gmfg glia maturation factor, gamma 7.16E−05 114905 C1qtnf7 C1q and tumor necrosis factor related p 7.18E−05 10123 Arl4c ADP-ribosylation factor-like 4C 7.33E−05 51706 CYB5R1 cytochrome b5 reductase 1 7.42E−05 5552 srgn serglycin 7.47E−05 81619 TSPAN14 tetraspanin 14 7.64E−05 151295 SLC23A3 solute carrier family 23 (nucleobase tr 7.72E−05 55013 CCDC109B coiled-coil domain containing 109B 7.88E−05 6916 TBXAS1 thromboxane A synthase 1 (platelet) 7.88E−05 917 Cd3g CD3g molecule, gamma (CD3-TCR complex) 8.00E−05 55423 SIRPG signal-regulatory protein gamma 8.02E−05 441108 C5orf56 chromosome 5 open reading frame 56 8.13E−05 90826 PRMT10 protein arginine methyltransferase 10 ( 8.32E−05 23231 Sel1l3 KIAA0746 protein 8.35E−05 115330 GPR146 G protein-coupled receptor 146 8.65E−05 84465 Megf11 multiple EGF-like-domains 11 8.72E−05 2634 GBP2 guanylate binding protein 2, interferon 8.89E−05 83416 FCRL5 Fc receptor-like 5 9.17E−05 1326 MAP3K8 mitogen-activated protein kinase kinase 9.36E−05 10585 pomt1 protein-O-mannosyltransferase 1 9.46E−05 80709 Akna AT-hook transcription factor 9.52E−05 5583 PRKCH protein kinase C, eta 9.56E−05 2533 FYB FYN binding protein (FYB-120/130) 0.000101095 710 SERPING1 serpin peptidase inhibitor, clade G (C1 0.000101427 57545 CC2D2A coiled-coil and C2 domain containing 2A 0.000101929 57477 Shroom4 shroom family member 4 0.000102322 27113 BBC3 BCL2 binding component 3 0.000104668 257019 frmd3 FERM domain containing 3 0.000105901 915 CD3D CD3d molecule, delta (CD3-TCR complex) 0.000108676 29851 ICOS inducible T-cell co-stimulator 0.000114201 387357 THEMIS thymocyte selection pathway associated 0.00011469 4065 Ly75 CD302 molecule; lymphocyte antigen 75 0.000116227 4794 Nfkbie nuclear factor of kappa light polypepti 0.000117246 64407 RGS18 regulator of G-protein signaling 18 0.000118196 7052 tgm2 transglutaminase 2 (C polypeptide, prot 0.000120567 2857 GPR34 G protein-coupled receptor 34 0.000120768 128346 C1orf162 chromosome 1 open reading frame 162 0.000123894 3683 ITGAL integrin, alpha L (antigen CD11A (p180) 0.00012454 2123 Evi2a ecotropic viral integration site 2A 0.000127081 55784 MCTP2 multiple C2 domains, transmembrane 2 0.000127734 919 Cd247 CD247 molecule 0.000130792 3226 HOXC10 homeobox C10 0.000133565 83706 fermt3 fermitin family homolog 3 (Drosophila) 0.000135104 7412 Vcam1 vascular cell adhesion molecule 1 0.000136061 9372 zfyve9 zinc finger, FYVE domain containing 9 0.000136444 55920 RCC2 regulator of chromosome condensation 2 0.000136649 5359 plscr1 phospholipid scramblase 1 0.000140346 837 Casp4 caspase 4, apoptosis-related cysteine p 0.000141051 57685 CACHD1 cache domain containing 1 0.00014644 51809 Galnt7 UDP-N-acetyl-alpha-D-galactosamine:poly 0.000149312 29992 PILRA paired immunoglobin-like type 2 recepto 0.000149525 259307 IL4I1 interleukin 4 induced 1 0.000151253 162394 Slfn5 schlafen family member 5 0.000153617 2124 EVI2B ecotropic viral integration site 2B 0.000154185 57580 prex1 phosphatidylinositol-3,4,5-trisphosphat 0.000156406 114614 MIR155 microRNA host gene 2 (non-protein codin 0.000158216 51411 Bin2 bridging integrator 2 0.000159986 4481 Msr1 macrophage scavenger receptor 1 0.000161335 26157 GIMAP2 GTPase, IMAP family member 2 0.000163916 92241 Rcsd1 RCSD domain containing 1 0.000164738 123920 Cmtm3 CKLF-like MARVEL transmembrane domain c 0.000165918 51284 TLR7 toll-like receptor 7 0.000170376 3796 KIF2A kinesin heavy chain member 2A 0.000170538 961 CD47 CD47 molecule 0.000170747 54900 LAX1 lymphocyte transmembrane adaptor 1 0.000173443 23670 Tmem2 transmembrane protein 2 0.000174023 1475 cstA cystatin A (stefin A) 0.00017513 4067 LYN v-yes-1 Yamaguchi sarcoma viral related 0.000175578 10406 WFDC2 WAP four-disulfide core domain 2 0.000180471 7913 Dek DEK oncogene 0.000180846 346389 Macc1 metastasis associated in colon cancer 1 0.000181678 84230 LRRC8C leucine rich repeat containing 8 family 0.000181977 10460 TACC3 transforming, acidic coiled-coil contai 0.000182925 1051 CEBPB CCAAT/enhancer binding protein (C/EBP), 0.000184525 114793 FMNL2 formin-like 2 0.000185065 1794 DOCK2 dedicator of cytokinesis 2 0.000199278 7305 TYROBP TYRO protein tyrosine kinase binding pr 0.00019956 9180 OSMR oncostatin M receptor 0.000202103

TABLE 13 2-Way 2-Step NGS Analysis (AR v. subAR; AR v. TX; and subAR v. TX) using biopsy samples-Results Real\Predicted TX SCAR AR TX 23 0 2 SCAR 0 19 3 AR 0 6 15 % Positive Negative Predictive Sensitivity Specificity Predictive Predicitve Method Classifies Accuracy (%) (%) Value (%) Value (%) AUC Nearest Centroid TX vs. AR  95% 100%  88%  92% 100% 0.943 (2 Step Prediction) TX vs. SCAR 100% 100% 100% 100% 100% 1.000 AR vs. SCAR  79%  76%  83%  83%  72% 0.792

TABLE 14 Blood Microarray Signatures for subAR using a 3-Way 1-Step approach (AR vs. subAR vs. TX): full gene list (818 genes) at FDR < 5% Probeset ID Gene Symbol Gene Title p-value 225640_PM_at LOC401504 hypothetical LOC401504 2.19E−11 222562_PM_s_at TNKS2 tankyrase, TRF1-interacting ankyrin-related 1.57E−10 ADP-ribose polymerase 2 218273_PM_s_at PDP1 pyruvate dehyrogenase phosphatase catalytic 1.44E−09 subunit 1 206848_PM_at FAM36A /// family with sequence similarity 36, member A 8.49E−09 HOXA7 /// homeobox A7 207236_PM_at ZNF345 zinc finger protein 345 1.01E−08 225565_PM_at CREB1 cAMP responsive element binding protein 1 1.23E−08 215342_PM_s_at RABGAP1L RAB GTPase activating protein 1-like 1.85E−08 235461_PM_at TET2 tet oncogene family member 2 2.06E−08 232008_PM_s_at BBX bobby sox homolog (Drosophila) 2.53E−08 230058_PM_at SDCCAG3 serologically defined colon cancer antigen 3 3.73E−08 241955_PM_at HECTD1 HECT domain containing 1 3.86E−08 240554_PM_at AKAP8L A kinase (PRKA) anchor protein 8-like 4.07E−08 214499_PM_s_at BCLAF1 BCL2-associated transcription factor 1 4.21E−08 216450_PM_x_at HSP90B1 heat shock protein 90 kDa beta (Grp94), 4.57E−08 member 1 226404_PM_at RBM39 RNA binding motif protein 39 4.65E−08 222729_PM_at FBXW7 F-box and WD repeat domain containing 7 6.21E−08 222538_PM_s_at APPL1 adaptor protein, phosphotyrosine interaction, 6.21E−08 PH domain and leucine zipper containing 1 214045_PM_at LIAS lipoic acid synthetase 7.24E−08 215220_PM_s_at TPR translocated promoter region (to activated 8.45E−08 MET oncogene) 1557193_PM_at EST1557193_PM_at — 9.35E−08 225551_PM_at CNST consortin, connexin sorting protein 1.06E−07 235811_PM_at EST235811_PM_at — 1.11E−07 1558747_PM_at SMCHD1 structural maintenance of chromosomes 1.22E−07 flexible hinge domain containing 1 214496_PM_x_at MYST4 MYST histone acetyltransferase (monocytic 1.35E−07 leukemia) 4 222406_PM_s_at PNRC2 proline-rich nuclear receptor coactivator 2 1.43E−07 212417_PM_at SCAMP1 secretory carrier membrane protein 1 1.78E−07 227144_PM_at C22orf9 chromosome 22 open reading frame 9 1.98E−07 244611_PM_at MED13 Mediator complex subunit 13 2.23E−07 219024_PM_at PLEKHA1 pleckstrin homology domain containing, 2.62E−07 family A (phosphoinositide binding specific) mem 1559051_PM_s_at C6orf150 chromosome 6 open reading frame 150 2.78E−07 231418_PM_at EST231418_PM_at — 2.88E−07 202818_PM_s_at TCEB3 transcription elongation factor B (SIII), 3.30E−07 polypeptide 3 (110 kDa, elongin A) 201728_PM_s_at KIAA0100 KIAA0100 3.32E−07 201083_PM_s_at BCLAF1 BCL2-associated transcription factor 1 3.64E−07 208615_PM_s_at PTP4A2 protein tyrosine phosphatase type IVA, 3.88E−07 member 2 200745_PM_s_at GNB1 guanine nucleotide binding protein (G 4.45E−07 protein), beta polypeptide 1 215586_PM_at EST215586_PM_at — 4.62E−07 228801_PM_at ORMDL1 ORM1-like 1 (S. cerevisiae) 5.52E−07 208879_PM_x_at PRPF6 PRP6 pre-mRNA processing factor 6 homolog 5.70E−07 (S. cerevisiae) 208003_PM_s_at NFAT5 nuclear factor of activated T-cells 5, tonicity- 6.96E−07 responsive 216449_PM_x_at HSP90B1 heat shock protein 90 kDa beta (Grp94), 7.21E−07 member 1 201235_PM_s_at BTG2 BTG family, member 2 8.31E−07 236484_PM_at EST236484_PM_at — 1.02E−06 227082_PM_at EST227082_PM_at — 1.21E−06 236841_PM_at LOC100134445 hypothetical LOC100134445 1.27E−06 236207_PM_at SSFA2 sperm specific antigen 2 1.28E−06 215282_PM_at ANAPC13 anaphase promoting complex subunit 13 1.58E−06 1555568_PM_at GUSBL1 glucuronidase, beta-like 1 1.60E−06 236512_PM_at EST236512_PM_at — 1.85E−06 224687_PM_at ANKIB1 ankyrin repeat and IBR domain containing 1 2.08E−06 202719_PM_s_at TES testis derived transcript (3 LIM domains) 2.27E−06 213311_PM_s_at TCF25 transcription factor 25 (basic helix-loop-helix) 2.29E−06 229193_PM_at LUC7L3 LUC7-like 3 (S. cerevisiae) 2.33E−06 221905_PM_at CYLD cylindromatosis (turban tumor syndrome) 2.48E−06 217418_PM_x_at MS4A1 membrane-spanning 4-domains, subfamily A, 2.73E−06 member 1 217234_PM_s_at EZR ezrin 2.75E−06 222866_PM_s_at FLVCR2 feline leukemia virus subgroup C cellular 2.78E−06 receptor family, member 2 209207_PM_s_at SEC22B SEC22 vesicle trafficking protein homolog B (S. 2.80E−06 cerevisiae) (gene/pseudogene) 232127_PM_at CLCN5 chloride channel 5 2.82E−06 243559_PM_at EST243559_PM_at — 3.05E−06 241668_PM_s_at EST241668_PM_s_at — 3.13E−06 203145_PM_at SPAG5 sperm associated antigen 5 3.17E−06 235430_PM_at C14orf43 chromosome 14 open reading frame 43 4.05E−06 222628_PM_s_at REV1 REV1 homolog (S. cerevisiae) 4.08E−06 209920_PM_at BMPR2 bone morphogenetic protein receptor, type II 4.18E−06 (serine/threonine kinase) 206668_PM_s_at SCAMP1 secretory carrier membrane protein 1 4.29E−06 1555562_PM_a_at ZCCHC7 zinc finger, CCHC domain containing 7 4.31E−06 1562031_PM_at JAK2 Janus kinase 2 4.42E−06 236109_PM_at EST236109_PM_at — 4.50E−06 200598_PM_s_at HSP90B1 heat shock protein 90 kDa beta (Grp94), 4.92E−06 member 1 210356_PM_x_at MS4A1 membrane-spanning 4-domains, subfamily A, 5.02E−06 member 1 240859_PM_at EST240859_PM_at — 5.15E−06 202173_PM_s_at VEZF1 vascular endothelial zinc finger 1 5.21E−06 200900_PM_s_at M6PR mannose-6-phosphate receptor (cation 5.75E−06 dependent) 212027_PM_at RBM25 RNA binding motif protein 25 5.96E−06 222915_PM_s_at BANK1 B-cell scaffold protein with ankyrin repeats 1 6.07E−06 230028_PM_at EST230028_PM_at — 6.08E−06 200950_PM_at ARPC1A actin related protein 2/3 complex, subunit 1A, 6.24E−06 41 kDa 240220_PM_at EST240220_PM_at — 6.48E−06 204565_PM_at ACOT13 acyl-CoA thioesterase 13 6.48E−06 210172_PM_at SF1 splicing factor 1 6.66E−06 1554249_PM_a_at ZNF638 zinc finger protein 638 6.73E−06 228818_PM_at EST228818_PM_at — 6.88E−06 212574_PM_x_at C19orf6 chromosome 19 open reading frame 6 7.23E−06 239077_PM_at CSGALNACT2 chondroitin sulfate N- 7.51E−06 acetylgalactosaminyltransferase 2 209281_PM_s_at ATP2B1 ATPase, Ca++ transporting, plasma membrane 7.92E−06 1 224989_PM_at EST224989_PM_at — 7.93E−06 240718_PM_at LRMP Lymphoid-restricted membrane protein 8.17E−06 229268_PM_at FAM105B family with sequence similarity 105, member 8.39E−06 B 203141_PM_s_at AP3B1 adaptor-related protein complex 3, beta 1 8.46E−06 subunit 236254_PM_at VPS13B vacuolar protein sorting 13 homolog B (yeast) 8.55E−06 216263_PM_s_at NGDN neuroguidin, EIF4E binding protein 8.70E−06 235119_PM_at TAF3 TAF3 RNA polymerase II, TATA box binding 8.72E−06 protein (TBP)-associated factor, 140 kDa 213649_PM_at SRSF7 serine/arginine-rich splicing factor 7 8.73E−06 1559485_PM_at ATG2B ATG2 autophagy related 2 homolog B (S. 9.15E−06 cerevisiae) 243414_PM_at PPIL2 Peptidylprolyl isomerase (cyclophilin)-like 2 9.30E−06 212658_PM_at LHFPL2 lipoma HMGIC fusion partner-like 2 9.40E−06 AFFX-r2-Bs-dap-5_at ESTAFFX-r2-Bs-dap- — 9.55E−06 5_at 230466_PM_s_at EST230466_PM_s_at — 9.98E−06 240690_PM_at EST240690_PM_at — 1.01E−05 236414_PM_at EST236414_PM_at — 1.02E−05 241702_PM_at EST241702_PM_at — 1.07E−05 202631_PM_s_at APPBP2 amyloid beta precursor protein (cytoplasmic 1.15E−05 tail) binding protein 2 224350_PM_at EST224350_PM_at — 1.16E−05 217896_PM_s_at FAM192A family with sequence similarity 192, member 1.17E−05 A 239046_PM_at EST239046_PM_at — 1.20E−05 1564063_PM_a_at ATP11B ATPase, class VI, type 11B 1.23E−05 243206_PM_at EST243206_PM_at — 1.24E−05 238506_PM_at LRRC58 leucine rich repeat containing 58 1.27E−05 210042_PM_s_at CTSZ cathepsin Z 1.32E−05 227410_PM_at FAM43A family with sequence similarity 43, member A 1.37E−05 1557529_PM_at C12orf51 chromosome 12 open reading frame 51 1.39E−05 1552978_PM_a_at SCAMP1 secretory carrier membrane protein 1 1.39E−05 213272_PM_s_at TMEM159 transmembrane protein 159 1.39E−05 244090_PM_at EST244090_PM_at — 1.40E−05 229033_PM_s_at MUM1 melanoma associated antigen (mutated) 1 1.42E−05 1565852_PM_at EST1565852_PM_at — 1.52E−05 216069_PM_at EST216069_PM_at — 1.53E−05 216915_PM_s_at PTPN12 protein tyrosine phosphatase, non-receptor 1.60E−05 type 12 1557895_PM_at FLJ35934 FLJ35934 1.66E−05 240613_PM_at JAK1 Janus kinase 1 1.73E−05 241755_PM_at UQCRC2 ubiquinol-cytochrome c reductase core 1.74E−05 protein II 1561058_PM_at EST — 1.75E−05 1561058_PM_at 222633_PM_at TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 1.78E−05 207318_PM_s_at CDK13 cyclin-dependent kinase 13 1.82E−05 203823_PM_at RGS3 regulator of G-protein signaling 3 1.83E−05 242049_PM_s_at NBAS neuroblastoma amplified sequence 1.83E−05 1559397_PM_s_at PRR14 proline rich 14 1.87E−05 1555185_PM_x_at TERF2 telomeric repeat binding factor 2 1.96E−05 204199_PM_at RALGPS1 Ral GEF with PH domain and SH3 binding 2.00E−05 motif 1 217818_PM_s_at ARPC4 actin related protein 2/3 complex, subunit 4, 2.04E−05 20 kDa 230404_PM_at FLJ44606 glutaredoxin-like protein YDR286C homolog 2.05E−05 237184_PM_at EST237184_PM_at — 2.11E−05 219498_PM_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 2.11E−05 213688_PM_at CALM1 calmodulin 1 (phosphorylase kinase, delta) 2.13E−05 201777_PM_s_at KIAA0494 KIAA0494 2.15E−05 213235_PM_at C16orf88 chromosome 16 open reading frame 88 2.15E−05 236524_PM_at EST236524_PM_at — 2.16E−05 235547_PM_at N4BP2L2 NEDD4 binding protein 2-like 2 2.20E−05 224684_PM_at SNX12 sorting nexin 12 2.22E−05 212467_PM_at DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 2.23E−05 13 1553304_PM_at LSM14B LSM14B, SCD6 homolog B (S. cerevisiae) 2.44E−05 215489_PM_x_at HOMER3 homer homolog 3 (Drosophila) 2.44E−05 220843_PM_s_at DCAF13 DDB1 and CUL4 associated factor 13 2.52E−05 223217_PM_s_at NFKBIZ nuclear factor of kappa light polypeptide gene 2.59E−05 enhancer in B-cells inhibitor, zeta 232323_PM_s_at TTC17 tetratricopeptide repeat domain 17 2.60E−05 232353_PM_s_at STYXL1 serine/threonine/tyrosine interacting-like 1 2.65E−05 1563674_PM_at FCRL2 Fc receptor-like 2 2.69E−05 208325_PM_s_at AKAP13 A kinase (PRKA) anchor protein 13 2.71E−05 1560814_PM_a_at C15orf57 chromosome 15 open reading frame 57 2.77E−05 201085_PM_s_at SON SON DNA binding protein 2.77E−05 1568680_PM_s_at YTHDC2 YTH domain containing 2 2.80E−05 217979_PM_at TSPAN13 tetraspanin 13 2.82E−05 241237_PM_at EST241237_PM_at — 2.85E−05 243739_PM_at EST243739_PM_at — 5.74E−05 212022_PM_s_at MKI67 antigen identified by monoclonal antibody Ki- 3.10E−05 67 236562_PM_at ZNF439 zinc finger protein 439 3.12E−05 214869_PM_x_at GAPVD1 GTPase activating protein and VPS9 domains 1 3.14E−05 1553961_PM_s_at SNX21 sorting nexin family member 21 3.17E−05 203958_PM_s_at ZBTB40 zinc finger and BTB domain containing 40 3.24E−05 240593_PM_x_at EST240593_PM_x_at — 3.31E−05 216901_PM_s_at IKZF1 IKAROS family zinc finger 1 (Ikaros) 3.34E−05 225878_PM_at KIF1B kinesin family member 1B 3.42E−05 224818_PM_at SORT1 sortilin 1 3.47E−05 225240_PM_s_at MSI2 musashi homolog 2 (Drosophila) 3.51E−05 222522_PM_x_at MRPS10 mitochondrial ribosomal protein S10 3.56E−05 228147_PM_at EST228147_PM_at — 3.62E−05 222575_PM_at SETD5 SET domain containing 5 3.75E−05 214474_PM_at PRKAB2 protein kinase, AMP-activated, beta 2 non- 3.80E−05 catalytic subunit 233409_PM_at RHBDL3 rhomboid, veinlet-like 3 (Drosophila) 3.84E−05 239815_PM_at EST239815_PM_at — 3.95E−05 213998_PM_s_at DDX17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 4.03E−05 AFFX-DapX-5_at ESTAFFX-DapX-5_at — 4.20E−05 1567045_PM_at EST1567045_PM_at — 4.23E−05 204324_PM_s_at GOLIM4 golgi integral membrane protein 4 4.27E−05 208835_PM_s_at LUC7L3 LUC7-like 3 (S. cerevisiae) 4.40E−05 210214_PM_s_at BMPR2 bone morphogenetic protein receptor, type II 4.41E−05 (serine/threonine kinase) 210282_PM_at ZMYM2 zinc finger, MYM-type 2 4.44E−05 222873_PM_s_at EHMT1 euchromatic histone-lysine N- 4.44E−05 methyltransferase 1 243932_PM_at EST243932_PM_at — 4.63E−05 1568907_PM_at EST1568907_PM_at — 4.65E−05 208797_PM_s_at GOLGA8A golgin A8 family, member A 4.69E−05 218393_PM_s_at SMU1 smu-1 suppressor of mec-8 and unc-52 4.69E−05 homolog (C. elegans) 239027_PM_at DOCK8 dedicator of cytokinesis 8 4.74E−05 215894_PM_at PTGDR prostaglandin D2 receptor (DP) 4.82E−05 208114_PM_s_at ISG20L2 interferon stimulated exonuclease gene 4.83E−05 20 kDa-like 2 212076_PM_at MLL myeloid/lymphoid or mixed-lineage leukemia 4.90E−05 (trithorax homolog, Drosophila) 222326_PM_at EST222326_PM_at — 5.04E−05 215603_PM_x_at GGT2 gamma-glutamyltransferase 2 5.04E−05 224933_PM_s_at JMJD1C jumonji domain containing 1C 5.08E−05 242197_PM_x_at CD36 CD36 molecule (thrombospondin receptor) 5.28E−05 230629_PM_s_at EP400 E1A binding protein p400 5.31E−05 243361_PM_at SREK1 splicing regulatory glutamine/lysine-rich 5.32E−05 protein 1 237884_PM_x_at TRPM7 transient receptor potential cation channel, 5.35E−05 subfamily M, member 7 236557_PM_at ZBTB38 zinc finger and BTB domain containing 38 5.36E−05 223307_PM_at CDCA3 cell division cycle associated 3 5.42E−05 218321_PM_x_at STYXL1 serine/threonine/tyrosine interacting-like 1 5.48E−05 205179_PM_s_at ADAM8 ADAM metallopeptidase domain 8 5.49E−05 227329_PM_at ZBTB46 zinc finger and BTB domain containing 46 5.67E−05 222395_PM_s_at UBE2Z ubiquitin-conjugating enzyme E2Z 5.69E−05 201488_PM_x_at KHDRBS1 KH domain containing, RNA binding, signal 5.72E−05 transduction associated 1 200806_PM_s_at HSPD1 heat shock 60 kDa protein 1 (chaperonin) 5.73E−05 244233_PM_at C18orf10 chromosome 18 open reading frame 10 0.000168658 225098_PM_at ABI2 abl-interactor 2 5.74E−05 222540_PM_s_at RSF1 remodeling and spacing factor 1 5.82E−05 242422_PM_at G3BP1 GTPase activating protein (SH3 domain) 5.85E−05 binding protein 1 206371_PM_at FOLR3 folate receptor 3 (gamma) 5.98E−05 204270_PM_at SKI v-ski sarcoma viral oncogene homolog (avian) 5.99E−05 207826_PM_s_at ID3 inhibitor of DNA binding 3, dominant negative 6.00E−05 helix-loop-helix protein 235216_PM_at ESCO1 establishment of cohesion 1 homolog 1 (S. 6.01E−05 cerevisiae) 1558088_PM_a_at UBE2I ubiquitin-conjugating enzyme E2I (UBC9 6.18E−05 homolog, yeast) 206521_PM_s_at GTF2A1 general transcription factor IIA, 1, 19/37 kDa 6.21E−05 210693_PM_at SPPL2B signal peptide peptidase-like 2B 6.27E−05 202953_PM_at C1QB complement component 1, q subcomponent, 6.31E−05 B chain 227918_PM_s_at ZYG11B zyg-11 homolog B (C. elegans) 6.37E−05 223569_PM_at PPAPDC1B phosphatidic acid phosphatase type 2 domain 6.43E−05 containing 1B 215667_PM_x_at LOC441259 /// PMS2L2 PMS2 postmeiotic segregation increased 2 (S. 6.50E−05 /// PMS2P1 /// cerevisiae)-like /// postmeiotic segregati PMS2P6 222563_PM_s_at TNKS2 tankyrase, TRF1-interacting ankyrin-related 6.50E−05 ADP-ribose polymerase 2 209076_PM_s_at WDR45L WDR45-like 6.56E−05 233261_PM_at EBF1 Early B-cell factor 1 6.68E−05 229389_PM_at ATG16L2 ATG16 autophagy related 16-like 2 (S. 6.70E−05 cerevisiae) 223969_PM_s_at RETNLB resistin like beta 6.72E−05 228868_PM_x_at CDT1 Chromatin licensing and DNA replication 6.80E−05 factor 1 1558173_PM_a_at LUZP1 leucine zipper protein 1 6.90E−05 243319_PM_at EST243319_PM_at — 6.92E−05 203479_PM_s_at OTUD4 OTU domain containing 4 7.03E−05 35201_PM_at HNRNPL heterogeneous nuclear ribonucleoprotein L 7.13E−05 244696_PM_at EST244696_PM_at — 7.18E−05 202705_PM_at CCNB2 cyclin B2 7.25E−05 239154_PM_at EST239154_PM_at — 7.31E−05 230270_PM_at PRPF38B PRP38 pre-mRNA processing factor 38 (yeast) 7.31E−05 domain containing B 209583_PM_s_at CD200 CD200 molecule 7.37E−05 214250_PM_at NUMA1 nuclear mitotic apparatus protein 1 7.37E−05 222508_PM_s_at ARGLU1 arginine and glutamate rich 1 7.38E−05 201347_PM_x_at GRHPR glyoxylate reductase/hydroxypyruvate 7.44E−05 reductase 1552812_PM_a_at SENP1 SUMO1/sentrin specific peptidase 1 7.83E−05 202773_PM_s_at SFSWAP splicing factor, suppressor of white-apricot 8.00E−05 homolog (Drosophila) AFFX-r2-Bs-dap-M_at ESTAFFX-r2-Bs-dap- — 8.02E−05 M_at 218474_PM_s_at KCTD5 potassium channel tetramerisation domain 0.000187936 containing 5 209582_PM_s_at CD200 CD200 molecule 8.08E−05 211417_PM_x_at GGT1 gamma-glutamyltransferase 1 8.10E−05 201996_PM_s_at SPEN spen homolog, transcriptional regulator 8.45E−05 (Drosophila) 222996_PM_s_at CXXC5 CXXC finger protein 5 8.51E−05 215937_PM_at PTGDR prostaglandin D2 receptor (DP) 8.56E−05 230424_PM_at C5orf13 chromosome 5 open reading frame 13 8.66E−05 203796_PM_s_at BCL7A B-cell CLL/lymphoma 7A 8.88E−05 241619_PM_at CALM1 calmodulin 1 (phosphorylase kinase, delta) 8.90E−05 238277_PM_at EST238277_PM_at — 9.06E−05 208268_PM_at ADAM28 ADAM metallopeptidase domain 28 9.25E−05 226079_PM_at FLYWCH2 FLYWCH family member 2 9.43E−05 212119_PM_at RHOQ ras homolog gene family, member Q 9.49E−05 235956_PM_at KIAA1377 KIAA1377 9.61E−05 230245_PM_s_at LOC283663 hypothetical LOC283663 9.61E−05 1559589_PM_a_at EST1559589_PM_a_at — 9.62E−05 AFFX-M27830_5_at ESTAFFX-M27830_5_at — 9.63E−05 219751_PM_at SETD6 SET domain containing 6 9.94E−05 207655_PM_s_at BLNK B-cell linker 0.000100294 227849_PM_at RP9 Retinitis pigmentosa 9 (autosomal dominant) 0.000100349 243236_PM_at EST243236_PM_at — 0.000100441 1556983_PM_a_at EST1556983_PM_a_at — 0.000101358 201537_PM_s_at DUSP3 dual specificity phosphatase 3 0.000102353 203276_PM_at LMNB1 lamin B1 0.000103605 1555913_PM_at GON4L gon-4-like (C. elegans) 0.00010638 244011_PM_at PPM1K protein phosphatase, Mg2+/Mn2+ 0.000106418 dependent, 1K 226647_PM_at TMEM25 transmembrane protein 25 0.000107452 221220_PM_s_at SCYL2 SCY1-like 2 (S. cerevisiae) 0.000109068 227101_PM_at ZNF800 zinc finger protein 800 0.000109971 231235_PM_at NKTR natural killer-tumor recognition sequence 0.000112022 235112_PM_at EST235112_PM_at — 0.000112143 215270_PM_at LFNG LFNG O-fucosylpeptide 3-beta-N- 0.000113268 acetylglucosaminyltransferase 224918_PM_x_at MGST1 microsomal glutathione S-transferase 1 0.000120191 243381_PM_at EST243381_PM_at — 0.000121699 227173_PM_s_at BACH2 BTB and CNC homology 1, basic leucine zipper 0.000122183 transcription factor 2 201236_PM_s_at BTG2 BTG family, member 2 0.000124084 235003_PM_at UHMK1 U2AF homology motif (UHM) kinase 1 0.000124901 206983_PM_at CCR6 chemokine (C-C motif) receptor 6 0.000129751 206708_PM_at FOXN2 forkhead box N2 0.000130568 233955_PM_x_at CXXC5 CXXC finger protein 5 0.000132557 238743_PM_at EST238743_PM_at — 0.000133124 239130_PM_at MIR101-1 microRNA 101-1 0.000133903 208478_PM_s_at BAX BCL2-associated X protein 0.000134313 213315_PM_x_at CXorf40A chromosome X open reading frame 40A 0.000134499 227894_PM_at WDR90 WD repeat domain 90 0.000134921 212382_PM_at TCF4 transcription factor 4 0.000135201 209773_PM_s_at RRM2 ribonucleotide reductase M2 0.000137305 1561872_PM_at EST1561872_PM_at — 0.000138018 212961_PM_x_at CXorf40B chromosome X open reading frame 40B 0.000140653 240521_PM_at EST240521_PM_at — 0.000142199 222922_PM_at KCNE3 potassium voltage-gated channel, Isk-related 0.000142431 family, member 3 232070_PM_at LOC100499193 hypothetical LOC100499193 0.000144063 217230_PM_at EZR ezrin 0.000144366 233252_PM_s_at STRBP spermatid perinuclear RNA binding protein 0.000145405 228643_PM_at EST228643_PM_at — 0.000147578 214352_PM_s_at KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene 0.000148531 homolog AFFX-DapX-M_at ESTAFFX-DapX-M_at — 0.000148867 235376_PM_at EST235376_PM_at — 0.000150505 223701_PM_s_at USP47 ubiquitin specific peptidase 47 0.000151065 231823_PM_s_at SH3PXD2B SH3 and PX domains 2B 0.000151285 222891_PM_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 0.000151761 207629_PM_s_at ARHGEF2 Rho/Rac guanine nucleotide exchange factor 0.000153859 (GEF) 2 1558662_PM_s_at BANK1 B-cell scaffold protein with ankyrin repeats 1 0.000156425 243798_PM_at EST243798_PM_at — 0.000157554 222787_PM_s_at TMEM106B transmembrane protein 106B 0.000158414 215621_PM_s_at IGHD immunoglobulin heavy constant delta 0.000158835 236820_PM_at EST236820_PM_at — 0.000159122 221962_PM_s_at UBE2H ubiquitin-conjugating enzyme E2H (UBC8 0.000159574 homolog, yeast) 229072_PM_at EST229072_PM_at — 0.000160113 223568_PM_s_at PPAPDC1B phosphatidic acid phosphatase type 2 domain 0.000160614 containing 1B 224472_PM_x_at SDF4 stromal cell derived factor 4 0.000164081 239497_PM_at EST239497_PM_at — 0.000164848 224592_PM_x_at HP1BP3 heterochromatin protein 1, binding protein 3 0.000165271 235288_PM_at EST235288_PM_at — 0.000165435 205419_PM_at GPR183 G protein-coupled receptor 183 0.000166502 241205_PM_at EST241205_PM_at — 0.000167418 209926_PM_at LOC729991 hypothetical protein LOC729991 0.000168054 202004_PM_x_at SDHC succinate dehydrogenase complex, subunit C, 0.000168296 integral membrane protein, 15 kDa 201918_PM_at SLC25A36 solute carrier family 25, member 36 0.000168448 225179_PM_at UBE2K ubiquitin-conjugating enzyme E2K (UBC1 0.000308015 homolog, yeast) 237340_PM_at SLC26A8 solute carrier family 26, member 8 0.000170412 212807_PM_s_at SORT1 sortilin 1 0.000170978 208814_PM_at HSPA4 heat shock 70 kDa protein 4 0.000175793 236198_PM_at EST236198_PM_at — 0.000181184 236375_PM_at EST236375_PM_at — 0.000182487 223860_PM_at EST223860_PM_at — 0.000183192 217606_PM_at EST217606_PM_at — 0.000183954 202082_PM_s_at SEC14L1 SEC14-like 1 (S. cerevisiae) 0.000184816 216401_PM_x_at EST216401_PM_x_at — 0.000184974 226975_PM_at RNPC3 RNA-binding region (RNP1, RRM) containing 3 0.0004054 229353_PM_s_at NUCKS1 nuclear casein kinase and cyclin-dependent 0.000188103 kinase substrate 1 239292_PM_at EST239292_PM_at — 0.000188651 200921_PM_s_at BTG1 B-cell translocation gene 1, anti-proliferative 0.000189007 242225_PM_at EST242225_PM_at — 0.000191962 231736_PM_x_at MGST1 microsomal glutathione S-transferase 1 0.000192368 207165_PM_at HMMR hyaluronan-mediated motility receptor 0.000192879 (RHAMM) 1555978_PM_s_at EST1555978_PM_s_at — 0.000201472 226879_PM_at HVCN1 hydrogen voltage-gated channel 1 0.00020194 221234_PM_s_at BACH2 BTB and CNC homology 1, basic leucine zipper 0.000202403 transcription factor 2 AFFX-r2-Bs-lys-3_at ESTAFFX-r2-Bs-lys-3_at — 0.000203767 226968_PM_at KIF1B kinesin family member 1B 0.000204386 210384_PM_at PRMT2 protein arginine methyltransferase 2 0.000207517 219667_PM_s_at BANK1 B-cell scaffold protein with ankyrin repeats 1 0.000209859 202723_PM_s_at FOXO1 forkhead box O1 0.000210019 211217_PM_s_at KCNQ1 potassium voltage-gated channel, KQT-like 0.000210371 subfamily, member 1 238511_PM_at LOC440288 similar to FLJ16518 protein 0.000211154 221601_PM_s_at FAIM3 Fas apoptotic inhibitory molecule 3 0.000212934 219806_PM_s_at C11orf75 chromosome 11 open reading frame 75 0.000213004 210596_PM_at MAGT1 magnesium transporter 1 0.000217053 226008_PM_at NDNL2 necdin-like 2 0.000219345 213517_PM_at PCBP2 poly(rC) binding protein 2 0.000220506 1569894_PM_at PPP2R3C protein phosphatase 2, regulatory subunit B″, 0.000220967 gamma 211074_PM_at FOLR1 folate receptor 1 (adult) 0.000225092 226094_PM_at PIK3C2A phosphoinositide-3-kinase, class 2, alpha 0.0002278 polypeptide 202371_PM_at TCEAL4 transcription elongation factor A (SII)-like 4 0.000228612 201072_PM_s_at SMARCC1 SWI/SNF related, matrix associated, actin 0.000229302 dependent regulator of chromatin, subfamily c 215457_PM_at EST215457_PM_at — 0.000230542 220436_PM_at CNTNAP3B similar to cell recognition molecule CASPR3 0.000231163 200810_PM_s_at CIRBP cold inducible RNA binding protein 0.000233312 201073_PM_s_at SMARCC1 SWI/SNF related, matrix associated, actin 0.000233789 dependent regulator of chromatin, subfamily c 235852_PM_at STON2 Stonin 2 0.000236399 1569385_PM_s_at TET2 tet oncogene family member 2 0.000237687 228592_PM_at MS4A1 membrane-spanning 4-domains, subfamily A, 0.000238044 member 1 205726_PM_at DIAPH2 diaphanous homolog 2 (Drosophila) 0.000239122 223766_PM_at LOC100133130 PRO1102 0.000240505 228487_PM_s_at EST228487_PM_s_at — 0.000243645 231340_PM_at EST231340_PM_at — 0.000244821 222228_PM_s_at ALKBH4 alkB, alkylation repair homolog 4 (E. coli) 0.000246256 202072_PM_at HNRNPL heterogeneous nuclear ribonucleoprotein L 0.000246632 206881_PM_s_at LILRA3 leukocyte immunoglobulin-like receptor, 0.000247423 subfamily A (without TM domain), member 3 230128_PM_at IGL@ Immunoglobulin lambda locus 0.000247531 209060_PM_x_at NCOA3 nuclear receptor coactivator 3 0.000247993 1557270_PM_at EST1557270_PM_at — 0.000249224 233078_PM_at API5 apoptosis inhibitor 5 0.000253409 1553793_PM_a_at KIAA1109 KIAA1109 0.000254467 215339_PM_at NKTR natural killer-tumor recognition sequence 0.000255637 1556314_PM_a_at EST1556314_PM_a_at — 0.000255826 208079_PM_s_at AURKA aurora kinase A 0.000257743 218300_PM_at C16orf53 chromosome 16 open reading frame 53 0.000258687 1556461_PM_at EST1556461_PM_at — 0.000259468 1558733_PM_at ZBTB38 zinc finger and BTB domain containing 38 0.000260942 225742_PM_at MDM4 Mdm4 p53 binding protein homolog (mouse) 0.000264828 204028_PM_s_at RABGAP1 RAB GTPase activating protein 1 0.000265807 1559618_PM_at LOC100129447 hypothetical protein LOC100129447 0.000268803 1564494_PM_s_at P4HB prolyl 4-hydroxylase, beta polypeptide 0.000269853 212452_PM_x_at MYST4 MYST histone acetyltransferase (monocytic 0.000270084 leukemia) 4 201960_PM_s_at MYCBP2 MYC binding protein 2 0.000275031 1561286_PM_a_at DIP2A DIP2 disco-interacting protein 2 homolog A 0.000276434 (Drosophila) 219581_PM_at TSEN2 tRNA splicing endonuclease 2 homolog (S. 0.000276518 cerevisiae) 242946_PM_at EST242946_PM_at — 0.000277157 212684_PM_at ZNF3 zinc finger protein 3 0.00028112 214669_PM_x_at IGK@ /// IGKC immunoglobulin kappa locus /// 0.000282936 immunoglobulin kappa constant 217613_PM_at TMEM144 transmembrane protein 144 0.000285003 238811_PM_at ATP11B ATPase, class VI, type 11B 0.000286178 218039_PM_at NUSAP1 nucleolar and spindle associated protein 1 0.000287635 225095_PM_at SPTLC2 serine palmitoyltransferase, long chain base 0.000289913 subunit 2 208799_PM_at PSMB5 proteasome (prosome, macropain) subunit, 0.00029164 beta type, 5 230897_PM_at CCDC30 /// coiled-coil domain containing 30 /// 0.000292704 LOC100507214 hypothetical LOC100507214 214735_PM_at IPCEF1 interaction protein for cytohesin exchange 0.00029714 factors 1 239545_PM_at EST239545_PM_at — 0.000297175 243780_PM_at EST243780_PM_at — 0.000297494 201689_PM_s_at TPD52 tumor protein D52 0.000298768 209919_PM_x_at GGT1 gamma-glutamyltransferase 1 0.000299895 210052_PM_s_at TPX2 TPX2, microtubule-associated, homolog 0.000301428 (Xenopus laevis) 209994_PM_s_at ABCB1 /// ABCB4 ATP-binding cassette, sub-family B 0.000302891 (MDR/TAP), member 1 /// ATP-binding cassette, sub-fa 227466_PM_at FAM200B family with sequence similarity 200, member 0.000303971 B 209797_PM_at CNPY2 canopy 2 homolog (zebrafish) 0.000304017 229157_PM_at LOC100505483 hypothetical LOC100505483 0.000307218 201805_PM_at PRKAG1 protein kinase, AMP-activated, gamma 1 non- 0.000307861 catalytic subunit AFFX-r2-P1-cre-3_at ESTAFFX-r2-P1-cre-3_at — 0.000472245 200607_PM_s_at RAD21 RAD21 homolog (S. pombe) 0.00031137 212113_PM_at ATXN7L3B ataxin 7-like 3B 0.000314652 236327_PM_at EST236327_PM_at — 0.000315612 224795_PM_x_at IGK@ /// IGKC immunoglobulin kappa locus /// 0.000316664 immunoglobulin kappa constant 240826_PM_at EST240826_PM_at — 0.000318564 237560_PM_at MRPS5 Mitochondrial ribosomal protein S5 0.000320215 239902_PM_at EST239902_PM_at — 0.000322709 201825_PM_s_at SCCPDH saccharopine dehydrogenase (putative) 0.00032353 240965_PM_at EST240965_PM_at — 0.000324754 217813_PM_s_at SPIN1 spindlin 1 0.00032924 205770_PM_at GSR glutathione reductase 0.000330346 214263_PM_x_at POLR2C polymerase (RNA) II (DNA directed) 0.000331556 polypeptide C, 33 kDa 214677_PM_x_at IGL@ /// Immunoglobulin lambda locus /// 0.000332453 LOC100287927 Hypothetical protein LOC100287927 244456_PM_at EST244456_PM_at — 0.000333092 221651_PM_x_at IGK@ /// IGKC immunoglobulin kappa locus /// 0.000333367 immunoglobulin kappa constant 236650_PM_at EST236650_PM_at — 0.000337191 220946_PM_s_at SETD2 SET domain containing 2 0.000337367 224516_PM_s_at CXXC5 CXXC finger protein 5 0.000337471 212581_PM_x_at GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.000338308 212492_PM_s_at KDM4B lysine (K)-specific demethylase 4B 0.000338683 221969_PM_at PAX5 paired box 5 0.000340498 242498_PM_x_at EST242498_PM_x_at — 0.000342507 222737_PM_s_at BRD7 bromodomain containing 7 0.00034288 204714_PM_s_at F5 coagulation factor V (proaccelerin, labile 0.000343146 factor) 203671_PM_at TPMT thiopurine S-methyltransferase 0.000344362 225353_PM_s_at C1QC complement component 1, q subcomponent, 0.000345493 C chain 225709_PM_at ARL6IP6 ADP-ribosylation-like factor 6 interacting 0.000345892 protein 6 237040_PM_at CWF19L2 CWF19-like 2, cell cycle control (S. pombe) 0.000346442 226731_PM_at ITGA1 integrin, alpha 1 0.000348057 AFFX-r2-Bs-phe-5_at ESTAFFX-r2-Bs-phe- — 0.000348063 5_at 205467_PM_at CASP10 caspase 10, apoptosis-related cysteine 0.000348547 peptidase 209001_PM_s_at ANAPC13 anaphase promoting complex subunit 13 0.000349407 233982_PM_x_at STYXL1 serine/threonine/tyrosine interacting-like 1 0.000350724 239040_PM_at HNRNPD Heterogeneous nuclear ribonucleoprotein D 0.00035153 (AU-rich element RNA binding protein 1, 37 kDa 205756_PM_s_at F8 coagulation factor VIII, procoagulant 0.000357136 component 1554229_PM_at C5orf41 chromosome 5 open reading frame 41 0.00035719 1568877_PM_a_at ACBD5 acyl-CoA binding domain containing 5 0.000360867 207707_PM_s_at SEC13 SEC13 homolog (S. cerevisiae) 0.000360921 241403_PM_at CLK4 CDC-like kinase 4 0.00036609 208664_PM_s_at TTC3 tetratricopeptide repeat domain 3 0.000366897 225206_PM_s_at MTRF1L mitochondrial translational release factor 1- 0.000367409 like 201336_PM_at VAMP3 vesicle-associated membrane protein 3 0.000371211 (cellubrevin) 215121_PM_x_at IGLC7 /// immunoglobulin lambda constant 7 /// 0.000374949 IGLV1-44 /// immunoglobulin lambda variable 1-44 /// LOC100290481 immunoglob 210996_PM_s_at YWHAE tyrosine 3-monooxygenase/tryptophan 5- 0.000377721 monooxygenase activation protein, epsilon polypep 220590_PM_at ITFG2 integrin alpha FG-GAP repeat containing 2 0.000378104 1554745_PM_at RALGPS1 Ral GEF with PH domain and SH3 binding 0.000379212 motif 1 239833_PM_at EST239833_PM_at — 0.000379421 1553107_PM_s_at C5orf24 chromosome 5 open reading frame 24 0.000381869 216843_PM_x_at LOC441259 /// PMS2L2 PMS2 postmeiotic segregation increased 2 (S. 0.000384462 /// PMS2P1 /// cerevisiae)-like /// postmeiotic segregati PMS2P5 /// PMS2P6 202262_PM_x_at DDAH2 dimethylarginine dimethylaminohydrolase 2 0.000385193 236428_PM_at EST236428_PM_at — 0.000385729 230648_PM_at LOC283663 hypothetical LOC283663 0.000386276 243745_PM_at EST243745_PM_at — 0.000392422 212827_PM_at IGHM immunoglobulin heavy constant mu 0.000397367 212547_PM_at BRD3 bromodomain containing 3 0.000397485 214901_PM_at ZNF8 zinc finger protein 8 0.000397826 233031_PM_at ZEB2 zinc finger E-box binding homeobox 2 0.000401666 206370_PM_at PIK3CG phosphoinositide-3-kinase, catalytic, gamma 0.000403616 polypeptide 243005_PM_at EST243005_PM_at — 0.000404995 204562_PM_at IRF4 interferon regulatory factor 4 0.000405376 AFFX-r2-P1-cre-5_at ESTAFFX-r2-P1-cre-5_at — 0.000692881 1553313_PM_s_at SLC5A3 solute carrier family 5 (sodium/myo-inositol 0.000406242 cotransporter), member 3 239645_PM_at EST239645_PM_at — 0.00040727 35160_PM_at LDB1 LIM domain binding 1 0.000410024 225920_PM_at LOC148413 hypothetical LOC148413 0.000410869 205611_PM_at TNFSF12 tumor necrosis factor (ligand) superfamily, 0.000410968 member 12 227055_PM_at METTL7B methyltransferase like 7B 0.000413609 216308_PM_x_at GRHPR glyoxylate reductase/hydroxypyruvate 0.000414211 reductase 222858_PM_s_at DAPP1 dual adaptor of phosphotyrosine and 3- 0.000415151 phosphoinositides 1565162_PM_s_at MGST1 microsomal glutathione S-transferase 1 0.000421907 221602_PM_s_at FAIM3 Fas apoptotic inhibitory molecule 3 0.000427899 221671_PM_x_at IGK@ /// IGKC immunoglobulin kappa locus /// 0.000428838 immunoglobulin kappa constant 215176_PM_x_at IGK@ /// IGKC immunoglobulin kappa locus /// 0.000431177 immunoglobulin kappa constant 239001_PM_at MGST1 Microsomal glutathione S-transferase 1 0.000438289 232095_PM_at EST232095_PM_at — 0.00044223 1557780_PM_at EST1557780_PM_at — 0.000447614 221586_PM_s_at E2F5 E2F transcription factor 5, p130-binding 0.000451682 215359_PM_x_at ZNF44 zinc finger protein 44 0.000459167 205863_PM_at S100A12 S100 calcium binding protein A12 0.000462242 209226_PM_s_at TNPO1 transportin 1 0.000464987 215338_PM_s_at NKTR natural killer-tumor recognition sequence 0.000468526 201674_PM_s_at AKAP1 A kinase (PRKA) anchor protein 1 0.0004691 216591_PM_s_at SDHC succinate dehydrogenase complex, subunit C, 0.000471684 integral membrane protein, 15 kDa 1555779_PM_a_at CD79A CD79a molecule, immunoglobulin-associated 0.000473019 alpha 207983_PM_s_at STAG2 stromal antigen 2 0.00047413 1554696_PM_s_at TYMS thymidylate synthetase 0.000477028 226286_PM_at ELMOD3 ELMO/CED-12 domain containing 3 0.000481236 213986_PM_s_at C19orf6 chromosome 19 open reading frame 6 0.000485839 222343_PM_at BCL2L11 BCL2-like 11 (apoptosis facilitator) 0.000486282 218078_PM_s_at ZDHHC3 zinc finger, DHHC-type containing 3 0.000490729 223488_PM_s_at GNB4 guanine nucleotide binding protein (G 0.000490757 protein), beta polypeptide 4 206034_PM_at SERPINB8 serpin peptidase inhibitor, clade B 0.000490816 (ovalbumin), member 8 243771_PM_at EST243771_PM_at — 0.000491776 244804_PM_at SQSTM1 sequestosome 1 0.000491966 215012_PM_at ZNF451 zinc finger protein 451 0.000492264 225447_PM_at GPD2 glycerol-3-phosphate dehydrogenase 2 0.000494271 (mitochondrial) 239651_PM_at ANAPC5 anaphase promoting complex subunit 5 0.000497135 222728_PM_s_at TAF1D TATA box binding protein (TBP)-associated 0.000499059 factor, RNA polymerase 1, D, 41 kDa 1563253_PM_s_at ERBB3 v-erb-b2 erythroblastic leukemia viral 0.000499088 oncogene homolog 3 (avian) 224969_PM_at ATXN7L3 ataxin 7-like 3 0.000501076 235984_PM_at EST235984_PM_at — 0.000504457 231939_PM_s_at BDP1 B double prime 1, subunit of RNA polymerase 0.000505035 III transcription initiation factor IIIB 219420_PM_s_at C1orf163 chromosome 1 open reading frame 163 0.000505672 212804_PM_s_at GAPVD1 GTPase activating protein and VPS9 domains 1 0.000505681 243434_PM_at EST243434_PM_at — 0.000506264 201291_PM_s_at TOP2A topoisomerase (DNA) II alpha 170 kDa 0.000507872 209138_PM_x_at IGL@ Immunoglobulin lambda locus 0.000508704 1559263_PM_s_at PPIL4 /// peptidylprolyl isomerase (cyclophilin)-like 4 0.000511201 ZC3H12D /// zinc finger CCCH-type containing 12D 212994_PM_at THOC2 THO complex 2 0.000512681 209013_PM_x_at TRIO triple functional domain (PTPRF interacting) 0.000514112 208936_PM_x_at LGALS8 lectin, galactoside-binding, soluble, 8 0.000514485 215357_PM_s_at POLDIP3 polymerase (DNA-directed), delta interacting 0.000516138 protein 3 204970_PM_s_at MAFG v-maf musculoaponeurotic fibrosarcoma 0.00051907 oncogene homolog G (avian) 239780_PM_at EST239780_PM_at — 0.000519847 213648_PM_at EXOSC7 exosome component 7 0.000522394 238365_PM_s_at C1orf228 chromosome 1 open reading frame 228 0.000524946 238627_PM_at TRAPPC2L trafficking protein particle complex 2-like 0.000531608 224563_PM_at WASF2 WAS protein family, member 2 0.000531756 211310_PM_at EZH1 enhancer of zeste homolog 1 (Drosophila) 0.000535033 219497_PM_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 0.000536239 242115_PM_at EST242115_PM_at — 0.000536939 239486_PM_at EST239486_PM_at — 0.000538967 227057_PM_at ARHGAP27 Rho GTPase activating protein 27 0.000558167 243490_PM_at EST243490_PM_at — 0.000559582 208752_PM_x_at NAP1L1 nucleosome assembly protein 1-like 1 0.000559875 1554822_PM_at PHTF2 putative homeodomain transcription factor 2 0.000562813 33148_PM_at ZFR zinc finger RNA binding protein 0.000563495 226384_PM_at PPAPDC1B phosphatidic acid phosphatase type 2 domain 0.000567195 containing 1B 222158_PM_s_at PPPDE1 PPPDE peptidase domain containing 1 0.000568969 AFFX-r2-Bs-dap-3_at ESTAFFX-r2-Bs-dap- — 0.00056963 3_at 242916_PM_at CEP110 centrosomal protein 110 kDa 0.000570647 224877_PM_s_at MRPS5 mitochondrial ribosomal protein S5 0.000570714 235728_PM_at ZFP3 zinc finger protein 3 homolog (mouse) 0.000574739 233089_PM_at QRSL1 glutaminyl-tRNA synthase (glutamine- 0.000574905 hydrolyzing)-like 1 238602_PM_at DIS3L2 DIS3 mitotic control homolog (S. cerevisiae)- 0.000575483 like 2 207131_PM_x_at GGT1 gamma-glutamyltransferase 1 0.000581613 215942_PM_s_at GTSE1 G-2 and S-phase expressed 1 0.000584379 203485_PM_at RTN1 reticulon 1 0.000586494 1562364_PM_at GVIN1 GTPase, very large interferon inducible 1 0.000587505 224733_PM_at CMTM3 CKLF-like MARVEL transmembrane domain 0.000589647 containing 3 217898_PM_at C15orf24 chromosome 15 open reading frame 24 0.00059102 201401_PM_s_at ADRBK1 adrenergic, beta, receptor kinase 1 0.000595924 240174_PM_at EST240174_PM_at — 0.000598439 200623_PM_s_at CALM3 calmodulin 3 (phosphorylase kinase, delta) 0.000601157 206562_PM_s_at CSNK1A1 casein kinase 1, alpha 1 0.000602948 215495_PM_s_at SAMD4A sterile alpha motif domain containing 4A 0.000606 215293_PM_s_at PGAP2 post-GPI attachment to proteins 2 0.000609566 202971_PM_s_at DYRK2 dual-specificity tyrosine-(Y)-phosphorylation 0.000611919 regulated kinase 2 229571_PM_at EST229571_PM_at — 0.000616179 210787_PM_s_at CAMKK2 calcium/calmodulin-dependent protein kinase 0.000616474 kinase 2, beta 1569089_PM_a_at FLJ35390 hypothetical LOC255031 0.000619243 201739_PM_at SGK1 serum/glucocorticoid regulated kinase 1 0.000619837 221079_PM_s_at METTL2A /// methyltransferase like 2A /// 0.000620397 METTL2B methyltransferase like 2B 235792_PM_x_at PIK3C2A phosphoinositide-3-kinase, class 2, alpha 0.000623715 polypeptide AFFX- GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.000625862 HUMGAPDH/M33197_3_at 243182_PM_at EST243182_PM_at — 0.000626437 230735_PM_at EST230735_PM_at — 0.000630009 1555301_PM_a_at DIP2A DIP2 disco-interacting protein 2 homolog A 0.000632511 (Drosophila) 211721_PM_s_at ZNF551 zinc finger protein 551 0.000632559 1560020_PM_at DNAJC13 DnaJ (Hsp40) homolog, subfamily C, member 0.000634502 13 229327_PM_s_at EST229327_PM_s_at — 0.000644805 236237_PM_at EST236237_PM_at — 0.000644857 204214_PM_s_at RAB32 RAB32, member RAS oncogene family 0.000647569 227108_PM_at STARD9 StAR-related lipid transfer (START) domain 0.000649001 containing 9 227152_PM_at C12orf35 chromosome 12 open reading frame 35 0.000649869 213286_PM_at ZFR zinc finger RNA binding protein 0.000650155 210943_PM_s_at LYST lysosomal trafficking regulator 0.000652166 210281_PM_s_at ZMYM2 zinc finger, MYM-type 2 0.000655464 210131_PM_x_at SDHC succinate dehydrogenase complex, subunit C, 0.000660271 integral membrane protein, 15 kDa 219073_PM_s_at OSBPL10 oxysterol binding protein-like 10 0.000660978 201733_PM_at CLCN3 chloride channel 3 0.000662473 242732_PM_at EST242732_PM_at — 0.000665353 223997_PM_at FNIP1 folliculin interacting protein 1 0.000668942 228762_PM_at LFNG LFNG O-fucosylpeptide 3-beta-N- 0.000671686 acetylglucosaminyltransferase 216525_PM_x_at PMS2P3 postmeiotic segregation increased 2 0.000677006 pseudogene 3 226456_PM_at C16orf75 chromosome 16 open reading frame 75 0.000677438 209113_PM_s_at HMG20B high-mobility group 20B 0.000679675 224854_PM_s_at SLAIN2 SLAIN motif family, member 2 0.000682615 239235_PM_at EST239235_PM_at — 0.000683667 228718_PM_at ZNF44 zinc finger protein 44 0.000688863 217785_PM_s_at YKT6 YKT6 v-SNARE homolog (S. cerevisiae) 0.00069086 218240_PM_at NKIRAS2 NFKB inhibitor interacting Ras-like 2 0.000690947 236796_PM_at BACH2 BTB and CNC homology 1, basic leucine zipper 0.000691868 transcription factor 2 238893_PM_at LOC338758 hypothetical LOC338758 2.94E−05 212178_PM_s_at POM121 /// POM121 membrane glycoprotein /// POM121 0.000695226 POM121C membrane glycoprotein C 229243_PM_at EST229243_PM_at — 0.000699175 231188_PM_at ZSCAN2 zinc finger and SCAN domain containing 2 0.000705941 236408_PM_at EST236408_PM_at — 0.000706706 202954_PM_at UBE2C ubiquitin-conjugating enzyme E2C 0.00070987 241995_PM_at DGUOK deoxyguanosine kinase 0.00071203 213132_PM_s_at MCAT malonyl CoA:ACP acyltransferase 0.000713197 (mitochondrial) 243461_PM_at EST243461_PM_at — 0.000714864 209374_PM_s_at IGHM immunoglobulin heavy constant mu 0.000716721 1559587_PM_at SYMPK symplekin 0.000720074 239864_PM_at LOC100130175 hypothetical protein LOC100130175 0.000722172 226150_PM_at PPAPDC1B phosphatidic acid phosphatase type 2 domain 0.000722764 containing 1B 224227_PM_s_at BDP1 B double prime 1, subunit of RNA polymerase 0.000724793 III transcription initiation factor IIIB 202535_PM_at FADD Fas (TNFRSF6)-associated via death domain 0.000725868 243072_PM_at EST243072_PM_at — 0.00072676 226798_PM_at BCL2L13 BCL2-like 13 (apoptosis facilitator) 0.000726832 210218_PM_s_at SP100 SP100 nuclear antigen 0.000728004 224414_PM_s_at CARD6 caspase recruitment domain family, member 0.000729842 6 213453_PM_x_at GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.000732584 240124_PM_at EST240124_PM_at — 0.000735862 234258_PM_at EST234258_PM_at — 0.000737628 200972_PM_at TSPAN3 tetraspanin 3 0.000738686 221521_PM_s_at GINS2 GINS complex subunit 2 (Psf2 homolog) 0.000740977 229563_PM_s_at RPL10A ribosomal protein L10a 0.000743036 243690_PM_at TRIOBP TRIO and F-actin binding protein 0.000754519 228040_PM_at MGC21881 hypothetical locus MGC21881 0.000758151 214836_PM_x_at IGK@ /// IGKC /// immunoglobulin kappa locus /// 0.00076237 IGKV1-5 immunoglobulin kappa constant /// immunoglobulin kappa v 228813_PM_at HDAC4 histone deacetylase 4 0.000762977 216984_PM_x_at IGLV2-23 immunoglobulin lambda variable 2-23 0.000765219 243474_PM_at EST243474_PM_at — 0.000768017 240704_PM_at EST240704_PM_at — 0.000768307 209023_PM_s_at STAG2 stromal antigen 2 0.000770382 227198_PM_at AFF3 AF4/FMR2 family, member 3 0.00077081 211672_PM_s_at ARPC4 actin related protein 2/3 complex, subunit 4, 0.000773643 20 kDa 201536_PM_at DUSP3 dual specificity phosphatase 3 0.000774485 201840_PM_at NEDD8 neural precursor cell expressed, 0.000777605 developmentally down-regulated 8 1554453_PM_at HNRPLL heterogeneous nuclear ribonucleoprotein L- 0.000778138 like 1554516_PM_at LOC100288109 /// Hypothetical protein LOC100288109 /// 0.000779538 LOC203274 Hypothetical protein LOC203274 233745_PM_at EST233745_PM_at — 0.000780591 230370_PM_x_at STYXL1 serine/threonine/tyrosine interacting-like 1 0.000781146 211611_PM_s_at ATF6B /// TNXB activating transcription factor 6 beta /// 0.000784184 tenascin XB 206114_PM_at EPHA4 EPH receptor A4 0.00078538 225880_PM_at TOR1AIP2 torsin A interacting protein 2 0.000786899 217198_PM_x_at IGHA2 /// IGHD /// immunoglobulin heavy constant alpha 2 (A2m 0.000788023 IGHG1 /// marker) /// immunoglobulin heavy constant LOC100126583 /// de LOC100510361 215379_PM_x_at IGLC7 /// immunoglobulin lambda constant 7 /// 0.000796455 IGLV1-44 immunoglobulin lambda variable 1-44 208757_PM_at TMED9 transmembrane emp24 protein transport 0.000796492 domain containing 9 212979_PM_s_at FAM115A family with sequence similarity 115, member 0.000796767 A 213450_PM_s_at ICOSLG inducible T-cell co-stimulator ligand 0.000801819 244429_PM_at EST244429_PM_at — 0.000801949 211453_PM_s_at AKT2 v-akt murine thymoma viral oncogene 0.00080311 homolog 2 211352_PM_s_at NCOA3 nuclear receptor coactivator 3 0.000805416 239450_PM_at EST239450_PM_at — 0.000808718 226679_PM_at SLC26A11 solute carrier family 26, member 11 0.000810101 209567_PM_at RRS1 RRS1 ribosome biogenesis regulator homolog 0.000810395 (S. cerevisiae) 244498_PM_x_at LOC100505679 hypothetical protein LOC100505679 0.0008122 205731_PM_s_at NCOA2 nuclear receptor coactivator 2 0.000813451 212421_PM_at C22orf9 chromosome 22 open reading frame 9 0.000819733 1568702_PM_a_at PAAF1 proteasomal ATPase-associated factor 1 0.000820736 226160_PM_at H6PD hexose-6-phosphate dehydrogenase (glucose 0.000829239 1-dehydrogenase) 227882_PM_at FKRP fukutin related protein 0.000831453 211275_PM_s_at GYG1 glycogenin 1 0.000837756 240392_PM_at EST240392_PM_at — 0.000837778 214615_PM_at P2RY10 purinergic receptor P2Y, G-protein coupled, 0.000839839 10 219933_PM_at GLRX2 glutaredoxin 2 0.000844012 210264_PM_at GPR35 G protein-coupled receptor 35 0.000844817 236250_PM_at AFG3L1P AFG3 ATPase family gene 3-like 1 (S. 0.000853458 cerevisiae), pseudogene 201690_PM_s_at TPD52 tumor protein D52 0.000856129 230434_PM_at PHOSPHO2 phosphatase, orphan 2 0.000856483 205267_PM_at POU2AF1 POU class 2 associating factor 1 0.000857053 223234_PM_at MAD2L2 MAD2 mitotic arrest deficient-like 2 (yeast) 0.000860917 201259_PM_s_at SYPL1 synaptophysin-like 1 0.000861326 222387_PM_s_at VPS35 vacuolar protein sorting 35 homolog (S. 0.000862194 cerevisiae) 1555896_PM_a_at ADAM15 ADAM metallopeptidase domain 15 0.00086724 220112_PM_at ANKRD55 ankyrin repeat domain 55 0.000868721 212229_PM_s_at FBXO21 F-box protein 21 0.000873958 219737_PM_s_at PCDH9 protocadherin 9 0.000879071 212386_PM_at TCF4 transcription factor 4 0.000884201 223819_PM_x_at COMMD5 COMM domain containing 5 0.000886611 238477_PM_at KIF1C kinesin family member 1C 0.000886757 1554452_PM_a_at C7orf68 chromosome 7 open reading frame 68 0.000891429 242279_PM_at EST242279_PM_at — 0.000896083 202095_PM_s_at BIRC5 baculoviral IAP repeat-containing 5 0.000914017 228693_PM_at CCDC50 coiled-coil domain containing 50 0.000917681 225626_PM_at PAG1 phosphoprotein associated with 0.00091903 glycosphingolipid microdomains 1 1557117_PM_at EST1557117_PM_at — 0.00092373 208621_PM_s_at EZR ezrin 0.000926268 239213_PM_at SERPINB1 serpin peptidase inhibitor, clade B 0.000926276 (ovalbumin), member 1 206116_PM_s_at TPM1 tropomyosin 1 (alpha) 0.00092976 202689_PM_at RBM15B RNA binding motif protein 15B 0.000940032 242352_PM_at NIPBL Nipped-B homolog (Drosophila) 0.000940617 228364_PM_at ZNF784 zinc finger protein 784 0.000940805 241614_PM_at EST241614_PM_at — 0.000943349 201432_PM_at CAT catalase 0.000947049 218009_PM_s_at PRC1 protein regulator of cytokinesis 1 0.00095654 218862_PM_at ASB13 ankyrin repeat and SOCS box-containing 13 0.000957234 212392_PM_s_at PDE4DIP phosphodiesterase 4D interacting protein 0.000959054 215451_PM_s_at AFF1 AF4/FMR2 family, member 1 0.000961327 219267_PM_at GLTP glycolipid transfer protein 0.000963785 228377_PM_at KLHL14 kelch-like 14 (Drosophila) 0.000971257 226365_PM_at EST226365_PM_at — 0.000974061 227937_PM_at MYPOP Myb-related transcription factor, partner of 0.000983015 profilin 217148_PM_x_at EST217148_PM_x_at — 0.00098494 AFFX- ESTAFFX- — 0.000987735 HUMRGE/M10098_3_at HUMRGE/M10098_3_at 239061_PM_at TPRXL tetra-peptide repeat homeobox-like 0.000989572 1570021_PM_at EST1570021_PM_at — 0.000995573 205781_PM_at C16orf7 chromosome 16 open reading frame 7 0.000995722 1557388_PM_at RTTN rotatin 0.00099729 236215_PM_at EST236215_PM_at — 0.00100332 221239_PM_s_at FCRL2 Fc receptor-like 2 0.00100594 209680_PM_s_at KIFC1 kinesin family member C1 0.00101262 1560922_PM_s_at ZNF169 zinc finger protein 169 0.00101809 39318_PM_at TCL1A T-cell leukemia/lymphoma 1A 0.0010181 222292_PM_at CD40 CD40 molecule, TNF receptor superfamily 0.00102743 member 5 217398_PM_x_at GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.00102797 228599_PM_at MS4A1 membrane-spanning 4-domains, subfamily A, 0.00103001 member 1 240861_PM_at EST240861_PM_at — 0.00103147 202065_PM_s_at PPFIA1 protein tyrosine phosphatase, receptor type, f 0.0010369 polypeptide (PTPRF), interacting protein 234488_PM_s_at GMCL1 /// GMCL1L germ cell-less homolog 1 (Drosophila) /// 0.00104025 germ cell-less homolog 1 (Drosophila)-like 233375_PM_at EFCAB2 EF-hand calcium binding domain 2 0.00104248 1560724_PM_at EST1560724_PM_at — 0.00104357 209006_PM_s_at C1orf63 chromosome 1 open reading frame 63 0.00104379 214992_PM_s_at DNASE2 deoxyribonuclease II, lysosomal 0.00104413 218391_PM_at SNF8 SNF8, ESCRT-II complex subunit, homolog (S. 0.00104546 cerevisiae) 242288_PM_s_at EMILIN2 elastin microfibril interfacer 2 0.00104673 239926_PM_at EST239926_PM_at — 0.00105049 243699_PM_at LOC100507006 hypothetical LOC100507006 0.00105279 202016_PM_at MEST mesoderm specific transcript homolog 0.00105615 (mouse) 201211_PM_s_at DDX3X DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, X- 0.00105627 linked 238130_PM_at NFATC2IP nuclear factor of activated T-cells, 0.00105997 cytoplasmic, calcineurin-dependent 2 interacting p 217378_PM_x_at EST217378_PM_x_at — 0.00106017 200868_PM_s_at RNF114 ring finger protein 114 0.00106168 209699_PM_x_at AKR1C2 aldo-keto reductase family 1, member C2 0.00106498 (dihydrodiol dehydrogenase 2; bile acid binding 225052_PM_at TMEM203 transmembrane protein 203 0.00106532 237464_PM_at EST237464_PM_at — 0.00106804 201944_PM_at HEXB hexosaminidase B (beta polypeptide) 0.00107107 234764_PM_x_at IGLV1-36 immunoglobulin lambda variable 1-36 0.00107144 223393_PM_s_at TSHZ3 teashirt zinc finger homeobox 3 0.00107465 240652_PM_at EST240652_PM_at — 0.00108224 231672_PM_at EST231672_PM_at — 0.00108448 230486_PM_at EST230486_PM_at — 0.00108996 212967_PM_x_at NAP1L1 nucleosome assembly protein 1-like 1 0.00109982 220068_PM_at VPREB3 pre-B lymphocyte 3 0.0011043 228250_PM_at FNIP1 folliculin interacting protein 1 0.00111525 222388_PM_s_at VPS35 vacuolar protein sorting 35 homolog (S. 0.00111739 cerevisiae) 241885_PM_at EST241885_PM_at — 0.00111828 229852_PM_at NMNAT1 nicotinamide nucleotide adenylyltransferase 1 0.0011245 232906_PM_at EST232906_PM_at — 0.00112623 213082_PM_s_at SLC35D2 solute carrier family 35, member D2 0.00112801 1569189_PM_at TTC9C tetratricopeptide repeat domain 9C 0.00113081 200709_PM_at FKBP1A FK506 binding protein 1A, 12 kDa 0.00113213 238860_PM_at C6orf130 chromosome 6 open reading frame 130 0.00113294 218149_PM_s_at ZNF395 zinc finger protein 395 0.00113365 226663_PM_at ANKRD10 ankyrin repeat domain 10 0.00113647 221837_PM_at KLHL22 kelch-like 22 (Drosophila) 0.00113942 222193_PM_at C2orf43 chromosome 2 open reading frame 43 0.00114481 201698_PM_s_at SRSF9 serine/arginine-rich splicing factor 9 0.00115792 209042_PM_s_at UBE2G2 ubiquitin-conjugating enzyme E2G 2 (UBC7 0.00115961 homolog, yeast) 235231_PM_at ZNF789 zinc finger protein 789 0.00116259 236799_PM_at EST236799_PM_at — 0.00116393 235409_PM_at MGA MAX gene associated 0.00116667 201456_PM_s_at BUB3 budding uninhibited by benzimidazoles 3 0.00116683 homolog (yeast) 226825_PM_s_at TMEM165 transmembrane protein 165 0.00117042 1556462_PM_a_at EST1556462_PM_a_at — 0.00117146 243667_PM_at EST243667_PM_at — 0.00117303 1566824_PM_at EST1566824_PM_at — 0.00117375 217078_PM_s_at CD300A CD300a molecule 0.00117516 208610_PM_s_at SRRM2 serine/arginine repetitive matrix 2 0.00117811 215954_PM_s_at C19orf29 chromosome 19 open reading frame 29 0.00117964 219443_PM_at TASP1 taspase, threonine aspartase, 1 0.00118869 207188_PM_at CDK3 cyclin-dependent kinase 3 0.00119927 235526_PM_at SOX6 SRY (sex determining region Y)-box 6 0.00119931 217927_PM_at SPCS1 signal peptidase complex subunit 1 homolog 0.00120191 (S. cerevisiae) 203096_PM_s_at RAPGEF2 Rap guanine nucleotide exchange factor (GEF) 0.00120412 2 243968_PM_x_at FCRL1 Fc receptor-like 1 0.00120435 235469_PM_at FAM133B /// family with sequence similarity 133, member 0.00120671 LOC728066 B /// family with sequence similarity 133, 205297_PM_s_at CD79B CD79b molecule, immunoglobulin-associated 0.00121583 beta 212177_PM_at SFRS18 splicing factor, arginine/serine-rich 18 0.00122218 203554_PM_x_at PTTG1 pituitary tumor-transforming 1 0.00122388 230533_PM_at ZMYND8 zinc finger, MYND-type containing 8 0.00122749 223161_PM_at KIAA1147 KIAA1147 0.00122827 208652_PM_at PPP2CA protein phosphatase 2, catalytic subunit, 0.0012327 alpha isozyme 235577_PM_at ZNF652 zinc finger protein 652 0.00123352 203222_PM_s_at TLE1 transducin-like enhancer of split 1 (E(sp1) 0.001235 homolog, Drosophila) 202871_PM_at TRAF4 TNF receptor-associated factor 4 0.00123923 223887_PM_at GPR132 G protein-coupled receptor 132 0.00123983 244015_PM_at EST244015_PM_at — 0.00124998 1558438_PM_a_at IGHA1 Immunoglobulin heavy constant alpha 1 0.00125035 202696_PM_at OXSR1 oxidative-stress responsive 1 0.00125038 228083_PM_at CACNA2D4 calcium channel, voltage-dependent, alpha 0.00125662 2/delta subunit 4 242712_PM_x_at RANBP2 /// RGPD1 /// RAN binding protein 2 /// RANBP2-like and 0.00126544 RGPD2 /// RGPD3 /// GRIP domain containing 1 /// RANBP2-like RGPD4 /// RGPD5 /// and RGPD6 /// RGPD8 221850_PM_x_at AGAP4 /// AGAP6 /// ArfGAP with GTPase domain, ankyrin repeat 0.00126719 AGAP7 /// AGAP8 and PH domain 4 /// ArfGAP with GTPase domain 236700_PM_at EIF3C eukaryotic translation initiation factor 3, 0.00126801 subunit C 208466_PM_at RAB3D RAB3D, member RAS oncogene family 0.00127517 243492_PM_at THEM4 thioesterase superfamily member 4 0.0012775 213448_PM_at EST213448_PM_at — 0.00128088 222800_PM_at TRNAU1AP tRNA selenocysteine 1 associated protein 1 0.00128375 232236_PM_at EST232236_PM_at — 0.00129017 213891_PM_s_at TCF4 transcription factor 4 0.00129164 202166_PM_s_at PPP1R2 protein phosphatase 1, regulatory (inhibitor) 0.00129303 subunit 2 228273_PM_at PRR11 proline rich 11 0.00129725 206896_PM_s_at GNG7 guanine nucleotide binding protein (G 0.00129953 protein), gamma 7 227616_PM_at BCL9L B-cell CLL/lymphoma 9-like 0.00130003 237778_PM_at EST237778_PM_at — 0.00130027 235662_PM_at EST235662_PM_at — 0.00130307 1554670_PM_at GGA1 golgi-associated, gamma adaptin ear 0.00130507 containing, ARF binding protein 1 236621_PM_at RPS27 ribosomal protein S27 0.00130665 214052_PM_x_at BAT2L2 HLA-B associated transcript 2-like 2 0.00130805 219382_PM_at SERTAD3 SERTA domain containing 3 0.00131171 211645_PM_x_at EST211645_PM_x_at — 0.00131608 242261_PM_at EST242261_PM_at — 0.00131609 201896_PM_s_at PSRC1 proline/serine-rich coiled-coil 1 0.00132007 202589_PM_at TYMS thymidylate synthetase 0.00132608 225602_PM_at GLIPR2 GLI pathogenesis-related 2 0.0013347 239760_PM_at EST239760_PM_at — 0.00133591 230000_PM_at RNF213 ring finger protein 213 0.00133665 238485_PM_at EST238485_PM_at — 0.00133773 1569320_PM_at GPBP1L1 GC-rich promoter binding protein 1-like 1 0.00134606 224766_PM_at LOC100506548 /// hypothetical LOC100506548 /// ribosomal 0.0013474 RPL37 protein L37 227062_PM_at EST227062_PM_at — 0.00134993 243919_PM_at EST243919_PM_at — 0.00135277 202942_PM_at ETFB electron-transfer-flavoprotein, beta 0.00135862 polypeptide 239266_PM_at EST239266_PM_at — 0.00135979 225259_PM_at RAB6B RAB6B, member RAS oncogene family 0.00136 239764_PM_at EST239764_PM_at — 0.00137061 234767_PM_at FAR1 fatty acyl CoA reductase 1 8.02E−05

TABLE 15 Blood Microarray Signatures for subAR using a 3-Way 1-Step approach (AR vs. subAR vs. TX): best performing gene signature (61 genes) Probe Set ID Gene Symbol Gene Title 1559249_PM_at ATXN1 ataxin 1 1559391_PM_s_at EST20 — 1570299_PM_at EST1 — 201015_PM_s_at JUP junction plakoglobin 201876_PM_at PON2 paraoxonase 2 203137_PM_at WTAP Wilms tumor 1 associated protein 204185_PM_x_at PPID peptidylprolyl isomerase D 206366_PM_x_at XCL1 chemokine (C motif) ligand 1 208249_PM_s_at TGDS TDP-glucose 4,6-dehydratase 209833_PM_at CRADD CASP2 and RIPK1 domain containing adaptor with death domain 211360_PM_s_at ITPR2 inositol 1,4,5-trisphosphate receptor, type 2 212872_PM_s_at MED20 mediator complex subunit 20 214567_PM_s_at XCL1 /// XCL2 chemokine (C motif) ligand 1 /// chemokine (C motif) ligand 2 215092_PM_s_at NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 215707_PM_s_at PRNP prion protein 215887_PM_at ZNF277 zinc finger protein 277 215933_PM_s_at HHEX hematopoietically expressed homeobox 217703_PM_x_at EST2 — 217982_PM_s_at MORF4L1 mortality factor 4 like 1 218178_PM_s_at CHMP1B charged multivesicular body protein 1B 218474_PM_s_at KCTD5 potassium channel tetramerization domain containing 5 220127_PM_s_at FBXL12 F-box and leucine-rich repeat protein 12 220221_PM_at VPS13D vacuolar protein sorting 13 homolog D (S. cerevisiae) 221579_PM_s_at NUDT3 /// RPS10- nudix (nucleoside diphosphate linked NUDT3 moiety X)-type motif 3 /// RPS10- NUDT3 readthrough 222489_PM_s_at WRNIP1 Werner helicase interacting protein 1 223819_PM_x_at COMMD5 /// COMM domain containing 5 /// COMM LOC101928879 /// domain-containing protein 5-like /// ZNF250 zinc finger protein 250 223937_PM_at FOXP1 forkhead box P1 225091_PM_at ZCCHC3 zinc finger, CCHC domain containing 3 225179_PM_at UBE2K ubiquitin-conjugating enzyme E2K 225399_PM_at TSEN15 TSEN15 tRNA splicing endonuclease subunit 225509_PM_at SAP30L SAP30-like 226975_PM_at RNPC3 RNA-binding region (RNP1, RRM) containing 3 227410_PM_at FAM43A family with sequence similarity 43, member A 228476_PM_at KIAA1407 KIAA1407 229243_PM_at RP11-111M22.4 — 230505_PM_at LOC145474 uncharacterized LOC145474 232031_PM_s_at EPG5 ectopic P-granules autophagy protein 5 homolog (C. elegans) 232284_PM_at PSMD6-AS2 PSMD6 antisense RNA 2 236168_PM_at EST3 — 236404_PM_at EST4 — 236883_PM_at EST5 — 237176_PM_at EST6 — 237544_PM_at CTD-2165H16.3 — 238317_PM_x_at EST7 — 239227_PM_at EST8 — 239404_PM_at EST9 — 239600_PM_at EST10 — 240498_PM_at EST11 — 241688_PM_at EST12 — 242060_PM_x_at PHF11 PHD finger protein 11 242352_PM_at NIPBL Nipped-B homolog (Drosophila) 242390_PM_at EST13 — 242824_PM_at EST14 — 242877_PM_at EST15 — 243739_PM_at EST16 — 244233_PM_at TPGS2 tubulin polyglutamylase complex subunit 2 244840_PM_x_at DOCK4 dedicator of cytokinesis 4 AFFX-CreX-5_at EST17 — AFFX-r2-P1-cre-3_at EST18 — AFFX-r2-P1-cre-5_at EST19 —

TABLE 16 Blood Microarray analysis results for subAR using a 3-Way 1-Step approach (AR vs. subAR vs. TX) TX SCAR AR TX 19 3 3 SCAR 1 21 1 AR 1 3 17 Positive Negative % Predictive Sensitivity Specificity Predictive Predicitve Method Classifies Accuracy (%) (%) Value (%) Value (%) AUC Nearest Centroid TX vs. AR 90% 95% 85% 86% 94% 0.898 (1 Step Prediction) TX vs. SCAR 91% 95% 87% 86% 95% 0.912 AR vs. SCAR 91% 88% 94% 95% 85% 0.905

TABLE 17 Blood PAXgene NGS Signatures for subAR using a 3-Way 1-Step approach (AR vs. subAR vs. TX): full gene list (123 genes) at p < 0.01 Probeset ID Gene Symbol Transcript p-value NM_001123228 > TMEM14E TMEM14E NM_001123228 1.79E−06 NM_001375 > DNASE2 DNASE2 NM_001375 6.30E−06 NM_003107 > SOX4 SOX4 NM_003107 1.77E−05 NM_148901 > TNFRSF18 TNFRSF18 NM_148901 0.00014023 NR_109780 > LOC100506860 LOC100506860 NR_109780 0.00019178 NM_001336 > CTSZ CTSZ NM_001336 0.00043567 NR_109851 > LINC-PINT LINC-PINT NR_109851 0.00045431 NM_021991 > JUP JUP NM_021991 0.00047653 NR_022011 > PWARSN PWARSN NR_022011 0.00073955 NM_001146190 > ZNF407 ZNF407 NM_001146190 0.00081929 NM_130771 > OSCAR OSCAR NM_130771 0.00087193 NM_133168 > OSCAR OSCAR NM_133168 0.00087195 NM_133169 > OSCAR OSCAR NM_133169 0.00087211 NM_032955 > AIF1 AIF1 NM_032955 0.00096137 NM_001286473 > C14orf159 C14orf159 NM_001286473 0.00096319 NM_020979 > SH2B2 SH2B2 NM_020979 0.00097423 NM_006428 > MRPL28 MRPL28 NM_006428 0.00098373 NM_001271819 > ORAI2 ORAI2 NM_001271819 0.00100025 NM_005798 > TRIM13 TRIM13 NM_005798 0.00104837 NM_001025238 > TSPAN4 TSPAN4 NM_001025238 0.0011929 NM_001284237 > ZFYVE16 ZFYVE16 NM_001284237 0.00139031 NR_047701 > COA1 COA1 NR_047701 0.00140464 NR_003140.7 > SNORD117 SNORD117 NR_003140.7 0.00145813 NM_001040440 > CCDC112 CCDC112 NM_001040440 0.0015703 NM_001243878 > FHL3 FHL3 NM_001243878 0.00172631 NM_001290222 > NQO2 NQO2 NM_001290222 0.00181379 NR_029478 > MIRLET7A3 MIRLET7A3 NR_029478 0.00183984 NM_001197234 > BTN2A1 BTN2A1 NM_001197234 0.00193406 NR_002605 > DLEU1 DLEU1 NR_002605 0.00195495 NR_028505 > MIR22HG MIR22HG NR_028505 0.00200373 NR_051980 > MINOS1P1 MINOS1P1 NR_051980 0.00201321 NM_001244898 > PTBP3 PTBP3 NM_001244898 0.00217963 NM_152889 > CHST13 CHST13 NM_152889 0.00224819 NM_001277224 > TAGLN2 TAGLN2 NM_001277224 0.00229155 NR_037937 > SCNM1 SCNM1 NR_037937 0.00233534 NM_138730 > HMGN3 HMGN3 NM_138730 0.00235072 NM_148962 > OXER1 OXER1 NM_148962 0.00240808 NM_002729 > HHEX HHEX NM_002729 0.00254469 NR_040030 > CFLAR-AS1 CFLAR-AS1 NR_040030 0.00289549 NR_110146 > VNN2 VNN2 NR_110146 0.00294559 NM_018993 > RIN2 RIN2 NM_018993 0.00302295 NM_002514 > NOV NOV NM_002514 0.00304015 NM_173527 > REM2 REM2 NM_173527 0.00356599 NR_103549 > LUCAT1 LUCAT1 NR_103549 0.00379271 NR_036503 > PRKCQ-AS1 PRKCQ-AS1 NR_036503 0.00382665 NM_001666 > ARHGAP4 ARHGAP4 NM_001666 0.00392569 NM_001164741 > ARHGAP4 ARHGAP4 NM_001164741 0.00392606 NR_120600 > PRMT5-AS1 PRMT5-AS1 NR_120600 0.00399138 NM_001012959 > DISC1 DISC1 NM_001012959 0.00412158 NM_003104 > SORD SORD NM_003104 0.00440187 NM_005461 > MAFB MAFB NM_005461 0.00461273 NM_207354 > ANKRD13D ANKRD13D NM_207354 0.00462185 NM_017723 > TOR4A TOR4A NM_017723 0.00473781 NM_001567 > INPPL1 INPPL1 NM_001567 0.00513417 NM_002068 > GNA15 GNA15 NM_002068 0.00516178 NM_006480 > RGS14 RGS14 NM_006480 0.00528027 NR_003042 > SNORD45C SNORD45C NR_003042 0.00533478 NM_014098 > PRDX3 PRDX3 NM_014098 0.00534763 NM_153690 > FAM43A FAM43A NM_153690 0.0053505 NM_001127586 > ING4 ING4 NM_001127586 0.00547331 NM_017628 > TET2 TET2 NM_017628 0.00547411 NM_182491 > ZFAND2A ZFAND2A NM_182491 0.00559846 NM_032353 > VPS25 VPS25 NM_032353 0.00564435 NM_016538 > SIRT7 SIRT7 NM_016538 0.00570906 NM_001242831 > ELOVL5 ELOVL5 NM_001242831 0.00579687 NR_120485 > IL7R IL7R NR_120485 0.00603421 NM_001289406 > MFSD1 MFSD1 NM_001289406 0.0061122 NR_038975 > MIR181A2HG MIR181A2HG NR_038975 0.00612369 NM_005999 > TSNAX TSNAX NM_005999 0.00613635 NR_030767 > ANKRD13D ANKRD13D NR_030767 0.00621972 NM_025080 > ASRGL1 ASRGL1 NM_025080 0.00626114 NM_003656 > CAMK1 CAMK1 NM_003656 0.00631752 NM_001291478 > AKAP8L AKAP8L NM_001291478 0.00634315 NM_001286766 > KIAA0226L KIAA0226L NM_001286766 0.00638614 NM_006793 > PRDX3 PRDX3 NM_006793 0.00639539 NR_103791 > LINC01127 LINC01127 NR_103791 0.00640001 NR_036514 > C17orf62 C17orf62 NR_036514 0.00656751 NM_001278243 > ZFAND5 ZFAND5 NM_001278243 0.00657954 NM_001040059 > CD68 CD68 NM_001040059 0.00664828 NM_001287060 > RABGEF1 RABGEF1 NM_001287060 0.00680239 NM_001113738.2 > ARL17A ARL17A NM_001113738.2 0.00682141 NM_152288 > ORAI3 ORAI3 NM_152288 0.00700377 NM_001167903 > MFSD1 MFSD1 NM_001167903 0.00705708 NM_021134 > MRPL23 MRPL23 NM_021134 0.00707961 NM_001012727 > AGPAT2 AGPAT2 NM_001012727 0.00714772 NM_018370 > DRAM1 DRAM1 NM_018370 0.00733689 NM_022898 > BCL11B BCL11B NM_022898 0.00735164 NM_001282238 > BCL11B BCL11B NM_001282238 0.00735456 NM_006720 > ABLIM1 ABLIM1 NM_006720 0.00741649 NR_027330 > SND1-IT1 SND1-IT1 NR_027330 0.00753502 NM_152581 > MOSPD2 MOSPD2 NM_152581 0.00761177 NM_001985 > ETFB ETFB NM_001985 0.00762131 NM_016243 > CYB5R1 CYB5R1 NM_016243 0.00764199 NM_203458 > NOTCH2NL NOTCH2NL NM_203458 0.00765447 NM_004907 > IER2 IER2 NM_004907 0.00767968 NM_001278245 > ZFAND5 ZFAND5 NM_001278245 0.00780399 NM_024832 > RIN3 RIN3 NM_024832 0.00799293 NR_103518 > LILRB1 LILRB1 NR_103518 0.00799882 NM_145030 > PPP1R35 PPP1R35 NM_145030 0.00804432 NM_002555 > SLC22A18 SLC22A18 NM_002555 0.00805737 NM_001142391 > SLC10A3 SLC10A3 NM_001142391 0.00826523 NM_017607 > PPP1R12C PPP1R12C NM_017607 0.0083532 NM_033313 > CDC14A CDC14A NM_033313 0.00835701 NM_001271618 > PPP1R12C PPP1R12C NM_001271618 0.00836024 NM_173804 > TMEM86B TMEM86B NM_173804 0.00852912 NR_034140 > LINC00612 LINC00612 NR_034140 0.00856223 NM_080590 > CAPS CAPS NM_080590 0.00868781 NR_046591 > DPYD-AS2 DPYD-AS2 NR_046591 0.00887841 NM_020170 > NCLN NCLN NM_020170 0.00906534 NM_023935 > DDRGK1 DDRGK1 NM_023935 0.00910211 NR_102308 > CACNG6 CACNG6 NR_102308 0.00910804 NR_027154 > SMG1P1 SMG1P1 NR_027154 0.00911855 NR_102405 > NBPF8 NBPF8 NR_102405 0.00916001 NM_183233 > SLC22A18 SLC22A18 NM_183233 0.0091612 NR_036512 > LOC100129917 LOC100129917 NR_036512 0.00924015 NM_002223 > ITPR2 ITPR2 NM_002223 0.00932503 NM_001282948 > JMJD1C JMJD1C NM_001282948 0.00945087 NM_001270483 > TST TST NM_001270483 0.00949873 NM_024537 > CARS2 CARS2 NM_024537 0.00957495 NM_174958 > ATP2A3 ATP2A3 NM_174958 0.0096019 NM_001669 > ARSD ARSD NM_001669 0.00974531 NM_001042572 > CHD2 CHD2 NM_001042572 0.0098763

TABLE 18 Blood PAXgene NGS for subAR using a 3-Way 1-Step approach (AR vs. subAR vs. TX): best performing gene signature (53 genes) Gene ID Gene Symbol Transcript NM_001123228 > TMEM14E TMEM14E NM_001123228 NM_001375 > DNASE2 DNASE2 NM_001375 NM_003107 > SOX4 SOX4 NM_003107 NM_148901 > TNFRSF18 TNFRSF18 NM_148901 NR_109780 > LOC100506860 LOC100506860 NR_109780 NM_001336 > CTSZ CTSZ NM_001336 NR_109851 > LINC-PINT LINC-PINT NR_109851 NM_021991 > JUP JUP NM_021991 NR_022011 > PWARSN PWARSN NR_022011 NM_001146190 > ZNF407 ZNF407 NM_001146190 NM_130771 > OSCAR OSCAR NM_130771 NM_133168 > OSCAR OSCAR NM_133168 NM_133169 > OSCAR OSCAR NM_133169 NM_032955 > AIF1 AIF1 NM_032955 NM_001286473 > C14orf159 C14orf159 NM_001286473 NM_020979 > SH2B2 SH2B2 NM_020979 NM_006428 > MRPL28 MRPL28 NM_006428 NM_001271819 > ORAI2 ORAI2 NM_001271819 NM_005798 > TRIM13 TRIM13 NM_005798 NM_001025238 > TSPAN4 TSPAN4 NM_001025238 NM_001284237 > ZFYVE16 ZFYVE16 NM_001284237 NR_047701 > COA1 COA1 NR_047701 NR_003140.7 > SNORD117 SNORD117 NR_003140.7 NM_001040440 > CCDC112 CCDC112 NM_001040440 NM_001243878 > FHL3 FHL3 NM_001243878 NM_001290222 > NQO2 NQO2 NM_001290222 NR_029478 > MIRLET7A3 MIRLET7A3 NR_029478 NM_001197234 > BTN2A1 BTN2A1 NM_001197234 NR_002605 > DLEU1 DLEU1 NR_002605 NR_028505 > MIR22HG MIR22HG NR_028505 NR_051980 > MINOS1P1 MINOS1P1 NR_051980 NM_001244898 > PTBP3 PTBP3 NM_001244898 NM_152889 > CHST13 CHST13 NM_152889 NM_001277224 > TAGLN2 TAGLN2 NM_001277224 NR_037937 > SCNM1 SCNM1 NR_037937 NM_138730 > HMGN3 HMGN3 NM_138730 NM_148962 > OXER1 OXER1 NM_148962 NM_002729 > HHEX HHEX NM_002729 NR_040030 > CFLAR-AS1 CFLAR-AS1 NR_040030 NR_110146 > VNN2 VNN2 NR_110146 NM_018993 > RIN2 RIN2 NM_018993 NM_002514 > NOV NOV NM_002514 NM_173527 > REM2 REM2 NM_173527 NR_103549 > LUCAT1 LUCAT1 NR_103549 NR_036503 > PRKCQ-AS1 PRKCQ-AS1 NR_036503 NM_001666 > ARHGAP4 ARHGAP4 NM_001666 NM_001164741 > ARHGAP4 ARHGAP4 NM_001164741 NR_120600 > PRMT5-AS1 PRMT5-AS1 NR_120600 NM_001012959 > DISC1 DISC1 NM_001012959 NM_003104 > SORD SORD NM_003104 NM_005461 > MAFB MAFB NM_005461 NM_207354 > ANKRD13D ANKRD13D NM_207354 NM_017723 > TOR4A TOR4A NM_017723

TABLE 19 Blood PAXgene NGS analysis results for subAR using a 3-Way 1-Step approach (AR vs. subAR vs. TX) Positive Negative % Predictive Sensitivity Specificity Predictive Predicitve Method Classifies Accuracy (%) (%) Value (%) Value (%) AUC Nearest Centroid TX vs. AR 92% 95% 90% 90% 95% 0.921 (1 Step Prediction) TX vs. SCAR 83% 83% 82% 83% 82% 0.829 AR vs. SCAR 93% 94% 95% 94% 95% 0.943 TX SCAR AR TX 19 4 2 SCAR 4 18 1 AR 1 1 19 

1. A method of detecting subclinical acute rejection (subAR) in a transplant recipient comprising: (a) obtaining nucleic acids, wherein the nucleic acids comprise mRNA extracted from a blood sample from the transplant recipient or nucleic acids derived from the mRNA extracted from the sample from the transplant recipient, wherein the transplant recipient has a serum creatinine level not exceeding 10% of a baseline value; (b) detecting expression levels in the subject of at least five genes using the nucleic acids of interest obtained in (a) by performing a microarray assay on the nucleic acids, wherein the at least five genes comprise at least two genes corresponding to gene symbols from Table 4; and (c) detecting subAR in the transplant recipient that has the serum creatinine level not exceeding 10% of a baseline value based on the expression levels detected in (b).
 2. (canceled)
 3. The method of claim 1, wherein the method detects subAR with an accuracy of greater than 85% or a sensitivity of greater than 85%.
 4. (canceled)
 5. (canceled)
 6. The method of claim 1, further comprising contacting the nucleic acids with probes, wherein the probes are specific for the at least five genes selected in (b).
 7. (canceled)
 8. (canceled)
 9. (canceled)
 10. (canceled)
 11. (canceled)
 12. (canceled)
 13. (canceled)
 14. (canceled)
 15. (canceled)
 16. The method of claim 1, wherein the method is repeated at different times on the transplant recipient that has the serum creatinine level not exceeding 10% of a baseline value.
 17. (canceled)
 18. The method of claim 1, wherein the transplant recipient that has the serum creatinine level not exceeding 10% of a baseline value has received a kidney transplant within 5 years of performing (a).
 19. (canceled)
 20. The method of claim 1, wherein the sample is a blood sample and comprises whole blood, peripheral blood, serum, plasma, PBLs, PBMCs, T cells, CD4 T cells CD8 T cells, or macrophages.
 21. The method of claim 1, wherein the transplant recipient that has the serum creatinine level not exceeding 10% of a baseline value also has a normal serum creatinine level.
 22. The method of claim 1, wherein the transplant recipient that has the serum creatinine level not exceeding 10% of a baseline value is a kidney transplant recipient.
 23. The method of claim 1, further comprising performing a kidney biopsy or serum creatinine test to detect subAR or risk thereof based on the expression levels detected in (b).
 24. The method of claim 1, wherein the transplant recipient that has the serum creatinine level not exceeding 10% of a baseline value has a serum creatinine not exceeding 20% of a baseline value of the kidney transplant recipient.
 25. The method of claim 1, Additionally comprising reporting the subAR detected in (c) or the expression levels detected in (b) to a caregiver.
 26. The method of claim 1, wherein the method has a negative predictive value (NPV) of greater than 85 percent for subAR.
 27. The method of claim 1, wherein the at least two genes comprise at least two of EXOC4, PKNOX1, or USP31.
 28. The method of claim 1, wherein the method has a sensitivity greater than 90 percent for subAR.
 29. The method of claim 1, wherein the method has a specificity of greater than 90% for subAR.
 30. The method of claim 1, wherein the transplant recipient is receiving an immunosuppressive drug.
 31. The method of claim 1, further comprising adjusting the dose of the immunosuppressive drug based on (c).
 32. The method of claim 26, wherein the transplant recipient is receiving an immunosuppressive drug.
 33. The method of claim 27, comprising decreasing or continuing the dose of the immunosuppressive drug when subAR is not detected.
 34. The method of claim 27, comprising increasing or the dose of the immunosuppressive drug when subAR is detected.
 35. The method of claim 32, wherein the immunosuppressive drug is a calcineurin inhibitor, an mTOR inhibitor, an anti-proliferative, a corticosteroid, basiliximab, daclizumab, orthoclone, anti-thymocyte globulin, or anti-lymphocyte globulin. 